Jla wbqšY KwgwUi 22 A‡±vei 2014 Zwi‡L AbyôZ 243 Zg mfvi Kvhweeiyx

¯v¯¨ I cwievi Kj¨vY gšYvj‡qi mwPe Rbve Gg Gg wbqvR DwÏb Gwu mfvcwZ‡Z Jla wbqšY KwgwUi 243 Zg mfv weMZ 11 A‡±vei 2014 Zwi‡L ‡ejv 3:30 NwUKvq gšYvj‡qi mfv K‡¶ Abyôz nq|

mfvq Kwমটির নিম্নবর্ণিত সদস্যগণ উপস্থিত ছিলেন (জ্যেষ্ঠতার ক্রমানুসারে নয়) ঃ

1| Rbve mykxgvi iÄb †Nvl, cwZwbwa, evsjv‡`k dvgwmDwUK¨vjm B‡¤úvUvm G‡mvwm‡qkb, XvKv|
2| ‡gRi †Rbv‡ij †gvt iweDj †nv‡mb, Kbmvju¨v›U wdRwkqvb ‡Rbv‡ij, evsjv‡`k AvgW †dv‡mm †gwW‡Kj mwf‡mm|
3| Rbve myfvm P›` miKvi, hyM¥ mwPe (Rb¯v¯¨), ¯v¯¨ I cwievi Kj¨vY gšYvjq, evsjv‡`k mwPevjq, XvKv|
4| Aa¨vcK ‡gvt mvBdzj Bmjvg, Wxb, dv‡gmx Abyôv`, XvKv wekwe`¨vjq|
5| Aa¨vcK Wvt †gvt BmgvBj Lvb, Wxb wPwKrmv Abyôv`, XvKv wekwe`¨vjq I cwZwbwa, dvgv‡KvjwR wefvM, XvKv †gwW‡Kj K‡jR|
6| Aa¨vcK dwi`v †eMg, wKwbK¨vj dv‡gmx I dvgv‡KvjwR wefvM, XvKv wekwe`¨vjq|
7| Wv. †gv‡gbyj nK, wmwbqi mn mfvcwZ, evsjv‡`k Jla wkí mwgwZ Ges e¨e¯vcbv cwiPvjK, †Rbv‡ij dvgwmDwUK¨vjm, wjt|
8| Rbve Ave`yj gy³wi`i, gnv-mwPe, evsjv‡`k Jla wkí mwgwZ Ges e¨e¯vcbv cwiPvjK, Bb‡mcUv dvgwmDwUK¨vjm wjt|
9| Aa¨vcK Avmjvg †nv‡mb, cwZwbwa, evsjv‡`k dvgwmDwUK¨vj †mvmvBwU|
10| Wvt †gvt bRiæj Bmjvg, cwZwbwa, evsjv‡`k †nwglc¨vw_K †evW|
11| nwmKg †gvt †di‡`Šm Iqwn`, cwZwbwa, evsjv‡`k BDbvbx I Avqtjve`K †evW|
12| ‡gRi †Rbv‡ij †gvt Rvnvsmxi †nv‡mb gwjK, gnvcwiPvjK, Jla ckvmb Awa`ßi, XvKv|

mfvq Av‡jvP¨ welq mgm¨t

1| weMZ 30-10-2013 Zwi‡L AbyôZ Jla wbqšY KwgwUi 242 Zg mfvi Kvhweeiyx wbwðZKiY cm‡½|
2| Jla wbqšY KwgwUi †UKwbK¨vj mve KwgwUi MZ 07-05-2014 Zwi‡L AbyôZ 60 Zg Ges 18-06-2014 Zwi‡L AbyôZ 61 Zg mfvi mycwikmg¨ni welq Av‡jvPbv I wm×vš MnY cm‡½|
3| Jla wbqšY KwgwUi 242 Zg mfvi wm×v‡ši cwi‡cwÿ‡Z nvevj G¨vWfvBRvix KwgwU KZK. mycwikKZK Jla ckvmb KZK.‡iwR‡÷kbKZ.nvevj Jlamgm¨Abyôvb welq Av‡jvPbv I wm×vš MnY cm‡½|
4| সভাপতি মহোদয়ের অনুমতিক্রমে যে কোন বিষয়।

mfvq Dcwi³ welqmgm¨we¯wiZ Av‡jvPbvceK wbgewYZ wm×vš MnY Kiv nj t

1| weMZ 30-10-2013 Zwi‡L AbyôZ Jla wbqšY KwgwUi 242 Zg mfvi Kvhweeiyx wbwðZKiY cm‡½|

weMZ 30-10-2013 Zwi‡L AbyôZ Jla wbqšY KwgwUi 242 Zg mfvi Kvhweeiyx mfvq Dc¯vcb Kiv nq| Kvhweeiyx mwVKfv‡e wjwce× n‡q‡Q e‡j m`m¨MY gZ ckvk K‡ib|

সভায় সর্বসম্মতিক্রমে 242 Zg mfvi Kvhweeiyx wbwðZ Kiv nq|

2| mfvq wbgewYZ bZzb JIa Ges cPwjZ JI‡ai by¨Zb gvÎvi JI‡ai †iwR‡÷kb m¤ú‡K we¯wiZ Av‡jvPbv K‡i wb‡gv³ gZvgZ c`vb Kiv nq t

2.1 Proposed Product for Locally manufacture (Human)

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
01.	**Linde Bangladesh Ltd., Dhaka**	a) Medical Air Medical Air EP 20.4% V/V Oxygen ± 0.5% + Balance with Nitrogen	Medical Air is used: ● As a replacement for atmospheric air when the atmosphere is contaminated by noxious fumes, vapours or gases. ● In anaesthesia as a carrier gas for volatile anaesthetic agents. ● As a power source for pneumatic equipment. ● in ventilators and incubators to provide uncontaminated and controlled air flows.	**Contraindications:** Medical Air is contraindicated where Oxygen or other gaseous combinations would be indicated (airways obstruction, pneumonia, and a myriad of cardio-respiratory conditions). **Side effects:** None applicable	New	MHRA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) Medical Carbon Dioxide (Liquified Gas) Carbon Dioxide EP 99.5 % V/V min. (Other component /Impurities: Carbon Monoxide - 5 ppm V/V maximum, Total Sulphur - 1 ppm V/V maximum, Nitrogen Monoxide and Nitrogen Dioxide - 2 ppm V/V maximum, Water - 67 ppm V/V maximum. Ref.: EP 2008)	Carbon dioxide is used; ● to increase depth of anaesthesia rapidly when volatile agents are being administered. It increases depth of respiration and helps to overcome breathholding and bronchial spasm ● to facilitate blind intubation in anaesthetic practice ● to facilitate vasodilation and thus lessen the degree of metabolic acidosis during the induction of hypothermia ● to increase cerebral blood flow in arteriosclerotic patients undergoing surgery ● to stimulate respiration after a period of apnoea ● in chronic respiratory obstruction after it has been relieved ● to prevent hypocapnia during hyperventilation ● for clinical and physiological investigations ● in gynaecological investigation for insufflation into fallopian Tubes and abdominal cavities. ● as solid Carbon Dioxide (dry ice) in tissue freezing techniques and for the destruction of warts by freezing.	**Contraindication:** Carbon Dioxide is contra-indicated: ● in acidosis ● in respiratory obstruction, the administration of Carbon Dioxide may be dangerous since any further increase in respiratory effort increases negative intra-thoracic pressure ● during resuscitation, where it can be dangerous and should be avoided **Side effects:** Carbon Dioxide may produce unconsciousness in concentrations over 10%. Cardiac dysrhythmias have been reported in patients undergoing laparoscopy as a result of high blood Carbon Dioxide levels. Cardiac arrest due to gas embolism has been reported.	New	MHRA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
02.	Beximco Pharmaceuticals Limited Tongi ,Gazipur	a) Canagliflozin 100 mg Tablet Canagliflozin INN 100 mg **Antidiabetic**	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . **Limitation of Use:** • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis	**Contraindications:** • History of a serious hypersensitivity reaction to canagliflozin • Patients having end stage renal disease or patients on dialysis **Side effects:** Most common adverse reactions associated with Canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract Infection and increased urination.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
	b) Canagliflozin 300 mg Tablet Canagliflozin INN 300 mg **Antidiabetic**	Do	Do	New	USFDA	D”Pgvîv nIqvi Kvi‡Y Av‡e`b bvgÄyK iv †h‡Z cv‡i	D”Pgvîv nIqvi Kvi‡Y Av‡e`b bvgÄyK iv nj	
	c) Fluticasone Furoate 0.10mg + Vilanterol 0.025mg DPI Capsule Fluticasone Furoate INN 0.10mg + Vilanterol Trifenatate INN 0.040 mg eq. to Vilanterol 0.025mg **Corticosteroid + long-acting beta 2-adrenergic agonist**	It is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. It is not indicated for the reliefof acute bronchospasm or for the treatment of asthma.	**Contraindication :** It is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either fluticasone furoate, vilanterol, or any of the excipients **Side Effects:** Runny nose and sore throat , upper respiratory tract infection , headache , thrush in the mouth and/or throat.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	d) Atorvastatin 10 mg + Ezetimibe 10 mg Tablet Atorvastatin Calcium USP 10.820 mg eqv. to Atorvastatin 10 mg + Ezetimibe INN 10 mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: ➢ Reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. (1.1) ➢ Reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. **Limitations of Use:** No incremental benefit of this product on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. It has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.	**Contraindications:** ➢ Active liver disease or unexplained persistent elevations of hepatic transaminase levels. ➢ Hypersensitivity to any component of this product. ➢ Women who are pregnant or may become pregnant. ➢ Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Atorvastatin 10mg Tablet, Ezetimibe 10 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	e) Atorvastatin 20 mg + Ezetimibe 10 mg Tablet Atorvastatin Calcium USP 21.640 mg eqv. to Atorvastatin 20 mg +Ezetimibe INN 10 mg **Antihyperlipidemic**	Do	Do	Atorvastatin 10mg Tablet, Ezetimibe 10 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv nj |
		f) Rupatadine 0.100gm/100ml Oral Solution Rupatadine Fumerate INN 0.128 gm eq. to Rupatadine 0.100gm/100ml **Antihistaminic agent**	Rupatadine oral solution relieves the symptoms of allergic rhinitis such as sneezing, runny nose, nasal congestion, itching in the eyes and nose in children aged 6 to 11 years.	**Contraindications:** It should not be administered in patients who show hypersensitivity to Rupatadine or any of the excipients. **Side effects:** Like all medicines, Rupatadine can cause side effects, although not everybody gets them. Common side effects (affects 1 to 10 users in 100) are sleepiness, headache and upper respiratory tract infection. Uncommon side effects (affects 1 to 10 users in 1000) are dizziness, influenza and eczema. In addition to the side effects listed above, the following side effects have been reported with the administration of rupatadine 10 mg tablets in adults and adolescents (over 12 years of age):. - Common side effects (affects 1 to 10 users in 100) are dizziness, dry mouth, sensation of weakness and fatigue. - Uncommon side effects (affects 1 to 10 users in 1000) are increased appetite, irritability, difficulty concentrating, nosebleed, nasal dryness, sore throat, cough, dry throat, runny nose, feeling sick, stomach pains, diarrhoea, indigestion, vomiting, constipation, rash, back pain, joint pain, muscle pain, thirst, general discomfort, fever, changes to blood tests that show how your liver is working and increased weight. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.	10 mg Tablet	UK MHRA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kvgv‡Ui 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	g) Azilsartan Medoxomil 40mg + Chlorthalidone 12.5mg Tablet Azilsartan Medoxomil Potassium INN 42.68 mg eqv. to Azilsartan Medoxomil 40 mg + Chlorthalidone USP 12.5 mg **Antihypertensive + Diuretic**	Indicated for the treatment of hypertension, to lower blood pressure: • In patients not adequately controlled with monotherapy • As initial therapy in patients likely to need multiple drugs to help achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.	**Contraindications:** It is contraindicated in patients with anuria. **Side Effects:** The most common side effects of the drug are dizziness and fatigue.	Chlorthalidone 25mg & 50mg Tablet	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		h) Azilsartan Medoxomil 40mg + Chlorthalidone 25mg Tablet Azilsartan Medoxomil Potassium INN 42.68mg eq. to Azilsartan Medoxomil 40mg + Chlorthalidone USP 25mg **Antihypertensive + Diuretic**	Do	Do	Chlorthalidone 25mg & 50mg Tablet	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		i) Buprenorphine 2mg + Naloxone 0.5mg Oral film; Sublingual Buprenorphine HCl BP 2.16 mg eq. to Buprenorphine 2mg + Naloxone HCl BP 0.61mg eq. to Naloxone 0.5mg **Narcotic antagonist (Opioid)**	It is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.	**Contraindications:** Hypersensitivity to buprenorphine or naloxone. **Side Effects:** Adverse events commonly observed with the sublingual administration of this sublingual film was oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.	Buprenorphine 200mcg Tablet, 300mcg/ml & 500mcg Injection Naloxone HCl 400mcg/ml Injection	USFDA	ïaygvÎ nvmcvZvj I wKwb‡K we‡klÁ KZ„K gv`Kvm³ †ivMxi wPwKrmvi Rb¨ Abyjgv`b Kiv †h‡Z cv‡i |	ïaygvÎ nvmcvZvj I wKwb‡K we‡klÁ KZ„K gv`Kvm³ †ivMxi wPwKrmvi Rb¨ Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	j) Buprenorphine 4 mg + Naloxone 1mg Oral film; Sublingual Buprenorphine HCl BP 4.32 mg eq. to Buprenorphine 4 mg + Naloxone HCl BP 1.22mg eq. o Naloxone 1mg **Narcotic antagonist (Opioid)**	It is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.	**Contraindications:** Hypersensitivity to buprenorphine or naloxone. **Side Effects:** Adverse events commonly observed with the sublingual administration of this sublingual film was oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.	Buprenorphine 200mcg Tablet, 300mcg/ml & 500mcg Injection Naloxone HCl 400mcg/ml Injection	USFDA	ïaygvÎ nvmcvZvj I wKwb‡K we‡klÁ KZ¸K gv`Kvm³ †ivMxi wPwKrmvi Rb¨ Abyjgv`b Kiv †h‡Z cv‡i	ïaygvÎ nvmcvZvj I wKwb‡K we‡klÁ KZ¸K gv`Kvm³ †ivMxi wPwKrmvi Rb¨ Abyjgv`b Kiv nj	
		k) Buprenorphine 8mg + Naloxone 2mg Oral film; Sublingual Buprenorphine HCl BP 8.64 mg eq. to Buprenorphine 8mg + Naloxone HCl BP 2.44mg eq. to Naloxone 2mg **Narcotic antagonist (Opioid)**	Do	Do	Buprenorphine 200mcg Tablet, 300mcg/ml & 500mcg Injection Naloxone HCl 400mcg/ml Injection	USFDA	D"PgvÎvi Kw¤‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	D"PgvÎvi Kw¤‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj	
		l) Buprenorphine 12 mg + Naloxone 3mg Oral film; Sublingual Buprenorphine HCl BP 12.96mg eq. to Buprenorphine 12 mg + Naloxone HCl BP 3.66 mg eq. to Naloxone 3mg **Narcotic antagonist (Opioid)**	Do	Do	Buprenorphine 200mcg Tablet, 300mcg/ml & 500mcg Injection Naloxone HCl 400mcg/ml Injection	USFDA	D"PgvÎvi Kw¤‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	D"PgvÎvi Kw¤‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	m) Chlordiazepoxide 5mg + Amitriptyline 12.5 mg Tablet Chlordiazepoxide USP 5 mg + Amitriptyline Hydrochloride USP 14.125mg eq. to Amitriptyline 12.5 mg **Anxiolytic + Antidepressant**	It is ndicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to the product occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia.	**Contraindications:** Contraindicated in patients with hypersensitivity to either benzodiazepines or tricyclic antidepressants. It should not be given concomitantly with a monoamine oxidase inhibitor. **Side effects:** Most frequently reported were drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating.	Amitriptyline 10mg & 25mg Tablet	USFDA	Ab¨gv`b Kiv †h‡Z cv‡i |	Ab¨gv`b Kiv nj |
		n) Chlordiazepoxide 10mg + Amitriptyline 25mg Tablet Chlordiazepoxide USP 10mg + Amitriptyline Hydrochloride USP 28.250 mg eq. to Amitriptyline 25mg **Anxiolytic + Antidepressant**	-do-	-do-	Amitriptyline 10mg & 25mg Tablet	Do	D"PgvÎvi Kw¤‡bkb c‡qvRb †bB wea‡q Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	D"PgvÎvi Kw¤‡bkb c‡qvRb †bB wea‡q Av‡e`b bvgÄy Kiv nj |
		o) Olmesartan Medoxomil 40mg + Amlodipine 5mg + Hydrochlorothiazide 12.5mg Tablet Olmesartan Medoxomil BP 40 mg + Amlodipine Besylate 6.940 mg eqv. to Amlodipine 5 mg + Hydrochlorothiazide BP 12.5 mg **Antihypertensive. (Calcium Channel Blocker + Angiotensin-II receptor Antagonists + Diuretics)**	Indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. The combination is not indicated for initial therapy.	**Contraindications:** • Anuria: Hypersensitivity to sulfonamide-derived drugs. • Do not co-administer aliskiren with this combination in patients with diabetes . **Side Effects:** Bloating or swelling of the face, arms, hands, lower legs, or feet rapid weight gain tingling of the hands or feet unusual weight gain or loss	Olmesartanl 40mg + Amlodipine 5mg Tablet & Hydrochlorothiazide 12.5mg + Olmesartan Medoxomil 40	USFDA	c‡qvRb †bB wea‡q Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	c‡qvRb †bB wea‡q Av‡e`b bvgÄy Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	p) Paracetamol 5.00gm/100ml Suspension (250mg/ml) Paracetamol BP 5.00gm/ 100ml **Analgesic & Antipyretic**	To relieve mild to moderate pain and reduce fever in many conditions including headache, toothache, feverishness, colds and influenza.	**Contraindications:** ● Caution in patients with severely impaired liver or kidney function. ● Do not give to children under 6 years of age. **Side Effects:** Rash, itchy skin, swelling of the lips, eyes, tongue, or difficulty in breathing, which may be signs of an allergic reaction.	120mg/5ml Suspension	BNF	D"Pgv‡Îv c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	D"Pgv‡Îvi Kw¤‡bkb c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	
		q) Paracetamol 1000mg Tablet Paracetamol BP 1000 mg **Analgesic & Antipyretic**	For the management of mild to moderate pain including osteoarthritis and for pyrexia.	**Contraindications:** Hypersensitivity to paracetamol or any other constituents. **Side Effects:** Adverse effect of paracetamol is rare but hypersensitivity to skin rash may occur. There have been rare reports of blood dyscrasias including thrombocytopenia and agranulocytopenia and agranulocytosis, but these were not necessarily causally related to paracetamol.	500mg,120mg Tablet	BNF, UK MHRA	D"Pgv‡Îv c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	D"Pgv‡Îvi Kw¤‡bkb c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	
		r) Paracetamol 160mg Orally Disintegreting Tablet Paracetamol BP 160 mg **Analgesic & Antipyretic**	It is used for temporarily relieves minor aches and pains due to the common cold, flu, headache, temporarily reduces fever	**-do-**	120mg Dispersible Tablet, 500mg Tablet	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kwgwdi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	s) Brimonidine 3.30mg/100gm Gel Brimonidine Tartarate INN 5 mg eq. to Brimonidine 3.30 mg/100 gm **Alpha adrenergic agonist**	It is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.	**Contraindication:** None **Side Effects:** In controlled clinical trials with Brimonidine topical gel the most common adverse reactions (incidence ≥1%) included erythema, flushing, skin burning sensation, and contact dermatitis.	Brimonidine Tartrate 0.2% Eye Drops	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		t) Methyl Salicylate 10% + L- menthol 3% Topical Patch Methyl Salicylate USP 10 gm + L- Menthol USP 3 gm/100 gm **Topical Analgesic**	Temporarily relieves mild to moderate aches and pains of muscles and joints associate with ● strains ●sprains ●simple backache ● arthritis ● bruises	**Contraindications:** Do not use: - On the face or rashes. -On wounds or damaged skin. -If allergic to aspirin or other NSAIDs. -With a heating pad. -When sweating (such as from exercise or heat). -Any patch from a pouch that has been open for 14 or more days. -Right before or after heart surgery **Side Effects:** Stinging of Skin, Skin Irritation, Burning sensation	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		u) Brinzolamide 10mg + Brimonidine Tartrate 2mg/ml Eye Drops Brinzolamide USP 10 mg + Brimonidine Tartrate INN 2 mg/ ml **Antiglaucoma**	It is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.	**Contraindications:** Hypersensitivity to any component of this product. Neonates and infants (under the age of 2 years). **Side Effects:** Most common adverse reactions occurring in approximately 3 to 5% of patients included blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, eye allergy.	Brimonidine Tartrate 0.2% Eye Drops	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	v) Montelukast 5mg Oral Thin Film Montelukast Sodium BP 5.20mg eq. to Montelukast 5mg **Leukotriene receptor antagonist**	It is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. It is indicated for the relief of symptoms of seasonal allergic rhinitis pediatric patients 2 years of age and older.	**Contraindications:** Hypersensitivity to any component of this product. **Side effects:** Most common adverse reactions (incidence ≥5% and greater than placebo listed in descending order of frequency, upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhea, otitis media, influenza, rhinorrhea, sinusitis, otitis.	5mg tablet		‡idv‡iÝ †bB wea\q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	‡idv‡iÝ †bB wea\q Av‡e`b bvgÄÿ Kiv nj	
		w) Montelukast 4 mg Oral Thin Film Montelukast Sodium BP 4.16 mg eq. to Montelukast 4 mg **Leukotriene receptor antagonist**	Do	Do	4mg tablet		‡idv‡iÝ †bB wea\q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	‡idv‡iÝ †bB wea\q Av‡e`b bvgÄÿ Kiv nj	
		x) Levocetirizine HCl 5 mg Oral Thin Film Levocetirizine HCl INN 5 mg **Antihistamine**	Treatment of symptoms associated with allergic conditions such as seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria	**Contraindications:** It is contraindicated in patients who are hypersensitive to any of the ingredients of this medication. **Side effects:** Generally Levocetirizine is well tolerated. However, a few side effects like headache, dry mouth, fatigue and skin rash have been reported rarely.	5mg tablet		‡idv‡iÝ †bB wea\q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	‡idv‡iÝ †bB wea\q Av‡e`b bvgÄÿ Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	z) Paracetamol 500 mg + Metoclopramide HCl 5 mg Tablet Paracetamol BP 500 mg + Metoclopramide HCl BP 5mg **Analgesic & Antipyretic + Antiemitic**	It is used to treat the signs of migraine, such as headache, feeling sick (nausea) or being sick (vomiting) in adults 18 years and over.	**Contraindications:** Do not take this medicine and tell your doctor if: - You are allergic to the active substances or any of the other ingredients Signs of an allergic reaction include: rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue - You have a blockage or bleeding in your stomach or intestine (gut) - You have had movements that you cannot control, mainly of the tongue, mouth, jaw, arms and legs after taking metoclopramide or medicines used to calm emotional and mental problems - You have epilepsy - You have had an operation on your stomach or intestine (gut). Do not take during the first 3 to 4 days after your operation - You have a tumour on the adrenal gland (called phaeochromocytoma) -You are taking a medicine called levodopa used to treat Parkinson's disease **Children:** It must not be given to patients under 18 years of age. **Side Effects:** Like all medicines, this medicine can cause side effects, although not everybody gets them. **Stop taking this tablet and see a doctor or go to a hospital straight away if:** • You have an allergic reaction. Severe allergic reactions can occur very rarely and usually happen soon after taking this tablet. These can involve diffiulty breathing, tightness in the throat, rapidly spreading rashes, dizziness, very fast heart beat or even loss of consciousness • You are short of breath, have bluish skin colouration, headache, tiredness, dizziness and loss of consciousness. These could be signs of a very rare but serious side effect called methaemoglobinaemia • You are paler than normal, are sweating, have a high temperature, fast heartbeat, stiff muscles, fast breathing and feel confused, drowsy or agitated. These could be signs of a serious side effectect called neuroleptic malignant syndrome	Paracetamol 120mg Dispersible Tablet, 500mg Tablet, 120mg/5ml syrup and suspension; Metoclopramide 10mg Tablet, 5mg/5ml Syrup, 1mg/1ml Drop, 10mg/2ml	MHRA	cPż cwigv‡b cwZwb‡`kbv I পার্শ্বপ্রতিক্রিয়ার কারনে Av‡e`b bvgÄyK iv †h‡Z cv‡i	cPż cwigv‡b cwZwb‡`kbv I পার্শ্বপ্রতিক্রিয়ার কv‡i‡b Av‡e`b bvgÄyK iv nj	

				• Shortness of breath, slow heart beat and chest pain • You have a fit (seizure) **Tell a doctor straight away if you notice any of the following serious side effects:** • Yellowing of your skin or eyes and your urine becomes darker in colour. This could be a liver problem, such as jaundice or hepatitis. • A severe blistering rash in which layers of the skin may peel off to leave large areas of raw exposed skin over the body or you develop skin blisters. You may also feel generally unwell, have a fever, chills and aching muscles. Severe stomach pain, which may reach through to your back. This could be a sign of inflammation of the pancreas (pancreatitis). This is a very rare side effect. • Problems controlling certain muscles of the body or you have muscle spasms or 'jerks'. The affected muscles may include your tongue, mouth, jaw, arms and legs. The spasms may cause unusual movements of the face, tongue, eyes, neck and affect speech, expression and/or lead to unnatural positioning of the head and shoulders • Decreased level of consciousness, confusion, hallucination • Rigid or stiff muscles, trembling or shaking or difficulty moving • You bruise more easily than usual. This could be because of a blood disorder (thrombocytopenia) • You get infections more often and easier than normal. This could be because you have a low number of white blood cells (agranulocytosis) • Depression **Tell your doctor as soon as possible if you have any of the following side effects:** • Diarrhoea • Dizziness, lightheadedness and fainting. This could be because of low blood pressure **Tell your doctor or pharmacist if any of the following side effects get serious or lasts longer than a few days:** • Abnormal production of breast milk in men and women • Breast enlargement in men • Loss of menstrual periods • Feeling nervous (anxious), restless or confused • Feeling drowsy • Lack or loss of strength (weakness) • Skin rash				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	aa) Rabeprazole Sodium 20mg + Domperidone 30mg Tablet Rabeprazole Sodium INN 20 mg + Domperidone BP 30 mg **Antiulcerant (PPI) + Antiemetic**	Treatment of gastroesophageal reflux disease (GERD) not responding to Rabeprazole alone	**Contraindications:** It is contraindicated in patients with known hypersensitivity to rabeprazole, domperidone or substituted benzimidazoles or to any excipient used in the formulation. Rabeprazole sodium/ Domperidone is contraindicated in patients with hepatic and/or renal impairment, prolactin-releasing pituitary tumour (prolactinoma). It is contraindicated in pregnancy and during breast feeding	Rabeprazole 10mg & 20mg Tablet & Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension		‡idv‡iÝ †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	‡idv‡iÝ †bB wea|q Av‡e`b bvgÄyK iv nj |
		ab) Vitamin A 2500 IU + Vitamin C 60 mg + Vitamin D 800IU + Vitamin E 33 IU + Thiamine Mononitrate 3mg + Riboflavin 3.4mg + Niacin 20mg+ Pyridoxine HCl 8mg + Folic Acid 0.400 mg+ Vitamin B_{12} 12mcg + Biotin 0.300mg+ Pantothenic Acid 15mg + Calcium 300mg + Iodine 150 mcg + Magnesium 50mg + Zinc 15mg + Selenium 20mcg+ Copper 1 mg + Manganese 2mg + Chromium 120mcg + Molybdenum 37.5 mcg + Soybean Isoflavones 60 mg Tablet Dry Vitamin A Acetate (Type 500-60) USP 5.00 mg eq. to Vitamin A 2500 IU + Ascorbic Acid (97% DC) USP 61.8555mg eq. to Vitamin C 60 mg + Dry Vitamin D3, Colicalciferol 100000 IU/g USP 8.00 mg eqv. to Vitamin D 800 IU+Dry Vitamin E Acetate(50%) USP 66.00 mg eqv. to Vitamin E 33IU + Thiamine Mononitrate USP 3mg + Riboflavin USP 3.4mg + Niacin USP 20 mg + Pyridoxine HCl USP 8mg + Folic Acid USP	A complete multivitamin-mineral mix to meet the complications and needs of the menopause women.	**Contraindications:** Pregnant, nursing mother or having a history of cancer **Side Effects:** Allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). Some vitamin may cause constipation in particular cases.	New		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

		0.400mg + Cyanocobalamin(0.1%) 12 mg eq. to Vitamin B_{12} 12 mcg+ Biotin USP 0.300 mg+ Calcium Pantothenate USP 16.305 mg eq. to Pantothenic Acid 15 mg + Calcium Carbonate BP 749.2163mg eqv. to Calcium 300 mg + Potassium Iodide USP 0.1962 mg eqv. to Iodin 150 mcg + Magnesium Oxide USP 82.9050 mg eqv. to Magnesium 50 mg+Zinc Oxide USP 18.6720 mg eqv. to Zinc 15 mg+ Sodium Selenate Anhydrous0.0478 mg Ph. grade eq. to Selenium 20 mcg+ Cupric Oxide Ph.grade 1.2518 mg eq. to Copper 1 mg +Manganese Sulfate USP 6.1522 mg eqv. to Manganese 2 mg+ Chromic Chloride USP 0.6149 mg eq. to Chromium 120 mcg + Sodium Molybdate Dihydrate USP 0.0946 mg eq. to Molybdenum 37.5 mcg + Soybean Isoflavones Ph. Grade 60 mg **Vitamins & Minerals**						

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	ac) Vitamin A 1750 IU (29% as Beta-Carotene)+ Vitamin C 30 mg+ Vitamin D 200 IU+ Vitamin E 15 IU+Vitamin K 12.5 mcg+Thiamine Mononitrate 0.75 mg+ Riboflavin 0.85 mg+ Niacin 10 mg+ Vitamin B6 2.5 mg + Folic Acid 200 mcg+ Vitamin B12 100 mcg+ Biotin 15 mcg+ Pantothenic Acid 5 mg+ Calcium 54 mg + Iron 3 mg+ Phosphorus 40 mg+ Iodine 75 mcg+ Magnesium 20 mg+ Zinc 3.75 mg+ Selenium 10 mcg + Copper 0.35 mg+ Manganese 1 mg+ Chromium 60 mcg+ Molybdenum 37.5 mcg+ Chloride 29 mg+ Potassium 32 mg+ Boron 16 mcg+ Nickel 2.5 mcg+ Tin 5 mcg + Vanadium 5mcg + Phytosterols 400mg Tablet Beta Carotene (20%) USP 1.5195 mg eqv. to Vitamin A 507.50 IU and Dry Vitamin A Acetate(Type 500-60) USP 2.4850mg eqv. to Vitamin A 1242.50IU+ Ascorbic Acid (97% DC) USP 30.9278mg eq. to Vitamin C 30mg+ Dry Vitamin D_3,Colicalciferol 100000 IU/g USP 2mg eq. to Vitamin D 200 IU+ Dry Vitamin E Acetate(50%) USP 30mg eq. to Vitamin E 15 IU+Dry Vitamin K_1 5% USP 0.250 mg eqv. to Vitamin K 125mcg+ Thiamine Mononitrate USP 0.750 mg+ Riboflavin USP 0.850 mg+ Pyridoxine HCl USP 2.500 mg+ Niacin(Granular) USP 10 mg+ Folic Acid USP 0.200mg+ Cyanocobalamin (0.1%) 100mg eqv. to Vitamin B_{12} 100 mcg+ Biotin USP	Indicated for the supports healthy heart and circulation. Prevents heart diseases	**Contraindications:** Not formulated for use in children. Dietary supplementation with phytosterols is not suitable for pregnant or lactating women. **Side Effects:** Long-term intake of high levels of vitamin A may increase the risk of osteoporosis in adults. Long-term intake of high levels of vitamin A (excluding that sourced from beta-carotene) may increase the risk of osteoporosis in adults.	New		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

		0.0150 mg+Calcium Pantothenate USP 5.4346 mg eqv. to Pantothenic Acid 5 mg+ Calcium Carbonate BP 4.678mg eqv. to Calcium 2.2478 mg+ Dibasic Calcium Phosphate Anhydrous USP 175.6679 mg eqv. Calcium 51.7522 mg & Phosphorous 40 mg +Dried Ferrous Sulphate BP 9.4890 mg eqv. to Iron 3mg+Potassium Iodide USP 0.0981 mg eqv. to Iodin 75 mcg+ Magnesium Oxide USP 33.1620 mg eqv. to Magnesium 20 mg+ Zinc Oxide USP 4.6688 mg eqv. to Zinc 3.75 mg+ Sodium Selenate Anhydrous 0.0239 mg Ph. Grade eqv. to Selenium 10mcg+ Cupric Oxide Ph.grade 0.43813 mg eqv. to Copper 0.35mg+ Manganese Sulfate USP 3.0761 mg eqv. to Manganese 1.00 mg+ Chromic Chloride USP 0.3074 mg eqv. to Chromium 60 mcg+ Sodium Molybdate Dihydrate BP 0.0630 mg eqv. to Molybdenum 37.5 mcg+ Potassium Chloride USP 61.0080mg (eqv. to Potassium 32.00 mg &Chloride 29.00 mg)+ Boron Citrate(as Boron Citrate Blend 5%) Ph.grade 0.320 mg eqv. to Boron 16mcg+ Nickel Sulphate Hexahydrate Ph.grade 0.0112 mg eqv. to Nickel 25mcg+ Stannous Chloride Dihydrate BP 0.0095 mg eqv. to Tin 5mcg+ Sodium Metavenadate Tetrahydrate Ph.grade 0.0191mg eqv. to Vanadium 5mcg+ Phytosterols Ph.grade 400 mg **Vitamins & Minerals**						

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	ad) Vitamin A 3500 IU , Vitamin C 60 mg, Vitamin D 400 IU, Vitamin E 22.5 IU, Vitamin K 25 mcg, Thiamin Mononitrate (B1) 3 mg, Riboflavin (B2) 3.4 mg, Pyridoxine HCl(B6) 4 mg, Niacin 40 mg, Folic Acid 400 mcg, Vitamin B_{12} 12 mcg, Biotin 300 mcg, Pantothenic Acid USP 10 mg, Calcium (elemental) 250 mg, Iron BP 9 mg, Iodine 150 mcg, Magnesium 40 mg, Zinc 15 mg, Selenium 45 mcg, Copper 2 mg, Manganese 2 mg, Chromium 100 mcg, Molybdenum 25 mcg, Potassium 99 mg, Nickel 5 mcg, Tin 10 mcg,Silicon 5 mg, Caffeine Anhydrous 90 mg Tablet Beta Carotene (20%) USP 4.1916mg eq. to Vitamin A 1400IU and Dry Vitamin A Acetate (Type 500-60) USP 4.200mg eq. to Vitamin A 2100IU + Ascorbic Acid (97% DC) USP 61.8556mg eqv. to Vitamin C 60 mg + Dry Vitamin D3, Colicalciferol 100000 IU/g USP 4mg eqv. to Vitamin D 400 IU+ Dry Vitamin E Acetate(50%) USP 45mg eqv. to Vitamin E 22.5 IU+ Dry Vitamin K_1 5% USP 0.500 mg eqv. to Vitamin K 25.00mcg +Thiamine Mononitrate USP 3.00mg + Riboflavin USP 3.400 mg + Pyridoxine HCl USP 4.00mg + Niacin USP 40.00 mg + Folic Acid USP 0.400mg + Cyanocobalamin (0.1%) 12.00mg eq. to Vitamin B_{12} 12.00 mcg+ Biotin USP 0.300 mg+ Calcium Pantothenate USP 10.8692 mg eq. to Pantothenic	Indicated for Physical Energy, Mental Alertness, and Malnutrition and for healthy immunity.	**Contraindications:** Do not take this product if taking other vitamin A supplements. **Side effects:** Long-term intake of high levels of vitamin A may increase the risk of osteoporosis in adults. Long-term intake of high levels of vitamin A (excluding that sourced from beta-carotene) may increase the risk of osteoporosis in adults.	New		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

		Acid 10.00 mg + Calcium Carbonate BP 624.3469mg eq. to Calcium 250.00 mg + Dried Ferrous Sulphate BP 27.9765 mg eq. to Iron 9.00mg+ Potassium Iodide USP 0.1962mg eqv. to Iodine 150.00 mcg+ Magnesium Oxide USP 66.3240 mg eqv. to Magnesium 40.00 mg+,Zinc Oxide USP 18.6750 mg eqv. to Zinc 15.00 mg+ Sodium Selenate Anhydrous Ph. grade 0.1076 mg eqv. to Selenium 45.00mcg+Cupric Oxide Ph. grade 2.5036 mg eqv. to Copper 2.00mg+Manganese Sulfate USP 6.1522 mg eqv. to Manganese 2.00 mg+Chromic Chloride USP 0.5124mg eqv. to Chromium 100.00 mcg+Sodium Molybdate Dihydrate BP 0.0630 mg eqv. to Molybdenum 25.00 mcg+Potassium Chloride USP 188.7435mg eqv. to Potassium 99.00 mg +Nickel Sulphate Hexahydrate Ph.grade 0.0224 mg eq. to Nickel 5.00mcg+ Stannous Chloride Dihydrate BP 0.019 mg eqv. to Tin 10.00mcg+ Sodium Metasilicate Nonahydrate Ph.grade 0.050mg eq. to Silicon 5.00 mg+ Caffeine Anhydrous BP 90.00mg **Vitamins & Minerals**						

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	ae) Paracetamol 325 mg + Phenylephrine HCl 5 mg Tablet Paracetamol BP 325 mg + Phenylephrine HCl BP 5 mg **Analgesic & Antipyrectic + Decongestant**	For temporary relief of symptoms associated with hay fever or other respiratory allergies and common cold and flu, like- • sinus congestion and pressure • headache • nasal congestion • minor aches and pains	**Contraindications:** With any other drug containing Paracetamol. If patient is now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug.. If patients have ever had an allergic reaction to this product or any of its ingredients **Side Effects:** Hepatic dysfunction, Thrombocytopenia, anaphylaxis, bronchospam, nausea, headache, vomoting etc.	New		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	ag) Diphenhydramine HCl 12.5mg Oral Thin Film Diphenhydramine HCl BP 12.5mg **Antihistamine**	It is indicated for the treatment of followings: Seasonal, perennial, vasomotor rhinitis, Urticaria, angioneurotic oedema, anaphylaxis Pruiritic conditions, Premedication for emesis and motion sickness, Miscellaneous like Ménière's disease and parkinsonism,An aid to the relief of temporary sleep disturbance.	**Contraindication:** Patients with known hypersensitivity to Diphenhydramine or any components of the product. Care should be taken in administration during pregnancy. **Side Effects:** Side effect includes sedation, dizziness, tinnitus, fatigue, ataxia, blurred vision, diplopia, euphoria, and epigastric discomfort.	50 mg Tablet, 10mg/5ml Syrup		cÖgj¶vq‡bi wbwg‡Ë cieZx mfvq Dc¯vc‡bi Rb¨ ¯wMZ ivLv nj|	
		ah) Vitamin A 2566 IU + Vitamin B1 1.4mg + Vitamin B2 1.4mg + Nicotinamide 18mg + Vitamin B5 6mg + Vitamin B6 1.9mg + Biotin 30mcg + Vitamin B9 800mcg + Vitamin B12 2.6mcg + Vitamin C 85mg + Vitamin D3 200IU + Vitamin E 15mg + Calcium 125mg + Copper 1mg + Iodine 220mcg + Iron 45mg + Magnesium 100mg + Manganese 2mg + Selenium 50mcg + Zinc 11mg Tablet Dry Vitamin A Acetate, Type 500-60 USP 5.1320 mg (eq. to Vitamin A 2566 IU) + Thiamine Mononitrate USP 1.4000 mg (Vitamin B_1) + Riboflavin USP 1.4000 mg (Vitamin B_2) + Niacin (Granular) USP 18.0000 mg (Nicotinamide)+ Calcium Pantothenate USP 6.5215 mg (eq. to Pantothenic Acid 6 mg) (Vitamin B_5) + Pyridoxine Hydrochloride USP 1.9000 mg (Vitamin B_6)+ Biotin USP 0.0300mg + Folic Acid USP 0.8000 mg (Vitamin B_9) + Cyanocobalamin 0.1% USP	Formulated to meet the needs of women who are trying to conceive, pregnant or breastfeeding and provide baby with the best possible nutritional support. It provides – • Prevention of micronutrient deficiencies during pregnancy and lactation. • Prevention of iron and/or folate deficiency anemia during pregnancy and lactation. • Reduction of the risk of the first occurrence of neural tube defects (NTDs).	**Contraindications:** • Hypersensitivity to the active substances or to any of the excipients. • Existing hypervitaminosis A. • Concomitant treatment with vitamin A or with the synthetic isomers, isotretinoin and etretinate (beta-carotene is considered as a source of vitamin A supplementation). • Impaired renal function. • Existing hypervitaminosis D. • Iron and/or copper metabolism disorders. **Side effects:** Gastrointestinal disorders like Abdominal discomfort, constipation, flatulence, vomiting, diarrhea, nausea can occur.	New	MHRA	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i|	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj|

		2.6000 mg (eq. to Vitamin B12 2.6 mcg) + Ascorbic Acid (97% DC) USP 87.6288 mg (eq. to Viatamin C 85 mg) + Dry Vitamin D3, Colecalciferol 1,00,000 IU/g USP 2.0000 mg (eq. to Vitamin D 200 IU) + Dry Vitamin E Acetate 50% USP 30.00 mg (eq. to Vitamin E 15 mg) + Calcium Carbonate (Heavy) BP 312.1735 mg (eq. to Calcium 125.00mg) + Cupric Oxide Ph.Grade 1.2518 mg (eq. to Copper 1 mg) + Potassium Iodide USP 0.2878 mg (eq. to Iodine 220 mg) + Dried Ferrous Sulphate BP 139.8825 mg (eq. to Iron 45 mg) + Magnesium Oxide (Heavy) USP 165.8100 mg(eq. to Magnesium 100 mg)+ Manganese Sulfate USP 6.1522 mg(eq. to Manganese 2 mg) + Sodium Selenate Anhydrous Ph. Gr. 0.1196 mg (eq. to Selenium 50 mcg) + Zinc Oxide USP 13.6950mg (eq. to Zinc 11 mg) **Vitamins & Minerals**						

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	ai) Acetylcysteine 300 mg + Cefixime 200 mg Tablet Acetylcysteine USP 300 mg + Cefixime USP 224.00 eq. to 200 mg anhydrous Cefixime **Mucolytic + Antibiotic (Cephalosporin)**	Indicated for the treatment Typhoid, URTI, LRTI, secretory otitis media, COPD, acute exacerbations of chronic bronchitis	**Contraindications:** Patients with known hypersensitivity to cephalosporin antibiotics. None accept hypersensitivity against acetylcysteine. **Adverse reactions:** Cefixime may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away: Upset stomach Diarrhea Vomiting Mild skin rash Headache	New		‡idv‡iÝ †bB weavq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	‡idv‡iÝ †bB weavq Av‡e`b bvgÄÿ Kiv nj	
		aj) Metformin Hydrochloride 1000mg/ Sachet Metformin Hydrochloride BP 1000mg/Sachet **Hypoglycemic**	Treatment of type 2 diabetes mellitus, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. • In adults, Metformin may be used as monotherapy or in combination with other oral antidiabetic agents or with insulin. • In children from 10 years of age and adolescents, Metformin may be used as monotherapy or in combination with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure.	**Contraindications:** Hypersensitivity to metformin or to any of the excipients • Diabetic ketoacidosis, diabetic pre-coma. • Renal failure or renal dysfunction (creatinine clearance < 60 ml/min). • Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock. • Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock. • Hepatic insufficiency, acute alcohol intoxication, alcoholism. **Adverse effects:** During treatment initiation, the most common adverse reactions are nausea, vomiting, diarrhoea, abdominal pain and loss of appetite which resolve spontaneously in most cases. To prevent them, it is recommended to take metformin in 2 or 3 daily doses and to increase slowly the doses.The following adverse reactions may occur under treatment with metformin. Gastrointestinal disorders such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite. These undesirable effects occur most frequently during initiation of therapy and resolve spontaneously in most cases. To prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.	500mg,1000mg Tablet	BNF	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beximco Pharmaceuticals Limited Tongi ,Gazipur	ak) Metformin Hydrochloride 500mg/ Sachet Metformin Hydrochloride BP 500 mg/Sachet **Hypoglycemic**	Do	**Do**	500mg,1000mg tablet	BNF	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj	
		al) Salbutamol 2.5 mg/3 ml Respirator Solution Salbutamol Sulphate BP 3.00mg eq. to Salbutamol 2.5 mg/3 ml **Bronchodilator**	It is used to treat or prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases. nduced bronchospasm	Salbutamol sulphate respirator solution is contraindicated in patients with a history of hypersensitivity to any of its components	Salbutamol 1mg/ml, 5mg/ml & 2.5mg/2.5 ml Nebulizer Solution	USFDA	Abyjgv`b †h‡Z cv‡i	Abyjgv`b Kiv nj	
		am) Salbutamol 2.5 mg + Ipratropium Bromide 0.5mg/3 ml Respirator Solution Salbutamol Sulphate BP 3.00mg eq. to Salbutamol 2.5mg + Ipratropium Bromide BP 0.5 mg/3 ml **Bronchidilator**	It is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator.	Contraindicated in patients with a history of hypersensitivity to any of its components	Salbutamol 2.5mg + Ipratropium Bromide 500mcg/2.5 ml	USFDA	Abyjgv`b †h‡Z cv‡i	Abyjgv`b Kiv nj	
		an) Ipratropium Bromide 0.5mg/2.5 ml Respirator Solution Ipratropium Bromide BP 0.5 mg/2.5 ml Respirator Solution **Bronchidilator**	Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease,	It is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.	Ipratropium 250mcg/ml Solution	USFDA	Abyjgv`b †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
03.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	a) Lurasidone Hydrochloride 40mg Tablet Lurasidone Hydrochloride INN 40mg **Antipsychotic agent**	It is an atypical antipsychotic for the treatment of Schizophrenia and depressive episodes associated with Bipolar I Disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate.	**Contraindication:** Known hypersensitivity to lurasidone or any components in the formulation. Concurrent use of strong CYP3A4 inhibitors (eg, ketoconazole). Concurrent use with of strong CYP3A4 inducers (eg, rifampin). **Adverse effects:** Commonly observed adverse reactions (incidence ≥5% and at least twice the rate for placebo) schizophrenia: somnolence, akathisia, extrapyramidal symptoms and nausea. Bipolar depression: akathisia, extrapyramidal symptoms, and somnolence	New	USFDA	Abyjgv`b †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		b) Lurasidone Hydrochloride 80mg Tablet Lurasidone Hydrochloride INN 80mg **Antipsychotic agent**	Do	Do	New	USFDA	GB gvÎv c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GB gvÎv c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv nj |
		c) Lurasidone Hydrochloride 120mg Tablet Lurasidone Hydrochloride INN 120mg **Antipsychotic agent**	Do	Do	New	USFDA	GB gvÎv c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GB gvÎv c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv nj |
		d) Eslicarbazepine Acetate 800mg Tablet Eslicarbazepine Acetate INN 800mg **Anti-epileptic**	It is indicated as adjunctive treatment of partial-onset seizures.	**Contraindications: H**ypersensitivity to eslicarbazepine acetate or oxcarbazepine. **Side effects:** The most common adverse reactions in patients receiving this medicine (≥4% and ≥2% greater than placebo) were dizziness, somnolence, nausea, headache, diplopia, vomiting, fatigue, vertigo, ataxia, blurred vision, and tremor	400mg Tablet	USFDA	c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	e) Simethicone USP 80mg Chewable Tablet Simethicone 100 DC Pharma grade 133.333mg eq. to Simethicone USP 80mg **Anti-flatulent**	1. Flatulence, abdominal distention, fullness, gas and windy colic 2. Large bowel preparation 3. Treatment of poisoning	**Contraindications:** There are no reports of any side effects due to this medication. **Side effects:** Simethicone is physiologically inert and no adverse effect has been noted after oral ingestion.	40mg Tablet & 67mg/ml Paediatic Drops		†idv‡iÝ †bB weavq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	†idv‡iÝ †bB weavq Av‡e`b bvgÄÿ Kiv nj	
		f) Sodium Alginate 5gm + Sodium Bicarbonate 2.13gm + Calcium Carbonate (Light) 3.25gm/100ml Suspension Sodium Alginate USP 5gm + Sodium Bicarbonate USP 2.13gm + Calcium Carbonate (Light) BP 3.25gm/100ml **Anti-flatulent**	It is indicated for the treatment of gastro-oesophageal reflux, such as acid regurgitation, heartburn and indigestion, and for example following meals or during pregnancy, and for symptoms of excess stomach acid (hyperacidity).	**Contraindications:** Hypersensitivity to any of the ingredients, including the esters of hydroxybenzoates (parabens). **Side effects:** Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions. Ingestion of large quantities of calcium carbonate may cause alkalosis, hypercalcaemia, acid rebound, milk alkali syndrome or constipation. These usually occur following larger than recommended dosages		MHRA	c‡qvRb ‡bB weavq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv nj
		g) Sodium Alginate 5gm + Sodium Bicarbonate 2.67gm + Calcium Carbonate (Light) 1.6gm/100ml Suspension Sodium Alginate USP 5gm + Sodium Bicarbonate USP 2.67gm + Calcium Carbonate (Light) BP 1.6gm/100ml **Drug used dyspepsia & Gastroesophageal reflux**	Gastric reflux, heartburn, flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.	**Contraindication:** Hypersensitivity to any of the ingredients, including the esters of hydroxybenzoates (parabens). **Side effects:** Very rarely (<1/10,000) patients sensitive to the ingredients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions. Ingestion of large quantities of calcium carbonate may cause alkalosis, hypercalcaemia, acid rebound, milk alkali syndrome or constipation. These usually occur following larger than recommended dosages	New		c‡qvRb ‡bB weavq Av‡e`b bvgÄÿ Kiv ‡h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	h) Trimebutine Maleate 480mg/100ml Powder for Suspension Trimebutine Maleate INN 480mg/100ml **Lower GI tract motility regulator**	Functional digestive disorders accompanied by abdominal pain, spasm, fullness, flatulence, constipation or diarrhea, Irritable bowel syndrome.	**Contraindications:** Patients with known hypersensitivity to Trimebutine maleate. **Side Effects:** Dry mouth, foul taste, nausea, diarrhea, constipation, drowsiness, dizziness, fatigue or headache may occur. If any of these effects continue or become bothersome, inform your doctor	100mg Tablet		†id dv‡iÝ †bB wea vq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	†id dv‡iÝ †bB wea vq Av‡e`b bvgÄÿ Kiv nj	
		i) Nimodipine 300mg/100ml Oral Solution Nimodipine BP 300mg/100ml **Anti-hypertensive- Calcium channel blocker**	It is a dihydropyridine calcium channel blocker indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e. Hunt and Hess Grades I-V).	**Contraindication:** None **Adverse reactions/side effects:** Most common adverse reactions (incidence ≥1% and ≥1% placebo) were hypotension, headache, nausea, and bradycardia.	30mg Tablet	USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄÿ Kiv nj	
		j) Nebivolol 10mg Tablet Nebivolol HCl INN 10.90mg eq. to 10mg Nebivolol **Anti-hypertensive- Beta blocker**	It is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.	**Contraindications:** - Severe bradycardia - Heart block greater than first degree - Patients with cardiogenic shock - Decompensated cardiac failure - Sick sinus syndrome (unless a permanent pacemaker is in place) **Side effects:** Most adverse reactions are headache, fatigue	2.5mg & 5mg Tablet	USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄÿ Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	k) Fluoxetine HCl 400mg/100ml Syrup Fluoxetine HCl BP 447.14mg eq. to 400mg Fluoxetine /100ml **Selective serotonin reuptake inhibitors**	Prozac is indicated for the treatment of major depressive disorder.	**Contraindications:** It is contraindicated in patients known to be hypersensitive to it.. **MAO inhibitors** : There have been reports of serious, sometimes fatal, reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) in patients receiving fluoxetine in combination with a monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued fluoxetine and are then started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, it should not be used in combination with an MAOI, or within a minimum of 14 days of discontinuing therapy with an MAOI. Since fluoxetine and its major metabolite have very long elimination half-lives, at least 5 weeks [perhaps longer, especially if fluoxetine has been prescribed chronically and/or at higher doses should be allowed after stopping this medicine before starting an MAOI. **Pimozide:** Concomitant use in patients taking pimozide is contraindicated. **Thioridazine:** Thioridazine should not be administered with it or within a minimum of 5 weeks after this medicine has been discontinued. **Side Effects:** Most common adverse reactions are Headache, Nausea, Insomnia, Nervousness, Anxiety, Somnolence, Dizziness, Tremor, and Diarrhea.	20mg Tablet	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvlbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	l) Olanzapine 6mg + Fluoxetine 25mg Capsule Olanzapine BP 6mg + Fluoxetine HCl BP 27.95 mg eq. to 25mg Fluoxetine **Antipsychotic + Selective serotonin reuptake inhibitors**	It combine olanzapine, an atypical antipsychotic and fluoxetine, a selective serotonin reuptake inhibitor, indicated for acute treatment of depressive Episodes Associated with Bipolar I Disorder and treatment Resistant Depression	**Contraindication:** **MAOI:** Because of the risk of serotonin syndrome, do not use MAOIs intended to treat psychiatric disorders with Ii or within 5 weeks of stopping treatment with it. Do not use it within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start it in a patient who is being treated with linezolid or intravenous methylene blue. **Pimozide:** Do not use. Risk of QT interval prolongation **Thioridazine:** Do not use. Risk of QT interval prolongation. Do not use thioridazine within 5weeks of discontinuing it. **Adverse Reactions** Most common adverse reactions (≥5% and at least twice that for placebo) in adults: sedation, weight increased, appetite increased, dry mouth, fatigue, edema, tremor, disturbance in attention, blurred vision. Children and adolescents: sedation, weight increased, appetite increased, tremor, triglyceride increased, hepatic enzymes increased.	Olanzapine 5g& , 10mg Tablet Fluoxetine 20mg Capsule	USFDA	K¡¤‡bkb¡U c‡qvRb †bB ¡eavq Av‡e`b bvgÄý Ki v †h‡Z cv‡i	K¡¤‡bkb¡U c‡qvRb †bB ¡eavq Av‡e`b bvgÄý Ki v nj	
		m) Olanzapine 6mg + Fluoxetine 50mg Capsule Olanzapine BP 6mg + Fluoxetine Hydrochloride BP 55.90mg eq. to 50mg Fluoxetine **Antipsychotic+ Selective serotonin reuptake inhibitors**	Do	Do	Olanzapine 5g& , 10mg Tablet Fluoxetine 20mg Capsule	USFDA	K¡¤‡bkb¡U c‡qvRb †bB ¡eavq Av‡e`b bvgÄý Ki v †h‡Z cv‡i	K¡¤‡bkb¡U c‡qvRb †bB ¡eavq Av‡e`b bvgÄý Ki v nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	n) Olanzapine 12mg + Fluoxetine 50mg Capsule Olanzapine BP 12mg + Fluoxetine Hydrochloride BP 55.90mg eq. to 50mg Fluoxetine **Antipsychotic + Selective serotonin reuptake inhibitors**	Do	Do	Olanzapine 5mg , 10mg Tablet Fluoxetine 20mg Capsule	USFDA	Kw¤‡bkbwU c‡qvRb †bB wecvq Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	Kw¤‡bkbwU c‡qvRb †bB wecvq Av‡e`b bvgÄy Kiv nj |
		o) Paracetamol 5gm/100ml Suspension (250mg/5ml) Paracetamol BP 5gm/100ml **Antipyretic & analgesic**	For the treatment of mild to moderate pain and as an anti-pyretic. Used for the relief of pain and feverishness associated with teetihing, toothcare, headache, colds, and flu.	**Contraindication:** Hypersensitivity to paracetamol or any of the other constituents. **Side effect:** Adverse effects of paracetamol are rare but hypersensitivity including skin rash may occur. There have been reports of blood dyscrasias including thrombocytopenia and aggranulocytosis but these were not necessarily causally related to paracetamol. With prolonged use or overdose, hepatic necrosis, acute pancreatitis and nephrotoxicity have been reported.	120mg/5ml Syrup/Susp, 80mg/ml PD, 500mg Tab	MHRA	D”PgvÎv c‡qvRb †bB wecvq Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	D”PgvÎv c‡qvRb †bB wecvq Av‡e`b bvgÄy Kiv nj |
		p) Pizotifen 5mg/100ml Elixir (Oral Liquid) Pizotifen Malate BP 7.270mg eq. to 5mg Pizotifen/100ml **Antimigraine agent**	Prophylactic treatment of recurrent vascular headaches, including classical migraine, common migraine and cluster headaches (periodic migrainous neuralgia). The International Classification of Headache Disorders 2nd edition (ICHD-II) are standard classifications of headache used by health professionals and describe the above-mentioned disorders as follows: prophylactic treatment of recurrent migraine headache with or without aura and of cluster headache. It is not effective in relievingmigraine attacks once in progress.	**Contraindication:** Known hypersensitivity to pizotifen or any of the excipients. **Side effects:** The most common side-effects are appetite stimulating effect, increase in body weight and drowsiness (including somno lence and fatigue).	0.5mg Tablet & 1.5mg Tablet	BNFC	c‡qvRb †bB wecvq Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	c‡qvRb †bB wecvq Av‡e`b bvgÄy Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	q) Pizotifen 5mg/100ml Syrup Pizotifen Malate BP 7.270mg eq. to 5mg Pizotifen/100ml **Antimigraine agent**	Anorexia in underweight patients, mood elevation in the elderly, prophylactic (interval) treatment of migraine.	**Contraindication:** Known hypersensitivity to Pizotifen or any of the excipients. It should not be given in children under 2 years of age. **Side effects:** Symptoms of allergy such as a rash, itching or hives on the skin or swelling of the face, Increase in appetite and weight gain, drowsiness, tiredness, dizziness, dry mouth, nausea, constipation, depression, excitability or restlessness, hallucinations, sleep disturbances, insomnia, anxiety, tingling or numbness of the hands or feet, muscle or joint pain, seizures.	0.5mg Tablet & 1.5mg Tablet		c‡qvRb †bB wea|q Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄy Kiv nj |
		r) Ambroxol Hydrochloride 0.6gm/100ml Syrup Ambroxol Hydrochloride BP 0.6gm/100ml **Expectorant**	Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.	**Contraindications:** It should not be used in patients known to be hypersensitive to ambroxol or other components of the formulation. **Side effects:** It is generally well tolerated. Mild upper gastro-intestinal side effects (primarily pyrosis, dyspepsia, and occasionally nausea, vomiting) have been reported, principally following parenteral administration. Allergic reactions have occured rarely, primarily skin rashes. There have been extremely rare case reports of severe acute anaphylactic-type reactions but their relationship to ambroxol is uncertain. Some of these patients have also shown allergic reactions to other substances.	0.3gm/100ml Syrup, 6mg/ml PDrop, 75 SR Capsule		D”Pgv‡Îv c‡qvRb †bB wea|q Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	D”Pgv‡Îv c‡qvRb †bB wea|q Av‡e`b bvgÄy Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	s) Cetirizine HCl 5mg + Pseudoephedrine HCl 120mg Extended release Tablet Cetirizine HCl BP 5mg + Pseudoephedrine HCl USP 120mg **Antihistamine + Decongestant**	Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Runny nose, sneezing, itchy, watery eyes, itching of the nose or throat, nasal congestion, reduces swelling of nasal passages, temporarily relieves sinus congestion and pressure, temporarily restores freer breathing through the nose.	**Contraindications:** It should not be used in patients having allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine. **Side effects:** Weakness, tremors (uncontrolled shaking), or sleep problems (insomnia); severe restless feeling, hyperactivity; extreme feeling of fear or confusion; increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure); problems with vision; or urinating less than usual or not at all. Less serious side effects may include: dizziness, drowsiness; tired feeling; dry mouth; nausea, stomach pain, constipation; problems with concentration; or ringing in your ears.	Cetirizine 10 mg Tablet; Pseudoephedrine 60mg Tablet	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		t) Fexofenadine HCl 180mg + Pseudoephedrine HCl 240mg Extended release Tablet Fexofenadine HCl BP 180mg + Pseudoephedrine HCl BP 240mg **Antihistamine + Decongestant**	It is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older.	**Contra-indications:** It should generally be avoided in patients with renal insufficiency. Due to its pseudoephedrine component, this is contraindicated in patients with narrow-angle glaucoma or urinary retention. **Side effects:** Side effects of this combination include stimulation of the nervous system leading to nervousness, restlessness, excitability, dizziness, headache, fear, anxiety, tremor, and even hallucinations and convulsions (seizures).	60mg + 120mg ER Tablet	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	u) Garlic Oil 10mg Li Cap Garlic Oil USP/BP 10mg	Hardening of the arteries, High blood pressure (mild), High cholesterol, Hyper lipidemia, Atherosclerosis, Peripheral arterial occlusive disease (PAOD), Decreased Platelet function, Colon cancer prevention	**Contraindications:** Some sources suggest that substantial amounts of garlic should not be consumed prior to surgery, since it can prolong bleeding time. WHO notes that garlic is contraindicated in those individuals who have a known allergy to garlic. **Side effects:** In rare instances there may be gastrointestinal symptoms, changes to the flora of the intestine, or allergic reactions. The odor of garlic may pervade the breath and skin.	New		Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		v) Ubedecarenone (as Co-enzyme Q10) 0.6gm/100ml Syrup Ubedecarenone (as Co-enzyme Q10) USP 0.6gm/100ml **Anti-oxidant**	• HMG CoA reductase inhibitor mediated decreased level of Coenzyme Q10 in blood • Drug induced Myopathy • Protects body against free radial damage with its antioxidant property • Adjuvant therapy in cardiovascular disease especially in angina and congestive heart failure • Immune system depression • Cognitive decline • Useful in the management of Periodontal Disease	**Contra-indication:** Patients with a known hypersensitivity to any component of this product. **Side effects:** This product usually has very few side effects. Nausea, loss of appetite, upset stomach, or diarrhoea may infrequently occur. A very serious allergic reaction to this product is rare. However, allergic reaction: rash, itching/swelling (especially of the face/tongue/throat), dizziness may occur.	30mg & 60mg Capsule		GB †Ww‡Rm dig c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	GB †Ww‡Rm dig c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	
		w) Guanethidine Monosulphate 10mg Tablet Guanethidine Monosulphate BP 10mg **Antihypertensive**	Indicated for the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension, including that secondary to pyelonephritis, renal amyloidosis, and renal artery stenosis	**Contra-indication:** Known or suspected pheochromocytoma; hypersensitivity; frank congestive heart failure not due to hypertension; use of monoamine oxidase (MAO) inhibitors. **Side effects:** Diarrhea, vomiting, nausea, dry mouth, chest pains (angina), bradycardia, dyspnea, asthma, nasal congestion, dizziness; blurred vision, muscle tremor, mental depression, fatigue, myalgia, urinary incontinence, inhibition of ejaculation, nocturia, Weight gain, dermatitis, scalp hair loss.	New	USFDA	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	x) Guanethidine Monosulphate 25mg Tablet Guanethidine Monosulphate BP 25mg **Antihypertensive**	Do	Do	New	USFDA	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv nj	
		y) Zuclopenthixol Acetate 50mg/ml Injection Zuclopenthixol Acetate BP 50mg/ml **Antipsychotic**	Initial treatment of acute psychoses, mania and exacerbation of chronic psychoses.	**Contraindication:** Known hypersensitivity to the thioxanthenes. The possibility of cross-sensitivity between the thioxanthenes and phenothiazine derivatives should be kept in mind. Known hypersensitivity to any of the excipients of the particular It presentation. Acute alcohol, barbiturate or opiate intoxication. Circulatory collapse, depressed level of consciousness due to any cause, coma, suspected or established subcortical brain damage. Blood dyscrasias. Phaeochromocytoma. Leucopenia and/or previous agranulocytosis. **Side effects:** The most common adverse reaction reported with zuclopenthixol has been extrapyramidal disorder. Adverse events listed below reflect those which have been observed during clinical trials, published reports and in the overseas post marketing period. Events described as "rarely" are those which were reported on 1 - 3 occasions irrespective of the formulation used and without regard to causality, while those described as "occasionally" were reported on 4 - 10 occasions. Other events were reported more frequently. Because zuclopenthixol shares many of the pharmacological properties of other	New	BNF 57	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄÿ Kiv nj	

				thioxanthenes and phenothiazines, the possible occurrence of the known adverse effects of these drug classes exists. **Central Nervous System** Extrapyramidal symptoms, including hypo- and hyperkinetic states, tremor, pseudoparkinsonism, dystonia, hypertonia, rigidity, akathisia, oculogyric crises, opisthotonos, hyper-reflexia and tardive dyskinesia (see below). These symptoms (if they occur) usually appear within the first few days of treatment and can usually be controlled or totally curtailed by reduction in dosage and/or standard antiparkinsonian medication. However, the routine prophylactic use of antiparkinsonian medication is not recommended. Extrapyramidal reactions may be alarming and patients should be forewarned and reassured . Other CNS effects include drowsiness and somnolence. **Persistent Tardive Dyskinesia** As with all antipsychotic agents, tardive dyskinesia may appear in some patients during longterm use or may occur after drug therapy has been discontinued. Elderly patients on high dose therapy, especially elderly females, may be at greater risk. The symptoms may be persistent and, in some patients, appear to be irreversible. The syndrome is characterised by rhythmical, involuntary movements of the tongue, face, mouth or jaw (e.g. protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of the extremities. There is no known effective treatment for tardive dyskinesia; antiparkinsonian agents usually do not alleviate the symptoms of this syndrome. If these symptoms appear, it is suggested that all antipsychotic agents be discontinued. Should it be necessary to reinstitute treatment, increase dosage or change the antipsychotic agent, the				

				syndrome may be masked. If manifestations are recognised, particularly in patients over the age of fifty, the risk of this syndrome developing may be reduced by avoiding unnecessary neuroleptic medication, reducing the dose or discontinuing the drug altogether (if possible). It has been reported that if the medication is stopped at the first signs of fine vermicular movements of the tongue, which may be an early manifestation, the syndrome may not develop. **Cardiovascular** Orthostatic dizziness may occur. Tachycardia, palpitations and fainting have been observed. Hypotension, hypertension, fluctuations in blood pressure, non-specific ECG changes and cardiac arrhythmias have been reported with related drugs. If hypotension occurs, adrenalin should **not** be used as a pressor agent since a paradoxical further lowering of blood pressure may result. As with other drugs belonging to the therapeutic class of antipsychotics, rare cases of QT prolongation, ventricular arrhythmias - ventricular fibrillation, ventricular tachycardia, Torsade de Pointes and sudden unexplained death have been reported for zuclopenthixol. **Vascular Disorders** Incidence of venous thromboembolism - very rare. **Autonomic Nervous System :** Dry mouth, blurred vision, constipation, excessive salivation, excessive perspiration, nausea, difficulty in micturition and urinary retention have been observed. Miosis, mydriasis, paralytic ileus, polyuria, nasal congestion and glaucoma have been reported with related drugs. **Metabolic and Endocrine** Weight change and menstrual disturbance have been reported. Transient galactorrhoea has been reported occasionally.				

				Gynaecomastia, thyroid disorder and impotence have been observed rarely. Related drugs have been associated with breast enlargement, menstrual irregularities, false positive pregnancy tests, peripheral oedema, hypo- and hyperglycaemia and glycosuria. **Pregnancy, puerperium and perinatal conditions** Neonatal drug withdrawal syndrome – frequency not known. **Toxic and Allergic** Alterations in liver function, particularly increased bilirubin levels have been observed. Transient increases in ALT and ALP values may occur. Transient, benign leucopenia has been reported rarely. Peripheral oedema has occasionally been reported. Skin reactions such as pruritus, rash and erythema have been reported rarely. Eosinophilia, jaundice and increased levels of alkaline phosphatase have been reported with related drugs. Other antipsychotic drugs have been associated with leucopenia, agranulocytosis, thrombocytopenic or non-thrombocytopenic purpura, haemolytic anaemia and pancytopenia.				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg		wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	aa)	Esomeprazole 40mg + Domperidone 30mg Capsule Esomeprazole 40mg (as Esomeprazole Magnesium Trihydrate USP) + Domperidone 30mg (as Domperidone Maleate BP) **Antiulcerant (PPI) + Antiemetic**	Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of H /K⁺ -ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion. In a pharmacodynamic study involving patients with gastroesophageal reflux disease, oral Esomeprazote 20 and 40 mg once daily maintained an intragastric pH of greater than 4 for a significantly longer period of time (13 and 17 hours, respectively). Than omeprazole 20 mg once daily (11 hours) on day 5 of therapy. The 24-hour median gastric pH on day 5 was significantly higher with both doses of Esomeprazole compared to omeprazole.	**Contraindication:** It is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. It should not be used whenever stimulation of gastrointestinal mololtty might be dangerous such as in the presence of gastrointestinal haemorrhage, mechanical obstruction, or perforation. It is contraindicated in patients with prolactinoma (a prolactin releasing pituitarytumour).	Esomeprazole 20mg, 40mg Tablet/Capsule Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension		c‡qvRb †bB wewq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	ab) Esomeprazole 20mg + Domperidone 30mg Capsule Esomeprazole 20mg (as Esomeprazole Magnesium Trihydrate USP) + Domperidone 30mg (as Domperidone Maleate BP) **Antiulcerant (PPI) + Antiemetic**	Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of H /K⁺ -ATPase in the gastric parietal cell. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40 mg and leads to inhibition of gastric acid secretion. In a pharmacodynamic study involving patients with gastroesophageal reflux disease, oral Esomeprazote 20 and 40 mg once daily maintained an intragastric pH of greater than 4 for a significantly longer period of time (13 and 17 hours, respectively). Than omeprazole 20 mg once daily (11 hours) on day 5 of therapy. The 24-hour median gastric pH on day 5 was significantly higher with both doses of Esomeprazole compared to omeprazole. Domperidone is a peripheral dopamine antagonist with anliemelic properties similar to those of metoclopramide and certain neuroleplic drugs. Unlike these agents, however, Domperidone does not readily cross the blood-brain barrier. It seldom causes extrapyramidal side effects, but does cause a rise in prolactin levels. Its anliemelic effect may be due to a combination of peripheral (gastroldnelic) effects and antagonism of central dopamine receptors in the chemoreceptor trigger zone which lies in the area postrema and is regarded as being outside the blood-brain barrier.	**Contraindication:** It is contraindicated in patients with known hypersensitivity to Esomeprazole or other substituted benzimidazoles or to Domperidone or other dopamine antagonists. It should not be used whenever stimulation of gastrointestinal molilty might be dangerous such as in the presence of gastrointestinal haemorrhage, mechanical obstruction, or perforation. It is contraindicated in patients with prolactinoma (a prolactin releasing pituitarytumour).	Esoomeprazole 20mg, 40mg Tablet/Capsule Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension		c‡qvRb ‡bB wea vq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
04	Square Pharmaceuticals Ltd., Dhaka Unit, Gazipur	a) Metronidazole 750mg Extended Release Tablet Metronidazole BP 750mg **Antiprotozoal**	This product is indicated in the treatment of women with bacterial Vaginosis	**Contraindication:** It is contraindicated in patients with a history of hypersensitivity to Metronidazole or other Nitroimidazole derivatives. It is also contraindicated during the first trimester of pregnancy. **Side effects:** Pain, tenderness, redness, or swelling over vein in which the medicine is given. Other side-effects are unsteadiness, fever or chills, sore throat, headache, numbness, tingling pain or weakness in the hands or feet, pain, seizures, skin itching, unusual tiredness or weakness, vaginal irritation or discharge.	400mg Tablet, 200mg/5ml Suspension, 500mg in 100ml Injection vial	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |
		b) Moxifloxacin 500mg + Dexamethasone Phosphate100 mg/100ml Eye drop Moxifloxacin Hydrochloride BP 545mg eq. to 500mg Moxifloxacin + Dexamethasone Sodium Phosphate BP 109.3mg eq. to 100mg Dexamethasone Phosphate/100ml Eye drop **Antibiotic + Anti-inflammatory**	This combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. The combination can also be used for post-operative inflammation and any other ocular inflammation associated with infection.	**Contraindication:** It is contraindicated in epithelial herpes simplex keratitis (Dendritic keratitis), vaccinia, varicella, and in many other viral diseases of the conjunctiva and cornea, Mycobacterial infection of the eye and fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication. **Side effects:** The most frequently reported drug-related undesirable effects seen with Moxifloxacin are conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis	Moxifloxacin 5mg/ml Eye Drop Dexamethasone 1mg/ml Eye Drop		†idv‡iÝ †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |
		c) Anhydrous Caffeine 30mg + Citric Acid Monohydrate 15mg/3ml IV Injection Anhydrous Caffeine BP 30mg + Citric Acid Monohydrate BP 15mg/3ml IV Injection	It is indicated for the short term treatment of apnea of prematurity in infants between 28 and < 33 weeks gestational age.		New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg		wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Dhaka Unit, Gazipur	d)	Montelukast 10mg + Levocetirizine Dihydrochloride 5mg Tablet Montelukast Sodium USP 10.5mg eq. to 10mg Montelukast + Levocetirizine Dihydrochloride INN 5mg **Leukotriene receptor antagonist + Antihistamine**	It is indicated for the relief and/or prevention of symptoms of persistent allergic rhinitis (seasonal and perennial) along with asthma.	**Contraindication:** Patients with known aspirin sensitivity should continue avoidance of aspirin or non-steroidal antiinflammatory agents while taking Montelukast. Concurrent use of levocetirizine with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur. **Side effects:** Common side effects include dyspepsia, abdominal pain, rash, dizziness, headache, fatigue, fever, trauma, cough, nasal congestion, influenza. Use of levocetirizine has been associated with somnolence, fatigue, nasopharyngitis, dry mouth, and pharyngitis in subjects 12 years of age and older. Further uncommon incidences of adverse reactions like asthenia or abdominal pain were observed.	Montelukast 4mg, 5mg & 10mg Tablet Levocetirizine 5mg Tablet		c‡qvRb ‡bB wewfbœ Av‡e`b bvgÄyi Kiv ‡h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	
		e)	Ibuprofen 200mg + Diphenhydramine Citrate 38mg Tablet Ibuprofen USP 200mg + Diphenhydramine Citrate USP 38mg **Analgesic + Antihistmaine**	for relief of occasional sleeplessness when associated with minor aches and pains	**Contraindications:** if anyone have ever had an allergic reaction to any other pain reliever in children under 12 years of age right before or after heart surgery with any other product containing diphenhydramine, even one used on skin if anyone you have sleeplessness without pain. **Side effects:** Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include hives, facial swelling, asthma (wheezing), shock skin reddening, rash, blisters. This product contains an NSAID, which may cause severe stomach bleeding. So, patients having age 60 or older & patients having stomach ulcers or bleeding problem should have to be cautious.	Ibuprofen 200mg, 400mg & 600mg Tablet Diphenhydramine 50mg Tablet	USFDA	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg		wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Dhaka Unit, Gazipur	f)	ketoprofen 200mg + Omeprazole 20mg Modified release capsule Ketoprofen Pellets (69.64% w/w) Ph. Grade 287.191mg eq. to ketoprofen BP 200mg + Omeprazole Pellets (15%) w/w Ph. Grade 1333.333mg eq. to Omeprazole BP 20mg **Analgesic + Antiulcerant (PPI)**	Symptomatic treatment of Rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers or duodenal ulcers.	**Contra-indications:** Hypersensitivity to Ketoprofen or to Omeprazole, Last trimester of pregnancy, Severe hepatic failure, renal failure, heart failure patients, Combination therapy with Clarithromycin should not be used in patients with Hepatic impairment. **Side effects:** Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include Drowsiness, Trouble sleeping, Spinning sensation, Headache, GI side effects like, nausea, vomiting, diarrhea, constipation rash, blisters	Ketoprofen 50mg, 100mg & 200mg Tablet/Capsule Omeprazole 20mg & 40mg Capsule	BNF 63	Ac‡qvRbxq I A‡hŠw³K Kw¤‡bkb weavq Av‡e`b bvgÄy Kiv †h‡Z cv‡i	Ac‡qvRbxq I A‡hŠw³K Kw¤‡bkb weavq Av‡e`b bvgÄy Kiv nj	
		g)	Ketoprofen 100mg + Omeprazole 20mg Modified release capsule Ketoprofen Pellets (69.64% w/w) Pharma grade 143.596mg eq. to ketoprofen BP 100mg + Omeprazole Pellets (15%) w/w Pharma grade 1333.333mg eq. to Omeprazole BP 20mg **Analgesic + Antiulcerant (PPI)**	Symptomatic treatment of Rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers or duodenal ulcers.	Do	Ketoprofen 50mg, 100mg & 200mg Tablet/Capsule Omeprazole 20mg & 40mg Capsule	BNF 63	Ac‡qvRbxq I A‡hŠw³K Kw¤‡bkb weavq Av‡e`b bvgÄy Kiv †h‡Z cv‡i	Ac‡qvRbxq I A‡hŠw³K Kw¤‡bkb weavq Av‡e`b bvgÄy Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Dhaka Unit, Gazipur	h) Ketoprofen 150mg + Omeprazole 20mg Modified release capsule Ketoprofen Pellets (69.64% w/w) Pharma grade 215.393mg eq. to ketoprofen BP 150mg + Omeprazole Pellets (15%) w/w Pharma grade 1333.333mg eq. to Omeprazole BP 20mg **Analgesic + Antiulcerant (PPI)**	Symptomatic treatment of Rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers or duodenal ulcers.	Do	Ketoprofen 50mg, 100mg & 200mg Tablet/Capsule Omeprazole 20mg & 40mg Capsule	BNF 63	Ac‡qvRbxq I A‡hŠw³K Kw¤‡bkb weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	Ac‡qvRbxq I A‡hŠw³K Kw¤‡bkb weavq Av‡e`b bvgÄyi Kiv nj	
		i) Ceftriaxone 250mg + Sulbactam 125 mg /Vial Injection Ceftriaxone Sodium USP 297.50mg eq. to 250mg Ceftriaxone + Sulbactam Sodium USP 137.38 mg eq. to 125mg Sulbactam/Vial **Antibiotic-Cephalosporin**	Renal and urinary tract infections, Lower respiratory tract infections, particularly pneumonia, Gonococcal infections, Skin and soft tissue, bone and joint infections, Bacterial meningitis, Serious bacterial infections e.g. septicemia, ENT infections, Infections in cancer patients, Prevention of postoperative infection, Perioperative prophylaxis of infections associated with surgery, Typhoid fever.	**Contraindications:** It is contraindicated in patients with known allergy to Cephalosporin group of antibiotics. Hypersensitivity to penicillin may pre-dispose the patient to the possibility of allergic cross-reactions. Transient elevations of BUN and serum creatinine have been observed, at recommended doses, the nephrotoxic potential of ceftriaxone is same as other cephalosporins. Since Ceftriaxone is excreted both via renal and bile patients with renal failure normally require no adjustment in dosage when usual doses of Ceftriaxone are administered. **Adverse effects:** The following side effects, reported to occur during Ceftriaxone therapy, may be seen with the combination as well: Gastrointestinal: Diarrhoea, nausea & vomiting (less frequent), stomatitis, and glossitis. Hepatic: Elevations of SGOT/SGPT. Hematological: Eosinophilia, thrombocytopenia, leukopenia, granulocytopenia, hematoma or bleeding. Hemolytic anemia is observed less frequently.	New		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Dhaka Unit, Gazipur	j) Ceftriaxone 500mg + Sulbactam 250mg/Vial Injection Ceftriaxone Sodium USP 595 mg eq. to 500mg Ceftriaxone + Sulbactam Sodium USP 274.75mg eq. to 250mg Sulbactam/Vial **Antibiotic-Cephalosporin**	Renal and urinary tract infections, Lower respiratory tract infections, particularly pneumonia, Gonococcal infections, Skin and soft tissue, bone and joint infections, Bacterial meningitis, Serious bacterial infections e.g. septicemia, ENT infections, Infections in cancer patients, Prevention of postoperative infection, Perioperative prophylaxis of infections associated with surgery, Typhoid fever.	**Contraindications:** It is contraindicated in patients with known allergy to Cephalosporin group of antibiotics. Hypersensitivity to penicillin may pre-dispose the patient to the possibility of allergic cross-reactions. Transient elevations of BUN and serum creatinine have been observed, at recommended doses, the nephrotoxic potential of ceftriaxone is same as other cephalosporins. Since Ceftriaxone is excreted both via renal and bile patients with renal failure normally require no adjustment in dosage when usual doses of Ceftriaxone are administered. **Adverse effects:** The following side effects, reported to occur during Ceftriaxone therapy, may be seen with the combination as well: Gastrointestinal: Diarrhoea, nausea & vomiting (less frequent), stomatitis, and glossitis. Hepatic: Elevations of SGOT/SGPT. Hematological: Eosinophilia, thrombocytopenia, leukopenia, granulocytopenia, hematoma or bleeding. Hemolytic anemia is observed less frequently.	New		‡idv‡iÝ Ges c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv †h‡Z cv‡i |	‡idv‡iÝ Ges c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv nj |
		k) Ceftriaxone 1000mg + Sulbactam 500mg /Vial Injection Ceftriaxone Sodium USP 1190 mg eq. to 1000mg Ceftriaxone + Sulbactam Sodium USP 549.50mg eq. to 500mg Sulbactam/Vial **Antibiotic-Cephalosporin**	-do-	**-do-**	New		‡idv‡iÝ Ges c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv †h‡Z cv‡i |	‡idv‡iÝ Ges c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
05	Navana Pharmaceuticals Ltd., Rupshi, Rupgonj, Narayangonj	a) Dapagliflozin 5 mg Tablet Dapagliflozin Propanediol Monohydrate USP 5.677mg eq. to 5mg Dapagliflozin	It is a sodium-glucose cotransporter-2 (SGLT2) inhibitor Indicated as an adjunct to diet and exercise to improve glycemic control with type 2 diabetes mellitus. **Limitation of use:** • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.	**Contraindications:** ➢ History of serious hypersensitivity raction to Dapagliflozin. ➢ Severe renal impairment, end-stage renal disease, or dialysis. **Side effects:** The most common adverse reactions associated with this tablet (5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
06	Navana Health Care Ltd., Rupshi, Rupgonj, Narayangonj	a) Ferric carboxymaltose 750mg/15 ml IV Injection Ferric carboxymaltose INN 750mg/15 ml	It is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients: ➢ who have intolerance to oral iron or have had unsatisfactory response to oral iron; ➢ who have non-dialysis dependent chronic kidney disease.	**Contraindication**: Hypersensitivity to Ferric carboxymaltose or any of its inactive components. **Adverse effects**: The most common adverse reactions (>2%) are nausea, hypertension, flushing, hypophosphatemia, and dizziness.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
07.	ACI Ltd., Narayanganj	a) Domperidone 10mg + Rabeprazole 20mg Coated Tablet Domperidone Maleate BP 12.726 mg eq. to Domperidone 10mg + Rabeprazole Sodium INN 20mg **Antiulcerant (PPI) + Antiemetic**	It is indicated for relief of symptoms of: Dyspepsia, GERD, Nausia associated with acid peptic disorders, post operative nausea & vomiting, chronic gastritis**.**	**Contraindication:** It is contraindicated in patients with known hypersensitivity to these molecule, substituted benzimidazole, and domperidone or to any component of the formulation. It should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, eg. In presence of gastro-intestinal haemorrhage, obatruction or perforation. It is also contraindicated in patients with a prolactin-releasing pituitary tumour (Prolactinomia). **Side effects:** Adverse effects with Rabeprazole are mild to moderate in intensity and included malaise, diarrhea, nausea, skin eruptions,headache & dizziness, etc. Domperidone has been found to be associated with increased serum prolactin which may be associated with galactorrhea, less frequently gynaecomastia, breast enlargement & soreness. Reduced libido has been reported. Occational rashes & other allergic phenomena are also reported. Domperidone does not cross the blood brain barrier and is therefore less likely to interfere with the central dopaminargic function.	Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension Rabeprazole 10mg & 20mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyb Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyb Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd., Narayanganj	b) Domperidone 30mg + Rabeprazole 20mg Sustained Released Tablet Domperidone Maleate BP 38.178mg eqv. to Domperidone 30mg + Rabeprazole Sodium INN 20mg **Antiulcerant (PPI) + Antiemetic**	It is indicated for relief of symptoms of: Dyspepsia, GERD, Nausia associated with acid peptic disorders, post operative nausea & vomiting, chronic gastritis**.**	**Contraindication:** It is contraindicated in patients with known hypersensitivity to these molecule, substituted benzimidazole, and domperidone or to any component of the formulation. It should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, eg. In presence of gastro-intestinal haemorrhage, obatruction or perforation. It is also contraindicated in patients with a prolactin-releasing pituitary tumour (Prolactinomia). **Side effects:** Adverse effects with Rabeprazole are mild to moderate in intensity and included malaise, diarrhea, nausea, skin eruptions,headache & dizziness, etc. Domperidone has been found to be associated with increased serum prolactin which may be associated with galactorrhea, less frequently gynaecomastia, breast enlargement & soreness. Reduced libido has been reported. Occational rashes & other allergic phenomena are also reported. Domperidone does not cross the blood brain barrier and is therefore less likely to interfere with the central dopaminergic function.	Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension Rabeprazole 10mg & 20mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyb Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyb Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd., Narayanganj	c) Domperidone 10mg + Pantoprazole 20mg Coated Tablet Domperidone Maleate BP 12.726 mg eq. to Domperidone 10mg + Pantoprazole Sesquihydrate USP 22.556mg eqv.to Pantoprazole 20mg **Antiulcerant (PPI) + Antiemetic**	It is indicated in the management of: GERD, non-ulcer Dyspepsia, gastric/duodenal ulcer, dyspepsia, bloating, fullness, belching,NSAID induced dyspepsia, gastritis**.**	**Contraindication:** It is contraindicated in patients with known hypersensitivity to domperidone or pantoprazole. **Side effects: Pantoprazole:** Adverse reaction associated with Pantoprazole include headache, diarrhea, skin rash, pruritis & dizziness. **Domperidone:** Serum prolactin may rise resulting in galactorrhes in females and less frequently gynaecomastia in males due to domperidone. Dry mouth, thirst, headache, nervousness, drowsiness, diarrhea, skin rash and itching may follow treatment with domperidone.	Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension Pantoprazole 20mg & 40mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	
		d) Domperidone 30mg + Pantoprazole 40mg Sustained Released Tablet Domperidone Maleate BP 38.178 mg eq. to Domperidone 30mg + Pantoprazole Sesquihydrate USP 45.112mg eq.to Pantoprazole 40mg **Antiulcerant (PPI) + Antiemetic**	It is indicated in the management of: GERD, non-ulcer Dyspepsia, gastric/duodenal ulcer, dyspepsia, bloating, fullness, belching, NSAID induced dyspepsia, gastritis**.**	Do	Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension Pantoprazole 20mg & 40mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd., Narayanganj	e) Rabiprazole 40 Delayed Release Enteric coated Tablet Rabiprazole Sodium INN 40mg **Antiulcerant (PPI)**	It is indicated for treatment of Benign gastric and peptic ulcer, erosive of ulcerative GERD, Zollinger Ellison Syndrome.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to Rabeprazole, substituted benzimidazoles, or to any component of the formulation. **Side effects:** An analysis of adverse reactions appearing in ≥ 2% of oral rabeprazole patients and with greater frequency than placebo. Revealed the following adverse reactions: pain, pharyngitis, flatulence, infection, constipation. Other adverse reactions that were seen in controlled clinical trials which do not meet the above criteria (≤2% of Rabeprazole treated patients and > placebo) and for which there is a possibility of a causal relationship to Rabeprazole include the following : headache, abdominal pain, diarrhea, dry mouth, dizziness, peripheral edema, hepatic enzyme increase, hepatitis, hepatic encephalopathy, myalgia and arthralgia.	Rabeprazole 10mg & 20mg Tablet		c‡qvRb †bB wea‡q Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄ¡y Kiv nj	
		f) Indacaterol 0.075mg Capsule Indacaterol Maleate INN 0.097mg eq. to Indecaterol 0.075mg **Bronchodilator**	It is indicated for long term, once daily maintenance bronchodilator treatment of air flow obstruction in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and or emphysema.	**Contraindication:** It is contraindicated in patients with known or suspected hypersensitivity to sertaconazole nitrate or any component of the formulation or other imidazoles. **Side effects:** Most common adverse reactions are cough, oropharyngeal pain, nasophryngitis, headache and nausea.			‡idv‡iÝ I c‡qvRb †bB wea‡q Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wea‡q Av‡e`b bvgÄ¡y Kiv nj	
		g) Cetylpyridinum Chloride 0.05gm/100ml Fresh Mint Mouth Wash Cetylpyridinum Chloride BP 0.05gm/100ml	It is indicated for control of dental plaque & gingivitis.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to Cetylpyridinum Chloride. **Side effects:** Generally safe. However, any complication like dental staining, irritation, consult with physician. Swallowing too much mouth wash can have serious side effects that require emergency medical treatment.			c‡qvRb †bB wea‡q Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄ¡y Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd., Narayanganj	h) Cetylpyridinum Chloride 0.05gm/100ml Peeper Mint Mouth Wash Cetylpyridinum Chloride BP 0.05gm/100ml	It is indicated for control of dental plaque & gingivitis.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to Cetylpyridinum Chloride. **Side effects:** Generally safe. However, any complication like dental staining, irritation, consult with physician. Swallowing too much mouth wash can have serious side effects that require emergency medical treatment.			c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj	
		i) Flupirtine 100mg Capsule Flupirtine Maleate (Micronized) INN 100mg **Analgesic and antipyretic agent**	It is a centrally acting non-opioid analgesic with muscle relaxant and neuro protective drugs.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to Flupiritin Maleate. It should not be given to patients at risk of hepatic encephalopathy nor to patients suffering from cholestasis. Patient with liver disease and alcohol abusers should not be given. **Side effects**: Most common adverse reactions are drowsiness, dizziness, heartburn, headache, fatigue & nausea, dry mouth.			‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj
		j) Glycopyrrolate 0.05mg Capsule Dry Powder Inhaler Glycopyrrolate (Micronized) USP 0.063mg eq. to Glycopyrronium 0.05mg **Antispasmodic**	It is indicated as a maintenance bronchodialator treatment to relieve symptoms in adult patient with chronic obstructive palmunary diseases (COPD).	**Contraindications**: Hypersensityvity to the active substances or to any of the excipients. . **Side effects**: As with all medicines, patients using this product may experience side effects, although not everybody gets them. Some side effects are common (*may affect up to 1 in 10 people*): stomach discomfort after meal (possible symptoms of dyspepsia), pain in extremities (e.g. arms or legs), feeling of pressure or pain in the cheeks and forehead (possible symptoms of sinus congestion), dry mouth, nausea, vomiting, diarrhea and abdominal pain (possible symptoms of gastroenteritis), difficulty sleeping, symptoms of common cold (runny or stuffy nose, cough, sore throat, sneezing), musculoskeletal pain, neck pain. Some side effects are uncommon (*may affect up to 1 in 100 people*): dental caries, rash, tiredness, weakness, cough with sputum, throat irritation, nose bleeds, urinary retention, diabetes mellitus (high level of blood sugar, excessive urination, persistent thirst), palpitations, numbness. Some elderly patients above 75 years of age have also experienced headache and urinary tract infection.		BNF	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd., Narayanganj	k) Ibuprofen 200mg + Paracetamol 500mg Tablet Ibuprofen BP 200mg + Paracetamol BP 500mg **Analgesic and antipyretic agent**	For the temporary relief of mild to moderate pain associated with migrane, heachache, backache, period pain, dental pain, rheumatic and muscular pain, pain of non serious arthritis, cold and flu symptoms, sore throat, and fever. This product is suitable for pain which requires stronger analgesia than ibuprofen or paracetamol.	**Contraindications:** This product is contraindicated: •In patients with a known hypersensitivity to Ibuprofen, Paracetamol or any other excipients. •In patients with a history of hypersensitivity reactions (e.g. bronchospasm, angioedema, asthma, rhinitis, or urticaria) associated with acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). •In patients with a history of, or an existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs. •Patients with defects in coagulation. •In patients with severe hepatic failure, severe renal failure or severe heart failure. •In concomitant use with other NSAID containing products, including cyclo-oxygenase-2 (COX-2) specific inhibitors and doses of acetylsalicylic acid above 75 mg daily – increased risk of adverse reactions. •In concomitant use with other Paracetamol-containing products – increased risk of serious adverse effects. •During the last trimester of pregnancy due to risk of premature closure of the foetal ductus arteriosus with possible pulmonary hypertension **Side effects:** Clinical trials with this product have not indicated any other undesirable effects other than those for Ibuprofen or Paracetamol alone. Common side effects are Disturbances of the gut such as nausea, vomiting, abdominal pain, indigestion, diarrhoea. Uncommon side effects are headache, dizziness, flatulence, constipation, skin reactions such as itching, stomach or duodenal ulcer.		MHRA	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
08.	Orion Pharma Ltd.	a) Magaldrate 480mg + Simethicone 100mg + Sodium Alginate 50mg /5ml Suspesion Magaldrate 20% Paste 48.00gm eq. to Magaldrate USP 9.6gm + Simethicone 30% Emulsion Ph. Gr. 6.666gm eq. to Simethicone USP 2.0gm + Sodium Alginate BP 1.0gm/100ml	Hyperacidity associated with the peptic ulcer, gastritis, GERD. Peptic esophagitic, gastric hyperacidity, heartburn, sour stomach, acid indigestion and hartal hernia.	**Contra-indications:** Magaldrate is contraindicated in patients with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patients with impaired renal functions. Sodium alginate is contraindicated in patients with known hypersensitivity to these. **Side-effect-** there are no side effects.	Magaldrate 2gm+ Simethicone 0.40gm Suspension & Magaldrate 280mg+ Simethicone 20mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	
		b) Canagliflozin 100 mg Tablet Canagliflozin INN 100 mg **Antidiabetic**	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. **Limitation of Use:** • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis	**Contraindications:** History of serious hypersensitivity reaction to Canagliflozin. Severe renal impairment, ESRD, or on dialysis. **Side Effects:** Most common adverse reactions associated with Canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination		USFDA	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Orion Pharma Ltd.	c) Meclofenamate 50mg Capsule Meclofenamate Sodium USP 56.75mg eq. to 50mg Meclofenamic Acid **Analgesic and Antipyretic**	It is indicated: 1) Reduction of fever in adults, 2) For the relief of mild to moderate pain in adults, 3) For relief of signs and symptoms of juvenile arthritis, 4) For relief of the signs and symptoms of rheumatoid arthritis, 5) For relief of the signs and symptoms of osteoarthritis, 6) For treatment of primary dysmenorrhea, 7) For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis, Acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis), Acoute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss As with all non-steroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out.	**Contra-indications:** Meclofenamate sodium capsules are contraindicated in patients with known hypersensitivity to Meclofenamate sodium. It should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients Meclofenamate sodium capsules are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery **Side-effects: Gastrointestinal:** The most frequently reported adverse reactions associated with it Involve the GI system. diarrhea (10% to 33%), nausea with or without vomiting (11%), other gastrointestinal Disorders (10%), and abdominal pain. Other reactions less frequently reported were pyrosis , flatulence , anorexia, constipation, stomatitis, and peptic ulcer. The majority of the patients with peptic ulcer had either a history of ulcer disease or were receiving concomitant anti-inflammatory drugs, including corticosteroids		USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Orion Pharma Ltd.	d) Meclofenamate 100mg Capsule Meclofenamate Sodium USP 113.50 mg eq. to 100mg Meclofenamic Acid **Analgesic and Antipyretic**	It is indicated: 1. Reduction of fever in adults, 2. For the relief of mild to moderate pain in adults, 3. For relief of signs and symptoms of juvenile arthritis, 4. For relief of the signs and symptoms of rheumatoid arthritis, 5. For relief of the signs and symptoms of osteoarthritis, 6. For treatment of primary dysmenorrhea, 7. For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis, Acute painful shoulder (acute subacromial bursitis/supraspinatus tendonitis), Acoute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss As with all non-steroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio. Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out.	**Contra-indications:** Meclofenamate sodium capsules are contraindicated in patients with known hypersensitivity to Meclofenamate sodium. It should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients Meclofenamate sodium capsules are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery **Side-effects: Gastrointestinal:** The most frequently reported adverse reactions associated with it Involve the GI system. diarrhea (10% to 33%), nausea with or without vomiting (11%), other gastrointestinal Disorders (10%), and abdominal pain. Other reactions less frequently reported were pyrosis , flatulence , anorexia, constipation, stomatitis, and peptic ulcer. The majority of the patients with peptic ulcer had either a history of ulcer disease or were receiving concomitant anti-inflammatory drugs, including corticosteroids		USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		e) Mirabegron 50mg ER Tablet Mirabegron INN 50mg β_3-Adrenoceptor Agonist	It is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.	**Contraindications:** None **Side effects:** Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache	New	USFDA BNF-66, Page-538	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Orion Pharma Ltd.	f) Cyclizine HCl 50mg Tablet Cyclizine HCl BP 50mg **Antiemetic agent**	Indicated for the prevention and treatment of nausea and vomiting including • Motion sickness. • Nausea and vomiting caused by narcotic analgesics and by general anaesthetics in the post-operative period. • Vomiting associated with radiotherapy especially for breast cancer since Cyclizine does not elevate prolactin levels. Cyclizine may be of value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance	**Contra-indications** Contraindicated in individuals with known hypersensitivity to cyclizine. **Side effects:** Blood and lymphatic system disorders Agranulocytosis Cardiac disorders Tachycardia Eye disorders Blurred vision, oculogyration Gastrointestinal system disorders Dryness of the mouth, nose and throat, constipation General disorders and administration site conditions Asthenia, malaise Hepatobiliary disorders Hepatic dysfunction including hepatitis due to hypersensitivity. Cholestatic jaundice and cholestatic hepatitis have occurred in association with cyclizine. Immune system disorders Hypersensitivity reactions, including anaphylaxis, hypersensitivity hepatitis have occurred Musculoskeletal and connective tissue disorders Twitching, muscle spasms Nervous system disorders Effects on the central nervous system have been reported with cyclizine these include somnolence, headache, dystonia (sometimes associated with transient episodes of loss of consciousness and/or responsiveness to stimuli), dyskinesia, extrapyramidal motor disturbances, tremor, convulsions, dizziness, decreased consciousness, transient speech disorders, paraesthesia and generalised chorea. Psychiatric disorders Disorientation, restlessness, nervousness, insomnia and auditory and visual hallucinations have been reported, particularly when dosage recommendations have been exceeded. Renal and urinary disorders Urinary retention Respiratory, thoracic and mediastinal disorders Bronchospasm, apnoea Skin and subcutaneous tissue disorders Urticaria, drug rash, angioedema, allergic skin reactions, fixed drug eruption Vascular disorders Hypertension	New	BNF-61 Page-251, MHRA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Orion Pharma Ltd.	g) Pentazocine 50mg + Naloxone 0.5 mg Tablet Pentazocine HCl USP 56.395mg eq. to Pentazocine 50mg + Naloxone HCl USP 0.556mg eq. to 0.50 mg Naloxone **Analgesic + Opioid (narcotic) antagonist**	It is indicated for the relief of moderate to severe pain.	**Contra-indications:** It is contraindicated to either pentazocine or naloxone. **Side-effect:** **Cardiovascular.** Hypertension, hypotension, circulatory depression, tachycardia, syncope. **Respiratory.** Rarely, respiratory depression. **Acute CNS Manifestations.** Hallucinations (usually visual), disorientation, and confusion. **Other CNS Effects.** Grand mal convulsions, increase in intracranial pressure, dizziness, lightheadedness, hallucinations, sedation, euphoria, headache, confusion, disorientation; infrequently weakness, disturbed dreams, insomnia, syncope, and depression; and rarely tremor, irritability, excitement, tinnitus. **Autonomic.** Sweating; infrequently flushing; and rarely chills. **Gastrointestinal.** Nausea, vomiting, constipation, diarrhea, anorexia, dry mouth, biliary tract spasm, and rarely abdominal distress. **Allergic.** Edema of the face; anaphylactic shock; dermatitis, including pruritus; flushed skin, including plethora; infrequently rash, and rarely urticaria. **Ophthalmic.** Visual blurring and focusing difficulty, miosis. **Hematologic.** Depression of white blood cells (especially granulocytes), with rare cases of agranulocytosis, which is usually reversible, moderate transient eosinophilia.		USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Orion Pharma Ltd.	h) Seratrodast 40 mg Tablet Seratrodast INN 40 mg **Antiasthmatic agent**	Is indicated in adults (18 years and above) for the prophylactic management of asthma. It also effective in the treatment of allergic rhinitis and COPD.	**Contra-indications:** Hypersensitivity to seratrodast or any of the ingredients. Patients with hepatic failure. **Side effects:** Adverse reactions are generally rare, but if present, range form mild to moderate in severity. Generally, rash, inching (hypersensitivity); elevated liver enzymes (hepatic); nausea, loss of appetite, stomach discomfort, abdominal pain, diarrhea, dry mout, anemia, drowsiness, headache,and palpitations, malaise observed,	New		‡idv‡iÝ Ges c‡qvRb †bB wea|vq Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wea|vq Av‡e`b bvgÄ¡y Kiv nj	
		i) Seratrodast 80 mg Tablet Seratrodast INN 80 mg **Antiasthmatic agent**	-do-	**-do-**	New		‡idv‡iÝ Ges c‡qvRb †bB wea|vq Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wea|vq Av‡e`b bvgÄ¡y Kiv nj	
		j) Ferric Carboxymaltose as Iron 750mg/15 ml Injection Ferric Carboxymaltose (As 25% Iron) INN 3.0gm eq. to Iron 750mg/15 ml	It is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients: ▪ who have intolerance to oral iron or have had unsatisfactory response to oral iron; ▪ who have non-dialysis dependent chronic kidney disease.	**Contra-indications:** Hypersensitivity to ferric carboxymaltose or any of its inactive components. **Side effects:** The side-effects of ferric carboxymaltose are The most common adverse reactions (>2%) are nausea, hypertension, flushing, hypophosphatemia, and dizziness	New	USFDA	c‡qvRb †bB wea|vq Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i	c‡qvRb †bB wea|vq Av‡e`b bvgÄ¡y Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Orion Pharma Ltd.	k) Baclofen 5mg/5ml Syrup Baclofen BP 0.1g/100ml **Skeletal Muscle Relaxant**	It is indicated for the relief of spasticity of voluntary muscle resulting from such disorders as: multiple sclerosis, other spinal lesions, e.g. tumours of the spinal cord, syringomyelia, motor neurone disease, transverse myelitis, Traumatic partial section of the cord. It is also indicated in adults and children for the relief of spasticity of voluntary muscle arising from e.g. cerebrovascular accidents, cerebral palsy, meningitis, traumatic head injury. Patient selection is important when initiating it therapy; it is likely to be of most benefit in patients whose spasticity constitutes a handicap to activities and/or physiotherapy. Treatment should not be commenced until the spastic state has become stabilised.	**Contra-indication :** Hypersensitivity to baclofen, peptic ulceration. **Side effects:** Unwanted effects occur mainly at the start of treatment, if the dosage is raised too rapidly, if large doses are employed, or in elderly patients. They are often transitory and can be attenuated or eliminated by reducing the dosage; they are seldom severe enough to necessitate withdrawal of the medication. Should nausea persist following a reduction in dosage, it is recommended that it be ingested with food or a milk beverage. In patients with a case history of psychiatric illness or with cerebrovascular disorders (e.g. stroke) as well as in elderly patients, adverse reactions may assume a more serious form. Frequency estimates: frequent > 10%, occasional > 1% - 10%, Rare > 0.001% - 1%, isolated cases < 0.001%. **Central Nervous System:** Frequent: particularly at the start of treatment daytime sedation, drowsiness, and nausea may frequently occur. Occasional: respiratory depression, light-headedness, lassitude, exhaustion, mental confusion, dizziness, headache, insomnia, euphoria, depression, muscular weakness, ataxia, tremor, hallucinations, nightmares, myalgia, nystagmus, dry mouth. Rare: paraesthesia, dysarthria. Lowering of the convulsion threshold and convulsions may occur, particularly in epileptic patients. **Sense organs:** Occasional: accommodation disorders, visual disturbance. Rare: dysgeusia. **Gastro-intestinal tract:** Frequent: nausea. Occasional: mild gastro-intestinal	5mg,10mg Tablet	MHRA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

				disturbances, constipation, diarrhoea, retching and vomiting. Rare: abdominal pain **Cardiovascular system:** Occasional: hypotension, diminished cardiovascular function. **Urogenital system:** Frequent: frequency of micturition, enuresis, dysuria. Rare: urinary retention, impotence. **Liver:** Rare: disorders of hepatic function. **Skin:** Occasional: hyperhydrosis, skin rash. Certain patients have shown increased spasticity as a paradoxical reaction to the medication. An undesirable degree of muscular hypotonia - making it more difficult for patients to walk or fend for themselves - may occur and can usually be relieved by re-adjusting the dosage (i.e. by reducing the doses given during the day and possibly increasing the evening dose).				
09.	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	a) Alverine Citrate 120mg Capsule Alverine Citrate BP 120mg **Antispasmodic agent**	Adjunct in gastro-intestinal disorders characterised by smooth muscle spasm; dysmenorrhoea.	**Contraindications:** Paralytic ileus. **Side Effects:** Nausea; dyspnoea; headache, dizziness; pruritus, rash; hepatitis also reported.	60mg Tablet	BNF-62 Page-48	*Abyjgv`b Kiv †h‡Z cv‡i |*	*Abyjgv`b Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kwgwdi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	b) Benzocaine 14gm + Butyl Aminobenzoate 2gm+ Tetracaine HCl 2gm/100gm topical Anesthetic Gel Benzocaine BP 14gm + Butyl Aminobenzoate USP 2gm+ Tetracaine HCl BP 2gm/100gm **Topical Anesthetic**	It is a topical anesthetic indicated for the production of anesthesia of all accessible mucous membrane except the eyes. It is indicated for use to control pain or gagging. This Medication in all forms is indicated to control pain and for use for surgical or endoscopic or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. It may also be used for vaginal or rectal procedures when feasible.	**Contraindications:** This Medication is not suitable and should never be used for injection. Do not use on the eyes. To avoid excessive systemic absorption, This Medication should not be applied to large areas of denuded or inflamed tissue. This Medication should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. Tolerance may vary with the status of the patient. This Medication should not be used under dentures or cotton rolls, as retention of the active ingredients under a denture or cotton roll could possibly cause an escharotic effect. Routine precaution for the use of any topical anesthetic should be observed when using this Medication. **Side Effects:** Hypersensitivity Reactions: Unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. Localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. The most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. This occurs most commonly in patients following prolonged self-medication, which is contraindicated. If rash, urticaria, edema, or other manifestations of allergy develop during use, the drug should be discontinued. To minimize the possibility of a serious allergic reaction. This Medication preparation should not be applied for prolonged periods except under continual supervision. Dehydration of the epithelium or an escharotic effect may also result from prolonged contact.	New		c‡qvRbxqZv Av‡Q wea|q Av‡e`b Abyhvqx K|v †h‡Z cv‡i|	Abyhvqx K|v nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	c) Biotin 5mg Capsule Biotin BP 5mg **Vitamin**	Biotin deficiency (prophylaxis and treatment) The B vitamins are indicated for prevention and treatment of vitamin B deficiency. Vitamin B deficiency may occur as a result of inadequate nutrition or intestinal malabsorption but does not occur in healthy individuals receiving an adequate balanced diet. Simple nutritional deficiency of individual B vitamins is rare since dietary inadequacy usually results in multiple deficiencies. For prophylaxis of biotin deficiency, dietary improvement, rather than supplementation, is advisable. For treatment of biotin deficiency, supplementation is preferred. Biotin deficiency may lead to dermatitis, alopecia, hypercholesterolemia, and cardiac abnormalities. Requirements may be increased and/or supplementation may be necessary in the following conditions (based on documented biotin deficiency): ▪ Biotinidase deficiency ▪ Gastrectomy ▪ Seborrheic dermatitis of infancy ▪ Administration of large amounts of the biotin antagonist, avidin, which is found in raw egg whites, has also been found to cause	**Contraindications:** None known. **Side Effects:** Biotin may not have any known side effects through normal use, but that does not mean that an excess use of the vitamin does not have its drawbacks. Even with using too much of the vitamin, there aren't many side effects reported. Even in cases where extremely high doses were given (either by mouth or IV) there aren't many instances of side effects. <u>These few instances have arisen over the years:</u> One documented case involved a very high dose of vitamin B7 (biotin) along with vitamin B5 that caused a life-threatening condition called eosinophilic pleuropericardial effusion. The condition promptly subsided once the treatment with vitamin B7 and vitamin B5 was stopped. There is a possibility that the combination of the two vitamins in high doses caused the condition, but it could have also been something completely unrelated. In animal studies, pregnant rats were given high doses of biotin. The test results showed that the placenta of the fetal rats decreased in size which increased the possibility of miscarriage. It is not known why or how this occurred and is unknown if the same problem could happen in human mothers.	New	USFDA	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

			biotin deficiency. ▪ Some unusual diets (e.g., reducing diets that drastically restrict food selection) may not supply minimum daily requirements of biotin ▪ Supplementation may be necessary in patients receiving total parenteral nutrition (TPN) or undergoing rapid weight loss or in those with malnutrition, because of inadequate dietary intake. ▪ <u>Unaccepted</u> Biotin has not been proven effective in the treatment of acne, seborrheic eczema, or alopecia.						
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	d)	Bromelain 90mg + Trypsin 48mg + Rutoside Trihydrate 100mg Tablet Bromelain INN 90mg + Trypsin BP 48mg + Rutoside Trihydrate BP 100mg	**Natural Medicines:** *Comprehensive Database* rates effectiveness based on scientific evidence according to the following scale: The effectiveness ratings for bromelain are as follows: <u>Possibly effective for..</u> - Arthritis (osteoarthritis) pain and knee function when used in combination with trypsin and rutin (Combination of Bromelain, trypsin & Rutosid Trihydrate). This combination seems to be about as effective as some prescription painkillers. <u>Possibly ineffective for</u> - Preventing muscle soreness (myalgia) after	**Contraindications:** Bromelain can raise the risk of bleeding. Make sure to stop taking it at least two weeks before surgery. Check with a doctor before using bromelain if you have any health conditions, such as a bleeding disorder, asthma, heart problems, liver or kidney disease, or stomach ulcers. **Side Effects:** It is possibly safe for most people when taken in appropriate amounts. Bromelain may cause some side effects, such as <u>diarrhea</u> and <u>stomach</u> and intestinal discomfort. Bromelain may also cause allergic reactions, especially in people who have other <u>allergies</u>. If you have allergies, be sure to check with your healthcare provider before taking bromelain.	New		‡idv‡iÝ Ges c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	

			exercise. Taking bromelain orally, immediately following intense exercise does not seem to delay onset of muscle soreness and has no effect on pain, flexibility, or skeletal weakness. - Insufficient evidence to rate effectiveness for Knee pain. There's some evidence that taking bromelain by mouth can reduce mild acute knee pain that's lasted for less than three months in otherwise healthy people. - Reducing swelling after surgery or injury. Some research suggests bromelain might reduce swelling and pain after surgery or injury. Interestingly, bromelain doesn't seem to reduce swelling after mouth surgery. - Severe burns. - Inflammation. - Improving antibiotic absorption. - Hay fever. - Preventing cancer. - Shortening of labor. - Ulcerative colitis. - Other conditions. More evidence is needed to rate the effectiveness of bromelain for these uses.					

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	e) Budesonide 9mg Extended Release Tablet Budesonide BP 9mg	It is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis	**Contraindications:** Known hypersensitivity to budesonide or any of the ingredients in this tablet**.** **Side Effects:** Most common adverse reactions (incidence ≥2%) are headache, nausea, decreased blood cortisol, upper abdominal pain, fatigue, flatulence, abdominal distension, acne, urinary tract infection, arthralgia, and constipation.	200mcg, 400mcg Inhalation Capsule	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		f) Dexpanthenol 5gm/100gm Ointment Dexpanthenol BP 5gm/100gm	It is used to treat vaginal yeast infections. This medication is an azole antifungal. It works by stopping the growth of yeast (fungus) that causes the infection. This medication is a moisturizer, prescribed for dry skin (xerosis). It forms an oily layer on the top of the skin thereby makes the skin softer.	**Contraindications:** Do not use dexpanthenol Ointment if: - You are allergic to any ingredient in dexpanthenol Ointment - Contact your doctor or health care provider right away if any of these apply to you. **Side Effects:** Skin- Irritation, burning and itching.	New		‡idv‡iÝ Ges c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	
		g) Fosfomycin 3gm/Sachet Granules for oral Solution Fosfomycin Tromethamine USP 5.631gm eq. to 3gm Fosfomycin/Sachet **Antibiotic**	It is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of *Escherichia coli and Enterococcus faecalis*. It is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with MONUROL, other therapeutic agents should be selected.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to the drug. **Side effects:** In clinical trials, the most frequently reported adverse events occurring in > 1% of the 314 study population regardless of drug relationship were: diarrhea 10.4%, headache 10.3%, vaginitis 7.6%, nausea 5.2%, rhinitis 4.5%, back pain 3.0%, dysmenorrheal 2.6%, pharyngitis 2.5%, dizziness 2.3%, abdominal pain 2.2%, pain 2.2%, dyspepsia 1.8%, asthenia 1.7%, and rash 1.4%. The following adverse events occurred in clinical trials at a rate of less than 1%, regardless of drug relationship: abnormal stools, anorexia, constipation, dry mouth, dysuria, ear disorder, fever, flatulence, flu syndrome, hematuria, infection, insomnia, mphadenopathy, menstrual disorder, migraine, myalgia, nervousness, paresthesia, pruritus, SGPT increased, skin disorder, somnolence,	New	USFDA	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	h) Lidocaine HCl 30mg + Hydrocortisone Acetate 5mg/gm Rectal cream Lidocaine HCl BP 30mg + Hydrocortisone Acetate BP 5mg/gm **Anesthetic + Anti-inflammatory (steroidal)**	Symptomatic relief of pain and irritation associated with haemorrhoids, anal fissure, pruritus ani, and proctitis and for palliative use postoperatively. This combination is intended for short-term palliative use only.	**Contraindications:** Children under 12 years; allergy to local anaesthetics of the amide type or to other components of the product; tuberculous, fungal or viral infections; traumatised mucosa and/or sepsis in anorectal region; concurrent oral or intravenous corticosteroid therapy. This drug should not be used on atrophic skin. **Side effects:** This drug is well tolerated. It may be used in patients with a previous history of allergy to procaine and other para-aminobenzoic acid derivatives. Contact sensitivity to lignocaine has been reported after perianal use and may also occur after the use of topical hydrocortisone. The following local reactions after treatment with corticosteroids have been reported: - atrophy of the skin, often irreversible, with thinning of the skin, telangiectasia, purpura and striae - rosacea-like and perioral dermatitis,with or without atrophy of the skin - rebound-effect, which may cause dependency on steroids - slowing of the healing process	Lidocaine 2% Gel, 5% ointment, 10% Spray, Hydrocortisone 1% Cream & Ointment		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	i) L-Methylfolate Calcium 3mg + Pyridoxal-5-Phosphate 35mg + Methylcobalamin 2mg Capsule L-Methylfolate Calcium INN 3mg + Pyridoxal-5-Phosphate INN 35mg + Methylcobalamin INN 2mg	It is used to treat patients who have too much homocysteine in their blood, especially patients who have certain blood vessel problems or decreased vitamin B12 levels. It may also be used to treat other conditions as determined by your doctor.	**Contraindications:** Do not use this medication if: you are allergic to any ingredient Contact your doctor or health care provider right away if any of these apply to you. **Side effects:** Side Effects that may occur while taking this medicine include headache; drowsiness; nausea; or mild, occasional diarrhea. Check with your doctor as soon as possible if you experience any numbness, tingling, or a sensation of swelling of your body. An allergic reaction to this medicine is unlikely, but seeks immediate medical attention if it occurs. Symptoms of an allergic reaction include rash, itching, swelling, dizziness, or trouble breathing. If you notice other effects not listed above, contact your doctor, nurse, or pharmacist. This is not a complete list of all side effects that may occur.	New		‡idv‡iÝ Ges c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv nj	
		j) Mepenzolate Bromide 25mg Tablet Mepenzolate Bromide INN 25mg **Anticholinergic**	It is indicated for use as adjunctive therapy in the treatment of peptic ulcer. It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.	**Contraindications:** ▪ Glaucoma ▪ Obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy) ▪ Obstructive disease of the gastrointestinal tract (for example, pyloroduodenal stenosis, achalasia) ▪ Paralytic ileus ▪ Intestinal atony of the elderly or debilitated patient ▪ Unstable cardiovascular status in acute gastrointestinal hemorrhage ▪ Toxic megacolon complicating ulcerative colitis ▪ Myasthenia gravis ▪ Allergic or idiosyncratic reactions to Mepenzolate Bromide or related	New	USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv nj

				compounds Mepenzolate Bromide may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug. **Side effects:** Precise frequency data from controlled clinical studies with Mepenzolate Bromide are not available. ▪ Gastrointestinal System: vomiting, nausea, constipation, loss of taste, bloated feeling, dry mouth ▪ Central Nervous System: mental confusion, dizziness, weakness, drowsiness, headache, nervousness ▪ Ophthalmologic: increased ocular tension, cycloplegia, blurred vision, dilation of the pupil ▪ Dermatologic-Hypersensitivity: anaphylaxis, urticaria ▪ Cardiovascular: tachycardia, palpitations ▪ Genitourinary: urinary retention, urinary hesitancy ▪ Miscellaneous: decreased sweating, drowsiness, insomnia, impotence, suppression of lactation				
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	k) Mirabegron 25mg Extended Release Tablet Mirabegron INN 25mg **β_3-Adrenoceptor Agonist**	It is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.	**Contraindications:** None **ADR/Side effects:** Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	l) Phenazopyridine HCl 200mg Tablet Phenazopyridine HCl USP 200mg **Analgesic**	It is used to relieve symptoms caused by irritation of the urinary tract such as pain, burning, and the feeling of needing to urinate urgently or frequently. This drug does not treat the cause of the urinary irritation, but it can help relieve the symptoms while other treatments take effect. It is a dye that works as a painkiller to soothe the lining of the urinary tract.	**Contraindications:** Do not take Phenazopyridine if you are allergic to phenazopyridine, or if you have kidney disease. Before using it, tell your doctor if you are allergic to any drugs, or if you have: • liver disease; • diabetes; or • A condition called G6PD (glucose-6-phosphate dehydrogenase) deficiency If you have any of these conditions, you may not be able to use Phenazopyridine, or you may need dosage adjustments or special tests during treatment. FDA pregnancy category B. Phenazopyridine is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether Phenazopyridine passes into breast milk or if it could harm a nursing baby. Do not use Phenazopyridine without telling your doctor if you are breast-feeding a baby. **ADR/Side effects:** Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using Phenazopyridine and call your doctor at once if you have any of these serious side effects: - pale skin, fever, confusion or weakness; - jaundice (yellowing of your skin or eyes); - urinating less than usual or not at all; - drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting; - swelling, weight gain, feeling short of breath; or - Blue or purple coloring in your skin. Less serious side effects of Phenazopyridine may include: o headache; o dizziness; o stomach pain, upset stomach; or o Skin itching.	New		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyb Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyb Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	m) Prednisolone 2mg Tablet Prednisolone BP 2mg	Moderate to severe rheumatoid arthritis in adults, particularly if joint pain and stiffness is worse in the morning.	**Contraindications:** - People with widespread infection, unless this is being treated with specific anti-infectives. - Corticosteroids should not be used for the management of head injury or stroke because they are unlikely to be of benefit and may even be harmful. - Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption (Lodotra tablets contain lactose). - This medicine is not recommended for children and adolescents. This medicine should not be used if you are allergic to any of its ingredients. Please inform your doctor or pharmacist if you have previously experienced such an allergy. If you feel you have experienced an allergic reaction, stop using this medicine and inform your doctor or pharmacist immediately. **ADR/Side effects:** Medicines and their possible side effects can affect individual people in different ways. The following are some of the side effects that are known to be associated with this medicine. Just because a side effect is stated here, it does not mean that all people using this medicine will experience that or any side effect. Common (affect between 1 in 10 and 1 in 100 people) • Headache. • Increased appetite and weight gain. • Cushing's syndrome, characterized by a moon-shaped face. • Decrease in the production of natural steroids by the adrenal glands (adrenal suppression – see warning section above). • Increased susceptibility to infections and increased severity of infections (see warnings above).	5mg, 10mg, 15mg Tablet	BNF-61 Page 171,173,448	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

				• Sodium and water retention. • Decrease in the level of potassium in the blood. • Raised blood sugar level and diabetes. • Raised levels of triglycerides in the blood (hypertriglyceridaemia). • Raised levels of cholesterol in the blood. (Hypercholesterolemia). • Eye problems such as cataract or glaucoma. • Insomnia (tell your doctor if you have lots of difficulty sleeping, as other steroids not taken at night may be better for you). • Disturbance in the normal numbers of blood cells in the blood.				
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	n) Propylthiouracil 50mg Tablet Propylthiouracil BP 50mg **Antithyroid agent**	It is indicated: • In patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option • to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole	**Contraindication:** Propylthiouracil is contraindicated in patients who have demonstrated hypersensitivity to the drug or any of the other product components. **ADR/Side effects:** Major adverse reactions (much less common than the minor adverse reactions) include inhibition of myelopoiesis (agranulocytosis, granulopenia, and thrombo-cytopenia), aplastic anemia, drug fever, a lupus-like syndrome including solenomegaly, hepatitis, periartentis, and hypoprothrombinemia and bleeding. Nephritis, glomerulonephritis, interstitial pneumonitis, exfoliative dermatitis, and erythema nodosum have been reported. Reports of a vasculitic syndrome associated with the presence of anti-neutrophilic cytoplasmic antibodies (ANCA) have also been received. Manifestations of ANCA-positive vasculitis may include rapidly progressive glomerulonephritis (crescentic and pauci-immune necrotizing glomerulonephritis) sometimes leading to acute renal	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

				failure; fever; pulmonary infiltrates or alveolar hemorrhage; skin ulcers; and leucocytoclastic vasculitis. Minor adverse reactions include skin rash, urticaria, nausea, vomiting, epigastric distress, arthralgia, paresthesias, and loss of taste, abnormal loss of hair, myalgia, headache, pruritus, drowsiness, neuritis, edema, vertigo, skin pigmentation, jaundice, sialadenopathy, lymphadenopathy, vasculitis, glomerulonephritis, and taste perversion. It should be noted that about 10% of patients with untreated hyperthyroidism have leukopenia (white blood cell count of less than 4,000/mm^3), often with relative granulopenia.				
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	o) Rabeprazole Sodium 5mg Delayed Release Capsule Rabeprazole Sodium 15.0% Pellets (Pharma grade) 33.333mg containing Rabeprazole Sodium INN 5mg **Antiulcerant (PPI)**	<u>Healing of Erosive or Ulcerative GERD in Adults</u> RABEPRAZOLE SODIUM is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course may be considered. <u>Maintenance of Healing of Erosive or Ulcerative GERD in Adults</u> It is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond12 months. <u>Treatment of Symptomatic GERD in Adults</u> It is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults. <u>Healing of Duodenal Ulcers in Adults</u>	**Contraindication:** It is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles or to any component of theformulation. For information about contraindications of antibacterial agent (clarithromycin and amoxicillin) indicated in combination with rabeprazole sodium, refer to the *Contraindications* section of their package inserts. **ADR/Side effects:** Worldwide, over 2900 patients have been treated with rabeprazole in Phase II-III clinical trials involving various dosages and durations of treatment. Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.	10mg & 20mg Tablet	USFDA	*c‡qvRb †bB wea vq Av‡e`b bvgÄy Ki v †h‡Z cv‡i |*	*c‡qvRb †bB wea vq Av‡e`b bvgÄy Ki v nj |*

			RABEPRAZOLE SODIUM is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. *Helicobacter pylori* Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults RABEPRAZOLE SODIUM in combination with amoxicillin and clarithromycin as a three drug regimen is indicated for the treatment of patients with *H. pylori* infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate *H. pylori*. Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults It is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger- Short-term Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older RABEPRAZOLE SODIUM is indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks. Treatment of GERD in Pediatric Patients 1 to 11 Years of Age It is indicated for treatment of GERD in children 1 to 11 years of age for up to 12 weeks				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	p) Simeprevir 150mg Capsule Simeprevir Sodium 154.40mg eq. to Simeprevir INN 150mg **Antiviral**	Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. SIMEPREVIR efficacy has been established in combination with peginterferon alfa and ribavirin, in HCV genotype 1 infected subject with compensated liver disease (including cirrhosis). The following points should be considered when initiating SIMEPREVIR for treatment of chronic hepatitis C infection: o Simeprevir must not be used as monotherapy. o Simeprevir efficacy in combination with peginterferon alfa and ribavirin is influenced by baseline host and viral factors and Clinical Studies o Simeprevir efficacy in combination with peginterferon alfa and ribavirin is substantially reduced in patients infected with HCV genotype 1a with an NS3 Q80K polymorphism at baseline compared to patients infected with hepatitis C virus (HCV) genotype1a without the Q80K polymorphism o Screening patients with HCV genotype1a infection for the presence of virus with the NS3 Q80K polymorphism at baseline is strongly recommended. Alternative therapy should be considered for patients infected with HCV genotype1a containing the Q80K polymorphism	**Contraindications:** Contraindications to peg interferon alfa and ribavirin also apply to Simeprevir combination treatment with peginterferon alfa and ribavirin. Simeprevir in combination with peginterferon alfa and ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant because of the risks for birth defects and fetal death associated with ribavirin Refer to the respective prescribing information for a list of the contraindications for peginterferon alfa and ribavirin **ADR/Side effects:** Simeprevir should be administered with peginterferon alfa and ribavirin. Refer to the prescribing information of peginterferon alfa and ribavirin for a description of adverse reactions associated with their use. The following serious and otherwise important adverse drug reactions (ADRs) are discussed in detail in another section of the labeling: • Embryo-Fetal Toxicity (Use with Ribavirin and Peginterferon alfa) • Photosensitivity • Rash	New	USFDA	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
		r) Vortioxetine HBr 10mg Tablet Vortioxetine HBr 12.71mg eq. to Vortioxetine 10mg **Antidepressant**	It is indicated for the treatment of major depressive disorder (mdd). The efficacy of vortioxetine was established in six 6 to 8 week studies (including one study in the elderly) and one maintenance study in adults.	**Contraindications:** Hypersensitivity to vortioxetine or any components of the formulation. Angioedema has been reported in patients treated with Vortioxetine HBr. \The use of MAOIs intended to treat psychiatric disorders with Vortioxetine HBr or within 21 days of stopping treatment with Vortioxetine HBr is contraindicated because of an increased risk of serotonin syndrome. The use of Vortioxetine HBr within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated Starting Vortioxetine HBr in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome **Side effects**: The following adverse reactions are discussed in greater detail in other sections of the label. • Hypersensitivity • Clinical Worsening and Suicide Risk • Serotonin Syndrome • Abnormal Bleeding • Activation of Mania/Hypomania • Hyponatremia	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		s) Vortioxetine HBr 20mg Tablet Vortioxetine HBr 25.42mg eq. to Vortioxetine 20mg **Antidepressant**	Do	Do	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	t) Phosphorated Carbohydrate Solution (Sucrose 74.80gm + Phosphoric Acid 0.430gm per 100ml Syrup) Sucrose (as total sugar) BP 74.80gm + Phosphoric Acid BP 0.430gm/100ml	Phosphorated carbohydrate solution is used for the relief of nausea from upset stomach caused by flu, food or drink.	**Contraindications** Some medical conditions may interact with Phosphorated Carbohydrate solution. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you: - if you are pregnant, planning to become pregnant, or are breast-feeding - if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement - if you have allergies to medicines, foods, or other substances - if you have diabetes Some medicines may interact with Phosphorated Carbohydrate solution. However, no specific interactions with Phosphorated Carbohydrate solution are known at this time. This may not be a complete list of all interactions that may occur. Ask your health care provider if Phosphorated Carbohydrate solution may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine. **Side effects:** Side effects that you should report to your doctor or health care professional as soon as possible: o allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue o diarrhea o Stomach pain**.**	New		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	u) Zinc Oxide (Microfine) 10% + Octyl Methoxycinnamate 7% + 4 -Methylbenzylidene camphor 3.5% + Avobenzone 1% Cream Zinc Oxide (Microfine) INN 10gm + Octyl Methoxycinnamate INN 7gm + 4 -Methylbenzylidene Camphor INN 3.5gm + Avobenzone INN 1gm/100gm	Help prevent premature skin - aging and skin cancer and to protect against photosensitive dermatoses. Used in conjunction with hydroquinone to treat dark lesions e.g., melasma and hyperpigmented spots for post-operative skin.	**Contraindications:** Avoid contact with eyes. Discontinue use if there are signs of irritation. **Side effects:** Signs of irritations (including erythema, burning or rash) may appear when applied to sensitive or broken skin	New		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		v) Naproxen Sodium 220mg + Diphenhydramine HCl 25mg Tablet Naproxen Sodium USP 220mg + Diphenhydramine HCl USP 25mg **Analgesic + Antihistamine**	Naproxen is a nonsteroidal anti-inflammatory drug (NSAID). Naproxen works by reducing hormones that cause inflammation and pain in the body. It is used to temporarily relieve minor aches and pains due to arthritis, muscular aches, backache, menstrual cramps, headache, toothache, and the common cold. It is also used to temporarily reduce fever. It may also be used for purposes not listed in this medication guide.	**Contraindication:** You should not use Naproxen & Diphenhydramine HCl if you have a history of allergic reaction to aspirin or other NSAID (nonsteroidal anti-inflammatory drug). Naproxen & Diphenhydramine HCl may increase your risk of heart attack or stroke, especially if you use it long term or have heart disease. Do not use this medicine just before or after heart bypass surgery (coronary artery bypass graft, or CABG). Naproxen & Diphenhydramine HCL may also cause stomach or intestinal bleeding, which can be fatal. These conditions can occur without warning while you are taking Naproxen & Diphenhydramine HCL. **Side effects:** Get emergency medical help if you have any of these signs of an allergic reaction to Naproxen & Diphenhydramine HCL: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using Naproxen & Diphenhydramine HCL and call your doctor at once if you have: - chest pain, weakness, shortness of breath, slurred speech, problems with vision or balance; - black, bloody, or tarry stools; - coughing up blood or vomit that looks like coffee grounds;	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj

				- swelling or rapid weight gain, little or no urinating; - nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); - bruising, severe tingling, numbness, pain, muscle weakness; - fever, headache, neck stiffness, chills, increased sensitivity to light, purple spots on the skin, and/or seizure (convulsions) or - severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling. Common Naproxen & Diphenhydramine HCL side effects may include: - upset stomach, mild heartburn or stomach pain, diarrhea, constipation; - bloating, gas; - dizziness, headache, nervousness; - skin itching or rash; - blurred vision; or - Ringing in your ears.				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	w) Doxylamine Succinate 10mg + Pyridoxine HCl 10mg Tablet Doxylamine Succinate BP 10 mg + Pyridoxine HCl BP 10mg **Anticholinergic + Vitamin**	It is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.	**Contraindications:** It is contraindicated in women with any of the following conditions: - Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation - Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of this drug **Side Effects:** The following adverse reactions are discussed elsewhere in the labeling: - Somnolence - Fall or other accidents resulting from the effect of the combined use of this drug with CNS depressants including alcohol	New		c‡qvRb ‡bB wea|q Av‡e`b bvgÄÿ Ki| ‡h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Ki| nj |
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	x) Sodium Alginate 225mg + Magnessium Alginate 87.5mg/Sachet Powder for suspension Sodium Alginate BP 225.0mg + Magnessium Alginate INN 87.5mg/Sachet	It helps to prevent gastric regurgitation in infants where competence of the cardiac sphincter has not been fully established. The indications for use are gastric regurgitation, gastro-oesophageal reflux and reflux associated with hiatus hernia in infants and young children.	**Contraindication:** Contraindicated in cases of intestinal obstruction and in cases of established diarrhoea. Not to be used except on a doctor or other health professionals recommendation. Not to be used in situations where excessive water loss is likely, e.g. fever, diarrhoea, vomiting or high room temperature. Not to be used in gastroenteritis where the appropriate treatment is rehydration with fluid replacement. Not to be used when treating infants with known or suspected impairment of renal function as the sodium content (approximately 21 mg or 0.92 mmol per dose) may add to the risk of hypernatraemia. **Side Effects:** It's mode of action is physical, resulting in a thickening of the gastric contents. An excessive concentration of Gaviscon Infant may lead to gastric distension.	New	BNF-61 Page: 47	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Ki| †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Ki| nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
10.	Radiant Pharmaceuticals Ltd., Tongi, Gazipur.	a) Biotin 5000mcg Tablet Biotin BP 5000 mcg	Biotin, one of the B-complex vitamins, is an essential nutrient functioning as a part of the enzyme systems of the human body that are involved in carboxylation and decarboxylation reactions. Biotin deficiency may result in the urinary excretion of organic acids and changes in skin and hair.	**Contraindications:** It is Contraindicated in patients having hypersensitivity to biotin or any other excipients of formulation. **Side Effects:** Although very rare, allergic skin reactions (urticaria) and gastrointestinal upset have occurred in some cases.	New	USFDA	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	
		b) Vitamin C Extended Release 1000mg Capsule Vitamin C extended release pellets (Ready to fill pellets, potency 92%) Ph. Grade. 1086.95mg eq. to Ascorbic Acid BP 1000mg	It is indicated mainly in the prevention and treatment of ascorbic acid deficiency. It is also indicated in following conditions: • Vitamin C supports a healthy cardiovascular function • Vitamin C is Key to the production of collagen • Vitamin C strengthens blood vessels • It supports healthy brain function • It increases iron absorption • Vitamin C is needed for proper adrenal gland function • Vitamin C promotes healthy healing of wounds and burns • Vitamin C promotes a healthy immune function • It decreases the length and severity of a cold/flu • It is a powerful antioxidant • It helps minimize the effects of bruising • Vitamin C is also important for gum health • It prevents scurvy • It also aids in absorption of vitamin E • It may support healthy histamine response	**Contraindications:** Contraindicated in patients having hypersensitivity to ascorbic acid or any other excipients of formulation. **Side Effects:** Vitamin C is likely safe for most people when taken by mouth in recommended doses or when applied to the skin. In some people, vitamin C might cause nausea, vomiting, heartburn, stomach cramps, headache, and other side effects. The chance of getting these side effects increases the more vitamin C you take. Amounts higher than 2000 mg per day are possibly unsafe and may cause a lot of side effects, including kidney stones and severe diarrhea. In people who have had a kidney stone, amounts greater than 1000 mg per day greatly increase the risk of kidney stone recurrence.	250mg, 500mg Tablet/Capsule 1000mg Effervescent Tablet		‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Radiant Pharmaceuticals Ltd., Tongi, Gazipur.	c) Naproxen 750mg Sustained Released Tablet Naproxen Sodium USP 821.40mg eq. to 750mg Naproxen **Analgesic**	It is indicated for Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gout, tendinitis, bursitis, mild to moderate pain, primary dysmenorrhea.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to Naproxen. It should not given to patients who have experienced Asthman, Articuria, Allergic Type Reactions after taking NSAIDS. Contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. **Side Effects :** Heart attack, stroke high blood pressure, heart failure from body swelling (fluid retention), kidney problems including kidney failure, bleeding and ulcers in the stomach and intestine, low red blood cells (anemia), life-threatening skin reactions, life-threating allergic reactions, liver problems including liver failure,asthma attacks in people who have asthma. Stomach pain, constipation, diarrhea, gas, heartburn, nausea, vomiting, dizziness.	500mg, 250mg Tablet	USFDA	GB gv‡Îv c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	GB gv‡Îv c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Radiant Pharmaceuticals Ltd., Tongi, Gazipur.	d) Multi Vitamins & Multi Minerals Tablet (31 High potency multivitamin preparations with minerals & trace elements with lycopene) Ascorbic acid (Vitamin C, coated) USP 60.0mg + Beta Carotene (Dry powder, Potency 20%) BP 9.0mg (eq. to 1000IU Vit. A)+ Biotin USP 30 µg + Boron Citrate (Potency 5% Pharma Grade 3mg (eq.to150µgBoron) + Calcium Pantothenate USP10.88mg (eq. to 10mg Pantothenic acid) + Calcium Carbonate USP 344.60 mg (eq. 138mg Calcium) + Colecalciferol (Vitamin D3) BP 4.0mg(eq. to 400 IU Colecalciferol) + Chromium Chloride hexahydrate USP 0.76875mg (eq. to 150µg Chromium) + Cyanocobalamin (VitaminB12) (Potency 0.1%) BP 25.0mg (eq. to 25µg of Vit. B12) + Cupric Oxide USP 2.503 mg (eq. to 2mg Copper) + Dry Vitamin A Palmitate – 500 USP 8.0mg (eq. to 4000 IU Vit A) + Dry Vitamin E acetate (Potency 50% DC grade) (Alpha TocopherylAcetate) BP 90.0mg (eq. to 45IU Vit. E)+ Dibasic Calcium Phosphate USP 210.80mg (eq. to 48mg Phosphorous & 62mg Calcium) + Dry Vitamin K, (Phytonadione) (Potency5%) USP 0.3mg (eq. to 15 µg Phytonadione) + Folic Acid USP 400 µg + Lutein (potency 5%) USP 5mg (eq. to 250µg Lutein) + Magnesium Oxide (Heavy) USP165.00mg (eq. to 100mg Magnesium) + Manganese Sulphate USP6.15mg (eq. to 2mg Manganese) + Niacin (Nicotinamide) USP 20.0 mg + Nickel Sulphate Hexahydrate USP	Multi-vitamin & Multi-minerals A-Z tablet is a once-daily tablet indicated for use to improve the nutritional status of women throughout pregnancy and in the postnatal period for both lactating and non-lactating mothers.This tablet is also indicated to meet the increased demands of vitamins and minerals in the conditions like – physical emotional stress, chronic disease, infection illness, osteoporosis, injuries & wound surgery,poor digestion,old age.	**Contraindication**: This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. **Side effects:** A 31 High potency multivitamin preparation with minerals & trace elements tablet is generally well tolerated.	Multi-vitamin & minerals A-Z tablet; **Additional Lycopene**		c‡qvRb †bB wea vq Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄÿ Kiv nj	

			0.0224mg (eq. to 5µg Nickel) + Potassium Chloride USP 152.52mg (eq. to 72mg Chloride & 80mg Potassium) + Potassium Iodide BP 0.196mg (eq. to150µg Iodine) + Pyridoxine Hydrochloride (Vit. B6) BP 2.0 mg + Riboflavin BP 1.7 mg + Sodium Selenate USP 0.0438mg (eq. to 20µg Selenium) + Sodium Molybdate Dihydrate BP 0.189mg (eq. to 75µg Molybdenum) + Silicon Dioxide USP 4.279 mg (eq. to 2mg Silicon) + Sodium Metavandate Tetrahydrate Pharma Grade0.239mg (eq. to10µg Vanadium) + Thiamine Mononitrate USP 1.85 mg (eq. to1.5mg Thiamine)+Zinc Oxide BP18.66mg (eq. to 15mg Zinc) + Lycopene (potency 10%)USP 3.00mg (eq. to 300µg Lycopene)						
	Radiant Pharmaceuticals Ltd., Tongi, Gazipur.	**e)**	Methyltetrahydrofolate 800mcg Tablet L-5 Methyltetrahydrofolate INN 0.80mg	a) Folate-deficient megaloblastic anaemia b) Prophylaxis in chronic haemolytic states, malabsorption,or in renal dialysis c) prophylaxis in pregnancy	**Contraindication**: Cautions should never be given alone for pernicious Anaemia and other vitamin-B eficiency states (may precipitate subacute combined degeneration of the spinal cord). **Side effects:** Folic acid is generally well tolerated. Gastrointestinal disturbances and hypersensitivity reactions have been reported rarely.	Levomefolate Calcium 0.451 mg	USFDA	*GB gv Îv c‡qvRb †bB wea vq Av‡e`b bvgÄy Ki v †h‡Z cv‡i |*	*GB gv Îv c‡qvRb †bB wea vq Av‡e`b bvgÄy Ki v nj |*
11.	Pharmacil Limited. Tongi, Gazipur.	**a)**	Clonazepam 0.25mg Chewable Tablet Clonazepam USP 0.25mg **Anticonvulsant**	Seizure Disorder & Panic Disorder. Most clinical forms of epilepsy in infants and children, in particular typical and atypical absences (Lennox-Gastaut syndrome), nodding spasms, primary or secondary generalised tonic-clonic seizures. It may also be used in epilepsy of adults and in focal seizures.	**Contraindications:** It must not be used in patients with known hypersensitivity to benzodiazepines or pf the medicines excipients. Clonazepam must not be used in patients with severe respiratory insufficience or severe hepatic insufficience. **Side effects:** Immune system Disorders: Allergic reactions and very few cases of anaphylaxis have been reported to occur with benzodiazepines. **Eye Disorders:** Particularly in long-term of high-dose treatment, reversible disorders of vision may occur. **Cardiac Disorders:** Cardiac failure including cardiac arrest has been reported. Gastrointestinal Disorders: The following effects have been reported in rare cases: nausea and epigastric symptoms. Renal and Urinary Disorders: In rare cases urinary incontinence may occur.	0.5 mg, 1mg, 2 mg Tablet	USFDA	*GB gv Îv c‡qvRb †bB wea vq Av‡e`b bvgÄy Ki v †h‡Z cv‡i |*	*GB gv Îv c‡qvRb †bB wea vq Av‡e`b bvgÄy Ki v nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
12.	Popular Pharmaceuticals Limited	a) Bisoprolol Fumarate 5 mg + Amlodipine 5mg Film Coated Tablet Bisoprolol Fumarate USP 5.00mg + Amlodipine Besilate BP 6.93mg eq. to Amlodipine 5mg **Antihypertensive**	It is indicated for the treatment of hypertension, alone or with other antihypertensive agents. It may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. It is also used to treat angina pectoris, stable chronic heart failure.	**Contraindications:** It is contraindicated in patients who are hypersensitive to any component of this product or to any of its ingredients. **Side effects:** The common side effects include edema, upper respiratory tract infection, hypotension, dizziness, headache, nausea, vomiting, diarrhoea, constipation, hypersensitivity reactions (itching, flush, rash) etc.	Bisoprolol 2.5mg, 5mg & 10mg Tablet, Amlodipine 5mg & 10mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj	
		b) Cefixime 1gm + Clavulanic Acid 0.625gm/ 100ml Powder for Suspension Cefixime BP 1.00gm + Diluted Clavulanate Potassium BP 1.4892gm eq. to Clavulanic Acid 0.625gm/ 100ml	It should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Cefixime-Clavulanic Acid is indicated for the treatment of – 1) Uncomplicated Urinary Tract Infections. 2) Otitis Media. 3) Pharyngitis and Tonsillitis. 4) Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis. 5) Uncomplicated gonorrhea etc.	**Contraindications:** It is contraindicated in patients with known allergy to the Cephalosporin class of antibiotics. Clavulanic Acid does not inactivate all β-Lactamases. Most chromosomally mediated β-Lactamases, the enzyme produced by pseudomonas aeruginosa, are resistant to its action. Other organisms have different mechanisms of acquired resistance to β-Lactam antibiotics, against which clavulanic acid is ineffective. **Side effects:** Common side effects are diarrhea and stool changes. Events like nausea/ vomiting, transient elevation in liver transaminases, alkaline phosphatase and jaundice can also occur. Thrombocytosis, thrombocytopenia, leucopenis, hypereosinophilia, neutropenia and agranulocytosis may also occur. Other adverse events that may occur are abdominal pain, abdominal cramps, flatulence, indigestion, headache, vaginitis, vulvar itch, rash, hives, itch, dysuria, chills, chest pain, shortness of breath, mouth ulcers, swollen tongue, sleepiness, thirst, anorexia.			‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Popular Pharmaceuticals Limited	c) Ebastine 10mg + Montelukast 10mg Film Coated Tablet Ebastine BP 10mg + Montelukast Sodium BP 10.40mg eq. to Montelukast 10mg **Leukotriene receptor antagonist + Antiasthmatic**	It is indicated for the prophylaxis and chronic treatment of Asthma, Exercise-Induced Bronchoconstriction & Allergic Rhinitis	**Contraindications:** Hypersensitivity to any component of this product **Side effects:** The most frequently occurring adverse effects of Ebastine are: headache, dry mouth, drowsiness, nausea, and insomnia. The most frequently occurring adverse effects of Montelukast are: headache; stomach pain, heartburn, upset stomach, nausea, diarrhea; tooth pain; tired feeling; fever, stuffy nose, sore throat, cough, hoarseness; or mild rash.	Ebastine 10mg Tablet, 5mg/5ml Syrup Montelukast 4mg, 5mg & 10mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB wea vq Av‡e`b bvgÄyb Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wea vq Av‡e`b bvgÄyb Kiv nj	
		d) Olmesartan Medoxomil 40mg + Amlodipine 10mg Film Coated Tablet Olmesartan Medoxomil BP 40mg + Amlodipine Besilate BP 13.860mg eq. to Amlodipine 10mg **Antihypertensive**	It is a combination of dihydropyridine calcium channel blocker and angiotensin II receptor blocker combination product indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated as initial therapy in patients likely to need multiple anti - hypertensive agents to achieve their blood pressure goals.	**Contraindications:** None. **Side effects:** Most common adverse reaction (incidence ≥3%) is edema.	Olmesartanl 40mg + Amlodipine 5mg Tablet Olmesartanl 20mg + Amlodipine 5mg Tablet	**USFDA**	c‡qvRb †bB wea vq Av‡e`b bvgÄyb Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyb Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
13.	Beacon Pharmaceuticals Ltd.	a) Megestrol Acetate 40mg Tablet Megestrol Acetate USP 40 mg **Antineoplastic**	It is indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy.	**Contraindication** History of Hypersensivity to megestrol acetate or any component of the formulation. Side-effect: **Weight Gain:** Weight gain is a frequent side effect of Megace. This gain has been associated with increased appetite and is not necessarily associated with fluid retention. Thromboembolic Phenomena: Thromboembolic phenomena including thrombophlebitis and pulmonary embolism (in some cases fatal) have been reported. **Other Adverse Reactions:** Heart failure, nausea and vomiting, edema, breakthrough menstrual bleeding, dyspnea, tumor flare (with or without hypercalcemia), hyperglycemia, glucose intolerance, alopecia, hypertension, carpal tunnel syndrome, mood changes, hot flashes, malaise, asthenia, lethargy, sweating and rash.		USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) Trihexiphenidyl HCl 0.1gm/100ml Syrup Trihexiphenidyl HCl USP 0.1gm/100ml **Antiparkinsonian**	Parkinsonism; drug induced extrapyramidal symptoms (but not tardive dyskinesia).	**Contraindication:** Should be avoiding in gastro-intestinal obstruction and myasthenia gravis. **Side-effect:** Side effects include constipation, dry mouth, nausea, vomiting, tachycardia, dizziness, confusion, euphoria, hellucinations, impaired memory, anxiety, restlessness, urinary retention, blurred vision, and rash. Angle-closure glaucoma may occur very rarely.	New	BNF-61 Page No-307	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beacon Pharmaceuticals Ltd.	c) Erdosteine 300mg Capsule Erdosteine BP 300 mg **Mucolytic agent**	Symptomatic treatment of acute exacerbations of chronic bronchitis.	**Contraindication:** Contraindicated in know hypersensitivity to Erdosteine and if patient have severe liver failure, decreased kidney function and stomach ulcer. **Side-effect:** Very rarely nausea, vomiting, diarrhea abdominal pain, taste disturbance, headache, rash, and urticaria.		BNF-61 Page No-203	c‡qvRb ‡bB wea|q Av‡e`b bvgÄyi Kiv ‡h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		d) Cytarabine 500mg/Vial Injection Cytarabine USP 500mg /Vial **Antimetabolite**	It is indicated for the intrathecal treatment of lymphomatous meningitis.	**Contraindications:** It is contraindicated in patients who are hypersensitive to cytarabine or any component of the formulation, and in patients with active meningeal infection. **Side-effect:** The toxicity database consists of the observations made during Phase 1-4 studies. The most common adverse reactions in all patients and in patients with lymphoma are shown in Table 2 below.Arachnoiditis is an expected and well-documented side effect of both neoplastic meningitis and of intrathecal chemotherapy. The incidence of severe and life-threatening arachnoiditis in patients receiving DepoCyt was 19% (48/257) in all patients and 30% (10/33) in patients with lymphomatous meningitis. The incidence of symptoms possibly reflecting meningeal irritation are shown in Table.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beacon Pharmaceuticals Ltd.	e) Indomethacin 1mg/Vial Injection Indomethacin USP 1mg/Vial **Analgesic**	Indomethacin for Injection is a cardiovascular drug indicated: To close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1750g.	**Contraindication** Indomethacin for Injection is contraindicated in neonates: With Proven or suspected infection that is untreated. Who are bleeding, especially those with active intracranial hemorrhage or gastrointestinal bleeding. **Side-effect:** Most common adverse reactions are bleeding problems, higher incidence of transient oliguria and elevations of serum creatinine.	25mg & 75mg Capsule; 100mg Suppository	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		f) Edetate Calcium Disodium 200 mg/ml Injection Edetate Calcium Disodium USP 200 mg/ml **Heavy Metal Antagonist**	It is indicated for the reduction of blood levels and depot stores of lead in lead Poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead.	**Contraindications:** It should not be given during periods of anuria, nor to patients with active Renal disease or hepatitis. **Side-effect:** The following adverse effects have been associated with the use of edetate calcium disodium: Body as a Whole : pain at intramuscular injection site, fever, chills, malaise, fatigue, myalgia, arthralgia. Cardiovascular : hypotension, cardiac rhythm irregularities. Renal : acute necrosis of proximal tubules (which may result in fatal nephrosis), infrequent changes in distal tubules and glomeruli.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		g) Biotin 5mg Tablet Biotin BP 5mg **Vitamin**	It is used to prevent or treat Biotin deficiency in case of: Defects of biotin metabolism Isolated carboxylase defects	**Contraindication**: It is contraindicated in patients allergic or hypersensitive to any of its ingredients. **Side-effect:** Side effects from biotin supplements should not occur if the vitamin is taken within recommended amounts. Biotin supplements might interact with certain antibiotics and alcohol. Certain anti-seizure medicines might reduce the blood levels of Biotin. The bacteria that produce Biotin in the intestine could be affected by certain broad spectrum antibiotics. Biotin may increase the effects of lipid-lowering medicines.	New	BNF	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Beacon Pharmaceuticals Ltd.	h) Atosiban Acetate 7.5 mg/ml Injection Atosiban Acetate INN 7.5 mg/ml **Tocolytic agent**	It is indicated to uncomplicated premature labour	**Contraindication**: Eclampsia and severe pre-eclampsia, intra-uterine infection, intra-uterine fetal death, antepartum haemorrhage (requiring immediate delivery), placenta praevia, abruptio placenta, intra-uterine growth restriction with abnormal fetal heart rate, premature rupture of membranes after 30 weeks' gestation Hepatic impairment:-no information available Renal impairment: - no information available **Side-effect:** nausea, vomiting, tachycardia, hypotension, headache, dizziness, hot flushes, hyperglycaemia, injection-site reaction; less commonly pruritus, rash, fever, insomnia	New	BNF-61 Page No-489-490	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
14.	Momtaz Pharmaceuticals Ltd.	a) Hydrogen Peroxide 6% Solution Hydrogen Peroxide 50% BP 12 ml/100 ml	Hydrogen Peroxide is an oxidizing agent used as an antiseptic, disinfectant and deodorant.	**Contraindications:** The drug is contraindicated for the patients with known hypersensitive to this product or any of its components. **Side-effects:** Irritating burns on the skin reversible hypetrophy of the papillae of the tongue. Colonic lavage with solution of hydrogen peroxide has been followed by gas emboilism, repture of the colon, proctitis, ulcerative colitis and gangrene of the intestine.	New		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
15.	**Acme Laboratories Ltd.**	a) Guaifenesin 600mg Extended Release Tablet Guaifenesin USP 600mg **Expectorant**	➢ Helps loosen phlegm and thin bronchial secretions. ➢ Symptomatic relief of deep chesty coughs. ➢ Expectorant for productive cough.	**Contraindications:** Hypersensitivity (allergy) to the active substance or to any of the ingredients. **Side effects:** Guaifenesin has occasionally been reported to cause gastrointestinal (stomach) discomfort, nausea and vomiting, particularly in high doses. Kidney stones have been reported in patients seeking to abuse the sympathomimetic (decongestant) or opiate component of combination products; which resulted in them taking large doses of Guaifenesin for long periods of time; doses up to 24 g per day have been reported. The development of kidney stones in single active preparations of Guaiphenesin like Mucinex is extremely rare.	New	USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄ¡ Ki v †h‡Z cv‡i |	c‡qvRb †bB wea vq Av‡e`b bvgÄ¡ Ki v nj |
	b) Mesalamine 400mg Delayed-Release Tablet Mesalamine USP 400 mg **Gastrointestinal Agent**	It is an aminosalicylate indicated for: 1. Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. 2. Maintenance of remission of ulcerative colitis in adults.	**Contraindication:** Patients with hypersensitivity to salicylates or to any of the components of the product. **Side effects:** The most common adverse reactions (observed in greater than or equal to 5 percent of adults in controlled clinical studies) were abdominal pain, eructation, pain, back pain, rash, dyspepsia, rhinitis, flu syndrome, asthenia, flatulence, vomiting, fever, arthralgia, constipation, and gastrointestinal bleeding.	New	USFDA	Ab¨gv`b Ki v †h‡Z cv‡i |	Ab¨gv`b Ki v nj |
	c) Mesalamine 800mg Delayed-Release Tablet Mesalamine USP 800 mg **Gastrointestinal Agent**	It is an aminosalicylate indicated for the treatment of moderately Active ulcerative colitis in adults. **<u>Limitation of Use</u>:** Safety and effectiveness of Asacol HD beyond 6 weeks have not been established.	**Contraindication:** Patients with known hypersensitivity to salicylates or aminosalicylates or any of the components of this product. **Side effects:** The most common adverse reactions (observed in greater than 2% percent) were headache, nausea, nasopharyngitis, abdominal pain, and worsening of ulcerative colitis.	New	USFDA	GB gv‡Îv c‡qvRb †bB wea vq Av‡e`b bvgÄ¡ Ki v †h‡Z cv‡i |	GB gv‡Îv c‡qvRb †bB wea vq Av‡e`b bvgÄ¡ Ki v nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Acme Laboratories Ltd	d) Aclidinium 322mcg Powder for Inhalation Capsule Aclidinium Bromide INN 375 mcg eq. to 322mcg of Aclidinium **Bronchodilator**	It is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.	**Contraindication:** None **Side effects:** Most common adverse reactions (≥3% incidence and greater than placebo) are headache, nasopharyngitis and cough.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		e) Mirabegron 25mg Extended Release Tablet Mirabegron INN 25 mg **β3-Adrenoceptor Agonist**	It is a Beta-3 Adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.	**Contraindication:** None **Side effects:** Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		f) Mirabegron 50mg Extended Release Tablet Mirabegron INN 50 mg **β3-Adrenoceptor Agonist**	It is a Beta-3 Adrenergic Agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.	**Contraindication:** Contraindicated in patients with known hypersensitivity to Mirabegron or any other components of the product. **Side effects:** Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache.	New	USFDA	c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
16.	Opso Saline Ltd. Bagura road, Barisal, Bangladesh	**a)** Dexamethasone Sodium Phosphate 0.1% + Moxifloxacin HCl 0.5% Eye Drop Dexamethasone Sodium Phosphate BP 100mg + Moxifloxacin BP 500 mg (as Moxifloxacin HCl 545.50 mg) **Anti-inflammatory + Antibiotic (Ophthalmic)**	It is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. The combination can also be used for post-operative inflammation and any other ocular inflammation associated with infection.	**Contra-indication:** It is contraindicated in epithelial herpes simplex keratitis (Dendritic keratitis), vaccinia, varicella, and in many other viral diseases of the conjunctiva and cornea, Mycobacterial infection of the eye and fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication. **Side Effects:** The most frequently reported drug-related undesirable effects seen with moxifloxacin are conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis. Secondary Infection.	Dexamethasone 0.1% Eye drops, Moxifloxacin 0.5% sterile eye drops		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
17.	Opsonin Pharma Limited**,** Bagura Road, Barisal.	**a)** Azelastine HCl 137 mcg + Fluticasone Propionate 50mcg/0.137ml Nasal Spray Azelastine HCl BP 137 mcg + Fluticasone Propionate BP 50mcg/0.137 ml **Antihistamine + Steroid**	This nasal spray containing an H1-receptor antagonist and a corticosteroid, is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 12 years of age and older who require treatment with both azelastine hydrochloride and fluticasone propionate for symptomatic relief.	**Contraindication:** None. **Side effects:** The most common adverse reactions (≥2% incidence) are: dysgeusia, epistaxis, and headache.	Azelastine HCl 137 mcg/spray Fluticasone propionate 50mcg/spray	USFDA, BNF 65	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		b) Glycerol 11.25% Gel Glycerol BP 11.25 gm/100 gm **Topical emollients**	Helps lubricating in sex intercourse, Helps lubricating in body massage; Topical (for the skin) emollients are used to treat or prevent dry skin. Topical emollients also treat acne, chapped lips, diaper rash, cold sores, or other minor skin irritation, for lubrication during vaginal examinations, endoscopy, catheterization, for gloves and instruments.	**Contraindication:** Sensitivity to glycerol. **Side effects:** Hives, difficult breathing, swelling of face, lips, tongue, or throat, burning, stinging, redness, or irritation on the applied side.	1.15 gm & 2.30gm Suppository		Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Opsonin Pharma Limited, Bagura Road, Barisal.	**c)** Aceclofenac 150mg/3ml Injection Aceclofenac BP 150 mg /3ml **NSAID**	It is indicated for the relief of mild to moderate pain, Post Surgical Pain & Post Traumatic Pain.	**Contraindications:** It is contraindicated in patients previously sensitive to aceclofenac or aspirin or other NSAIDs. It should not be administered to patients with active or suspected peptic ulcer or gastrointestinal bleeding and moderate to severe renal impairment. **Side effects:** Generally aceclofenac is well tolerated. The majority of side effects are reversible and mild which include gastrointestinal disorders (dyspepsia, abdominal pain, nausea and diarrhoea) and occasional occurrence of headache, dizziness or tiredness. Dermatological complaints including rash or itching, pruritus, abnormal hepatic enzyme levels and raised serum creatinine have occasionally been reported**.**	50mg, 100mg Tablet		‡idv‡iÝ Ges c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv nj
		d) Norepinephrine 4 mg /4ml Injection Norepinephrine bitartrate USP 7.975 mg eq. to 4mg Norepinephrine/ 4ml **Cardiac stimulant/ vasopressor**	For blood pressure control in certain acute hypotensive states (e.g. pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension.	**Contraindications:** Hypotensive, mesenteric or peripheral vascular thrombosis, during cyclopropane and halothane anesthesia. **Side effects:** Ischemic injury, Bradycardia, rise in blood pressure, arrhythmias, Anxiety, transient headache, Respiratory difficulty.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Opsonin Pharma Limited, Bagura Road, Barisal.	**e)** Paracetamol 10.0gm + DL-methionine 1.0gm /100ml Paediatric drops Paracetamol BP 10.0gm + DL-methionine BP 1.0gm /100ml **Antipyretic & analgesic + Antidote: Treatment of paracetamol poisoning**	For fever, any kind of mild to moderate pain & in any case of paracetamol overdose	**Contraindications:** Known sensitivity or allergy to any ingredient, liver disease and any paracetamol preparation. **Side effects:** Blood disorders & Skin rashes may occur	New		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj	
		f) Multivitamin Multimineral tablet Biotin BP 30 mcg + Boron 32 mcg + Chloride BP 58 mg + Chromium USP 120 mcg + Elemental Calcium BP 103.5 mg + Elemental Calcium USP 4.5 mg + Elemental Copper 700 mcg + Elemental Iron BP 6 mg + Elemental Manganese BP 2 mg + Elemental Zinc BP 7.5 mg + Folic Acid BP 400 mcg + Iodine BP 150 mcg + Magnesium BP 40 mg + Molybdenum BP 75 mcg + Niacin USP 20 mg + Nickel 5 mcg + Pantothenic Acid BP 10 mg + Phosphorous BP 80 mg + Phytosterols BP 800 mg + Potassium BP 64 mg + Selenium 20 mcg + Silicon USP 2 mg + Tin USP 10 mcg + Vanadium 10 mcg + Vitamin A BP 2500 IU + Vitamin A USP 1000 IU + Vitamin B1 USP 1.5 mg + Vitamin B12 BP 200 mcg + Vitamin B2 BP 1.7 mg + Vitamin B6 BP 5 mg + Vitamin C BP 60 mg + Vitamin D3 BP 400 IU + Vitamin E BP 30 IU + Vitamin K BP 25 mcg/Tablet **Multivitamin Multimineral**	It is primarily used for lowering high cholesterol; it may also be effective at promoting heart health due to the high content of vitamins B6 and B12, preventing free-radical damage due to the antioxidant content, which includes vitamins C and E maintaining a healthy blood pressure due to the calcium and folic acid content.	**Contraindications:** Multivitamin Multimineral tablet are contraindicated in patients with Sitosterolemia (phytosterolaemia). **Side effects:** Constipation, indigestion and nausea are some of the possible side effects. Side effects may also include muscle aches, intestinal cramps, and vomiting.	New		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Opsonin Pharma Limited, Bagura Road, Barisal.	**g)** Multivitamin Multimineral Tablet Biotin BP 40 mcg + Chromium USP 120 mcg + Elemental Copper 700 mcg + Elemental Iron BP 14 mg + Elemental Manganese BP 4 mg + Elemental Zinc BP 7.5 mg + Folic Acid BP 400 mcg + Ginkgo Biloba Extract USP 60 mg + Ginseng Extract USP 50 mg + Iodine BP 150 mcg + Molybdenum BP 75 mcg + Niacin USP 36 mg + Pantothenic Acid BP 10 mg + Selenium 70 mcg + Vitamin A BP 2666.4 IU + Vitamin B1 USP 4.2 mg + Vitamin B12 BP 18 mcg + Vitamin B2 BP 4.8 mg + Vitamin B6 BP 6 mg + Vitamin C BP 120 mg + Vitamin D3 BP 0.5 IU + Vitamin E BP 26.8 IU + Vitamin K BP 25 mcg **Multivitamin Multimineral**	It is indicated for treating vitamin & mineral deficiency. It is also used to improve mental & physical performance.	**Contraindications:** It is contraindicated in patients with Wilson's disease. **Side effects:** Constipation, indigestion, and nausea are some of the possible side effects of Multivitamin Multimineral Tablet.	New		‡idv‡iÝ Ges c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wevwq Av‡e`b bvgÄyi Kiv nj	
		h) Baclofen 100mg/100ml Oral Solution Baclofen BP 100mg100ml **Muscle Relaxant**	It is indicated for Spasm, Tension type headache, the alleviation of spasticity resulting from multiple sclerosis, spinal cord diseases, Muscle spasm of cerebral origin especially infantile cerebral palsy, Cerebrovascular accidents or neoplastic or degenerative brain disease.	**Contraindications:** It is contraindicated in patients with hypersensitivity to any component of this product. **Side effects:** The most common side-effects include drowsiness, nausea, dizziness, lassitude, lightheadedness, confusion, fatigue, muscular pain and weakness, and hypotension. Other side-effects include euphoria, hallucinations, depression, headache, tinnitus, convulsions, paraesthesias, slurred speech, dry mouth, taste alterations, vomiting, diarrhoea or constipation, ataxia, tremors, insomnia, visual disturbances etc.	5 mg, 10 mg & 25mg Tablet	MHRA, BNF 64 (Page no. 685)	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Opsonin Pharma Limited, Bagura Road, Barisal.	**i)** Domperidone 30 mg Sustained Release Capsule Domperidone SR Pellets (20%w/w) Ph. Grade 150mg eq. to Domperidone BP 30 mg **Antiemetic**	Stimulation of gut motility: Non–ulcer dyspepsia, Esophageal reflux and gastritis, Diabetic gastroparesis, functional dyspepsia, prevention and symptomatic relief of acute nausea and vomiting from any cause but specifically cytotoxic therapy, radio therapy and anti-parkinsonism therapy, management of migraine	**Contraindications:** It is contraindicated to the patients who have hypersensitivity to this drug and in case of neonates. **Side effects:** It may produce hyperprolactinemia. This may result galactorrhoea, breast enlargement and soreness and reduced libido. Dry mouth, thirst headache, nervousness, drowsiness, diarrhea, skin rash and itching may occur during treatment with Domperidone. Extra-pyramidal reactions are seen in 0.055 of patients in clinical studies.	10 mg tablet, 15 mg & 30 mg suppository, 60 ml suspension, 15 ml paediatric drop		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj
		j) Alpha Lipoic Acid 200 mg + Metformin HCl 500 mg Tablet Alpha Lipoic Acid USP 200mg + Metformin HCl USP 500 mg **Anti-diabetic Agents (Oxidant + Hypoglycemic)**	Type-II diabetes (non-insulin dependent diabetes); Type-I diabetes (insulin dependent diabetes) as adjuvant therapy in combination with insulin; obesity and insulin resistance; hyperlipoproteinemia, diabetic peripheral neuropathy etc.	**Contraindications:** Impaired renal function, acute complications (severe infections, major operations and trauma), before X-ray examinations with iodinated contrast materials, liver damage, alcoholism, deficiencies of vitamin B12, folic acid and iron, ketosis prone diabetes, severe cardiovascular or respiratory disease, general ill health (malnutrition, dehydration, etc), diabetes with significant late complications (nephropathy, retinopathy). **Side Effects:** Lactic acidosis, vitamin B12 and folate malabsorption, hypoglycemia, diarrhoea, skin reactions, other hypersensitivity reactions.			‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj
18.	General Pharmaceutical Ltd. Mouchak, Kaliakair, Gazipur	a) Apixaban 2.5mg Tablet Apixaban INN 2.5mg **Anticoagulant agent**	It is a factor Xa inhibitor anticoagulant indicated: - to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. - for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.	**Contraindications:** • Active pathological bleeding • Severe hypersensitivity to apixaban **Side Effects:** Most common adverse reactions (>1%) are related to bleeding.	New	USFDA & BNF	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
		b) Apixaban 5mg Tablet Apixaban INN 5mg **Anticoagulant agent**	Do	Do	New	USFDA & BNF	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	General Pharmaceutical Ltd. Mouchak, Kaliakair, Gazipur	c) Mirabegron 25mg ER Tablet Mirabegron INN 25mg **β3-Adrenoceptor Agonist**	It is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.	**Contraindications:** None **Side Effects:** Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		d) Mirabegron 50mg ER Tablet Mirabegron INN 50mg **β3-Adrenoceptor Agonist**	Do	Do	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		e) Atorvastatin 10mg + Ezetimibe 10mg Tablet Atorvastatin Calcium Trihydrate USP 10.82mg eq. to Atorvastatin 10mg + Ezetimibe INN 10mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. **Limitations of Use:** • No incremental benefit of this medicine on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. This medicine has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.	**Contraindications:** 1. Active liver disease or unexplained persistent elevations of hepatic transaminase levels. 2. Hypersensitivity to any component of it. 3. Women who are pregnant or may become pregnant. 4. Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Atorvastatin 10mg Tablet, Ezetimibe 10 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ wea|q Kw¤‡bkb Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ wea|q Kw¤‡bkb Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	General Pharmaceutical Ltd. Mouchak, Kaliakair, Gazipur	f) Atorvastatin 20mg + Ezetimibe 10mg Tablet Atorvastatin Calcium Trihydrate USP 21.64mg eq. to Atorvastatin 20mg + Ezetimibe INN 10mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. **Limitations of Use:** • No incremental benefit of this medicine on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. This medicine has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.	**Contraindications:** 1. Active liver disease or unexplained persistent elevations of hepatic transaminase levels. 2. Hypersensitivity to any component of it. 3. Women who are pregnant or may become pregnant. 4. Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Atorvastatin 20mg Tablet, Ezetimibe 10 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj |
19.	General Pharmaceutical Ltd., Unit-2 Karolsurichala, Mouchak, Kaliakair, Gazipur	a) Loteprednol Etabonate 0.5gm/100gm Eye Ointment Loteprednol Etabonate INN 0.5gm/100gm **Corticosteroid**	It is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.	**Contraindications:** It is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. **Side Effects:** The most common ocular adverse event, reported in 27%, is anterior chamber inflammation. Other common adverse events, with an incidence of 4-5%, are conjunctival hyperemia, corneal edema, and eye pain	Loteprednol Etabonate INN 0.5gm/100ml Ophthalmic Suspension	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	General Pharmaceutical Ltd. Unit-2 Karolsurichala, Mouchak, Kaliakair, Gazipur	b) Brinzolamide 1gm + Brimonidine Tratrate 0.2gm/100ml Ophthalmic Suspension Brinzolamide USP 1gm + Brimonidine Tratrate INN 0.2gm/100ml **Antiglaucoma**	It is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.	**Contraindications:** • Hypersensitivity to any component of this product • Neonates and infants (under the age of 2 years). **Side Effects:** Most common adverse reactions occurring in approximately 3 to 5% of patients included blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, eye allergy	Brinzolamide 1% Eye Drops Brimonidine Tartrate 0.2% Eye Drops	USFDA	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	
20.	Drug International Ltd.	a) Arachis Oil Extract of Coal Tar 0.3gm + Cade Oil 0.30gm + Coal Tar Solution 0.10 gm + Tar 0.30gm /100ml Topical Liquid (Shampoo) Arachis Oil Extract of Coal Tar BP 0.3gm + Cade Oil INN 0.30gm + Coal Tar Solution BP 0.10 gm + Tar BP 0.30gm /100 ml	Polytar Liquid is indicated in the treatment of scalp disorders including psoriasis, dandruff, seborrhoea, eczema and pruritus. Polytar Liquid is also of value in the removal of ointments and pastes used in the treatment of psoriasis.	**Contraindications:** Known hypersensitivity to the ingredients. **Side Effects:** Tar products may cause skin irritation, rashes and rarely photosensitivity. If irritation occurs and persists, treatment should be discontinued. Experience of many years of marketing has shown that the incidence of adverse reactions to Polytar Liquid is less than one percent. These reactions of erythema, dryness, contact dermatitis, irritation and acne-like eruptions are mild and of very low incidence. An increased risk of skin cancer in patients with psoriasis treated with a combination of coal tar and UVB radiation has been reported. There is no unequivocal evidence to link the use of topically applied coal tar products with skin cancer.	New	BNF 59 Page-705	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
21.	IBN SINA Pharmaceutical Ind .Ltd Shafipur, Kaliakoyr, Gajipur	a) Ospemifene 60mg Tablet Ospemifene INN 60 mg **Endocrine-Metabolic Agent**	It is an estrogen agonist/ antagonist indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.	Contraindications: Undiagnosed abnormal genital bleeding. Known or suspected estrogen-dependent neoplasia. Active DVT, pulmonary embolism (PE), or a history of these conditions Active arterial thromboembolic disease (for example, stroke and myocardial infarction [MI]), or a history of these conditions. Known or suspected pregnancy **Side Effects:** Adverse reactions (≥1 percent) include: hot flush, vaginal discharge, muscle spasms, genital discharge, and hyperhidrosis.	New	USFDA	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	
		b) Canagliflozin 100mg Tablet Canagliflozin Hemihydrate INN 102mg eq.to Canagliflozin 100mg **Antidiabetic**	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. **Limitation of Use:** • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis	**Contraindications:** History of serious hypersensitivity reaction to Canagliflozin. Severe renal impairment, ESRD, or on dialysis. **Side Effects:** Most common adverse reactions associated with Canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		c) Alpha 250mg Tablet Alpha Lipoic Acid USP 250 mg	It is used for nutritional supplementation, also for treating dietary shortage or imbalance. Treating type 2 diabetes. For improving symptoms such as burning, pain, and numbness in the legs and arms of people with diabetes. To protect the brain and nerve tissue.	**Contraindications:** Contraindication has not yet determined. **Side Effects:** Generally side effects are uncommon. These supplements could cause nausea, dizziness, or a rash. Topical alpha-lipoic acid can irritate the skin.	New		‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	IBN SINA Pharmaceutical Ind .Ltd Shafipur, Kaliakoyr, Gajipur	d) Ezetimibe 10 mg + Atorvastatin 40mg Tablet Ezetimibe INN 10 mg + Atorvastatin Calcium Trihydrate BP 43.36 mg eq.to Atorvastatin 40mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. **Limitations of Use:** • No incremental benefit of this medicine on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. This medicine has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.	**Contraindications:** Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10mg Tablet, Atorvastatin 40mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	IBN SINA Pharmaceutical Ind .Ltd Shafipur, Kaliakoyr, Gajipur	e) Ezetimibe 10 mg + Atorvastatin 10mg Tablet Ezetimibe INN 10 mg+ Atorvastatin Calcium Trihydrate BP 10.840 mg eq. to Atorvastatin 10 mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. **Limitations of Use:** • No incremental benefit of this medicine on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. This medicine has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.	**Contraindications:** Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10 mg Tabet Atorvastatin 10mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv nj |
		f) Ezetimibe 10 mg + Atorvastatin 20 mg Tablet Ezetimibe INN 10 mg +Atorvastatin Calcium Trihydrate BP 21.68 mg eqv. to Atorvastatin 20 mg **Antihyperlipidemic**	Do	Do	Ezetimibe 10 mg Tabet Atorvastatin 20mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbviK bvg		wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	IBN SINA Pharmaceutical Ind .Ltd Shafipur, Kaliakoyr, Gajipur	g)	Ezetimibe 10 mg + Atorvastatin 80 mg Tablet Ezetimibe INN 10 mg + Atorvastatin Calcium Trihydrate BP 86.72 mg eq.to Atorvastatin 80 mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments. **Limitations of Use:** • No incremental benefit of this medicine on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established. This medicine has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.	**Contraindications:** Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10 mg Tabet Atorvastatin 80mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj |
		h)	Cysteamine 0.44gm/100ml Ophthalmic Solution Cysteamine Hydrochloride INN 0.65gm eq.to Cysteamine 0.44gm/100ml	It is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis	**Contraindications:** None **Side Effects:** The most common adverse reactions (incidence approximately 10% or greater) are sensitivity to light, redness, eye pain/irritation, headache and visual field defects	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		i)	Tafluprost 0.0015gm/100ml Ophthalmic Solution Tafluprost INN 0.0015gm/100ml **Antiglaucoma**	It is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.	Contraindications: None **Side Effects:** Most common ocular adverse reaction is conjunctival hyperemia (range 4% – 20%).	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	IBN SINA Pharmaceutical Ind .Ltd Shafipur, Kaliakoyr, Gajipur	j) Mipomersen Sodium 200mg/Vial Injection Mipomersen Sodium INN 200mg/Vial	It is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH) **Limitations of Use:** • The safety and effectiveness of this medicine have not been established in patients with hypercholesterolemia who do not have HoFH. • The effect of this medicine on cardiovascular morbidity and mortality has not been determined. • The use of this medicine as an adjunct to LDL apheresis is not recommended.	**Contraindications:** Moderate or severe hepatic impairment, or active liver disease, including unexplained persistent elevations of serum transaminases (4) • Known sensitivity to product components. **Side Effects:** The most commonly reported adverse reactions (incidence ≥ 10% and greater than placebo) are injection site reactions, flu-like symptoms, nausea, headache and elevations in serum transaminases, specifically ALT.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
22.	Aristopharma Ltd.	a) Brinzolamide (Sterile & Micronised) USP 1gm + Brimonidine Tartrate INN 0.2gm/100ml Ophthalmic Suspension Brinzolamide (Sterile & Micronised) USP 1gm + Brimonidine Tartrate INN 0.2gm/100ml **Anti-glaucoma and Ocular hypertension**	It is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.	**Contraindications:** ➢ Hypersensitivity to any component of this product. ➢ Neonates and infants (under the age of 2 years). . **Side effects:** Most common adverse reactions occurring in approximately 3 to 5% of patients included blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, eye allergy.	Brinzolamide 1% Ophthalmic Suspension, Brimonidine Tartrate INN 0.2% Ophthalmic Suspension,	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Aristopharma Ltd.	b) Nepafenac 0.3% Sterile Ophthalmic Suspension Nepafenac (Micronised & Sterile) INN 0.3gm/100ml **Anti-inflammatory and analgesic.**	Nepafenac Ophthalmic Suspension 0.3% is indicated for the treatment of pain & inflammation associated with cataract surgery	**Contraindications:** Hypersensitive to any of the the ingredients in this formulation / other NSAIDs. **Side effects:** Most common adverse reactions (5 to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation.	Nepafenac 0.1% Ophthalmic Suspension	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		c) Amitriptyline HCl 25mg + Perphenazine 2mg Film Coated Tablet Amitriptyline HCl BP 25mg + Perphenazine BP 2mg **TCA-antipsychotic**	It is used to treat depression, particularly when Anxiety is also present.	**Contraindications:** It should not be used in those who are hypersensitive to any of the ingredients of the tablets, in patients with glaucoma, porphyria, urinary retention, congestive heart failure, arrhythmias, coronary artery disease, recent myocardial infarction, heart block, epilepsy, severely impaired liver function, mania; concurrent administration of other antidepressant drugs especially monoamine oxidase inhibitors (MAOI'S). Amitriptyline Hydrochloride and Perphenazine should not be used for patients with leucopenia, or with drugs liable to cause bone marrow depression. **Side effects:** The undesirable effects of the tablet correspond to the relative effects of Perphenazine and amitriptyline included in the drug. During treatment with amitriptyline, somnolence, anxiety, dizziness, tremor, cephalalgia, occasional slight extrapyramidal symptoms, ataxia, seizure crises, confusion, mainly in elderly persons, hallucinations, disturbance of orientation are experienced. As far as the circulatory system is concerned, orthostatinc hypotension, tachycardia, palpitations, hypertension, arrhythmias and disturbances of the myocardium conduction are reported. From the autonomous Neural System hypo salivation, constipation, adaptation difficulties, mydriasis, urine retention, paralytic ileus may appear. The gastrointestinal system may be effected so	Amitriptyline 10mg/25mg Tablet,	USFDA (Discontinued) & BNF	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj	

				that the patient may present nausea, vomitus, diarrhea, jaundice, enlargement of the parotids. Also, eosinophilia, thrombocytopenia and occasionally granulocytopenis, skin rashes, edema, petechiae, pyrexia, numbness of the extremities, paresthesias, enlargement of the breast, libido changes and increase or decrease of the body weight may be observed. Swelling of the testicles and gynecomastia to men and enlargement of the breasts and galactorrhea to women may also appear. There are also disturbances to the secretion of the antidiuretic hormone. Long-term therapy may cause opacities to the cornea and the lenses as well as retinitis.				
	Aristopharma Ltd.	d) Lactase 9000 IU Chewable Tablet Lactase USP 9000 IU **Digestive enzyme**	Preventing symptoms of lactose intolerance, such as cramps, diarrhea and gas, when milk products or lactose are taken by people with lactose intolerance. Lactase can be taken before consuming lactose or it can be added to milk.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to any of the ingredients of the product **Side effects:** Lactase seems to be safe for most people. It is an FDA-approved, nonprescription product available in the US. There are no reported side effects.	New		c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRbxqZv we‡ePbvq Abyhvqx `b Kiv nj	
		e) Ferrous Ascorbate 100 mg + Folic Acid 5mg + Zinc 22.5mg Film Coated Tablet Ferrous Ascorbate INN 100 mg + Folic Acid BP 5mg + Zinc Sulphate (Monohydrate) USP 61.80mg eq. to Elemental Zinc 22.5mg	It is indicated on prophylaxis of iron deficiency especially when inadequate diet calls supplementary zinc and iron during pregnancy and anemia.	**Contraindications:** This product is contraindicated in patients with haemolytic anaemia and in conditions with increased hypersensitivity to any of the ingredients of the product and increased body iron content. **Side effects:** Side effects are mild and transient. These include epigastric pain, nausea, constipation, vomiting, diarrhea, heart burn etc.	New		‡idv‡iÝ Ges c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Aristopharma Ltd.	f) Calcium 600 mg + Vitamin D_3 500 IU+ Phosphorus 280 mg + Magnesium 50mg Film Coated Tablet Calcium (as Calcium Phosphate & Calcium Carbonate) BP 600 mg (544 mg Calcium eq.to 1403mg of Calcium Phosphate & 56mg Calcium eqv.to 139.86mg of Calcium Carbonate) + Vitamin D_3 BP 500IU (eq.to 5mg of Cholecalciferol) + Phosphorous (as Calcium Phosphate) BP 280mg (eq.to Calcium Phosphate 1403mg) + Magnesium (as Magnesium Oxide) BP 50mg (eq.to Magnesium Oxide 82.90mg)	It is used to prevent or treat low blood Calcium levels in people who do not get enough calcium from their diets. It may be used to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hyperparathyroidism) and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough calcium (e.g. women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, Phenobarbital or prednisone)	**Contraindications:** Known hypersensitivity to any of the ingredients of the Product. **Side effects:** It has no known side-effects when taken as directed. Do not exceed the recommended daily intake. It any one intake too much calcium then few side effects may include such as: • Stomach pain, vomiting, loss of appetite; • increased thirst or urination; • muscle pain or weakness, joint pain; or • Confusion, and feeling tired or restless. Common side effects may include: • an irregular heartbeat; • nausea, constipation; • weakness, drowsiness, headache; • dry mouth, or a metallic taste in your mouth; or • Muscle or bone pain.	New Combination		‡idv‡iÝ Ges c‡qvRb †bB wewq Av‡e`b bvgÄyb Kiv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB wewq Av‡e`b bvgÄyb Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Aristopharma Ltd.	g) Vitamin A 30000 IU + Vitamin D_3 2000 IU + L-Lysine HCl 0.8g + Vitamin C 0.678g + Elemental Magnesium 3.409g + Elemental Iron 0.7g + Nicotinamide 0.1g + Elemental Zinc 0.2744g + Vitamin E 0.06g + Dexpanthenol 0.05g + Vitamin B_1 0.03g + Vitamin B_2 0.0408g + Vitamin B_6 0.02 g + Cyanocobalamin 0.03g /100ml Syrup Vitamin A BP (as Retinol Propionate) 30000IU + Vitamin D_3 BP (as Cholecalciferol) 2000 IU + L-Lysine HCl BP 0.8g + Vitamin C USP (as Sodium Ascorbate) 0.678g +Elemental Magnesium USP (as Magnesium Gluconate) 3.409g + Elemental Iron BP (as Ferrous Sulphate Heptahydrate) 0.7g + Nicotinamide BP 0.1g + Elemental Zinc USP (as Zinc Sulphate Monohydrate) 0.2744g + Vitamin E USP (as dl-α Tocopherol Acetate) 0.06g + Dexpanthenol BP 0.05g + Vitamin B_1 BP (as Thiamine HCl) 0.03g + Vitamin B_2 BP (as Riboflavin Sodium Phosphate) 0.0408g + Vitamin B_6 BP (as Pyridoxine HCl) 0.02g + Cyanocobalamin BP 0.03g /100ml **Vitamins and Minerals**	It is especially formulated to safeguard the nutritional intake of growing, active Children. Even marginal micronutrient deficiencies during this period reduce children's performance and affect their physical growth and intellectual development. L-Lysine is one of the essential amino acids and is necessary building block for producing proteins to ensure healthy muscles of the body. It is essential for the repairment of the body and is good for those recovering from injury or trauma. Deficiency of L-Lysine may cause tiredness, nausea, loss of appetite, dizziness etc. This syrup provides daily nutritional supplementation of Zinc, Iron, Magnesium with Vitamins A, D, E, C, B-complex and Amino acid L-Lysine, positively influences all round growth and development in pre-school and school going children. L-Lysine has putative anti-herpes simplex virus activity and some anti-osteoporotic activity.	**Contraindications:** Known hypersensitivity to any of the ingredients of the Product. **Side effects:** This Syrup have no known side-effects when taken as directed.	New		‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i	‡idv‡iÝ Ges c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Aristopharma Ltd.	h) Rupatadine 0.1g/100 Syrup Rupatadine Fumarate INN 0.128g eq. to Rupatadine 0.100g/100 **Antihistamine and allergic rhinitis**	It is indicated for the symptomatic treatment of seasonal & perennial allergic rhinitis and idiopathic urticaria.	**Contraindications:** It should not be administered in patients who show hypersensitivity to Rupatadine or any of the excipients. **Side effects:** Rupatadine is a non-sedating antihistamine. However, as in other non-sedating second generation antihistamine, the most common side effects may be somnolence, headache and fatigue.	10 mg Tablet		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
23	Sun Pharmaceutical (Bangladesh) Ltd.	a) Quetiapine 200 mg Extended-Release Tablet Quetiapine Fumarate INN 200 mg **Antipsychotic Drug**	Schizophrenia; mania, either alone or with mood stabilisers; depression in bipolar disorder; adjunctive treatment in major depressive disorder.	**Contraindication:** Hypersensitivity to Quetiapine Side effects: The most commonly reported adverse effects with quetiapine are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension, dyspepsia, syncope, neuroleptic malignant syndrome, leucopenia, neutropenia, peripheral edema, weight gain, elevations in serum transaminases, and rhinitis.	25mg 100mg Tablet & 300mg ER Tablet	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) Quetiapine 400 mg Extended-Release Tablet Quetiapine Fumarate INN 400 mg **Antipsychotic Drug**	Schizophrenia; mania, either alone or with mood stabilisers; depression in bipolar disorder; adjunctive treatment in major depressive disorder.	**Contraindication:** Hypersensitivity to Quetiapine Side effects: The most commonly reported adverse effects with quetiapine are somnolence, dizziness, dry mouth, mild asthenia, constipation, tachycardia, orthostatic hypotension, dyspepsia, syncope, neuroleptic malignant syndrome, leucopenia, neutropenia, peripheral edema, weight gain, elevations in serum transaminases, and rhinitis.	25mg 100mg Tablet & 300mg ER Tablet	USFDA	GB gv‡Îv c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	GB gv‡Îv c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 60 Zg mfvi wm×vš	mfvi wm×vš
	Sun Pharmaceutical (Bangladesh) Ltd.	c) Mirtazapine 7.5 mg FC Tablet Mirtazapine 7.5 mg	It is indicated in the treatment of episodes of major depression.	**Contraindications**: It is contraindicated in patients with known hypersensitivity to the active substances or any of the excipients. Concomitant administration with monoamine oxidase (MAO) inhibitors. **Side effects:** Increase appetite, weight gain, dry mouth, postural hypotension, peripheral oedema, drowsiness, fatigue, tremor, dizziness, abnormal dreams, confusion, and anxiety. Insomnia, arthralgia, myalgia, hypotension etc.	30mg, 15mg Tablet	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

2.2 Proposed Product for locally manufacture (Human)

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
01.	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	a) **Ciclesonide In House 50mcg/Spray Nasal Spray** Ciclesonide In House 50mcg/Spray **Corticosteroid**	It is a corticosteroid indicated for treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and perennial allergic rhinitis in adults and adolescents 12 years of age and older.	**Contraindications:** It is contraindicated in patients with a hypersensitivity to any of its ingredients. **Side effects:** The most common adverse reactions (>2% incidence) included headache, epistaxis, nasopharyngitis, ear pain, and pharyngolaryngeal pain.	80 mcg/Metered Inhalation & 160 mcg/metered inhalation	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
		b) **Arachis oil extract of Coal Tar 0.3gm + Juniper Tar (Cade oil) 0.3gm + Coal tar solution 0.1gm + Tar 0.3gm/100ml Shampoo** Arachis oil extract of Coal Tar In House 0.3gm + Juniper Tar (Cade oil) In House 0.3gm + Coal tar solution BP 0.1gm + Tar In House 0.3 gm/100ml	It is indicated in the treatment of scalp disorders such as psoriasis, dandruff, seborrhoeic dermatitis, eczema and pruritus. Polytar Liquid is also of value in the removal of ointments and pastes used in the treatment of psoriasis.	**Contraindications:** None **Side effects:** Experience of many years of marketing has shown that the incidence of adverse reactions to Polytar Liquid is less than one percent. These reactions of erythema, dryness, contact dermatitis, irritation and acne-like eruptions are mild and of very low incidence	New	BNF-62, Page No.-748	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	c) **Citric Acid Anhydrous 1000mg + Sodium Bicarbonate 1940mg Tablet** Citric Acid Anhydrous BP 1000mg + Sodium Bicarbonate BP 1940mg	For the relief of - Heartburn - acid indigestion - upset stomach associated with these symptoms	**Contraindications:** Do not use Citric Acid & NaHC03 effervescent tablets if: - you are allergic to any ingredient in Citric Acid & NaHC03 effervescent tablets - you are a child or teenager with influenza (flu) or chickenpox - you have bleeding problems such as hemophilia, von Willebrand disease, or low blood platelets - you are taking oral anticoagulants (eg, warfarin), arginine derivatives (eg, argatroban), or methotrexate **Side effects:** All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most common side effects persist or become bothersome: - Heartburn; nausea; upset stomach - Seek medical attention right away if any of these severe side effects occur: - Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody or black stools; confusion; diarrhea; dizziness; drowsiness; hearing loss; ringing in the ears; severe stomach pain; unusual bruising; vomiting.	New		c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	d) **Ispaghula Husk 3.5gm + Mebeverine HCl 0.135gm/Sachet** Ispaghula Husk BP 3.5gm + Mebeverine HCl BP 0.135gm/Sachet	For the treatment of irritable bowel syndrome	**Contraindications:** 1. Contraindicated in cases of intestinal obstruction or faecal impaction. 2. Hypersensitivity to ispaghula or mebeverine **Side effects:** Ispaghula/psyllium husk contains potent allergens. The exposure to these allergens is possible through oral administration, contact with the skin and, in the case of powder formulations, also by inhalation. As a consequence to this allergic potential, individuals exposed to the product can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxia. Cutaneous symptoms as exanthema and/or pruritus have also been reported. Special attention should be given to individuals manipulating the powder formulations routinely.	New	BNF: 63 Page No: 49	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	e) **Tioconazole 300mg/4.6gm Applicator Ointment (Vaginal)** Tioconazole BP 300mg/4.6gm **Antifungal**	Vulvovaginal Candidiasis Treatment of uncomplicated vulvovaginal candidiasis (mild to moderate, sporadic or infrequent, most likely caused by Candida albicans, occurring in immunocompetent women), A drug of choice Self-medication (OTC use) for treatment of uncomplicated vulvovaginal candidiasis in otherwise healthy, non pregnant women who have been previously diagnosed by a clinician and are having recurrence of similar symptoms. Treatment of complicated vulvovaginal candidiasis, including infections that are recurrent (≥4 episodes in 1 year), severe (extensive vulvar erythema, edema, excoriation, fissure formation), caused by Candida other than C. albicans, or occurring in women with underlying medical conditions (uncontrolled diabetes mellitus, HIV infection, immunosuppressive therapy, pregnancy). Complicated infections generally require more prolonged treatment than uncomplicated infections. Optimal regimens for treatment of vulvovaginal candidiasis caused by Candida other than C. albicans (e.g., C. glabrata, C. krusei) not identified. CDC and others state these infections may respond to an intravaginal azole antifungal given for 7–14 days or to a 14-day regimen of intravaginal boric acid.	**Contraindications:** Known hypersensitivity to tioconazole, other imidazoles, or any ingredient in the formulation **Side effects**: Vulvovaginal burning, irritation, vaginitis, pruritus, headache.	1 gm/100 gm Cream	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	f) **Dexamethasone Sodium Phosphate 6.556mg eq. to Dexamethasone 6mg/ml Injection** Dexamethasone Sodium Phosphate USP 6.556mg eq. to 6mg Dexamethasone /ml	Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (stevens-johnson syndrome). Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous	**Contraindications:** Systemic fungal infections Dexamethasones are contraindicated in patients who are hypersensitive to any components of this product. **Side effects:** Allergic reactions: anaphylactoid reaction, anaphylaxis, angioedema. cardiovascular: bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see warnings, cardio-renal), edema, pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. dermatologic: acne, allergic dermatitis, dry scaly skin, ecchymoses and petechiae, erythema, impaired wound healing, increased sweating, rash, striae, suppression of reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria. Endocrine: decreased carbohydrate and glucose tolerance, development of cushingoid state, hyperglycemia, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients. Fluid and electrolyte disturbances: congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention. Gastrointestinal: abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea,	2 mg/ml Injection for Veterinary 1mg/ml Eye Drops & 0.5 mg Tab. 0.05 gm/100 gm Eye Ointment	WHO Recommended	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

			chemotherapy. Neoplastic diseases: for the palliative management of leukemias and lymphomas. Nervous system: acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: to induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.	pancreatitis, peptic ulcer with possible perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis. Metabolic: negative nitrogen balance due to protein catabolism. Musculoskeletal: aseptic necrosis of femoral and humeral heads, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, steroid myopathy, tendon rupture, vertebral compression fractures. Neurological/psychiatric: convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo. Ophthalmic: exophthalmos, glaucoma, increased intraocular pressure, posterior subcapsular cataracts. Other: abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, weight gain.				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kwgwdi 61 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	g) **Sofosbuvir 400mg Tablet** Sofosbuvir INN 400mg **Antiviral**	It is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. (1) • Its efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infections, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.	**Contraindications:** When used in combination with peginterferon alfa/ribavirin or ribavirin alone, all contraindications to peginterferon alfa and/or ribavirin also apply to its combination therapy. Because ribavirin may cause birth defects and fetal death, Sofosbuvir 400mg tablet in combination with peginterferon alfa/ribavirin or ribavirin is contraindicated in pregnant women and in men whose female partners are pregnant. **Side Effects:** The most common adverse events (incidence greater than or equal to 20%, all grades) observed with it in combination with ribavirin were fatigue and headache. The most common adverse events observed with it in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia and anemia.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	h) **Benzocaine 14% + Aminobenzoate 2% + Tetracaine 2% Topical Anesthetic Gel** Benzocaine BP 14% + Aminobenzoate USP 2% + Tetracaine BP 2%	It is indicated for the production of anesthesia of all accessible mucous membrane except the eyes. This Medication Spray is indicated for use to control pain or gagging. This Medication in all forms is indicated to control pain and for use for surgical or endoscopic or other procedures in the ear, nose, mouth, pharynx, larynx, trachea, bronchi, and esophagus. It may also be used for vaginal or rectal procedures when feasible.	**Contraindications**: It is not suitable and should never be used for injection. Do not use on the eyes. To avoid excessive systemic absorption, This Medication should not be applied to large areas of denuded or inflamed tissue. This Medication should not be administered to patients who are hypersensitive to any of its ingredients or to patients known to have cholinesterase deficiencies. Tolerance may vary with the status of the patient. This Medication should not be used under dentures or cotton rolls, as retention of the active ingredients under a denture or cotton roll could possibly cause an escharotic effect. Routine precaution for the use of any topical anesthetic should be observed when using this Medication. **Side Effects:** Hypersensitivity Reactions: Unpredictable adverse reactions (i.e. hypersensitivity, including anaphylaxis) are extremely rare. Localized allergic reactions may occur after prolonged or repeated use of any aminobenzoate anesthetic. The most common adverse reaction caused by local anesthetics is contact dermatitis characterized by erythema and pruritus that may progress to vesiculation and oozing. This occurs most commonly in patients following prolonged self-medication, which is contraindicated. If rash, urticaria, edema,	New		c‡qvRbxqZv Av‡Q wea|q Av‡e`b Abyjgv`b Kiv †h‡Z cv‡i|	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
02	Techno Drugs Ltd., Narshingdi	a) **Bleomycin 15 Units/Vial Injection** Bleomycin USP 15 Units/Vial **Antineoplastic**	Bleomycin Sulphate for Injection, USP should be used as first line therapy and/or adjuvant to surgery and radiation therapy. It has been shown to be useful in the following neoplasms: Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Pleurodysis and pleural fluid accumulation. Bleomycin has been shown to produce responses in some renal carcinomas and soft tissue Sarcomas.	**Contraindications: It** is contraindicated in patients who have demonstrated a Hypersensitive or an idiosyncratic reaction to the drug. When used as indicated, the physician must carefully weigh the therapeutic benefit versus risk of toxicity which may occur. **Side effects:** Skin: 50% of the patients develop either hyperpigmentation of the skin, hyperkeratosis of hands and nails, and edema and erythema of the hands and feet. The skin toxicity occurred more frequently at higher doses: 200-300 unit range and can be dose limiting. Rash forms on the pressure areas of the body and abdominal skin creases. It is a common side effect (due to accumulation of the bleomycin in the skin) and is reported to occur in 8% of treated patients within a few days to 2-3 weeks at doses of 1.25-35 mg/m2. Pulmonary : Pulmonary toxicity is potentially the most serious side effect, occurring in approximately 10% of treated patients. The most frequent manifestation is pneumonitis occasionally progressing to Pulmonary fibrosis which may result in death. Approximately 1% of patients treated succumb to pulmonary toxicity. Pulmonary toxicity is usually Both dose and age related, being more common in patients over 70 years of age receiving over 400units total dose. However, this toxicity is unpredictable and has been seen occasionally in young patients receiving low doses. The identification of patients with pulmonary toxicity due to bleomycin has been extremely difficult due to the lack of specificity of the clinical syndrome, the X-ray changes and even the tissue changes seen on examination of biopsy and autopsy specimens. Bleomycin-induced pneumonitis apparently produces dyspnea and fine rales that are in no way different from those produced by infectious pneumonias or the signs and symptoms produced by Primary or metastatic lung disease in some patients.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Techno Drugs Ltd., Narshingdi	b) **Cytarabine 500 mg/Vial Injection** Cytarabine USP 500mg/Vial **Anitcancer**	It is indicated for the intrathecal treatment of lymphomatous meningitis.	**Contraindications:** It is contraindicated in patients who are hypersensitive to cytarabine or any component of the formulation, and in patients with active meningeal infection. **Side-effect:** The toxicity database consists of the observations made during Phase 1-4 studies. The most common adverse reactions in all patients and in patients with lymphoma are shown in Table 2 below.Arachnoiditis is an expected and well-documented side effect of both neoplastic meningitis and of intrathecal chemotherapy. The incidence of severe and life-threatening arachnoiditis in patients receiving DepoCyt was 19% (48/257) in all patients and 30% (10/33) in patients with lymphomatous meningitis. The incidences of symptoms possibly reflecting meningeal irritation are shown in Table.	100mg/Vial Injection	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		c) **Thalidomide 100 mg Capsule** Thalidomide USP 100 mg **Leprostatic**	It is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). It is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. Thalidomide is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.	**Contraindications**: It is contraindicated in females who are pregnant. Thalidomide is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects, even after a single dose. Mortality at or shortly after birth has been reported in about of infants. If pregnancy occurs during thalidomide treatment, the drug should be discontinued immediately. Thalidomide is contraindicated in patients who have demonstrated hypersensitivity to the drug and its components. **Side Effects:** The most serious toxicity associated with thalidomide is its documented human teratogenicity. The risk of severe birth defects, primarily phocomelia or death to the fetus, is extremely high during the critical period of pregnancy. The critical period is estimated, depending on the source of information, to range from 35 to 50 days after the last menstrual period. The risk of other potentially severe birth defects outside this critical period is unknown, but may be significant. Based on present knowledge, thalidomide must not be used at any time during pregnancy.	200 mg Capsule 50mg Capsule	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Techno Drugs Ltd., Narshingdi	d) **Vinblastin Sulfate 10mg/Vial injection** Vinblastin sulfate (lyophilized) USP 10mg/Vial **Anticancer**	It is indicated in the palliative treatment of the following: **Frequently Responsive Malignancies:** Generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system) Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) Histiocytic lymphoma. Mycosis fungoides (advanced stages) Advanced carcinoma of the testis Kaposi's sarcoma Letterer-Siwe disease (histiocytosis X) **Less Frequently Responsive Malignancies:** Choriocarcinoma resistant to other chemotherapeutic agents Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.	**Contraindications:** It is contraindicated in patients who have significant granulocytopenia unless this is a result of the disease being treated. It should not be used in the presence of bacterial infections. Such infections must be brought under control prior to the initiation of therapy with vinblastine sulfate. **Side Effects:** In general, the incidence of adverse reactions attending the use of vinblastine sulfate appears to be related to the size of the dose employed. With the exception of epilation, leukopenia, and neurologic side effects, adverse reactions generally have not persisted for longer than 24 hours. Neurologic side effects are not common; but when they do occur, they often last for more than 24 hours. Leukopenia, the most common adverse reaction, is usually the dose-limiting factor. The following are manifestations which have been reported as adverse reactions, in decreasing order of frequency. The most common adverse reactions are underlined: **Hematologic:** Leukopenia (granulocytopenia), anemia, thrombocytopenia (myelosuppression). **Dermatologic:** Alopecia is common. A single case of light sensitivity associated with this product has been reported. **Gastrointestinal:** Constipation, anorexia, nausea, vomiting, abdominal pain, ileus, vesiculation of the mouth, pharyngitis, diarrhea, hemorrhagic enterocolitis, bleeding from an old peptic ulcer, rectal bleeding. **Neurologic:** Numbness of digits (paresthesias), loss of deep tendon refl exes, peripheral neuritis, mental depression, headache, convulsions. Treatment with vinca alkaloids has resulted rarely in both vestibular and auditory damage to the eighth cranial nerve.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

				Manifestations include partial or total deafness which may be temporary or permanent, and diffi culties with balance including dizziness, nystagmus, and vertigo. Particular caution is warranted when vinblastine sulfate is used in combination with other agents known to be ototoxic such as platinum-containing oncolytics. **Cardiovascular:** Hypertension. Cardiac effects such as myocardial infarction, angina pectoris and transient abnormalities of ECG related to coronary ischemia have been reported very rarely. Cases of unexpected myocardial infarction and cerebrovascular accidents have occurred in patients undergoing combination chemotherapy with vinblastine, bleomycin, and cisplatin. Raynaud's phenomenon has also been reported with this combination. **Pulmonary:** **Miscellaneous:** Malaise, bone pain, weakness, pain in tumor-containing tissue, dizziness, jaw pain, skin vesiculation, hypertension, Raynaud's phenomenon when patients are being treated with vinblastine sulfate in combination with bleomycin and cis-platinum for testicular cancer. The syndrome of inappropriate secretion of antidiuretic hormone has occurred with higher than recommended doses. Nausea and vomiting usually may be controlled with ease by antiemetic agents. When epilation develops, it frequently is not total; and, in some cases, hair regrows while maintenance therapy continues.				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
3.	Healthcare Pharmaceuticals Ltd.	a) **Filgrastim 120 µg/0.2ml prefilled syringe for Injection** Filgrastim Concentrate Solution (Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF, Filgrastim) BP 0.2ml containing Filgrastim 120 µg/ Prefilled Syringe **Antineutropenic**	It is indicated for cancer patients receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, cancer patients receiving bone marrow transplantation, cancer patients undergoing peripheral blood progenitor cell collection and chemotherapy, patients with severe chronic neutropenia.	**Contraindications:** It is contraindicated in patients with known hypersensitivity to *E.coli* derived proteins, Filgrastim or any component of the product. *Pregnancy and lactation:* There are no adequate and well controlled trials on pregnant women, the effect of Filgrastim on the developing fetus and mother is unknown. It is not known whether Filgrastim is excreted in human milk. **Adverse effects:** Nausea, vomiting, musculoskeletal pain, myalgia, headache, exacerbation of rheumatoid arthritis, splenic rupture, acute respiratory distress syndrome (ARDS), sickle cell disorders.	30 MIU/0.5ml & 30 MIU/ml Injection	BNF	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
		b) **Colistimethate 80mg/Vial Powder for solution for Injection** Colistimethate Sodium (Sterile Powder) USP 80mg (eq. to 10,00,000 IU)/Vial **Antibiotics**	It is indicated in the treatment of the following infections where sensitivity testing suggests that they are caused by susceptible bacteria: Intravenous administration for the treatment of some serious infections caused by Gram-negative bacteria, including those of the lower respiratory tract and urinary tract, when more commonly used systemic antibacterial agents may be contra-indicated or may be ineffective because of bacterial resistance. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	**Contraindications:** Hypersensitivity to colistimethate sodium (also known as colistin) or to polymyxin B. Myasthenia gravis. **Undesirable effects:** The likelihood of adverse events may be related to the age, renal function and condition of the patient. In cystic fibrosis patients neurological events have been reported in up to 27% of patients. These are generally mild and resolve during or shortly after treatment. Adverse effects on renal function have been reported, usually following use of higher than recommended dose in patients with renal impairment or during concomitant use of other nephrotoxic antibiotics. The effects are usually reversible on discontinuation of therapy. In cystic fibrosis patients treated within the recommended dosage limits, nephrotoxicity appears to be rare(less than 1%). In seriously ill hospitalized non-CF patients signs of nephrotoxicity have been reported in approximately 20% of patients. Neurotoxicity has been reported often in association with overdose, failure to reduce in patients with renal insufficiency and concomitant use of either curariform agents or drugs with similar neurological effects. Reducing the dose may alleviate symptoms.	New	BNF & MHRA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Healthcare Pharmaceuticals Ltd.	c) **Colistimethate 160mg/Vial Powder for solution for Injection** Colistimethate Sodium (Sterile Powder) USP 160mg (eq. to 20,00,000 IU)/Vial **Antibiotics**	It is indicated in the treatment of the following infections where sensitivity testing suggests that they are caused by susceptible bacteria: Intravenous administration for the treatment of some serious infections caused by Gram-negative bacteria, including those of the lower respiratory tract and urinary tract, when more commonly used systemic antibacterial agents may be contra-indicated or may be ineffective because of bacterial resistance. Consideration should be given to official guidance on the appropriate use of antibacterial agents.	**Contraindications:** Hypersensitivity to colistimethate sodium (also known as colistin) or to polymyxin B. Myasthenia gravis. **Undesirable effects:** The likelihood of adverse events may be related to the age, renal function and condition of the patient. In cystic fibrosis patients neurological events have been reported in up to 27% of patients. These are generally mild and resolve during or shortly after treatment. Adverse effects on renal function have been reported, usually following use of higher than recommended dose in patients with renal impairment or during concomitant use of other nephrotoxic antibiotics. The effects are usually reversible on discontinuation of therapy. In cystic fibrosis patients treated within the recommended dosage limits, nephrotoxicity appears to be rare(less than 1%). In seriously ill hospitalized non-CF patients signs of nephrotoxicity have been reported in approximately 20% of patients. Neurotoxicity has been reported often in association with overdose, failure to reduce in patients with renal insufficiency and concomitant use of either curariform agents or drugs with similar neurological effects. Reducing the dose may alleviate symptoms.	New	BNF	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Healthcare Pharmaceuticals Ltd.	d) **Atorvastatin 10 mg + Ezetimibe 10 mg Tablet** Atorvastatin Calcium (Trihydrate) INN 10.82mg eq. to 10 mg Atorvastatin + Ezetimibe INN 10 mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and Non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.	**Contraindications:** • Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. **Side Effects:** Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyi Kiv nj
		e) **Tafluprost 0.0015% Eye drop** Tafluprost INN 1.50mg/100ml **Antiglaucoma**	It is a prostaglandin analog indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension	**Contraindications:** None. **Adverse Reactions:** Most frequent ocular adverse reaction is conjuctivita hyperemia (range 4%-20%)	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
4.	Renata Limited Rajendrapur, Gazipur	a) **Meropenm 250mg/Vial I.V Injetion** Meropenem Trihydrate USP 285.24 mg eq. to 250 mg Meropenm/Vial **Antibiotic**	Neonatal sepsis, pediatric meningitis, pediatric pneumonia, complicated skin and skin structure infections, intra-abdominal infections.	Contraindication: It is contraindicated in the following patients' patients with a history of shock following exposure to any of the ingredients in this product. Side effects: Few major adverse events like pain, abdominal pain, chest pain, fever, back pain, abdominal enlargement, chills, and pelvic pain.	500 mg & 1gm/Vial Injection		ïaygvÎ wkï‡`i e¨envi‡i Rb¨ Abyjgv`b Kiv †h‡Z cv‡i	ïaygvÎ wkï‡`i e¨envi‡i Rb¨ Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
5.	Renata Ltd., Mirpur, Dhaka	a) **Ipriflavone 300mg Capsule** Ipriflavone INN 300 mg	It has been effective in the prevention and in the treatment of post-menopausal and senile osteoporosis: the characteristic symptoms of the disease (pain while resting, while walking, while performing rotational and bending movements) regress within the first weeks of therapy; the parameters expressing the state of the bone mass improve and stabilize after the first weeks of treatment (the bone density increases or stops to decrease, the number of vertebral collapses and fractures due to compression and the number of spontaneous or traumatic fractures of the long bones decreases). The antiosteoporosis activity and the tolerance to ipriflavone remain constant during long term treatments.	**Contraindications:** Hypersensitivity to the drug. Gastric or duodenal ulcer in active phase. Side effects: While treated with ipriflavone, the patient can show occasional hypersensitivity reactions (skin rashes, itch), gastrointestinal troubles (nausea, vomiting, gastralgia, diarrhea), dizziness. Occasionally increases in SGOT, SGPT and bilirubinemia can be observed: increases in azotaemia, reduction in red and white cells. Granulocytopenia and lymphocytopenya have been observed very rarely, and went back to normal after Interruption of the treatment. Overdose: There are no known cases of overdose with ipriflavone. In case an overdose should occur, it is suggested to perform a gastric washout and treat symptomatically. Preclinical security data: Ipriflavone has little acute toxicity and is well tolerated in long term treatments. The LD50 values for oral administration are higher than 10,000 mg/kg in mouse and rat, and 3,500 mg/kg in the	New		c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
6.	Delta Pharma Ltd.	a) **Atorvastatin 10 mg + Ezetimibe 10 mg tablet** Atorvastatin Calcium Trihydrate USP 10.84 mg eq. to 10mg Atorvastatin + Ezetimibe INN 10 mg **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.	Contraindications: • Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. Side Effects: Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj
		b) **Atorvastatin 20 mg + Ezetimibe 10 mg Tablet** Atorvastatin Calcium Trihydrate USP 21.68mg eq. to 20mg Atorvastatin + Ezetimibe INN 10mg **Antihyperlipidemic**	Do	Do	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
7.	Jayson Pharmaceuticals Ltd.	a) **Luliconazole 10mg/gm Cream** Luliconazole INN 10mg/gm **Antifungal**	Luliconazole 1.0% Cream, is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms *Trichophyton rubrum* and *Epidermophyton floccosum*, in patients 18 years of age and older	**Contraindications:** None **Side effects:** The most common adverse reactions observed in clinical trials were application site reactions, which occurred in less than 1% of subjects.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		b) **Sitagliptin 50mg + Simvastatin 10mg Tablet** Sitagliptin Phosphate Monohydrate INN 64.25mg eq. to 50mg Sitagliptin + Simvastatin BP 10mg **Antidiabetic + Antihyperlipidemic**	It is indicated in patients for whom treatment with both sitagliptin and simvastatin is appropriate. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Simvastatin is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbeta-lipoproteinemia. Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. Important Limitations of Use: It should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in patients with a history of pancreatitis.	Contraindication: History of a serious hypersensitivity reaction, such as anaphylaxis or angioedema, to any component of this medication. Concomitant administration of strong CYP3A4 inhibitors. Concomitant administration of gemfibrozil, cyclosporine, or danazol. Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels. Women who are pregnant or may become pregnant. Nursing mothers. Side Effects: Most common adverse reactions (incidence ≥5%) with simvastatin are: upper respiratory infection, headache, abdominal pain, constipation, and nausea. Adverse reactions reported in ≥ 5% of patients treated with sitagliptin and more commonly than in patients treated with placebo are: upper respiratory tract infection, nasopharyngitis and headache. In the add-on to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with sitagliptin compared to placebo.	Sitagliptin 25 mg, 50mg & 100 mg Tablet Simvastatin : 5mg, 10 mg, 20 mg & 40 mg Tablet	USFDA	Kw¤‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	Kw¤‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄy Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
8.	Labaid Pharmaceuticals Ltd.	a) **Macitentan 10 mg Tablet** Macitentan INN 10mg **Antihypertensive**	It is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). It also reduced hospitalization for PAH.	Contraindications: Pregnancy. Side Effects: Most common adverse reactions (more frequent than placebo by ≥3%) are anemia, nasopharyngitis/ pharyngitis, bronchitis, headache, influenza, and urinary tract infection.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		b) **Levomilnacipran 40mg ER Capsule** Levomilnacipran Extended Release Pellets (25%) Ph. Gr. 160 mg containing Levomilnacipran HCl 45.90 mg eq. to 40 mg Levomilnacipran INN **Antidepressant**	It is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD). Limitation of Use: It is not approved for the management of fibromyalgia. The efficacy and safety of this medicine for the management of fibromyalgia have not been established.	Contraindications: Hypersensitivity to Levomilnacipran or any excipient in the formulation. Serotonin Syndrome and MAOIs: Do Not use MAOIs intended to treat psychiatric disorders with it or within 7 days of stopping treatment with this capsule. Do not use this capsule within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start this capsule in a patient who is being treated with linezolid or intravenous methylene blue. Uncontrolled narrow-angle glaucoma. Side Effects: The most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) are: nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Labaid Pharmaceuticals Ltd.	c) **Levomilnacipran 80 mg ER Capsule** Levomilnacipran Extended Release Pellets (25%) Ph. Gr. 320mg containing Levomilnacipran HCl 91.80mg eq. to 80 mg Levomilnacipran INN **Antidepressant**	It is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD). Limitation of Use: It is not approved for the management of fibromyalgia. The efficacy and safety of this medicine for the management of fibromyalgia have not been established.	Contraindications: Hypersensitivity to Levomilnacipran or any excipient in the formulation. Serotonin Syndrome and MAOIs: Do Not use MAOIs intended to treat psychiatric disorders with it or within 7 days of stopping treatment with this capsule. Do not use this capsule within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start this capsule in a patient who is being treated with linezolid or intravenous methylene blue. Uncontrolled narrow-angle glaucoma. Side Effects: The most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) are: nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.	New	USFDA	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv nj	
		d) **Levomilnacipran 120mg ER Capsule** Levomilnacipran Extended Release Pellets (25%) Ph. Gr. 480mg containing Levomilnacipran HCl 137.80 mg eq. to 120mg Levomilnacipran INN **Antidepressant**	It is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD). Limitation of Use: It is not approved for the management of fibromyalgia. The efficacy and safety of this medicine for the management of fibromyalgia have not been established.	Do	New	USFDA	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Labaid Pharmaceuticals Ltd.	e) **Riociguat 1mg Tablet** Riociguat INN 1 mg **Antihypertensive**	It is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening.	Contraindications: • Pregnancy • Use with nitrates or nitric oxide donors in any form • Use with phosphodiesterase (PDE) inhibitors Side effect: Adverse reactions occurring more frequently (≥3%) on Riociguat compared to placebo are headache, dizziness, dyspepsia/ gastritis, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, and constipation.	New	USFDA	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv nj	
		f) **Riociguat 1.5 mg Tablet** Riociguat INN 1.5 mg **Antihypertensive**	Do	Do	New	USFDA	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv nj	
		g) **Riociguat 2 mg Tablet** Riociguat INN 2 mg **Antihypertensive**	Do	Do	New	USFDA	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Labaid Pharmaceuticals Ltd.	h) **Ezetimibe 10 mg + Atorvastatin 10 mg Tablet** Ezetimibe INN 10 mg + Atorvastatin Calcium USP 10.36mg eq. to 10 mg Atorvastatin **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.	Contraindications: • Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. Side Effects: Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj |
		i) **Ezetimibe 10 mg + Atorvastatin 20 mg Tablet** Ezetimibe INN 10 mg + Atorvastatin Calcium USP 20.72mg eq. to 20 mg Atorvastatin **Antihyperlipidemic**	It contains a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet to: • reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. • reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.	Contraindications: • Active liver disease or unexplained persistent elevations of hepatic transaminase levels. • Hypersensitivity to any component of it. • Women who are pregnant or may become pregnant. • Nursing mothers. Side Effects: Common adverse reactions (incidence ≥2% and greater than placebo) are: increased ALT, increased AST, and musculoskeletal pain.	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i |	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Labaid Pharmaceuticals Ltd.	j) **Vortioxetine 10 mg Tablet** Vortioxetine Hydrobromide INN 12.71 mg eq. to 10 mg Vortioxetine **Antidepressant**	It is indicated for the treatment of major depressive disorder (MDD).	Contraindications: • Hypersensitivity to vortioxetine or any components of this formulation. Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with it or within 21 days of stopping treatment with it. Do not use it within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start this tablet in a patient who is being treated with linezolid or intravenous methylene blue. Side Effects: Most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation and vomiting.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		k) **Vortioxetine 15 mg Tablet** Vortioxetine Hydrobromide INN 19.065 mg eq. to 15mg Vortioxetine **Antidepressant**	It is indicated for the treatment of major depressive disorder (MDD).	Contraindications: • Hypersensitivity to vortioxetine or any components of this formulation. Monoamine Oxidase Inhibitors (MAOIs): Do not use MAOIs intended to treat psychiatric disorders with it or within 21 days of stopping treatment with it. Do not use it within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start this tablet in a patient who is being treated with linezolid or intravenous methylene blue. Side Effects: Most common adverse reactions (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation and vomiting.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		l) **Vortioxetine 20 mg Tablet** Vortioxetine Hydrobromide INN 25.42 mg eq. to 20 mg Vortioxetine **Antidepressant**	Do	Do	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
9.	Nipro JMI Pharmaceuticals Ltd.	a) **Canagliflozin 100mg Tablet** Canagliflozin Hemihydrate INN 102.00mg eq. to 100mg Canagliflozin **Antidiabetic**	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. **Limitation of Use:** • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis	**Contraindications:** History of serious hypersensitivity reaction to Canagliflozin. Severe renal impairment, ESRD, or on dialysis. **Side Effects:** Most common adverse reactions associated with Canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **Canagliflozin 300mg Tablet** Canagliflozin Hemihydrate INN 306.00mg eq. to 300.00 mg Canagliflozin **Antidiabetic**	-Do-	-Do-	New	USFDA	D”PgvÎv nIqvi Kvi‡Y Av‡e`b bvgÄyK iv †h‡Z cv‡i	D”PgvÎv nIqvi Kvi‡Y Av‡e`b bvgÄyK iv nj	
		c) **Alprostadil 0.4% Cream** Alprostadil INN 0.4%	Erectile dysfunction	**Contraindications:** Predisposition to prolonged erection, not for use with other agents for erectile dysfunction, in patients with penile implants or when sexual activity medically inadvisable; urethral application also contra-indicated in urethral stricture, severe hypospadia, severe curvature, balanitis, urethritis. **Side effects:** Hypotension, hypertension, dizziness, headache, penile pain, urethral burning, urethral bleeding, penile oedema, penile rash.	New		c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Nipro JMI Pharmaceuticals Ltd.	d) **Glucose 4g Tablet** Glucose BP 4gm	For managing and correction of hypoglycemia in diabetic patients.	**Contraindications:** Hypersensitivity to the active substance. **Side Effects:** Nausea may occur.			c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj |
		e) **Ibandronic Acid 2.5 mg Tablet** Ibandronic Acid USP 2.5 mg **Calcium Regulator**	For the treatment & prevention of Postmenopausal Osteoporosis	**Contraindications:** Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia, Inability to stand or sit upright for at least 60 minutes Hypocalcemia, Hypersensitivity to Ibandronic Acid **Side effects:** Severe irritation of the upper gastrointestinal (GI), Hypocalcemia, Severe bone, joint, and muscle pain may occur.	150mg Tablet	USFDA 03/15/2011 (Tentative Approval) 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons*	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB weavq Av‡e`b bvgÄyK iv nj |
10.	Unimed & UniHealth Manufacturers Ltd.	a) **Calcium Dobesilate 500mg Capsule** Calcium Dobesilate INN 500mg	It is recommended as the vascular treatment of choice in diabetic retinopathy. • It has been used with good effect as a haemostatic during surgical procedures in otorhinolaryngology, ophthalmology and dentistry. • It has also shown benefits in chronic venous insufficiency and haemorrhoids.	**Contraindications:** There are no known contra-indications but on general principles Calcium Dobesilate capsules should not be administered during the first trimester of pregnancy. **Side-effects and special precautions:** Rarely in sensitive persons some nausea or gastric discomfort may occur but this rapidly disappears if the dose is decreased.			chvß Z_¨ I †idv‡iÝmn cieZx ‡UKwbK¨vj mve-KwgwUi mfvq Dc¯vb Kiv †h‡Z cv‡i |	chvß Z_¨ I †idv‡iÝmn cieZx ‡UKwbK¨vj mve-KwgwUi mfvq Dc¯vb Kiv †h‡Z cv‡i |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Unimed & UniHealth Manufacturers Ltd.	b) **Calcium Dobesilate 4gm + Lidocaine HCl 2gm + Dexamethasone Acetate 0.025gm/100gm Ointment with Applicator Nozzle** Calcium Dobesilate INN 4gm + Lidocaine HCl USP 2gm + Dexamethasone Acetate BP 0.025gm/100gm	It is indicated in: • Internal and external hemorrhoids. • Anal pruritus, anal eczema. • Anitis, perianitis, cryptitis, papillitis, acute hemorrhoidal thrombosis and fissure. • Pre- and post-operative treatment in cases of hemorrhoidectomy.	**Contraindications:** Hypersensitivity to the components of Calcium dobesilate. **Side Effects:** Very rare cases have been reported, including modifications of the intestinal transit, temporary burning sensation, and local pain. Hypesensitivity reactions together with skin reactions and/or fever can occur. These reactions can be of allergic origin and, if it is the case, the treatment must be discontinued.			c‡qvRbxqZv Av‡Q wea|q Abyôgv`b Kiv †h‡Z cv‡i|	Abyôgv`b Kiv nj|
		c) **Bismuth subsalicylate 262.5mg Chewable Tablet** Bismuth Subsalicylate BP 262.5mg	For fast relief of upset stomach, indigestion, heartburn and nausea. Controls diarrhoea.	**Contraindications:** It Should not be used by patients hypersensitive to Aspirin or other salicylates. It should not be used by patients hypersensitive to any ingredient in the formulation. Bismuth Subsalicylate should not be used by children under 16 years of age. **Side- effects:** Black tongue is common (>1/100, <1/10) undesired effect, the undesired effect of black stool is very common (>1/10)	Bismuth Subcitrate 120mg Tablet		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i|	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Unimed & UniHealth Manufacturers Ltd.	d) **Bismuth subsalicylate 17.5mg/ml Oral Suspension** Bismuth Subsalicylate BP 1.750gm/100ml	For upset stomach, indigestion, heartburn and nausea. Controls diarrhoea.	**Contraindications:** It should not be used by patients hypersensitive to Aspirin or other salicylates. Bismuth subsalicylate Suspension should not be used by patients hypersensitive to any ingredient in the formulation. Bismuth subsalicylate Suspension should not be used by children under 16 years of age. **Side- effects :** *Gastrointestinal disorders:* Black tongue is common (>1/100, <1/10), Black stool is very common (>1/10)	Bismuth Subcitrate 120mg Tablet		c‡qvRbxqZv Av‡Q wea|q Abyjgv`b Kiv hvB‡Z cv‡i |	Abyjgv`b Kiv nj |
		e) **Lyophilized Bacterial Lysates 50mg Sublingual Tablet** Lyophilized Bacterial Lysates INN 50mg (Lyophilized Bacterial Lysates of Staphylococcus aureus, Streptococcus pyogenes and viridans, Klebsiella pneumonia and ozaenae, Haemophilus influenzae, Neisseria catarrhalis Diplococcus pneumonia: 7 mg and 43mg of which corresponded to lyophilization substrate: Glycine)	Prevention of acute, subacute, chronic or recurrent infections of the upper and lower respiratory tract and bronchopulmonary; - Prevention and reduction of the intensity of relapses; - If necessary, the drug can be combined with other medicaments agents, antibiotics, mucolytics, inhaled corticosteroids and long-acting bronchodilators. Bacterial Lysates intended for adults and children 3 years and above.	**Contraindications:** Known hypersensitivity towards the constituents of Bacteria Lysates **Special warnings and special precautions for use:** The efficacy and safety of Bacteria Lysates has not been established in children below 4 years.			c¥we‡ePbvi wbwg‡Ë c‡qvRbxq Z_¨ I †id|v‡i iÝmn cieZx wgwUs‡q Dc¯vcb Kiv †h‡Z cv‡i |	c¥we‡ePbvi wbwg‡Ë c‡qvRbxq Z_¨ I †id|v‡i iÝmn cieZx wgwUs‡q Dc¯vcb Kiv †h‡Z cv‡i |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Unimed & UniHealth Manufacturers Ltd.	f) **Docusate Sodium 100mg Capsule** Docusate Sodium BP 100mg **Drugs for Constipation**	Constipation, adjunct in abdominal radiological procedures.	**Contraindication:** Stimulant laxatives increase intestinal motility and often cause abdominal cramp, Should be avoided in intestinal obstruction. **Side effects:** Excessive use of stimulant laxatives can cause diarrhea and related effects such as hypokalaemia.	Docusate Sodium 0.5% Ear Drops	BNF 65 Page 71	Abyjgv`b Kiv hvB‡Z cv‡i	Abyjgv`b Kiv nj	
		g) **Pirfenidone 200mg Tablet** Pirfenidone INN 200mg **Antineoplastic & Immunomodulating Agent**	Pirfenidone is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF).	**Contraindications** Hypersensitivity to the active substance or to any of the excipients. • concomitant use of fluvoxamine, • severe hepatic impairment or end stage liver disease, • severe renal impairment (CrCl <30 ml/min) or end stage renal disease requiring dialysis **Side Effects:** The most commonly reported (≥10%) adverse reactions during clinical study experience with Pirfenidone at a dose of 2403 mg/day compared to placebo, respectively, were nausea (32.8% versus 13.3%), rash (28.7% versus 8.6%), fatigue (22.3% versus 13.3%), diarrhoea (21.7% versus 13.5%), dyspepsia (16.8% versus 5.5%), and photosensitivity reaction (12.2% versus 1.7%). Serious adverse reactions were recorded at similar frequencies among patients treated with 2403 mg/day of Pirfenidone and placebo in clinical studies.	267mg Capsule		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
11.	ALCO PHARMA LTD. Plot No.33, Block No. 3/B Section No. 7,Mirpur Dhaka	a) **Rabeprazole 20 mg Capsule** Rabeprazole Sodium Pellets 8.5% (Enteric Coated) Ph. Gr. 235.29mg containning Rabeprazole INN 20 mg **Antiulcerant (PPI)**	Healing of Erosive or Ulcerative GERD, Maintenance of Healing of Erosive or Ulcerative GERD, Treatment of Symptomatic GERD, Healing of Duodenal Ulcers, Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence, Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome, and treatment of GERD in patients 1to 11 years of age.	**Contraindication:** It is contraindicated in patients with known hypersensitivity to RABEPRAZOLE, substituted benzimidazoles or to any component of the formulation. **Side Effects:** Dry mouth, GI disturbance, liver dysfunction, taste disturbance. Hypersensitivity reactions including rash, urticaria, angioedema, bronchospasm, anaphylaxis.	10mg & 20mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv nj	
12.	Eskayef Bangladesh Ltd. Tongi, Gazipur	a) **Brinzolamide 1% + Brimonidine Tartrate 0.2% Ophthalmic suspension** Brinzolamide USP 1.00g + Brimonidine Tartrate INN 0.2g/100ml	It is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.	**Contraindications:** • Hypersensitivity to any component of this product • Neonates and infants (under the age of 2 years). **Side Effects:** Most common adverse reactions occurring in approximately 3 to 5% of patients included blurred vision, eye irritation, dysgeusia (bad taste), dry mouth, eye allergy		USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
		b) **Dexamethasone Phosphate 0.1% + Moxifloxacin 0.5% Ophthalmic solution** Dexamethasone Sodium Phosphate USP 0.109g eq. to Dexamethasone Phosphate 0.1g + Moxifloxacin Hydrochloride USP 0.545g eq. to Moxifloxacine 0.5g/100ml **Anti-inflammatory + Antibiotic**	Treatment of ocular infections caused by susceptible microorganisms and prevention of inflammation and bacterial infection that may occur after ocular surgery	Hypersensitivity to other quinolones and any components, Patients with glaucoma and/or ocular disease causing thinning of the cornea or sclera, Inflammation in the eye caused by virus, fungi or mycobacteria, Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella and many other viral diseases of the cornea, and conjunctiva. Mycobacterial infection of the eye, Fungal diseases of ocular structures.			c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	c) **Prednisolone Acetate 1.00 gm + Gatifloxacin 0.3gm/100ml Ophthalmic suspension** Prednisolone Acetate USP 1 gm + Gatifloxacin Sesquihydrate INN 0.322g eq. to Gatifloxacin 0.30 gm/100ml	It is used for post-operative inflammation and any other ocular inflammation associated with infection.	**Contraindications:** It is contraindicated in epithelial herpes simplex keratitis (Dendritic keratitis), vaccinia, varicella, and in many other viral diseases of the conjunctiva and cornea, Mycobacterial infection of the eye and fungal diseases of ocular structures and in individuals hypersensitive to any of the components of the medication. **Side effects:** The most frequently reported drug-related undesirable effects seen with Gatifloxacin are conjunctival irritation, increased lacrimation, keratitis and papillary conjunctivitis.			c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		d) **Ospemifene 60mg FC Tablet** Ospemifene INN 60mg **Selective estrogen Modulator**	It is an estrogen agonist/ antagonist indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.	**Contraindications:** Undiagnosed abnormal genital bleeding. Known or suspected estrogen-dependent neoplasia. Active DVT, pulmonary embolism (PE), or a history of these conditions • Active arterial thromboembolic disease (for example, stroke and myocardial infarction [MI]), or a history of these conditions. • Known or suspected pregnancy **Side Effects:** Adverse reactions (≥1 percent) include: hot flush, vaginal discharge, muscle spasms, genital discharge, and hyperhidrosis.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		e) **Canagliflozin 100mg FC Tablet** Canagliflozin Hemihydrate INN 104.137mg Eqv. to Canagliflozin 100mg **Antidiabetic**	It is a sodium-glucose co-transporter 2 (SGLT2) inhibitor Indicated as an adjunct to diet and exercise to improve glycemic control in Adults with type 2 diabetes mellitus. **Limitation of Use:** • Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis	**Contraindications:** • History of a serious hypersensitivity reaction to canagliflozin • Patients having end stage renal disease or patients on dialysis **Side effects:** Most common adverse reactions associated with Canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract Infection and increased urination.	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	f) **Canagliflozin 300mg FC Tablet** Canagliflozin Hemihydrate INN 312.410mg eq. to Canagliflozin 300mg **Antidiabetic**	Do	Do	New	USFDA	D"PgvÎv nIqvi Kvi‡Y Av‡e`b bvgÄyK iv †h‡Z cv‡i	D"PgvÎv nIqvi Kvi‡Y Av‡e`b bvgÄyK iv nj	
		g) **Atorvastatin 10 mg + Ezetimib 10 mg FC Tablet** Atorvastatin Calcium Trihydrate USP 10.840mg Eqv. to Atorvastatin 10 mg + Ezetimib INN 10 mg **Antihyperlipidemic**	Reduce elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and to increase HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia. Reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), as an adjunct to other lipid-lowering treatments.	**Contraindications:** Active liver disease or unexplained persistent elevations of hepatic transaminase levels; Hypersensitivity to any component of Atorvastatin & Ezetimib; Women who are pregnant or may become pregnant; Nursing mothers. **Side effects:** Increased ALT; Increased AST; Musculoskeletal pain	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj	
		h) **Atorvastatin 20 mg + Ezetimib 10 mg FC Tablet** Atorvastatin Calcium Trihydrate USP 21.680mg Eqv. to Atorvastatin 20 mg + Ezetimib INN 10 mg **Antihyperlipidemic**	Do	Do	Ezetimibe 10 mg Tablet Atorvastatin 10mg, 20 mg, 40 mg & 80 mg Tablet	USFDA	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv †h‡Z cv‡i	GKK Jla wn‡m‡e KvhKwiZv cgwYZ weavq Kw¤‡bkb Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	i) **Paracetamol 325mg + Dextromethorphan Hbr 10mg + Phenylephrine HCl 5mg/15ml syrup** Paracetamol BP 325mg + Dextromethorphan Hbr USP 10mg + Phenylephrine HCl BP 5mg/15ml	Dry or Unproductive Cough, Fever, Body Ache, Sneezing, Watery Eyes	**Contraindications:** This product is contraindicated in patients hypersensitive to any of the ingredients **Side Effects:** General side effects include pallor, dizziness, excitability, headache, nausea, nervousness or anxiety, trouble sleeping, weakness.			c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		j) **Paracetamol 325mg + Dextromethorphan Hbr 15mg + Phenylephrine HCl 6.25mg/15ml syrup** Paracetamol BP 325mg + Dextromethorphan Hbr USP 15mg + Phenylephrine HCl BP 6.25mg/15ml	Dry or Unproductive Cough, Fever, Body Ache, Sneezing, Watery Eyes	**Contraindications:** This product is contraindicated in patients hypersensitive to any of the ingredients **Side Effects:** General side effects include pallor, dizziness, excitability, headache, nausea, nervousness or anxiety, trouble sleeping, weakness.			c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		k) **Mirabegron 25mg ER tablet** Mirabegron INN 25mg **β3-Adrenoceptor Agonist**	It is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.	**Contraindications:** None **ADR/Side effects:** Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache	New	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		l) **Mirabegron 50mg ER tablet** Mirabegron INN 50mg **β3-Adrenoceptor Agonist**	Do	Do	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	m) **Mesalamine 800mg DR Tablet** Mesalamine INN 800mg	It is an aminosalicylate indicated for the treatment of moderately Active ulcerative colitis in adults. **Limitation of Use:** Safety and effectiveness of Asacol HD beyond 6 weeks have not been established.	**Contraindication:** Patients with known hypersensitivity to salicylates or aminosalicylates or any of the components of this product. **Side effects:** The most common adverse reactions (observed in greater than 2% percent) were headache, nausea, nasopharyngitis, abdominal pain, and worsening of ulcerative colitis.	New	USFDA	GB gv‡Îv c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	GB gv‡Îv c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj |
		n) **Tenatoprazole 20mg EC Tablet** Tenatoprazole Sodium INN 21.327mg eq. to Tenatoprazole 20mg **Antiulcerant**	Tenatoprazole is a recently developed antiulcerative drug used for the treatment of both erosive and non erosive gastroesophageal reflux disease	**Contraindications:** in patients with known hypersensitivity to tenatoprazole. **Side Effects:** Most Common side effects are GI disturbances including diarrhea, nausea, vomiting, constipation, flatulence, abdominal apin, headache, hypersensitivity reactions, pruritis, dizziness, joint pain, malaise, blurred vision.	New		c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj |
		o) **Tenatoprazole 40mg EC Tablet** Tenatoprazole Sodium INN 42.654mg eq. to Tenatoprazole 40mg **Antiulcerant**	Do	Do	New		c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	p) **Vilazodone HCl 10mg FC Tablet** Vilazodone HCl INN 10mg **Antidepressant**	It is indicated for the treatment of major depressive disorder (MDD). The efficacy of this medicine was established in two 8-week, placebo-controlled trials in adult patients with MDD	**Contraindications:** **Serotonin Syndrome and MAOIs**: Do not use MAOIs intended to treat psychiatric disorders with it or within 14 days of stopping treatment with it. Do not use it within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start it in a patient who is being treated with linezolid or intravenous methylene blue. **Side effects:** The most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo) are: diarrhea, nausea, vomiting, and insomnia.	New	USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄyK i v †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyK i v nj |
		q) **Guaifenesin 100mg/5ml syrup** Guaifenesin USP 2.0g/100ml **Expectorant**	Helps loosen phlegm and thin bronchial secretions; Symptomatic relief of deep chesty coughs; Expectorant for productive cough	**Contraindications:** Hypersensitivity (allergy) to the active substance or to any of the ingredients Side effects: Guaifenesin has occasionally been reported to cause gastrointestinal (stomach) discomfort, nausea and vomiting, particularly in high doses. **Side Effects:** Most common side effects are nausea and vomiting. Dizziness, headache and rash repoted rarely.	New		c‡qvRb †bB wea vq Av‡e`b bvgÄyK i v †h‡Z cv‡i |	c‡qvRb †bB wea vq Av‡e`b bvgÄyK i v nj |
		r) **Levomilnacipran 20mg ER Capsule** Levomilnacipran Hydrochloride INN 22.96 mg eq. to Levomilnacipran 20mg **Antidepressant**	It is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder. **Limitation of Use:** It is not approved for the management of fibromyalgia. The efficacy and safety of this product for the management of fibromyalgia have not been established.	**Contraindications:** Hypersensitivity to levomilnacipran, milnacipran HCl, or any excipient in the formulation. Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with it or within 7 days of stopping treatment with this product. Do not use this product within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start this product in a patient who is being treated with linezolid or intravenous methylene blue. **Side effects:** The most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo) are: nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.	New	USFDA	c‡qvRb †bB wea vq Av‡e`b bvgÄyK i v †h‡Z cv‡i |	c‡qvRb †bB wea vq Av‡e`b bvgÄyK i v nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	s) **Levomilnacipran INN 40mg ER Capsule** Levomilnacipran HCl NN 45.92 mg eq. to Levomilnacipran 40mg **Antidepressant**	It is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder. **<u>Limitation of Use</u>:** It is not approved for the management of fibromyalgia. The efficacy and safety of this product for the management of fibromyalgia have not been established.	**Contraindications:** Hypersensitivity to levomilnacipran, milnacipran HCl, or any excipient in the formulation. Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with it or within 7 days of stopping treatment with this product. Do not use this product within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start this product in a patient who is being treated with linezolid or intravenous methylene blue. **Side effects:** The most common adverse reactions (incidence ≥ 5% and at least twice the rate of placebo) are: nausea, constipation, hyperhidrosis, heart rate increase, erectile dysfunction, tachycardia, vomiting, and palpitations.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄ¡y Kiv nj |
		t) **Levomilnacipran 80mg ER Capsule** Levomilnacipran Hydrochloride INN 67.800mg eqv. to Levomilnacipran 80mg **Antidepressant**	Do	Do	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄ¡y Kiv nj |
		u) **Levomilnacipran 120mg ER Capsule** Levomilnacipran Hydrochloride INN 90.40mg Eqv. to Levomilnacipran 120mg **Antidepressant**	Do	Do	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄ¡y Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄ¡y Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	v) **Metronidazole 750mg ER Tablet** Metronidazole BP 750mg	Bacterial Vaginosis (BV). Metronidazole tablets are indicated in the treatment of BV in non-pregnant women; To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.	**Contraindication:** It is contraindicated in patients with a history of hypersensitivity to Metronidazole or other Nitroimidazole derivatives. It is also contraindicated during the first trimester of pregnancy. **Side effects:**Pain, tenderness, redness, or swelling over vein in which the medicine is given. Other side-effects are unsteadiness, fever or chills, sore throat, headache, numbness, tingling pain or weakness in the hands or feet, pain, seizures, skin itching, unusual tiredness or weakness, vaginal irritation or discharge.	400mg Tablet, 200mg/5ml Suspension, 500mg in 100ml Injection vial	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		w) **Bimatoprost 0.03% +Timolol 0.5% Ophthalmic Solution** Bimatoprost INN 0.03g + Timolol Maleate BP 0.683g eq. to Timolol 0.5g/100ml **Antiglucoma**	For the reduction of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.	**Contraindications:**Contraindicated in patients with hypersensitivity to any component of this medication, in patients with bronchospasm, bronchial asthma or patients with a history of bronchial asthma, or severe chronic obstructive pulmonary disease, in patients with sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock. Side effects: No adverse drug reactions (ADR's) specific for brand name have been observed in clinical studies. The majority of ADR's were ocular, mild in severity and none were serious; Conjunctival hyperaemia	Bimatoprost 0.3% Eye Drop Timolol 0.5% Eye Drop		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	x) **Ceftriaxone 250mg + Sulbactam 125mg IM/IV Injection** Ceftriaxone Sodium BP 299.250mg eq. to Ceftriaxone 250mg + Sulbactam Sodium BP 137.375mg eq. to Sulbactam 125mg **Antibiotic-Cephalosporin**	It is indicated in infections caused by Ceftriaxone sodium-sensitive pathogens and may be used in the clinical settings in: Sepsis Meningitis, Abdominal Infections (e.g. Peritonitis, Infections of the Biliary tract), Infections of the Bones, Joints, Soft Tissue, Skin and of Wounds, Renal and Urinary Tract Infections, Respiratory Tract infections, particularly Pneumonia, and Ear, Nose and Throat Infections, and uncomplicated Gonorrhoea. Ceftriaxone & Sulbactam For Injection may also be used for Peri-operative Prophylaxis of Infections. A single dose given preoperatively may reduce chances of Postoperative Infection	**Contraindications:** Ceftriaxone & Sulbactam for Injection is contraindicated in patients with known allergy to Cephalosporin group of antibiotics. Hypersensitivity to penicillin may pre-dispose the patient to the possibility of allergic cross-reactions **Adverse effects:** The following side effects, reported to occur during Ceftriaxone therapy, may be seen with the combination as well: Gastrointestinal: Diarrhoea, nausea & vomiting (less frequent), stomatitis, and glossitis. Hepatic: Elevations of SGOT/SGPT. Hematological: Eosinophilia, thrombocytopenia, leukopenia, granulocytopenia, hematoma or bleeding. Hemolytic anemia is observed less frequently.			‡idv‡iÝ Ges c‡qvRb †bB wecixq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	†idv‡iÝ I c‡qvRb †bB wecixq Av‡e`b bvgÄyi Kiv nj
		y) **Ceftriaxone 500mg + Sulbactam 200mg IM/IV injection** Ceftriaxone Sodium BP 598.500mg eq. to Ceftriaxone 500mg + Sulbactam Sodium BP 274.749mg eq. to Sulbactam 250mg **Antibiotic-Cephalosporin**	Do	Do			‡idv‡iÝ Ges c‡qvRb †bB wecixq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	†idv‡iÝ I c‡qvRb †bB wecixq Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	z) **Ceftriaxone 1g + Sulbactam 500mg IM/IV injection** Ceftriaxone Sodium BP 1.197g eq. to Ceftriaxone 1.0g + Sulbactam Sodium BP 549.498mg eq. to Sulbactam 500mg **Antibiotic-Cephalosporin**	It is indicated in infections caused by Ceftriaxone sodium-sensitive pathogens and may be used in the clinical settings in: Sepsis Meningitis, Abdominal Infections (e.g. Peritonitis, Infections of the Biliary tract), Infections of the Bones, Joints, Soft Tissue, Skin and of Wounds, Renal and Urinary Tract Infections, Respiratory Tract infections, particularly Pneumonia, and Ear, Nose and Throat Infections, and uncomplicated Gonorrhoea. Ceftriaxone & Sulbactam For Injection may also be used for Peri-operative Prophylaxis of Infections. A single dose given preoperatively may reduce chances of Postoperative Infection	**Contraindications:** Ceftriaxone & Sulbactam for Injection is contraindicated in patients with known allergy to Cephalosporin group of antibiotics. Hypersensitivity to penicillin may pre-dispose the patient to the possibility of allergic cross-reactions **Adverse effects:** The following side effects, reported to occur during Ceftriaxone therapy, may be seen with the combination as well: Gastrointestinal: Diarrhoea, nausea & vomiting (less frequent), stomatitis, and glossitis. Hepatic: Elevations of SGOT/SGPT. Hematological: Eosinophilia, thrombocytopenia, leukopenia, granulocytopenia, hematoma or bleeding. Hemolytic anemia is observed less frequently.	Ceftriaxone 1000mg/Vial Injection		‡idv‡iÝ Ges c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv †h‡Z cv‡i |	†idv‡iÝ I c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv nj |
		aa) **Omeprazole 2.5mg/Sachet DR Powder for suspension** Omeprazole Magnesium USP 2.581mg eq. to Omeprazole 2.5mg/Sachet **Antiulcerant (PPI)**	Dyspepsia, Gastro-oesophageal reflux disease	**Contraindications:** Pregnancy. Domperidone is contraindicated in conditions associated with rise in prolactin level. Omeprazole is contraindicated in hypersensitive patients	20/40mg/Sachet Powder for suspension	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv †h‡Z cv‡i |	†idv‡iÝ I c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	ab) **Omeprazole 20mg + Ketoprofen 100mg MR Capsule** Omeprazole USP 20mg + Ketoprofen BP 100mg **Antiulcerant (PPI) + Analgesic**	Symptomatic treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis in patients with a previous history or who are at risk of developing NSAID associated gastric ulcers, duodenal ulcers and gastroduodenal erosions in whom continued treatment with ketoprofen is essential.	**Contraindications:** Hypersensitivity to ketoprofen or to omeprazole or to any of the excipients; Last trimester of pregnancy; History of asthma induced by administration of ketoprofen or similar acting substances, such as other non-steroidal anti-inflammatory agents (NSAIDs) or acetylsalicylic acid; Severe hepatic, renal and heart failure ; Active peptic ulcer; Gastrointestinal bleeding, cerebrovascular bleeding or other active bleeding; Combination therapy with clarithromycin should not be used in patients with hepatic impairment **Side effects:** GI bleeding; Headache; Dizziness; Nausea ;Vomiting	Ketoprofen 50mg, 100mg & 200mg Tablet/Capsule Omeprazole 20mg & 40mg Capsule	MHRA	Ac‡qvRbxq I A‡hŠw³K K¬v¤‡bkb weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	Ac‡qvRbxq I A‡hŠw³K K¬v¤‡bkb weavq Av‡e`b bvgÄyi Kiv nj
		ac) **Omeprazole 20mg + Ketoprofen 150mg MR capsule** Omeprazole USP 20mg + Ketoprofen BP 150mg **Antiulcerant (PPI) + Analgesic**	Do	Do	Ketoprofen 50mg, 100mg & 200mg Tablet/Capsule Omeprazole 20mg & 40mg Capsule	MHRA	Ac‡qvRbxq I A‡hŠw³K K¬v¤‡bkb weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	Ac‡qvRbxq I A‡hŠw³K K¬v¤‡bkb weavq Av‡e`b bvgÄyi Kiv nj
		ad) **Omeprazole 20mg + Ketoprofen 200mg MR capsule** Omeprazole USP 20mg + Ketoprofen BP 200mg **Antiulcerant (PPI) + Analgesic**	Do	Do	Ketoprofen 50mg, 100mg & 200mg Tablet/Capsule Omeprazole 20mg & 40mg Capsule	MHRA	Ac‡qvRbxq I A‡hŠw³K K¬v¤‡bkb weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	Ac‡qvRbxq I A‡hŠw³K K¬v¤‡bkb weavq Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	ae) **Montelukast 5mg + Levocetirizine Dihydrochloride 2.5mg FC tablet** Montelukast Sodium USP 5.197mg eq. to Montelukast 5mg + Levocetirizine Dihydrochloride INN 2.5mg **Leukotriene receptor antagonist + Antihistamine**	Asthma; Exercise induced Bronchospasm; Allergic Rhinitis; Urticaria; Used for seasonal and perennial allergic rhinitis; Used for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria	**Contraindications:** Hypersensitivity to montelukast & levocetirizine. **Side effects:** Headaches; Abdominal pain; Abnormal dreams; Drowsiness; Insomnia; Nausea; Hypersensitivity reactions; Heartburn; Infections; Muscle aches	Montelukast 4mg, 5mg & 10mg Tablet Levocetirizine 5mg Tablet		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		af) **Guaifenesin 2.0 gm + Dextromethorphane Hbr 0.2gm/100ml Syrup** Guaifenesin USP 2.0gm + Dextromethorphane Hbr USP 0.2gm/100ml	Dry Cough, Chest Congestion caused by the common cold, Infections or allergies	**Contraindications:** This product is contraindicated in patients hypersensitive to any of the ingredients. **Side Effects:**			c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		ag) **Guaifenesin 1200mg ER Tablet** Guaifenesin USP 1200mg **Expectorant**	Helps loosen phlegm and thin bronchial secretions; Symptomatic relief of deep chesty coughs; Expectorant for productive cough	**Contraindications:** Hypersensitivity(allergy) to the active substance or to any of the ingredients **Side effects:** Guaifenesin has occasionally been reported to cause gastrointestinal (stomach) discomfort, nausea and vomiting, particularly in high doses.	New	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	ah) **Omeprazole 20mg + Domperidone 10mg Capsule** Omeprazole USP 20mg + Domperidone BP 10mg **Antiulcerant (PPI) + Antiemetic**	Dyspepsia; Gastro-oesophageal reflux disease	**Contraindications:** Pregnancy. Domperidone is contraindicated in conditions associated with rise in prolactin level. Omeprazole is contraindicated in hypersensitive patients. **Side effects:** Domperidone: Dry mouth, transient skin rash, itching, headache, diarrhoea and rarely nervousness; Omeprazole: Anaemia, eosinopaenia, urinary tract infection, skin rash, urticaria and pruritus, diarrhoea, headache, constipation, nausea, vomiting, flatulence and abdominal pain.	Omeprazole 20mg Capsule Domperidone 10mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄ ¨ K i v †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄ ¨ K i v nj	
		ai) **Montelukast 10mg + Fexofenadine 120mg Film Coated Tablet** Montelukast Sodium USP 10.375mg eq. to Montelukast 10mg + Fexofenadine Hydrochloride USP 120mg **Leukotriene receptor antagonist + Antihistamine**	Asthma; Allergic rhinitis	**Contraindications:** Hypersensitivity to any ingredients of the product. **Side effects:** Headache, dizziness, cough and fever	Montelukast 10mg Tablet Fexofenadine 120mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄ ¨ K i v †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄ ¨ K i v nj	
		aj) **Guaifenesin 2.0gm + Dextromethorphan HBr 0.1gm + Phenylephrine HCl 0.05gm/20ml Syrup** Guaifenesin USP 2.0gm + Dextromethorphan HBr USP 0.1gm + Phenylephrine HCl USP 0.05gm/20ml	Dry Cough, Chest Congestion caused by the common cold,Infections or allergies	**Contraindications:** This product is contraindicated in patients hypersensitive to any of the ingredients. **Side Effects:** Dizziness, sleepness, persistent headache, rash.	New		c‡qvRb †bB wea vq Av‡e`b bvgÄ ¨ K i v †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄ ¨ K i v nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd. Tongi, Gazipur	ak) **Chlordiazepoxide 5mg + Amitriptyline 12.5mg Film Coated Tablet** Chlordiazepoxide USP 5mg + Amitriptyline Hydrochloride USP 14.143mg eq. to Amitriptyline 12.5mg **Anxiolytic + Antidepressant**	It is ndicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to the product occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia.	**Contraindications:** Contraindicated in patients with hypersensitivity to either benzodiazepines or tricyclic antidepressants. It should not be given concomitantly with a monoamine oxidase inhibitor. **Side effects:** Most frequently reported were drowsiness, dry mouth, constipation, blurred vision, dizziness and bloating.	Amitriptyline 10mg & 25mg Tablet	USFDA	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		al) **Chlordiazepoxide 10mg + Amitriptyline 25mg Film Coated Tablet** Chlordiazepoxide USP 10mg + Amitriptyline Hydrochloride USP 28.286mg eq. to Amitriptyline 25mg **Anxiolytic + Antidepressant**	Do	Do	Amitriptyline 10mg & 25mg Tablet	USFDA	D"PgvÎvi K¬v‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	D"PgvÎvi K¬v‡bkb c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj |
		am) **Chlordiazepoxide 10mg IR + Amitriptyline 25mg ER Film Coated Tablet** Chlordiazepoxide USP 10mg + Amitriptyline Hydrochloride USP 28.286mg eq. to Amitriptyline 25mg **Anxiolytic + Antidepressant**	Do	Do			c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
13.	Eskayef Bangladesh Ltd, Mirpur, Dhaka	a) **Luliconazole 1% cream** Luliconazole INN 1 g/100g	It is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.	**Contraindications:** None. **Side Effects:** The most common adverse reactions observed in clinical trials were application site reactions, which occurred in less than 1% of subjects.		USFDA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **Clobetasol propionate 0.05% + Neomycin sulphate 0.5% + Miconazole nitrate 2% Cream** Clobetasol propionate USP 0.05g + Neomycin sulphate USP 0.5g + Miconazole nitrate BP 2g/100g	Atopic eczema. Allergic contact dermatitis. Primary irritant dermatitis. Seborrheic dermatitis. Psoriasis of face, flexures. Varicose eczema. Cystic acne. Alopecia areata. Hypertrophied scars, keloids. Nail disorders. Psoriasis of palm, sole, elbow, knee. A combination of steroid with proper antibiotic cover may also be used for: Impetigo, furunculosis, secondary infected dermatoses, napkin rash, otitis externa, intertriginous eruptions.	**Contraindications:** Hypersensitivity, Porphyria			c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		c) **Salicylic acid 6% + Clobetasol propionate 0.05% Ointment** Salicylic acid BP 6g + Clobetasol propionate USP 0.05g/100g	It is indicated for the treatment of resistant dermatoses such as psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus and discoid lupus erythematosus and other skin conditions which do not respond satisfactorily to less active steroids.	**Contraindications:** Rosacea, acne vulgaris and perioral dermatitis. Primary cutaneous viral infections (e.g. herpes simplex, chickenpox)	Salicylic Acid 3gm + Clobetasol Propionate 0.05gm/100 gm		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
14.	Sanofi-Aventis Bangladesh Limited	a) **Glimepiride 1 mg+ Metformin BP 500mg Bilayer Tablet** Glimepiride BP 1mg + Metformin BP 500mg **Antidiabetic**	As an adjunct to diet and exercise in type 2 diabetes mellitus patients	**Contraindication:** In patients hypersensitive to glimepiride, other sulfonylureas, other sulfonamides, or any of the excipients of it. In pregnant women, in breast-feeding women. **Side effects:** Hypoglycemia, nausea, vomiting, abdominal pain and diarrhea, itching, urticarial.	Glimepiride 1/2/3/4mg Tablet Metformin 500/850/ 1000mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	JlaUi Safety, Efficacy & Usefullness m¤ú‡K (1) Aa¨vcK Rvjj, wefvMxq cavb, G‡ÛvKvB‡bvj wR wefvM, XvKv †gvW‡Kj K‡jR, (2) Aa¨vcK dvi`Dïxb Avn‡g`, †Pqvig¨vb, G‡ÛvKvB‡bvj wR wefvM, weGmGgGgBD, Ges (3) Aa¨vcK nv‡RivgvnZve, evi‡Wg nvmcvZvj, XvKv Gi gZvgZ MnY Kiv n‡e Ges D³ gZvgZ cieZx mfvq Dc¯vcb Kivi wm×vš Mp Z nq|
	b)	**Glimepiride 2mg + Metformin BP 500mg Bilayer Tablet** Glimepiride BP 2mg + Metformin BP 500mg **Antidiabetic**	As an adjunct to diet and exercise in type 2 diabetes mellitus patients	**Contraindication:** In patients hypersensitive to glimepiride, other sulfonylureas, other sulfonamides, or any of the excipients of it. In pregnant women, in breast-feeding women. **Side effects:** Hypoglycemia, nausea, vomiting, abdominal pain and diarrhea, itching, urticarial.	Glimepiride 1/2/3/4mg Tablet Metformin 500/850/ 1000mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	-H-
	c)	**Risperidone 100mg/100ml Syrup** Risperidone USP 100mg /100ml	It is an atypical antipsychotic indicated for: • Treatment of schizophrenia • As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder • Treatment of irritability associated with autistic disorder	**Contraindication-** Hypersensitivity to Risperidone or or any of its ingredients **Side effects:** The most common adverse reactions in clinical trials (≥5% and twice placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain.	1mg, 2mg, 4mg Tablet and 25mg/Vial Injection	USFDA & MHRA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
15.	Radiant Pharmaceuticals Ltd., Tongi, Gazipur.	a) **Mebeverine HCl 135mg + Psyllium Husk 3.5gm/ Sachet Effervescent Granules** Mebeverine HCl BP 135mg + Psyllium Husk BP 3.5gm/ Sachet	Used for the symptomatic relief of irritable bowel syndrome.	**Contraindications:** Contraindicated in patients having hypersensitivity to Psyllium or Mebeverine Hydrochloride or other excipients of formulation. **Side Effects:** Flatulence and bloating may be experienced during the first few days of treatment, but should diminish during continued treatment.	New	BNF-64; Page: 50	Abyjgv`b Kiv ‡h‡Z cv‡i |	Abyjgv`b Kiv nj |
16.	ACI Ltd.	a) **Cefixime 3gm/100ml Podwer for Suspension (150mg/5ml)** Cefixime Trihydrate (Micronized) USP 3.358gm eq.to Cefixime 3gm **Antibiotic-Cephalosporin**	It is indicated for the treatment of upper and lower respiratory tract infections. Urinary tract infections, gonococcal urethritis, typhoid fever & acutee otitis media. Clinical efficacy has been demonstrated in infections caused by commonly occurring pathogens including Stretococcus pneumoniae, Streptococcus pyogenes, Escherechia coli, Proteus mirabilis, Klebsiella species, Hemophyllus influenzae (β-lactamase positive and negative), Moraxella catarrhalis (β-lactamase positive and negative), and Enterobacter species. Cefixime is highly stable in the presence of β –lactamase enzymes.	**Contraindications:** Patients with known hypersensitivity to Cefixime or cephalosporin group of drugs. **Side effects:** Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials are mild and self limiting in nature. **GI disturbance:** Diarrhea (if severe diarrhea occurs, Cefixime should be discontinued), changes in the color of stool, nausea, abdominal pain, dyspepsia, vomiting, flatulence have been reported. **CNS disturbances:** Headache, dizziness. **Others:** Hypersensitivity reactions which usually subsided upon discontinuation of therapy; infrequent and reversible hematological changes; elevation of serum amylase.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	b) **Cefixime 1gm + Lactobacillus acidophilus 800 Million spores/100ml Powder for Suspension** Cefixime Trihydrate USP 1.119gm eq. to Cefixime 1gm + Lactobacillus acidophilus Ph. Grade 0.133gm eq. to 800Million Lactobacillus Acidophilus spores/100ml	It is indicated for the treatment of uncomplicated UTIs, otitis media, pharyngitis, tonsillitis, acute bronchitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea caused by susceptible strains of specific organisms.	**Contraindications:** It is contraindicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature. **GI disturbances:** The most frequent side effects seen with cefixime are diarrhoea and stool changes; diarrhoea has been more commonly associated with higher doses. Some cases of moderate to severe diarrhoea have been reported; this has occasionally warranted cessation of therapy. Cefixime should be discontinued if marked diarrhoea occurs. Other gastrointestinal side effects seen less frequently are nausea, abdominal pain, dyspepsia, vomiting and flatulence. Pseudomembranous colitis has been reported. **Central Nervous System:** Headache and dizziness.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	c) **Cefixime 1gm + 1200 Million Lactobacillus Acidophilus spores/100ml Powder for Suspension** Cefixime Trihydrate USP 1.119gm eq. to Cefixime 1gm + Lactobacillus acidophilus Ph. Grade 0.200gm eqv. to 1200Million Lactobacillus Acidophilus spores/100ml	It is indicated for the treatment of uncomplicated UTIs, otitis media, pharyngitis, tonsillitis, acute bronchitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea caused by susceptible strains of specific organisms.	**Contraindications:** It is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature. **Gastrointestinal disturbances:** The most frequent side effects seen with cefixime are diarrhoea and stool changes; diarrhoea has been more commonly associated with higher doses. Some cases of moderate to severe diarrhoea have been reported; this has occasionally warranted cessation of therapy. Cefixime should be discontinued if marked diarrhoea occurs. Other gastrointestinal side effects seen less frequently are nausea, abdominal pain, dyspepsia, vomiting and flatulence. Pseudomembranous colitis has been reported. **Central Nervous System:** Headache and dizziness.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	d) **Cefixime Trihydrate USP 1.119gm eqv. to Cefixime 1gm + Lactobacillus acidophilus Ph. Grade 0.067gm eqv. to 400Million Lactobacillus Acidophilus spores/100ml Powder for Suspension** Cefixime Trihydrate USP 1.119gm eqv. to Cefixime 1gm + Lactobacillus acidophilus Ph. Grade 0.067gm eqv. to 400Million Lactobacillus Acidophilus spores/100ml	It is indicated for the treatment of uncomplicated UTIs, otitis media, pharyngitis, tonsillitis, acute bronchitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea caused by susceptible strains of specific organisms.	**Contraindications:** It is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Cefixime is generally well tolerated. The majority of adverse reactions observed in clinical trials were mild and self-limiting in nature. **Gastrointestinal disturbances:** The most frequent side effects seen with cefixime are diarrhoea and stool changes; diarrhoea has been more commonly associated with higher doses. Some cases of moderate to severe diarrhoea have been reported; this has occasionally warranted cessation of therapy. Cefixime should be discontinued if marked diarrhoea occurs. Other gastrointestinal side effects seen less frequently are nausea, abdominal pain, dyspepsia, vomiting and flatulence. Pseudomembranous colitis has been reported. **Central Nervous System:** Headache and dizziness.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv nj
	ACI Ltd.	e) **Cefixime 4gm + 1200Million Lactobacillus Acidophilus spores/100ml Powder for Suspension** Cefixime Trihydrate USP 4.477gm eq. to Cefixime 4gm + Lactobacillus acidophilus Ph. Grade 0.200gm eqv. to 1200Million Lactobacillus Acidophilus spores/100ml	It is indicated for the treatment of uncomplicated UTIs, otitis media, pharyngitis, tonsillitis, acute bronchitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea caused by susceptible strains of specific organisms.	**Contraindications:** It is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Most adverse reactions observed with these combinations are of a mild and transient nature. Frequently reported adverse reactions include diarrhea, abdominal pain, nausea, dyspepsia and flatulence. Skin rashes, urticaria, drug fever, headaches and dizziness have also been reported.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	f) **Cefixime 2gm + 1200 Million Lactobacillus Acidophilus spores/100ml Powder for Suspension** Cefixime Trihydrate USP 2.238gm eq. to Cefixime 2gm + Lactobacillus acidophilus Ph. Grade 0.200gm eqv. to 1200Million Lactobacillus Acidophilus spores/100ml	It is indicated for the treatment of uncomplicated UTIs, otitis media, pharyngitis, tonsillitis, acute bronchitis, acute exacerbations of chronic bronchitis, and uncomplicated gonorrhea caused by susceptible strains of specific organisms.	**Contraindications:** It is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Most adverse reactions observed with these combinations are of a mild and transient nature. Frequently reported adverse reactions include diarrhea, abdominal pain, nausea, dyspepsia and flatulence. Skin rashes, urticaria, drug fever, headaches and dizziness have also been reported.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ K i| †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ K i| nj |
		g) **Cefixime 200mg + 60Million Lactobacillus Acidophilus spores film coated Tablet** Cefixime Trihydrate USP 2.238gm eqv. to Cefixime 200mg + Lactobacillus acidophilus Ph. Grade 10mg eqv. to 60 Million Lactobacillus Acidophilus spores	It is indicated in the treatment of the following infections: • Urinary tract infections •Respiratory tract infections • Typhoid • Otitis media •Gonorrhea (cervical/urethral) • Switch therapy (switch from parenteral to oral therapy)	**Contraindications:** It is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Most adverse reactions observed with these combinations are of a mild and transient nature. Frequently reported adverse reactions include diarrhea, abdominal pain, nausea, dyspepsia and flatulence. Skin rashes, urticaria, drug fever, headaches and dizziness have also been reported.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ K i| †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ K i| nj |
		h) **Cefixime 100mg + 60 Million Lactobacillus Acidophilus spores Dispersible Tablet** Cefixime Trihydrate USP 111.92mg eqv. to Cefixime 100mg + Lactobacillus acidophilus Ph. Grade 10mg eqv. to 60 Million Lactobacillus Acidophilus spores	It is indicated in the treatment of the following infections: • Urinary tract infections •Respiratory tract infections • Typhoid • Otitis media •Gonorrhea (cervical/urethral) • Switch therapy (switch from parenteral to oral therapy)	**Contraindications:** It is contra-indicated in patients with known allergy to the cephalosporin group of antibiotics. **Side effects:** Most adverse reactions observed with these combinations are of a mild and transient nature. Frequently reported adverse reactions include diarrhea, abdominal pain, nausea, dyspepsia and flatulence. Skin rashes, urticaria, drug fever, headaches and dizziness have also been reported.	Cefixime 100mg/5ml and 200mg/5ml Powder for suspension		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ K i| †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ K i| nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	i) **Esomeprazole 20mg + Domperidone 15mg Capsule** Esomeprazole Magnesium Trihydrate USP 22.27mg eq. to 20mg Esomeprazole + Domperidone Maleate BP 19.089mg eq. to Domperidone 15mg **Antiulcerant (PPI) + Antiemetic**	Esomeprazole Magnesium & Domperidone is indicated for the relief of symptoms of Dyspepsia, GERD, Nausea associated with acid peptic disorders Post-operative nausea and vomitingChronic gastritis.	**Contraindications:** Esomeprazole Magnesium & Domperidone is contraindicated in patients with known hypersensitivity to Esomeprazole, substituted benzimidazole, domperidone or to any component of the formulation. It should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, e,g, in the presence of gastro-intestinal haemorrhage, obstruction or perforation. **Side effects:** Headache, Nausea, Vomiting, Dizziness, Vertigo, Reversible confusion, Agitation, Depression and hallucinations.	Esomeprazole 20mg, 40mg Tablet/Capsule Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension		c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv nj	
		j) **Esomeprazole 20mg + Domperidone 15mg Tablet** Esomeprazole Magnesium Trihydrate USP 22.27mg eqv. to 20mg Esomeprazole + Domperidone Maleate BP 19.089mg eq. to Domperidone 15mg **Antiulcerant (PPI) + Antiemetic**	Esomeprazole magnesium & Domperidone is indicated for the relief of symptoms of Dyspepsia, GERD Nausea associated with acid peptic disorders Post-operative nausea& vomitingChronic gastritis.	**Contraindications:** Esomeprazole Magnesium & Domperidone is contraindicated in patients with known hypersensitivity to Esomeprazole, substituted benzimidazole, domperidone or to any component of the formulation. It should not be used whenever stimulation of gastric motility is to be avoided or could be harmful, e,g, in the presence of gastro-intestinal haemorrhage, obstruction or perforation. **Side effects:** Headache, Nausea, Vomiting, Dizziness, Vertigo, Reversible confusion, Agitation, Depression and hallucinations.	Esomeprazole 20mg, 40mg Tablet/Capsule Domperidone 10mg Tablet, 15mg & 30mg Suppository, 5mg/ml drops and 5mg/5ml Supension		c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewaq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	k) **Omeprazole 20 mg + Domperidone 30mg SR Capsule** Omeprazole BP 20 mg + Domperidone Maleate BP 38.178mg eq. to Domperidone 30mg **Antiulcerant (PPI) + Antiemetic**	This combination is indicated for the treatment of dyspepsia and gastro-oesophageal reflux diseases.	**Contraindications:** This combination is contraindicated in patients with known hypersensitivity to omeprazole or domperidone. Domperidone is also contraindicated in case of neonates. Domperidone should not be used whenever gastro-intestinal stimulation might be dangerous i.e. gastro-intestinal hemorrhage, mechanical obstruction or perforation. It is also contraindicated in patients with prolactin releasing pituitary tumor (prolactinoma). **Side effects:** The most common side effects with omeprazole and domperidone are headache, diarrhoea, skin rash, itching, diarrhoea, abdominal pain, confusion. **Omeprazole:** It is well tolerated and adverse reactions have generally been mild and reversible. Side-effects may include headache, diarrhoea, constipation, abdominal pain, nausea/vomiting and flatulence, dizziness, paraesthesia, somnolence, insomnia and vertigo, increased liver enzymes, rash, dermatitis and/or pruritis, urticaria, Malaise. Others include hypersensitivity reactions e.g. angioedema, fever, bronchospasm, interstitial nephritis and anaphylactic shock. **Domperidone** Domperidone may produce hyperprolactinemia. This may result in galactorrhea, breast enlargement and soreness and reduced libido. Dry mouth, thirst, headache, nervousness, drowsiness, diarrhea, skin rash and itching may occur during treatment with Domperidome. Extra-pyramidal reactions are seen in 0.05% of patients in clinical studies.	Omeprazole 10, 20 & 40 mg Tablet & Capsule Domperdone 10 mg Tablet and 15 mg & 30 mg Suppository		c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewagvq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	l) **Clonazepam 0.5mg + Escitalopram 5mg Tablet** Clonazepam BP 0.5mg + Escitalopram Oxalate USP 6.39mg eqv. to Escitalopram 5mg	It is a Clonazepam & Escitalopram Oxalate combination product indicated to treat co-exist Anxiety & Depression.	**Contraindication:** Patients with known sensitivity to benzodiazepines (Clonazepam), Escitalopram or any of the drug's excipients; acute pulmonary insufficiency; severe respiratory insufficiency, sleep apnoea syndrome, myasthenia gravis, severe hepatic insufficiency. It must not be used in patients in a coma, or in patients known to be abusing pharmaceuticals, drugs or alcohol. Concomitant treatment with non-selective, irreversible monoamine oxidase inhibitors (MAO-inhibitors) is contraindicated due to the risk of serotonin syndrome with agitation, tremor, hyperthermia etc. **Side effects:** Most common side effects of Clonazepam are Somnolence, slowed reaction, muscular hypotonia, dizziness, ataxia, impaired concentration; restlessness & confusional state have been observed. Most common side effects of Escitalopram are headache, Insomnia, somnolence, dizziness, paraesthesia, tremor, Decreased appetite, increased appetite, weight increased, sweating increased and fatigue.	Clonazepam 0.5mg, 1mg & 2mg Tablet Escitalopram 5mg & 10mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄy Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄy Kiv nj	
		m) **Clonazepam 0.5mg + Escitalopram 10mg Tablet** Clonazepam BP 0.5mg + Escitalopram Oxalate USP 12.78mg eq. to Escitalopram 10mg	-Do-	**-Do-**	Clonazepam 0.5/1/2mg Tablet Escitalopram 5/10mg Tablet		c‡qvRb †bB wea vq Av‡e`b bvgÄy Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄy Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	ACI Ltd.	n) **Daosmin 90% 900mg + Flavonoids as Hespiridine 10% 100mg Tablet** Micronized Purified Flavonoids Ph. Grade. 1040mg contaning Daosmin 90% INN 900mg + Flavonoids as Hespiridine 10% Ph. Eur. 100mg Tablet	It is indicated in Varicose Veins/Chronic Venous Insufficiency, emorrhoids, Lymphedema.Diosmin can normalize capillary filtration rate and prevent ischemia in diabetics and improve factors associated with diabetic complications. It is used as chemopreventive and antiproliferative for cancer patients, stasis dermatitis, premenstrual syndrome, dermatofibrosclerosis, wound healing, mastodynia, viral infections, and colitis.	**Contraindications:** Hypersensitivity to the active substances, or to any of the excipients **Commonly reported adverse events** Gastrointestinal disturbances and headaches, rash (1%) Cramping in lower limb (2%), phlebitis (2%), Venous thrombosis (4%) Skin changes around existing ulcer Swelling of the extremities and body rash (1.6%) Dyspepsia, or non-specific mild stomach upset, occurred in up to 7% of subjects **Rare adverse events:** Inguinal pain, cystitis, asthenia, metrorrhagia, menometrorrhagia, neurovegetative disorders	Daosmin 90% 450mg + Flavonoids as Hespiridine 10% 50mg Tablet		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |
		o) **Indapamide 1.5mg + Amlodipine 5mg FC Bilayer Tablet** Indapamide BP 1.5mg + Amlodipine Besilate BP 6.935mg eq.to Amlodipine 5mg **Diuretics + Calcium Channel Blocker**	It is indicated as substitution therapy for treatment of essential hypertension in patients already controlled with indapamide and amlodipine given concurrently at the same dose level.	**Contraindication:** Hypersensitivity to the active substances, or to any of the excipients Severe renal failure (creatinine clearance below 30 ml/min) Hepatic encephalopathy or severe impairment of liver function Hypokalaemia Lactation Severe hypotension Shock (including cardiogenic shock) Obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis) Haemodynamically unstable heart failure after acute myocardial infarction **Side Effects:** Common side effects are: Headache, dizziness, sleepiness, Palpitations, flushing Abdominal pain, nausea,Oedema, skin rashes, Hypokalemia, fatigue.	Indapamide 1.5/2.5mg Tablet Amlodipine 5/10mg Tablet		c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄÿ Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
18.	Drug International Ltd.	a) **Metoprolol Tartrate 100mg + Hydrochlorothiazide 25mg Film Coated Tablet** Metoprolol Tartrate USP 100mg + Hydrochlorothiazide USP 25mg **Beta Blockers + Diuretics**	It is a combination tablet of metoprolol succinate, a beta adrenoceptor blocking agent and hydrochlorothiazide, a diuretic. IT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the	**Contraindication:** Metoprolol succinate extended release/hydrochlorothiazide is contraindicated in patients in cardiogenic shock, overt cardiac failure (see WARNINGS), second or third degree AV block, marked sinus bradycardia, anuria, and hypersensitivity to either component of this product or to other sulfonamide-derived drugs. **Side Effects:** Most adverse effects have been mild and transient. The following adverse reactions have been reported for immediate release metoprolol tartrate. ***Central Nervous System*:** Tiredness and dizziness have occurred in about 10 of 100 patients. Depression has been reported in about 5 of 100 patients. Mental confusion and short-term memory loss have been reported. Headache, somnolence, nightmares, and insomnia have also been reported. ***Cardiovascular*:** Shortness of breath and bradycardia have occurred in approximately 3 of 100 patients. Cold extremities; arterial insufficiency, usually of the Raynaud type; palpitations; congestive heart failure; peripheral edema; syncope; chest pain; and hypotension have been reported in about 1 of 100 patients ***Respiratory*:** Wheezing (bronchospasm) and dyspnea have been reported in about 1 of 100 patients (see WARNINGS). *Gastrointestinal*: Diarrhea has occurred in about 5 of 100 patients. Nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders, and heartburn have been reported in about 1 of 100 patients. ***Hypersensitive Reactions*:** Pruritus or rash have occurred in about 5 of 100 patients. Worsening of psoriasis has also been reported. *Miscellaneous*: Peyronie's disease has been reported in fewer than 1 of 100,000 patients. Musculoskeletal pain, blurred vision, decreased libido, and tinnitus have also been reported.	Metoprolol 25/50/100mg Tablet Hydrochlorothiazide 25/50mg Tablet	USFDA	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

			risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be administered with other antihypertensive agents.					
	Drug International Ltd.	b) **Metoprolol Tartrate 50mg + Hydrochlorothiazide 25mg Film Coated Tablet** Metoprolol Tartrate USP 50mg + Hydrochlorothiazide USP 25mg **Beta Blockers + Diuretics**	Do	**Do**	Metoprolol 25/50/100mg Tablet Hydrochlorothiazide 25/50mg Tablet	USFDA	*c‡qvRb †bB wmavq Av‡e`b bvgÄy Kiv †h‡Z cv‡i |*	*c‡qvRb †bB wmavq Av‡e`b bvgÄy Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
19	Mundipharma (Bangladesh) Pvt.Ltd., Mirzapur, Gazipur	a) **L-Ornithine-L-Aspartate 150 mg + Pancreatin 100mg Enteric Coated Tablet** L-Ornithine-L-Aspartate INN 150 mg +Pancreatin USP 100 mg	Acute and chronic liver disease, accompanied by hyperammonemia, hepatic encephalopathy (latent and severe), including in the complex treatment of disorders of consciousness (coma or precoma) parenteral nutrition in pateints with protein deficiency (as a corrective supplement).	**Contraindications:** Although possible side-effects have so far not been reported however patient with severe renal insufficiency, blood urea and serum creatinine must be monitored regularly; serum creatinine value exceeding 3 mg per 100 ml is regarded as a reference value. **Side effects:** Unwanted, adverse or side effects of its are not known so far.			ïaygvÎ Paliative care in Hyper ammonia wb‡`kbvq Abyôgv`b Kiv †h‡Z cv‡i|	ïaygvÎ Paliative care in Hyper ammonia wb‡`kbvq Abyôgv`b Kiv nj|

2.3 Proposed Product for locally manufacture (Veterinary)

bs	*c¯ZKvi‡Ki bvg*	*Jl‡ai bvg I †Rvbv‡iK bvg*	*wb‡`kbv*	**Contra-indication & Side-effect**	**Status (New Molecule/ Existing)**	***Av‡e`bKvix c`Ë USFDA or MHRA Ref.***	*‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš*	***mfvi wm×vš***
01.	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	a) **Phenyl Butazone 2gm + Sodium Salicylate 0.2gm/10ml Injectable Solution (Vet)** Phenyl Butazone BP 20gm + Sodium Salicylate BP 0.2gm/10ml	**In Cattle, Sheep, Dog, Cat & Horses:** Somatic or visceral pain, Ephemeral fever, arthritis, laminitis, luxations, etc Relief of inflammatory conditions associated with the musculoskeletal system, trauma and microbial infections Fever due to various etiology associated with pain.	**Contraindication:** Serious cardiac, hepatic or renal dysfunction, history of blood disorders (especially haemoglobinuria), gastro-intestinal disturbances. **Adverse effects:** Toxic reactions to Phenesprin are uncommon, but may be expressed as oedema of legs, jaundice, blood dyscrasia or gastric irritation.	New		*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |*	*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj |*
		b) **Phenyl Butazone 6gm + Sodium Salicylate 0.60gm/30ml Injectable Solution (Vet)** Phenyl Butazone BP 6gm + Sodium Salicylate BP 0.6gm/30ml	**In Cattle, Sheep, Dog, Cat & Horses:** Somatic or visceral pain, Ephemeral fever, arthritis, laminitis, luxations, etc Relief of inflammatory conditions associated with the musculoskeletal system, trauma and microbial infections Fever due to various etiology associated with pain.	**Contraindication:** Serious cardiac, hepatic or renal dysfunction, history of blood disorders (especially haemoglobinuria), gastro-intestinal disturbances. **Adverse effects:** Toxic reactions to Phenesprin are uncommon, but may be expressed as oedema of legs, jaundice, blood dyscrasia or gastric irritation.	New		*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |*	*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj |*
		c) **Phenyl Butazone 20gm + Sodium Salicylate 2gm/100ml Injectable Solution(Vet)** Phenyl Butazone BP 20gm + Sodium Salicylate BP 2gm/100ml	**In Cattle, Sheep, Dog, Cat & Horses:** Somatic or visceral pain, Ephemeral fever, arthritis, laminitis, luxations, etc Relief of inflammatory conditions associated with the musculoskeletal system, trauma and microbial infections Fever due to various etiology associated with pain.	**Contraindication:** Serious cardiac, hepatic or renal dysfunction, history of blood disorders (especially haemoglobinuria), gastro-intestinal disturbances. **Adverse effects:** Toxic reactions to Phenesprin are uncommon, but may be expressed as oedema of legs, jaundice, blood dyscrasia or gastric irritation.	New		*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |*	*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj |*

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Square Pharmaceuticals Ltd., Pabna Unit, Salgaria, Pabna	d) **Amprolium 10gm + Ethopabate 0.5gm + Sulfaquinoxaline 6gm + Menadione (Vitamin K_3) 0.2gm + Ascorbic Acid (Vitamin-C) 2gm/100gm Powder (Vet)** Amprolium HCl BP (vet) 11.3gm (eq. to Amprolium 10gm) + Ethopabate BP (vet) 0.5gm + Sulfaquinoxaline Sodium INN 6.44gm (eq. to Sulfaquinoxaline 6gm) + Menadione Sodium Bisulphite INN 0.382gm [eq. to Menadione (Vitamin K_3) 0.2gm] + Ascorbic Acid (Vitamin-C) BP 2gm /100gm	This is an anticoccidial drug for treatment and control of coccidiosis in poultry. This combination is developed to take the advantage of the synergistic benefits of the three chemicals against a mixed infection of *Eimeria acervulina, Eimeria maxima, Eimeria necatrix, Eimeria tenella, Eimeria brunette* at relatively safe levels of each drug by itself.	**Contra-indications:** Do not administer to animals with kidney dysfunctions. **Adverse effects:** No adverse effects on the growth of chicken, on feed efficiency or on egg production and hatchability.	New		c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj
02.	**Acme Laboratories Ltd.**	a) **Penicillin G Procaine (sterile Powder) 2.0 gm eq. to 20,00,000 IU + Dihydrostreptomycin Sulfate (Sterile Powder) 2.50 gm + Dexamethasone (Sterile Powder) 0.01gm/10ml Vial Injectable suspension (Vet)** Penicillin G Procaine (sterile Powder) USP 2.0 gm eq. to 20,00,000 IU + Dihydrostreptomycin Sulfate (Sterile Powder) USP 2.50 gm + Dexamethasone (Sterile Powder) BP 0.01gm/10ml	Pneumonia, bronchitis, septicemia, mastitis, joint ill, stomatitis, endometritis, bacterial pyelitis, laryngeal inflammation. Poultry: Respiratory disease (*E. coli* CRD, CCRD & Mycoplasmosis).	**Contraindications:** Contraindicated in animals with known hypersensitivity to Penicillin, Dihydrostreptomycin, Dexamethasone or any other ingredients of the product. This preparation is also contraindicated in milking cow whose milk is for supplying and pregnant animal. **Side effects:** Usually well tolerated. However irritation may occur at injection site.			c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbvwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Acme Laboratories Ltd.	b) **Penicillin G Procaine (sterile Powder) 6.0 gm eq. to 60,00,000 IU + Dihydrostreptomycin Sulfate (Sterile Powder) 7.50 gm + Dexamethasone (Sterile Powder) 0.03gm/30ml Vial Injectable suspension (Vet)** Penicillin G Procaine (sterile Powder) USP 6.0 gm eq. to 60,00,000 IU + Dihydrostreptomycin Sulfate (Sterile Powder) USP 7.50 gm + Dexamethasone (Sterile Powder) BP 0.03 gm/30ml	Pneumonia, bronchitis, septicemia, mastitis, joint ill, stomatitis, endometritis, bacterial pyelitis, laryngeal inflammation. Poultry: Respiratory disease (*E. coli* CRD, CCRD & Mycoplasmosis).	**Contraindication:** Contraindicated in animals with known hypersensitivity to Penicillin, Dihydrostreptomycin, Dexamethasone or any other ingredients of the product. This preparation is also contraindicated in milking cow whose milk is for supplying and pregnant animal. **Side effects:** Usually well tolerated. However irritation may occur at injection site.			c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj
		c) Penicillin G Procaine (sterile Powder) 10.0 gm eq. to 100,00,000 IU + Dihydrostreptomycin Sulfate (Sterile Powder) 12.50 gm + Dexamethasone (Sterile Powder) 0.05gm/50ml Vial Injectable suspension (Vet) Penicillin G Procaine (sterile Powder) USP 10.0 gm eq. to 100,00,000 IU + Dihydrostreptomycin Sulfate (Sterile Powder) USP 12.50 gm + Dexamethasone (Sterile Powder) BP 0.05 gm/50ml	Pneumonia, bronchitis, septicemia, mastitis, joint ill, stomatitis, endometritis, bacterial pyelitis, laryngeal inflammation. Poultry: Respiratory disease (*E. coli* CRD, CCRD & Mycoplasmosis).	**Contraindication:** Contraindicated in animals with known hypersensitivity to Penicillin, Dihydrostreptomycin, Dexamethasone or any other ingredients of the product. This preparation is also contraindicated in milking cow whose milk is for supplying and pregnant animal. **Side effects:** Usually well tolerated. However irritation may occur at injection site.			c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
03.	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	a) **Azithromycin 5.00gm + Diprophylline 5.0gm + Chlorpheniramine Maleate 0.50gm/100gm Powder (Vet)** Azithromycin USP 5.0 gm + Diprophylline BP 5.0gm + Chlorpheniramine Maleate BP 0.50gm/100gm	It is mainly used for poultry's snore cough, eyelid swelling, nasal discharge and other respiratory tract disease symptoms caused by *Newcastle disease*, *mycoplasma chlamydia*, *Rickettsia spp* or *mixed virus infection*. Repairing respiratory tract mucosa cell rapidly, preventing inflammatory secretion exudation.	**Contraindications:** It is contraindicated in animals with hyper sensitivity to any active ingrediants. Do not mixes use this product with acidic material. **Side Effects:** Itching, severe allergic reactions, irritation, fungal infection, sweating, hives and blistering, Hearing Loss and/or tinnitus, abnormalities in taste and smell sensation.			c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		b) **Doxycycline HCl 10.0gm + Gentamicin 10.0gm/100gm Powder** Doxycycline HCl BP 10.0gm + Gentamicin Sulfate USP 10.0gm/100gm	In chickens, prevention and treatment of chronic respiratory disease (CRD), mycoplasmosis, Gastrointestinal and respiratory infections caused by micro-organisms sensitive to Doxycycline and/or Gentamicin like *Bordetella, Campylobacter, Chlamydia, E. coli, Klebsiella, Haemophilus, Mycoplasma, Pasteurella, Rickettsia, Salmonella, Staphylococcus and Streptococcus* spp. Gram-negative bacteria including *Pseudomonas*, *Proteus*, *Serratia*, and the Gram-positive *Staphylococcus*. in poultry.	**Contraindication:** Do not use in animals hypersensitive to any active ingrediants of this combination in animals with hepatic dysfunction or for laying hens. **Side Effects:** Nausea and vomiting are the most common side effects associated with doxycycline. This side effect can typically be overcome by providing food along with the medication. While most tetracycline-type medications are not given with food because food prevents the antibiotic from being absorbed, this does not seem to be a problem with doxycycline..			Abygv`b Kiv †h‡Z cv‡i |	Abygv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	c) **Gentamicin 400 mg + Ciprofloxacin HCl 500mg + Ribavirin INN 200 mg/100ml Oral Solution** Gentamicin USP 400 mg + Ciprofloxacin HCl USP 500mg + Ribavirin INN 200 mg/100ml	In chickens, prevention and treatment of chronic respiratory disease (CRD), mycoplasmosis, Gastrointestinal and respiratory infections caused by micro-organisms sensitive to Doxycycline and/or Gentamicin like *Bordetella, Campylobacter, Chlamydia, E. coli, Klebsiella, Haemophilus, Mycoplasma, Pasteurella, Rickettsia, Salmonella, Staphylococcus and Streptococcus* spp. Gram-negative bacteria including *Pseudomonas*, *Proteus*, *Serratia*, and the Gram-positive *Staphylococcus*. in poultry.	**Contraindication:** Hypersensitivity to amino glycosides and/or tetracyclines, renal dysfunctions, vestibular, earorvisus dysfunctions, liver dysfunctions, combination with potential nephrotoxic or muscle Paralysing medicines. **Side Effects:** The important side affects are vestibular auditory otoxicity and nephrotoxicity. Incase of long term use it may particularly toxic to the auditory & renal system.			c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj
		d) **Ivermectin 500mg/100ml Solution** Ivermectin BP 500mg/100ml	Ivermectin Pour-On applied at the recommended dose level of 500 mcg/kg is indicated for the effective control of these parasites. Like *Ostertagia ostertagi* (including inhibited stage) (adults and L_4), *Haemonchus placei* (adults and L_4), *Trichostrongylus axei* (adults and L_4), *T. colubriformis* (adults and L_4), *Cooperia spp.* (adults and L_4), *Oesophagostomum radiatum* (adults and L_4), *Strongyloides papillosus* (adults), *Trichuris spp.* (adults)	**Contraindication:** Hypersensitivity to its active ingradients.Administration to animals with seriously impaired renal and/or hepatic functions. Concurrent administration of Penicillins & Cephalosporines **Side Effects:** Ivermectin has a fairly high margin of safety. When seen, side effects include: agitation, crying, lack of appetite, dilated pupils, paralysis of hind legs, muscle tremors, disorientation, blindness, other neurological signs, such as head pressing or wall climbing	1% (Vet) Injection & 1% Solution		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eon Pharmaceuticals Ltd., Chandan, Joydevpur, Gazipur	e) **n-alkyl dimethyl benzyl ammonium chloride 40% & Urea 60% Solution** n-alkyl dimethyl benzyl ammonium chloride 40% & Urea 60%	For the prevention & treatment of FMD,For the prevention & treatment of Mastitis, For the prevention & treatment of Foot rot, For the prevention & treatment of various skin diseases, Cleaning & disinfection of udder& teat, Cleaning & disinfection of cattle farm, Cleaning & disinfection of utensils used in cattle farms.	**Contraindication & Side effects:** None	New		c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		f) **Neomycin Sulphate 20gm + Gentamycin Sulfate 2.5gm/100gm Powder** Neomycin Sulphate BP 20gm + Gentamycin Sulfate USP 2.5gm/100gm	Gastrointestinal and respiratory infections caused by micro-organisms sensitive to Neomycin and/or Gentamicin like *Bordetella, Campylobacter, Chlamydia, Pseudomonas, Proteus, Serratia, Staphylococcus*. In Poultry.	**Contraindication:** Concurrent use of other drug may induce ototoxicity or nephrotoxicity. **Side Effects:** The important side affects are vestibular auditory otoxicity and nephrotoxicity. Incase of long term use it may particularly toxic to the auditory & renal system.	New		Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		g) **Tylosin Tartrate 15gm + Doxycycline HCl 10gm + Colistin Sulphate 55500000 IU + Bromohexine HCl 100mg/100gm Powder** Tylosin Tartrate BP 15gm + Doxycycline HCl BP 10gm + Colistin Sulphate BP 55500000 IU + Bromohexine HCl BP 100mg/100gm	Gastrointestinal and respiratory infections caused by micro-organisms sensitive to Neomycin and/or Gentamicin like *Bordetella, Campylobacter, Chlamydia, Pseudomonas, Proteus, Serratia, Staphylococcus*. In Poultry.	**Contraindication:** Do not use in case of hypersensitivity to polypeptide antibiotics or to any of the excipients. Do not use in case of resistance to the polymyxin. Special warnings for each target species **Side Effects:** Side effects consisting of edema of the rectal mucosa, anal protrusion, diarrhea, erythema and pruritus have been observed in some hogs following the use of tylosin. Discontinuation of treatment effected an uneventful recovery. Drugs of the tetracycline class have potential to permanently stain teeth if given to immature animals. (It binds to calcium, which is needed for growing bones and teeth.) Doxycycline has the least potential for doing this. Certain types of urine dipstick tests can erroneously test positive for glucose in patients on tetracycline-type medications.	New		Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
04.	**Eskayef Bangladesh Ltd**, **Tongi, Gazipur. (Veterinary)**	**a) Amprolium 9.6% Oral Solution (Vet)** Amprolium USP 9.6g/100ml	It is indicated as an aid in the treatment and prevention of coccidiosis (bloody scours) caused by *Eimeria bovis* and *E. zurnii* in cattle/calves. For a satisfactory diagnosis a microscopic examination of the feces should be done before treatment. When treating outbreaks, drug should be administered promptly after diagnosis is determined.	**Contraindications:** The product should not be used in combination with Thiamin (Vitamin B_1). **Side effects:** No adverse reactions are observed.	60% & 20% Powder		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) Tildipirosin 18% subcutaneous Injection (Vet) Tildipirosin INN 18g/100ml	Prevention and treatment of bacterial respiratory disease in cattle and swine	**Contraindications** Tildipirosin® Injection is contraindicated to patients hypersensitive to Tildipirosin. **Side effects** Pain on injection and injection site swellings are very common in treated animals. Following the maximum recommended injection site volume of 10 ml, injection site swellings may be associated with pain on palpation for about one day in individual animals. The swellings are transient and will usually resolve within 7 to 16 days.			Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		c) Poloxalene 83.3g/100ml Oral solution(vet) Poloxalene USP 83.3g/100ml	Poloxalene is used for the treatment of Legume (alfalfa, clover) bloat in cattle.	**Contraindications** Poloxalene is contraindicated in animals with known hypersensitivity to Poloxalene. Use in pregnancy and lactation Do not show any harmful effect in pregnant animal. Can be used during lactation. **Side effects:** There are no known side effects of Poloxalene in cattle.			Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd, **Tongi, Gazipur. (Veterinary)**	**d)** **Disodium Zinc EDTA 24.443g + Disodium Manganese EDTA 7.083g + Disodium Copper EDTA 9.389g + Sodium selenium Pentahydrate 1.665g/100ml subcutaneous injection (vet)** Disodium Zinc EDTA INN 24.443g + Disodium Manganese EDTA INN 7.083g + Disodium Copper EDTA INN 9.389g + Sodium selenium Pentahydrate BP 1.665g/100ml	**Multimineral** contains the four most essential trace minerals for reproduction, immunity and growth in a balanced formulation. The concept is to "top up" essential trace mineral levels prior to critical events such as calving and joining. **Bulls:** 3 months before joining or semen collection or every 3-4 months. **Beef and dairy cows:** 4 weeks before joining or artificial insemination, 4 weeks before calving, 4 weeks before super ovulation (embryo transfer), 4 weeks before embryo transfer in the recipient female, 4 weeks before/at drying off (dairy). **Calves:** At marking/branding, at or 4 weeks before weaning. **Heifers:** Every 3 months, where required, 4 weeks before joining. **Additional:** Every 2 months in wet conditions.	**Contraindications:** The product should not be used when selenium intake from pasture or supplementation is excessive. Professional advice is recommended if selenium is provided by other means (such as pasture top dressing, vaccine, pellets or selenium drenches) or if blood selenium levels are high. Excessive copper is toxic, do not administer unless a requirement for copper has been confirmed. **Side effects:** Multimineral has a wide safety margin and can be used in all classes of cattle.			Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd, **Tongi, Gazipur. (Veterinary)**	**e) Tiamulin Hydrogen Fumarate 12.5% oral solution (Vet)** Tiamulin Hydrogen Fumarate BP 12.5 g/100ml	It can be used for the prevention and treatment of the following: Poultry: Mycoplasma gallisepticum, M. synoviae, M. meleagridis infection and Brachyspira spp. Pigs: Swine dysentery caused by Brachyspira hyodysenteriae and complicated by Fusobacterium and Bacteroides spp.	**Contraindication:** Animal treated with Tiamulin should not have access to feeds containing monensin, narasin, salinomycin and semduramicin during or 7 days before/after treatment. **Pregnancy and Lactation** The effects of tiamulin on swine reproductive performance, pregnancy and lactation have not been determined. **Side Effects:** On rare cases, erythema or mild oedema of the skin of pigs may occur following the use of tiamulin. Water intake may be suppressed in birds during the administration of tiamulin.	45% & 15 % Powder		Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	
		f) Colistin Sulphate 12g/100ml (20000IU/mg) 24 Lac IU Oral solution (Vet) Colistin Sulphate BP 12g/100ml	Colistin Sulphate acts mainly against gram-negative bacteria of poultry & livestock. It is very effective against Colibacillosis, Salmonellosis, Pasteurellosis, Shigellosis, Brucellosis, Enterobacteriasis, and Campylobacteriosis etc.	**Contra Indications:** Do not use in animals hypersensitive to colistin. **Side Effect;** At the recommended dosage side effects are rare and mild. Sometimes in long term usage hematological reaction & crystalluria may occur.		500 Lac & 1000 Lac IU Powder	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	
		g) Colistin Sulphate (20,000IU/mg) 12g + Trimethoprim 40g/100g Powder in Sachet (vet) Colistin Sulphate BP 12g (eq. to 24 million IU) + Trimethoprim BP 40g/100g	Infections caused by Colistin and Trimethoprim sensitive micro-organisms like E. coli, Haemophilus, Pasteurella, Salmonella, Staphylococcus and Streptococcus spp. in calves, goats, poultry, sheep and swine.	**Contra Indications** Do not use in animals hypersensitive to Colistin and Trimethoprim. **Side Effect** Renal dysfunction, neurotoxicity and neuromuscular blockade.			Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Eskayef Bangladesh Ltd, **Tongi, Gazipur. (Veterinary)**	**h) Tulathromycin 100 mg/ml SC/IM injection (Vet)** Tulathromycin INN 10g/100ml	It can be used for the prevention and treatment of the following diseases of cattle sheep/goat and swine: 1. Bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis. 2. Infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis. 3. Bovine foot rot (interdigital necrobacillosis) associated with Fusobacterium necrophorum and Porphyromonas levii. Swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.	**Contraindications:** The use of Tulathromycin injection is contraindicated in animals previously found to be hypersensitive to this drug. Subcutaneous injection can cause a transient local tissue reaction. **Pregnancy & lactation** The effects on bovine reproductive performance, pregnancy and lactation have not been determined. **Side effect:** Mild salivation may occur.			c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
05.	Bridge Pharmaceuticals Ltd.	**a)** **Levofloxacin 10 gm + Colistin 1.5 gm/100 ml Oral Solution (Vet)** Levofloxacin Hemihydrate USP 10.2492 gm eq. to 10 gm of Levofloxacin + Colistin Sulphate BP 1.6243 gm eq. to 1.5 gm of Colistin/100 ml	To control Gram Positive bacteria and most spp. of Mycoplasma. Levofloxacin and colisting controls infections against drug resistant bacterial causing sevee infection like CRD. CCRD. Colisepticaemia.	**Contraindications & Side-effect**: Administration of levofloxacin or other broad spectrum antibiotics is associated with clostridium difficile associated diarrhea which may range in severty from mild diarrhea to fatal colitis. Fluoroquionline administration may be associated with the acquisition and outgrowth of a particularly virulent.			c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea vq Av‡e`b bvgÄyi Kiv nj
06	Techno Drugs Ltd.	**a)** **Flunixin 2.50gm/50ml Solution for Injection (Vet)** Flunixin Megelumine USP 4.15gm eq. to 2.5gm Flunixin/50ml Solution	Flunixin meglumine is a potent non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. **Horse:** Flunixin Injectable Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse. **Cattle:** Flunixin Injectable Solution is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. Flunixin Injectable Solution is also indicated for the control of inflammation in endotoxemia.	**Contraindication:** **Horse:** There are no known contraindications to this drug when used as directed. Intro-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverst reactions. Signs can be ataxia, incoordination, and hyperventilation, hysteria, and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to flunixin meglumine. **Cattle:** There are no known contraindications to this drug in cattle when used as directed. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration are suspected. **Side Effects:** Flunixin should not be given for more than five days. Like most NSAIDs, it can produce gastrointestinal (GI) side effects if the drug is given in high doses or over several days. GI ulceration is the most common side effect, especially in the animal's large colon or stomach, and is most likely to occur if the drug is given for a prolonged period. Rare side effects include kidney damage and bleeding disorders. It should be used with caution in horses with kidney or liver disease.			Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

2.4 Proposed Product for Import (Human)

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
01.	Rohto-Mentholatum (Vietnam) Co. Ltd., Vietnam Rohto-Mentholatum (Bangladesh) Ltd., Dhaka	a) **Rohto ICE Lubricant Eye Drops** Tetrahydrozoline HCl USP 0.05 gm + Zinc Sulfate USP 0.250 gm + Hydroxypropyl Methylcellulose USP 0.20gm/100 ml	Temporarily relieves redness of the eye and discomfort due to minor eye irritations and exposure to wind or sun. Temporarily relieves burning and irritation due to dryness of the eye.	**Contraindication:** Hypersensitive to any of the ingredients. **Side-effect:** May cause transient mild stinging or temporarily blurred vision.	Country of Origin: Vietnam CPP: USA		c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	
		b) **Rohto Cool Lubricant Eye Drops** Naphazoline Hydrochloride USP 0.012 gm + Polysorbate 80 USP 0.20 gm/100 ml	Relieves redness of the eye due to minor eye irritations. Temporarily relieves burning and irritation due to dryness of the eye.	**Contraindication:** None **Side-effect:** None	Country of Origin: Vietnam CPP: USA		c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewfbœ Av‡e`b bvgÄyi Kiv nj	
02.	Bracco S.p.A., Italy (Shuvro Ltd)	a) **Iomeron 400 Solution for Injection** Iomeprol INN 400 mg/ml Contains 81.65% w/v of concentration of Iomeprol eq. to 40% iodine or 400mg iodine/ml	X-ray contrast medium used for: Peripheral arteriography Aortography, Angiogardiography and left ventriculography, Coronary arteriography, Visceral arteriography Digital subtraction angiography, Computed tomography enhancement, Urography, Dacryocystrography, Sialography, Fistulography, Galactography	**Contraindications:** Proven or suspected hypersensitivity to iodine containing preperations of this type. **Side Effects:** The use of iodinated contrast media may cause untoward side effects. They are usually mild to moderate and transient in nature. However, severe and life threatening reactions sometimes leading to death have been reported. In most cases, reactions occur within minutes of dosing but times reactions may occur at later time. After intra-thecal administration most side effects occur some hours (3 to 6 hours) after the producer, due to the distribution of the contrast medium in the cerebro-spinal fluid (CSF) circulation from the site of administration to the intravascular space. Most reactions usually occur within 24 hours after injection. After injection of an iodinated contras media in body cavities, the majority of the reactions occur some hours after the contrast administration due to slow absorption from the area of administration.	Italy & UK		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

				Anaphylaxis (anaphylactoid/ hypersensitivity reactions) may manifest with various symptoms, and rarely does any one patient develop all the symptoms. Typically, in 1 to 15 min (but rarely after as long as 2 h), the patient complains of feeling abnormal, agitation, flushing, feeling, sweating increased, dizziness,increased lacrimation, rhinitis, palpitations, paresthesia, pruritus, sore throat and throat tightness, dysphagia, caugh, sneezing, urticaria, erythema,mild localized oedema and/or spasm manifesting with wheezing and bronchospasm. Nausea, vomiting, abdominal pain, and diarrhea are reported. These reactions, which can occur independently of the dose administration or the route of administration, may represent the first signs of circulatory collapse. Administration of the contrast medium must be discontinued immediately and, if needed, appropriate specific treatment urgently initiated via venous access. Severe reactions involving the cardiovascular system, such as vasodilatation, with pronounced hypotension, trachycardia, dyspnoea, agitation, cyanosis and loss of consciousness progressing to respiratory and /or cardiac arrest may result in death. These events can occur can rapidly and require full and aggressive cardio-pulmonary resuscitation. Primary circulatory collapse can occur as the only and/ or initial presentation without respiratory symptoms or without other signs or symptoms outlined above.				

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Bracco S.p.A., Italy (Shuvro Ltd)	b) **Iomeron 300 Solution for Injection** Iomeprol INN 300 mg/ml Contains 61.24% w/v of concentration of Iomeprol eq. to 30% iodine or 300mg Iodine/ml	X-ray contrast medium used for: Peripheral arteriography Aortography, Angiogardiography and left ventriculography, Coronary arteriography, Visceral arteriography Digital subtraction angiography, Computed tomography enhancement, Urography, Dacryocystrography, Sialography, Fistulography, Galactography	do	Italy & UK		Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	
		c) **Iomeron 350 Solution for Injection** Iomeprol INN 350 mg/ml Contains 71.44% w/v of concentration of Iomeprol eq. to 35% Iodine or 350mg Iodine/ml	do	do	Italy & UK		Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
03.	Correvio International Sarl, Switzerland (Zain International Medical & SurgicalExport Import Ltd.)	a) **Aggrastat Concentrate Solution for Infusion, 50ml Vial** Tirofiban HCl Monohydrate 281mcg eq. to 250mcg Tirofiban/ml	Aggrastat is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non – Q – wave myocardial infarction with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes. Patients most likely to benefit from Aggrastat treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA. Aggrastat is intended for use with acetylsalicylic acid and unfractionated heparin.	**Contraindications:** AGGRASTAT is contraindicated in patients who are hypersensitive to the active substance or to any of the excipients of the preparation or who developed thrombocytopenia during earlier use of a GP IIb/IIIa receptor antagonist. Since inhibition of platelet aggregation increases the bleeding risk, Aggrastat is contra – indicated in patients with: • History of stroke within 30 days or any history of haemorrhagic stroke. • Known history of intercranial disease (e.g. neoplasm, arteriovenous malformation, aneurysm) • Active or recent (within the previous 30 days of treatment) clinically relevant bleeding (e.g. gastro – intestinal bleeding). • Malignant hypertension. • Relevant trauma or major surgery intervention within the past six weeks. • Thrombocytopenia (platelet count < 100000/mm3) disorder s of platelet function. • Clotting disturbances (e.g. prothrombin time> 1.3 times normal or INR>1.5) • Severe liver failure **Side Effects:** The most common adverse reaction reported during therapy with Aggrastat, when used concomitantly with heparin, aspirin and other oral anti – platelet agents, was bleeding, which usually involved mild mucocutaneousbleeding or mild catheterization – site bleeding. Gastro – intestinal, retro – peritoneal, intracranial, and haemorrhoidal and post – operative bleeding, epidural haematoma in the spinal region, haemopericardium and pulmonary (alveolar) haemorrhage have also been reported. Rates of TIMI major and intracranial bleeding in the pivotal	Country of Origin- Switzerland CPP – UK CPP– Germany		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
04.	S.C. Sindan Pharma S.R.L, Romania (Bots Pvt. Ltd.)	a) **Topotecan Actavis Powder for Concentrate for solution for Infusion** Topotecan Hydrochloride 4.35 mg eq. to Topotecan 4 mg/ml Vial **Anticancer**	It is indicated for the treatment of patient with relapsed small cell lung cancer for whom re-treatment with the first line regiment is not considered appropriate. Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage IVB disese. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination.	**Contraindications:** Topotecan is contraindicated in patients who -have a history of severe hypersensitivity to the active substance or to any of the excipients -are brest feeding -already have severe none marrow depression prior to starting first course, as evidenced by baseline neutrophils<1.5x10^9 /L and/or a Platelet count of <10010^9 /L **Side Effects:** **Blood and lymphatic system disorder:** Very Common febrile neutropenia, Neutropenia, Thrombocytopenia, anameia, leucopenia, and the side effects are pancytopenia and not Known severe bledding. **GI Disorder:** Very common: nausea, vomiting and diarrhea, constipation, abdominal pain, mucositis, neutropenic colitis, including fetal neutropenic colitis. Skin: Very Common: Alopecia	EMA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
05.	Actavis Italy, SpA, italy M/s. Bots Pvt. Ltd.	a) **Docetaxel Actavis 20mg/ml Vial Concentrate for Solution for Infusion** Docetaxel 20 mg/ml Vial	It is indicated for the adjuvant treatment of patients with operable node-positive breast cancer and operable node-negative brest cancer. For the treatment of patients with locally advanced or metastatic non small cell lung cancer after faiure of prior chemotherapy. treatment of patients with hormone refractory metastatic postate cancer	**Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Patients with baseline neutrophil count of less then 1500 cells/mm3. Patients with severe liver impairment. Contraindications for other medicinal products also apply, when combined with docetaxel. **Side effects:** Very common adverse reactions are Neutropenia, Anemia, Thrombocytopenia, nausea, stomatitis, vomiting, diarrhea, alopecia, anorexia, infection, and the common adverse reactions are blood bilirubin increased, arrhythmia, febrile neutropenia, myalgia, hypotension and hypersensitivity.	UK	20 mg/0.5 ml Prefilled Syring Injection	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Actavis Italy, SpA, Italy M/s. Bots Pvt. Ltd.,Dhaka	b) **Docetaxel Actavis 80mg/4ml Vial Concentrate for Solution for Infusion** Docetaxel 80mg/4ml Vial	It is indicated for the adjuvant treatment of patients with operable node-positive breast cancer and operable node-negative brest cancer. For the treatment of patients with locally advanced or metastatic non small cell lung cancer after faiure of prior chemotherapy. treatment of patients with hormone refractory metastatic postate cancer	**Contraindications:** hypersensitivity to the active substance or to any of the excipients. Patients with baseline neutrophil count of less then 1500 cells/mm3. patients with severe liver impairment. Contraindication fof other medicinal products also apply, when combined with docetaxel. **Side effect :** Very common adverse reactions are Neutropenia, Anemia, Thrombocytopenia, nausea, stomatitis, vomiting, diarrhea, alopecia, anorexia, infection, and the common adverse reactions are blood bilirubin increased, arrhythmia, febrile neutropenia, myalgia, hypotension and hypersensitivity.	UK	80 mg/2 ml Prefilled Syring Injection	Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
06.	**Manufacturer:** Novartis Farmaceutica SA, Spain. **MAH:**(Novartis Bangladesh Ltd)	a) **Diovan 320mg** **Film-Coated Tablet** Valsartan USP 320 mg	Treatment of mild and moderate essential hypertension. In the event of symptomatic hypotension or impairment of renal function, dose reduction should be considered. Diovan may be given concominantly with other preparations used following acute myocardial infarction, such as thrombolytic agent, acetylsalicylic acid, beta blockers or statins. Monitoring of patients following acute myocardial infarction should always include assessment of renal function.	**Contraindication:** Hypersensitivity to the active substances or to any of the excipients of this product. Pregnacy and lactation. There is no experience with this product inpatients with sever renal dysfunction (creatinine clearance <10ml/minute). Diovan is contraindicated in patients with herediatery angioedema or in those with a history of angioedema developing during treatment with an ACE inhibitor or angiotensin II receptor antagoniust. **Side effects:** Fatigue, cough, headache, dizziness.	Spain & Switzerland	40mg, 80, 160mg Tablet	c‡qvRb †bB weavq Av‡e`b bvgÄyi Ki v †h‡Z cv‡i |	c‡qvRbxqZv c¥tgj¨vqYcwK Abyjgv`b Ki v nj |
07.	**Manufacturer:** Novartis Pharma AG, Switzerland. **MAH:** (Novartis Bangladesh Ltd)	a) **Ultibro Breezhaler 110/50 mcg, Inhalation Powder, Hard Capsule** [Glycopyrronium Bromide INN 143 mcg eq. to Glycopyrronium 110 mcg (85mcg/actuation) + Indacaterol Maleate INN 63 mcg eq. to Indacaterol 50 mcg (43mcg/actuation)]	It is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	**Contraindication:** Hypersensitivity to the active substances or to any of the excipients of this product. **Side effects:** Diarrhea, weight gain, weight loss.	EMA		Abyjgv`b Ki v †h‡Z cv‡i |	Abyjgv`b Ki v nj |
		b) **Jakavi 5 mg Tablet** Ruxolitinib INN 5 mg Tablet	Treatment of splenomegalyor disease-associated symptoms in patients with intermediate or high-risk myelofibrosis with primary myelofibrosis or as a complication of polycythaemiavera or essential thrombocythaemia.	**Contraindication:** Hypersensitivity to the active substances or to any of the excipients of this product. **Side effects:** Dizziness, headache, flatulence, anemia etc.	Switzerland		Abyjgv`b Ki v †h‡Z cv‡i |	Abyjgv`b Ki v nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvwbwi‡K bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Manufacturer: Novartis Pharma AG, Switzerland. **MAH:** (Novartis Bangladesh Ltd)	c) **Jakavi 15 mg Tablet** Ruxolitinib INN 15 mgTablet	Treatment of splenomegalyor disease-associated symptoms in patients with intermediate or high-risk myelofibrosis with primary myelofibrosis or as a complication of polycythaemiavera or essential thrombocythaemia.	**Contraindication:** Hypersensitivity to the active substances or to any of the excipients of this product. **Side effects:** Dizziness, headache, flatulence, anemia etc.	Switzerland		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		d) **Jakavi 20 mg Tablet** Ruxolitinib INN 20 mgTablet	**-do-**	**-do-**	Switzerland		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
08.	Manufacturer: LTS Lohmann Therapie-Systeme, Germany. MAH: (Novartis Bangladesh Ltd)	a) **Exelon Patch 15 Transdermal Patch** Rivastigmine INN 13.3 mg/24hours Transdermal Patch	Symptomatic treatment of mild to moderately severe Alzheimer's dementia.	**Contraindications:** The use of this medicinal product is contraindicated in patients with known hypersensitivity to the active substances rivastigmine,, to other carbamate derivatives or to any of the excipients. Previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch. **Side effects:** Anxiety, headache, dizziness, vomiting&nausea.	EMA	Exelon Patch 5mg and 10mg	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
09.	Glaxo Wellcome S.A., Spain (GlaxoSmithKline Bangladesh Ltd.)	a) **Requip 2mg Prolonged Release Tablet** Ropinirol HCl INN 2.28 mg eq. to 2 mg Ropinirole	Indicated for the treatment of parkinson's disease, it is effective as early therapy in patients requiring dopaminergic therapy. As adjunctive treatment to L-dopa, ropinirole enhances the efficacy of L-dopa including control of on-off fluctuations and end of dose effects associated with chronic L-dopa therapy and permits reduction in daily L-dopa dose.	**Contraindications:** Hypersensitivity to ropinirole or to any of the excipients. **Side Effects:** Common adverse reactions are hallucinations, confusion, somnolence, syncope, dyskinesia, dizziness, postural hypotension, nausea, abdominal pain, vomiting, dyspepsia and constipation.	1. CPP- Spain (Country of origin) 2. CPP- UK		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj
		b) **Requip 4mg Prolonged Release Tablet** Ropinirol HCl INN 4.56 mg eq. to 4mg Ropinirole	Indicated for the treatment of parkinson's disease, it is effective as early therapy in patients requiring dopaminergic therapy. As adjunctive treatment to L-dopa, ropinirole enhances the efficacy of L-dopa including control of on-off fluctuations and end of dose effects associated with chronic L-dopa therapy and permits reduction in daily L-dopa dose.	**Contraindications:** Hypersensitivity to ropinirole or to any of the excipients. **Side Effects:** Common adverse reactions are hallucinations, confusion, somnolence, syncope, dyskinesia, dizziness, postural hypotension, nausea, abdominal pain, vomiting, dyspepsia and constipation.	1. CPP- Spain (Country of origin) 2. CPP- UK		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
10.	GlaxoSmithKline Manufacturing S.p.A., Italy (GlaxoSmithKline Bd. Ltd.)	a) **Hycamtin Hard Capsule; 1mg** Topotecan Hydrochloride INN 1.09 mg eq. to 1 mg Topotecan **Anticancer**	Indicated as monotherapy for the treatment of adult patients with relapsed small cell Lung Cancer (SCLC) for whom retreatment with the first line regimen is not considered appropriate.	**Contraindications:** It is contraindicated in patients who - have a history of severe hypersensitivity reactions to topotecan and/or its excipients - are breast-feeding - already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils less than 1.5 x10^9/L and/or a platelet count of less than100 x10^9/L **Side effects: Very common**: Infection, Anaemia, febrile neutropenia, leucopenia, neutropenia, Anorexia, Diarrhoea, nausea and vomiting, abdominal pain, constipation and stomatitis, Alopecia, Asthenia, fatigue, pyrexia **Common:** Sepsis, Pancytopenia, Hyperbilirubinaemia **Rare:** Interstitial lung disease	CPP-EMA (Country of Origin-Italy)		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	GlaxoSmithKline Manufacturing S.p.A., Italy (GlaxoSmithKline Bd. Ltd.)	b) **Hycamtin Hard Capsule; 0.25 mg** Topotecan Hydrochloride INN 0.27 mg eq. to 0.25 mg Topotecan **Anticancer**	Indicated as monotherapy for the treatment of adult patients with relapsed small cell Lung Cancer (SCLC) for whom retreatment with the first line regimen is not considered appropriate.	**Contraindications:** It is contraindicated in patients who - have a history of severe hypersensitivity reactions to topotecan and/or its excipients - are breast-feeding - already have severe bone marrow depression prior to starting first course, as evidenced by baseline neutrophils less than 1.5 $x10^9$/L and/or a platelet count of less than100 $x10^9$/L **Side effects: Very common**: Infection, Anaemia, febrile neutropenia, leucopenia, neutropenia, Anorexia, Diarrhoea, nausea and vomiting, abdominal pain, constipation and stomatitis, Alopecia, Asthenia, fatigue, pyrexia **Common:** Sepsis, Pancytopenia, Hyperbilirubinaemia **Rare:** Interstitial lung disease	CPP-EMA (Country of Origin-Italy)		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvwbwi‡K bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
11	Amgen Manufacturing Limited, USA (GlaxoSmithKline Bd. Ltd.)	c) **Vectibix 100 mg/5 ml Injection for Intravenous Infusion** Panitumumab INN 100 mg/5ml **Anticancer**	Vectibix is indicated for the treatment of adult patients with wild-type *RAS* metastatic colorectal cancer (mCRC): • in first-line in combination with FOLFOX. (FOLFOX is a chemotherapy regimen for treatment of colorectal cancer, made up of the drugs; FOL– Folinic acid (leucovorin) F – Fluorouracil (5-FU) OX – Oxaliplatin (Eloxatin) • In second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). • as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens	**Contraindications:** Patients with a history of severe or life-threatening hypersensitivity to the active substance or to any of the excipients. Patients with interstitial pneumonitis or pulmonary fibrosis. The combination of Vectibix with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant *RAS* mCRC or for whom *RAS* mCRC status is unknown **Side Effects:** Most common adverse reactions (≥ 20%) are skin toxicities (i.e. erythema, dermatitis acneiform, pruritus, exfoliation, rash, and fissures), paronychia, hypomagnesemia, fatigue, abdominal pain, nausea, diarrhea, and constipation.	CPP-USFDA		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
12.	Prizer Ireland Pharmaceuticals, Ireland (MH Traders)	a) **Premarin 0.3 mg Tablet** Conjugated Estrogens Ph. Eur 0.3 mg	Premarin is indicated for hormone replacement therapy for estrogen deficiency symptoms in menopausal women and postmenopausal women. Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis.	**Contraindications:** **1.** Known, past or suspected breast cancer. **2.** Known or suspected estrogen dependent malignant tumours **3.** Undiagnosed abnormal genital bleeding **4.** Untreated endometrial hyperplasia **5.** Previous or current venuous thromboembolism **6.** Active or recent arterial thromboembolic disease **7.** Acute liver disease or history of liver disease where the liver function tests have failed to return to normal. **Side Effects:** Common adverse reactions are depression, anthralgias, leg cramps, breast pain, tenderness, changes in weight (increase or decrease) and increase triglyceride	Ireland Australia	625 mcg Tablet	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
14.	Sanofi-Aventis Deutschland GmbH, Germany (Sanofi Aventis Bangladesh Ltd.)	a) **Zaltrap Concentrate for Solution for Infusion** Aflibercept INN 200 mg/8 ml Vial	ZALTRAP in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. **Special warning:** Increase risk of Haemorrhage, Gastrointestinal perforation, Fistula Formation, hypertension, thrombotic and embolic events.	**Contraindications:** Hypersensitivity to aflibercept or to any of the excipients. Ophthalmic / intravitreal use due to hyperosmotic properties of ZALTRAP. For contraindications related to FOLFIRI components (irinotecan, 5-FU, and folinic acid), refer to the current respective summary of product characteristics. **Undesirable effects:** Very common adverse reactions are Infection, leukopenia, neutropenia, thrombocytopenia, decreased appetite, weight loss, headache, Hypertension, Haemorrage, dysphonia, diarrhea, stomatitis, abdominal pain, abdominal pain upper, Incrased ALT, ASt Proteinuria, Increase serum creatinine, Asthenic conditions. Common adverse reactions are Neutropenic Infections, UTI, Nasopharyngitis, febrile neutropenia, hypersensitivity, Dehydration, Arterial thromboembolism, Rhinorrhoea, Rectal haemmorrage, Fistula, Apthous stomatitis, haemorroids, proctalgia, tothache	EMA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Sanofi-Aventis Deutschland GmbH, Germany (Sanofi Aventis Bangladesh Ltd.)	b) **Zaltrap Concentrate for Solution for Infusion** Aflibercept INN 100 mg/4 ml Vial	ZALTRAP in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. **Special warning:** Increase risk of Haemorrhage, Gastrointestinal perforation, Fistula Formation, hypertension, thrombotic and embolic events.	**Contraindications:** Hypersensitivity to aflibercept or to any of the excipients. Ophthalmic / intravitreal use due to hyperosmotic properties of ZALTRAP. For contraindications related to FOLFIRI components (irinotecan, 5-FU, and folinic acid), refer to the current respective summary of product characteristics. **Undesirable effects:** Very common adverse reactions are Infection, leukopenia, neutropenia, thrombocytopenia, decreased appetite, weight loss, headache, Hypertension, Haemorrage, dysphonia, diarrhea, stomatitis, abdominal pain, abdominal pain upper, Incrased ALT, ASt Proteinuria, Increase serum creatinine, Asthenic conditions. Common adverse reactions are Neutropenic Infections, UTI, Nasopharyngitis, febrile neutropenia, hypersensitivity, Dehydration, Arterial thromboembolism, Rhinorrhoea, Rectal haemmorrage, Fistula, Apthous stomatitis, haemorroids, proctalgia, tothache	EMA		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Sanofi-Aventis Deutschland GmbH, Germany (Sanofi Aventis Bangladesh Ltd.)	c) **LYXUMIA 10µg Solution for injection 1 pre-filled pen (0.2ml)** Lixisenatide 10µg	For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control.	**Contraindications:** Lyxumia is contraindicated in patients with known hypersensitivity to lixisenatide or to any of the inactive ingredients in the formulation. **Side effects:** Very common adverse reactions are Hypoglycemia, Headache, Nausea, vomiting, Diarrhea and the common adverse reactions are Influenza, upper respiratory tract infection, cystitis, viral infection, dizziness, somnolence, dyspepsia,Back pain, Injection site pruritus, urticaria.	EMA		c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	
		d) **LYXUMIA 20µg Solution for injection 1 pre-filled pen (0.2ml)** Lixisenatide 20µg	For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control.	**Contraindications:** Lyxumia is contraindicated in patients with known hypersensitivity to lixisenatide or to any of the inactive ingredients in the formulation. **Side effects:** Very common adverse reactions are Hypoglycemia, Headache, Nausea, vomiting, Diarrhea and the common adverse reactions are Influenza, upper respiratory tract infection, cystitis, viral infection, dizziness, somnolence, dyspepsia,Back pain, Injection site pruritus, urticaria.	EMA		c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
15.	Allergan Industrie, S.A.S., France (City Overseas Ltd.)	a) **Juvederm Voluma With Lidocaine Injectable Prefilled Syringe** Sodium Hyaluronate EP as Hyaluronic Acid Gel 20 mg + Lidocaine Hydrochloride EP 3mg/ml	It is an injectable implant intended to restore volume of the face. The presence of lidocaine is meant to reduce the patients' pain during treatment.	**Contra-indications:** •JUVÉDERM VOLUM is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies •It contains trace amounts of gram-positive bacterial proteins and is contraindicated for patients with a history of allergies to such material •JUVÉDERM VOLUM XC contains lidocaine and is contraindicated for patients with a history of allergies to such material **Side Effects:** The patient must be informed that there are potential side effects associated with implantation of this product, which may occur immediately or may be delayed. These include but are not limited to: Inflammatory reactions (redness, oedema, erythema etc.) which can occur simultaneously with itching or pain on pressure, can appear after the injection. These reactions can last for a week, Haematomas, indurations or nodules at the injection area, coloration or discoloration of the injection area, poor efficiency, or poor filling/restoration effect. Cases of necrosis in the glabelar region, abscesses, granuloma and immediate or delayed hypersensitivity after hyaluronic acid and/or lidocaine injections have been reported. It is therefore advisable to take these potential risks into account.	France		Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Allergan Industrie, S.A.S., France (City Overseas Ltd.)	b) **Juvederm Ultra XC Injectable Prefilled Syringe** Sodium Hyaluronat EP as Hyaluronic Acid Gel 24 mg/ml + Lidocaine Hydrochloride EP. 3 mg/ml	It is an injectable implant used for for filling any medium –sized depression of the skin via mid-dermis injection, as well as for lip definition. The presence of lidocaine is meant to reduce the patients' pain during treatment.	**Contraindications:** • Do not inject JUVÉDERM ULTRA XC in the eyelids. The application of JUVÉDERM ULTRA XC in the undereye area is to be performed only by specialists specifically trained in this technique who have a sound knowledge of the physiology of this particular area. - Do not inject into the blood vessel (intravascular) - Do not over correct - It must not be used in patients suffering from epilepsy, hypertropic scarring, and hypersensitivity to hyaluronic acid or Lidocaine HCl or to amide type local anesthetic, porphyria, brest feeding women, and children. . For surface peels, it is recommended not to inject the product if the inflammatory reaction generated is significant. **Side Effects:** The patient must be informed that there are potential side effects associated with implantation of this product, which may occur immediately or may be delayed. These include but are not limited to: Inflammatory reactions (redness, oedema, erythema etc.) which can occur simultaneously with itching or pain on pressure, can appear after the injection. These reactions can last for a week, Haematomas, indurations or nodules at the injection area, coloration or discoloration of the injection area, poor efficiency, or poor filling/restoration effect. Cases of necrosis in the glabelar region, abscesses, granuloma and immediate or delayed hypersensitivity after hyaluronic acid and/or lidocaine injections have been reported. It is therefore advisable to take these potential risks into account.	France		Abygv`b Kiv ‡h‡Z cv‡i	Abygv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
16.	Laboratories Merck Sharp & Dohme Chibret, France (Janata Traders)	a) **Cancidas Powder for Concentrate for Solution for Injection** Caspofungin Acetate INN 50 mg/vial	CANCIDAS is indicated in adults and pediatric patients (3 months and older) for empirical therapy for presumed fungal infections in febrile, neutropenic patients. Treatment of candidemia and the following Candida infections: intra-abdominal abscesses.	**Contraindications :** Cancidas is contraindicated in patients with hypersensitivity to any component of this product **Side-effects:** he following serious adverse reactions are discussed in detail in another section of the labeling: Hepatic effects Because clinical trials are conducted under widely varying conditions,adverse reaction rates observed in clinical trials of CANCIDAS cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does provide a basis for identifying adverse reactions that appear to be related to drug use and for approximating rates.	EMA		c‡qvRb †bB wewq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyK iv nj	
		b) **Cancidas Powder for Concentrate for Solution for Injection** Caspofungin Acetate INN 70 mg/vial	-do-	**-do-**	EMA		c‡qvRb †bB wewq Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
17.	Organon (Ireland) Ltd., Ireland (Janata Traders)	a) **Zoely Film Coated Tablet** Nomegrestrol Acetate Ph. Eur 2.5 mg + Estradiol hemihydrate Ph. Eur 1.55mg eq. to 1.5mg Estradiol **Oral Contraception**	Oral Contraception	**Contraindications:** Combined hormonal contraceptives (CHCs) should not be used in the following conditions. As no epidemiological data are yet available with 17β-estradiol containing CHCs, the contraindications for ethinylestradiol containing CHCs are considered applicable to the use of Zoely. Should any of the conditions appear for the first time during Zoely use, the medicinal product should be stopped immediately: • Presence or risk of venous thromboembolism (VTE) Venous thromboembolism - current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]). Known hereditary or acquired predisposition for venous thromboembolism, such as APC resistance (including Factor V Leiden), antithrombin-III-deficiency, protein C deficiency, protein S deficiency. Major surgery with prolonged immobilisation .A high risk of venous thromboembolism due to the presence of multiple risk factors . Presence or risk of arterial thromboembolism (ATE) Arterial thromboembolism - current arterial thromboembolism, history of arterial thromboembolism (e.g. myocardial infarction) or prodromal condition (e.g. angina pectoris). Cerebrovascular disease – current stroke, history of stroke or prodromal condition (e.g.transient ischaemic attack, TIA). Known hereditary or acquired predisposition for arterial thromboembolism, such as hyperhomocysteinaemia and antiphospholipid-antibodies (anticardiolipin-antibodies, lupus anticoagulant). History of migraine with focal neurological symptoms.	EMA		c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Organon (Ireland) Ltd., Ireland (Janata Traders)			**A high risk of arterial thromboembolism due to multiple risk factors (see section 4.4) or to the presence of one serious risk factor such as: diabetes mellitus with vascular symptoms, severe hypertension, severe dyslipoproteinaemia, Pancreatitis or a history thereof if associated with severe hypertriglyceridaemia. Presence or history of severe hepatic disease as long as liver function values have not returned to normal. Presence or history of liver tumours (benign or malignant). Known or suspected sex steroid-influenced malignancies (e.g., of the genital organs or the breasts). Undiagnosed vaginal bleeding. Hypersensitivity to the active substances or to any of the excipients.**				

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbwi‡K bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
18.	Pfizer Ireland Pharma, Ireland; Vetter Pharma-Fertigung GmbH & Co. KG, Germany & Wyeth Pharmaceuticals, UK (Janata Traders)	a) **ENBREL Solution for Injection in a pre-filled syringe, 25mg** Etanercept INN 25mg/syringe	It is indicated for the treatment of Rhematoid arthritis, psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis, Padistric plaque psoriasis.	**Contraindications:** Hypersensityvity to the active substances or to any of the excipients. Sepsis or risk of sepsis. Treatment with enbrel should not be initiated in patients with active infections, including chronic or localized infections **Side Effects:** The most commonly reported adverse reactions are injection site reaction (such as pain swelling, itching reddening and bleeding at the puncture site) infections (such as upper RTI, bronchitis, bladder infections and skin infections allergic reaction, development of autoantbodies itching and fever.	EMA		Black Box warning Gi eva¨evaKZvmn Abygv`b Kiv †h‡Z cv‡i	Black Box warning Gi eva¨evaKZvmn Abygv`b Kiv nj	
19	Baxter Healthcare Corporation, California, USA (Janata Traders)	**Hemofil M 500IU/vial, Togather with 10ml WFI** Antihemophelic Factor (Human) Method M, Monoclonal Purified, Nanofiltration) 220IU - 2000IU/Vial	It is indicated in hemophilia A (Classical Hemophilia) for the prevention and control of hemorrhagic episodes.	**Side Effects:** Blood and Lymphatic system disorder, dizziness, headache, pyrexia, infusion site inflamation, etc. **Contraindications:** It is contraindicated i patients with a known hypersensitivity to the active substance to excipients or to mouse proteins.	USA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj
		Hemofil M 1000IU/vial Togather with 10ml WFI Antihemophelic Factor (Human) Method M, Monoclonal Purified, Nanofiltration) 220IU - 2000IU/Vial	It is indicated in hemophilia A (Classical Hemophilia) for the prevention and control of hemorrhagic episodes.	**Side Effects:** Blood and Lymphatic system disorder, dizziness, headache, pyrexia, infusion site inflamation, etc. **Contraindications:** It is contraindicated i patients with a known hypersensitivity to the active substance to excipients or to mouse proteins.	USA		Abygv`b Kiv †h‡Z cv‡i	Abygv`b Kiv nj

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
20.	Manufactured by Patheon Inc., Canada Manufactured for: Gilead Sciences Inc., USA (UniHealth ltd. 34/1 Sonargaon Road, Paribagh, Dhaka.)	a) **Stribild Tablet** Elvitegravir INN 150mg + Cobicistat on Silicon Dioxide INN 288.50mg eq. to 150mg Cobicistat + Emtricitabine INN 200mg + Tenofovir Disoproxil Fumarate INN 300mg eq. to 245mg Tenofovir Disoproxil	STRIBILD, a combination of 1 integrase strand transfer inhibitor, 1 pharmacokinetic enhancer, and 2 nucleos(t)ide analog HIV-1 reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve.	**Contra-indications:** Coadministration of STRIBILD with drugs that: • are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening adverse events. • strongly induce CYP3A which may lead to lower exposure of one or more components and loss of efficacy of STRIBILD which may result in loss of virologic response and possible resistance. **Warning:** New onset or worsening renal impairment: Can include acute renal failure and Fanconi syndrome. Assess creatinine clearance (CLcr), urine glucose and urine protein before initiating treatment with STRIBILD. Monitor CLcr, urine glucose, and urine protein in all patients. Monitor serum phosphorus in patients at risk for renal impairment. Avoid administering STRIBILD with concurrent or recent use of nephrotoxic drugs. - Coadministration with other products: Do not use with drugs containing emtricitabine or tenofovir disoproxil fumarate including ATRIPLA, COMPLERA, EMTRIVA, TRUVADA, or VIREAD; with drugs containing lamivudine; or with drugs or regimens containing ritonavir. Do not administer in combination with HEPSERA. - Decreases in bone mineral density (BMD): Consider monitoring BMD in patients with a history of pathologic fracture or other risk factors of osteoporosis or bone loss. - Redistribution/accumulation of body fat: Observed in patients receiving antiretroviral therapy. - Immune reconstitution syndrome: May necessitate further evaluation and treatment. ***Side effects:*** Most common adverse drug reactions to STRIBILD (incidence greater than or equal to 10%, all grades) are nausea and diarrhea.	Country of Origin: Canada FSC – USFDA		Ab¨gv`b Kiv †h‡Z cv‡i	Ab¨gv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
21.	Baxter Healthcare SA, Singapore Branch, 2 Woodland IND Park, D# Singapore-738750, Singapore (National Trading Syndicate Ltd.)	a) **External Peritoneal Dialysis Solution 75gm/Liter** Icodextrin INN 75 gm /Liter	EXTRANEAL is indicated for use as an osmotic agent for the long dwell, up to 12 hours, in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD), Where it can be used for 14 and up to 16 hours.	**Contraindications:** * EXTRANEAL is contraindicated for use in patients with: * Acute renal failure * An allergy to starch –based polymers and / or icodextrin * Maltose or isomaltose intolerance * Glycogen storage disease * Pre-existing severe lactic acidosis * The product is also contraindicated in patients with a history of abdominal surgery in the months preceding commencement of therapy, patients with abdominal fistulae, tumors, open wounds, herniae or other conditions which compromise the integrity of the abdominal wall, abdominal surface or intra-abdominal cavity in common with other peritoneal dialysis fluids. In patients with impaired respiratory function or potassium deficiency, peritoneal dialysis may also be contraindicated. * EXTRANEAL is not recommended for use in children **Side-effects**: No clinical drug intraction studies were perfumed No evaluation of Extraneal's effects on the cytochrome P450 system was conducted. As with other dialysis solutions, blood concentrations of dialyzable drugs may be reduced by dialysis. Dosage adjustment of concomitant medications may be necessary. In patients using cardiac glycosides, plasma levels of calcium, potassium and magnesium must be carefully monitored.	Singapore Japan		Ab¨gvb Kiv †h‡Z cv‡i	Ab¨gvb Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
22.	Novocol Pharmaceutical of Canada Inc., Canada (Prayashi, Dhaka)	a) **Octocaine 100 Injection** Lidocaine HCl USP 21.34mg eq. to 20 mg Lidocaine + Epinephrine Bitartarte USP 0.18mg eq. to Epinephrine 0.010 mg/ml	It is used in dental anaesthesia only	**Contraindications:** Octocaine 100 is contraindicated in patients with a known history of hypersensitivity to local anaesthetics of the amide type or to any components of the injectable formulations. Since octocaine contains epinephrine the caution required of any vasoconstrictor drug is in order. **Side Effects:** Adverse experiences following the administration of Lidocaine are similar in nature to those observed with other amide local anesthetic agents. Common adverse reations are hypotension, GI disorders: nausea, vomiting, nervous system disorders: Paresthesia, dizziness, bradycardia.	Canada		Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
23.	Pfizer Inc., USA **Local agent:** Radiant Export Import Enterprise. Uttara, Dhaka.	**a) Eraxis Lyophilized powder for Injection for Intravenous use** Anidulafungin INN 100mg/Vial	Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: - Candidemia and other forms of *Candida* infections (intra-abdominal abscess and peritonitis) - Esophageal candidiasis **Limitations of use:** It has not been studied in endocarditis, osteomyelitis and meningitis due to *Candida* or in sufficient numbers of neutropenic patients	**Contraindications:** Persons with known hypersensitivity to anidulafungin, any component of ERAXIS, or other echinocandins **Side effects:** Candidemia and other forms of *Candida* infections: Most common adverse reactions (≥15%) are hypokalemia, nausea, diarrhea, vomiting, pyrexia, insomnia • Esophageal candidiasis: Most common adverse reactions (≥5%) are diarrhea, pyrexia, anemia, headache, vomiting, nausea and dyspepsia	USFDA approved. FSC not available (attached undertaking)		c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
24.	Performance Health Inc., Home Avenue Akron 1245LLC , USA MITOSIS 340/C, Ibrahimpur (2nd Floor) Kafrul, Dhaka	a) **BIOFREEZEPain Relieving Spray** **(59ml/118ml/473ml)** **Mentol USP 10%**	Temporary relief from minor aches and pains of sore muscle & joint associated with arthritis, backache, strains and sprains	**Contraindications:** BIOFREEZE is formulated for external .use only Incase of accidental ingestion seeks professional assistance or contact a poison control center .immediately dcontact with eyes or Avoi If .mucous membranes or if ,condition Worsens symptoms persist for more days or if (7)than seven up and -symptoms clear reoccur again within a few days discontinue use of BIOFREEZE gel and Do .consult a physician not bandage apply to .Wounds or damaged skin Do not use in conjunction ,with other ointments sprays or ,creams Do Not apply .Liniments to irritated skin or if skin or excessive irritation Do not bandage .develops affected areas where BIOFREEZE gel has been cool Store in a .applied dry place with the lid Keep away .tightly closed from excessive heat or do not use .open flame with heating pads or KEEP OUT OF .devices .REACH OF CHILDREN	**CPP: USFDA**	0.042gm/100 ml mouth wash	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †Rvbv‡iK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Performance Health Inc., Home Avenue Akron 1245LLC , USA MITOSIS 340/C, Ibrahimpur (2nd Floor) Kafrul, Dhaka	b) **BIOFREEZEPain Relieving Roll On** **(89ml)** **Menthol USP 4%**	Temporary relief from minor aches and pains of sore muscle & joint associated with arthritis, backache, strains and sprains	**Contraindications:** BIOFREEZE is al formulated for extern In.use onlycase of accidental ingestion seeks professional assistance or contact a poison control center .immediately Avoidcontact with eyes or If .mucous membranes or if ,condition Worsens symptoms persist for more days or if (7)than seven up and -learsymptoms c reoccur again within a few days discontinue use of BIOFREEZE gel and Do .consult a physician not bandage apply to .Wounds or damaged skin Do not use in conjunction ,with other ointments sprays or ,creams Do Not apply .Liniments n or if skin to irritated ski or excessive irritation Do not bandage .develops affected areas where BIOFREEZE gel has been Store in a cool .applied dry place with the lid Keep away .tightly closed from excessive heat or do not use .open flame with heating pads or KEEP OUT OF .devices .REACH OF CHILDREN	**CPP: USFDA**	0.042gm/100 ml mouth wash	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	Status (New Molecule/ Existing)	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
25	Manufactured by M/s Southern Drugs & Pharmaceuticals Andhra Pradesh, India for GalxoSmithKline Asia (PVT) Ltd (Glaxosmithkline Bangladesh ltd.)	a) **ENO Fruit Salt (Lemon Flavour)** **Active Ingredient:** Svarjiksara: 2.29 gm + Nimbukamalam: 2.16 gm/5gmSachet **Excipients:** Stabilizing salt: 0.5 gm + Trusil Lemon Special: 0.03 gm + Lime DCS 202/M: 0.01 gm + Sodium saccharine IP: 0.005 gm + Brilliant Blue FCF: 0.0191 mg + Tartrazine: 0.141 mg	It contains Svarjiksira & Nimbukamlam, as a combination of antacid product. The combination product is effective for the symptomatic relief of: • Heartburn • Acid indigestion • Sour stomach	**Contraindication:** Persons on a sodium restricted diet e.g. those suffering from hypertension or congestive heart failure should not use this product unless directed by a doctor. Patients with impaired hepatic and renal Eno is contraindicated in patients with a prior hypersensitivity reaction to any ingredient of the preparation. **Side Effects:** Stomach/gut irritations which could cause wind or bloating.	India		c‡qvRb †bB wea|q Av‡e`b bvgÄy Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄy Kiv nj |

2.5 Proposed Product for Import (Veterinary)

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK¨vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
01.	Merial Nanjing Health Co. Ltd., China Advance Animal Science Co. Ltd., Dhaka	a) **Reassortant Avain Influenza Virus Vaccine, Inactivated** Each Dose of vaccine contains : Inactivated Reassortant Avian Influenza Virus H5N1, Strain Re minimum titer before inactivation – $10^{8.0}$ EID_{50} Inactivated Avian Influenza Virus, H5N1 subtype ≥ 64 HI.U Thiomersal, at most 0.015 mg Oil Excipient Q.S. 0.5 ml	To prevent Avian Influenza in chicken, duch and goose induced by H5 subtype Avian Influenza virus. Potency will be obtained 14 days post vaccination and last for 6 months in chickens. A booster vaccination in duck after 3 weeks of vaccination in duck and goose, potency last 4 months.	**Contra indication:** None **Side effect :** A transient nodule may be observed at the injection site, if injection is not take care of.	China	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	
02.	Merial, France Advance Animal Science Co. Ltd., Dhaka	a) **Heartgard Plus Chewable Tablet For Cat** Ivermectin BP 55mcg	To prevent heartworm disease by eliminating the tissue stages of heartworm larvae(Dirofilaria immitis) acquired during the prior month (30days), and for the treatment and control infections due to adult and innature hookworm (Ancylostoma tubaeforme and Ancylostoma braziliense) in cats.	**Contraindications:** All should be tested for existing heartworm infection before starting treatment with the drug **Side-effect** : None	USA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **Heartgard Plus Chewable Tablet for Cat** Ivermectin BP 165mcg	Do	**Contra-indications:** All should be tested for existing heartworm infection before starting treatment with the drug **Side-effect :** None	USA	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Merial, France Advance Animal Science Co. Ltd., Dhaka	c) **Gallimune 208 ND + FLU H9 M.E. Vaccine** Virus Inactive De La Grippe Aviaire Souche H9N2, Titre Minimum Avant Inactivatio 10^8 DIO50 + Virus Inactive De La Maladie DE NewCastle Souche ULSTER 2C, Titre Minimum Avant Inactivatio 10^8 DIO50+ Inactive Avian Influenza Virus H9N2 strain, Minimum Titer before Inactivation 10^8 DIO50 + Inactivated Newcastle disease virus, Ulster 2C strain Minimum Titer before Inactivation 10^8 DIO50	Preventive vaccination of poultry against Avian Influenza (H9N2) and Newcastle disease.	**Contraindications :** Nill **Side-effect :** Vaccination with this vaccine is safe and satisfactory when as recommended hereby	France	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyK iv nj |
		d) **Certifect Spot on Solution for Dogs (Topical Spray)** Fipronil 10 gm + (s)-methoprene 9gm + Amitraz 20gm/100 ml	Treatment & prevention against different fleas & tics in dogs	**Contra-indications:** Do not use on sick & convalescent animals. Do not use on rabbits and cats. **Side effects:** No toxicity or side effects were observed during clinical trial.	EMA (France)	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
		e) **Frontline Plus for Cat (Spray)** Fipronil 10 gm + Methoprene 12gm/100ml	It is indicated against the Y-aminobutaric acid receptor chloride of many insects & arthropod pests. It is also indicated for reduction of ticks & fleas of cats.	**Contra-indications:** None **Side effects:** The product may cause mucous membrane and eye irritation. No recordable toxicity observed in mammals eg cats.	France	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
03.	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	a) **Genta-Flo 320 Water Soluble Powder** Gentamicin Sulfate 120 gm +Ofloxacin 200gm /Kg	It is indicated in bacterial enteritis caused by Gram positive bacteria such as camphylobacter spp, Salmonella Dublin and various Salmonella typhimurium stains. Specific indication for poultry is for salmonellosis, colibacillosis and staphylococcal infections. It is also used for the treatment and control of poultry respiratory disease and intestinal infections caused by E. Coli, Salmaonella, Pseudomonas Aeruginosa, Enterobacteriaceas, Haemophilus influenza, Pasteurella, Mycoplasma and Staphylococcus.	**Contraindications:** It is contra-indicated in animals' wityh a known history of hypersensitivity to it, and probably in those hypersensitive to other amonoglycosides. It should be avoided in animal with myasthenia gravis, and great care is required in animals with parkinsonism and other conditions characterized by muscular weakness. **Side effects:** The amino glycosides like gentamycin can produce irreversible, cumulative auto toxicity affecting bothe cochlea and the vestibular system. Reverse nephrotoxicity may occur and acute renal failure has been reported, often in assoiciation with the use of other nephrotoxicity drugs.	SIngapore	c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyb Kiv nj |
		b) **Neosyn 100 Water Soluble Powder** Neomycin Sulfate 100 gm/Kg	It is indicated in bacterial enteritis caused by Gram negative bacteria such as Campylobacter spp, Salmonella Dublin and various salmonella typhimurium strains. **Poultry:** Salmonellosis, Colibacilosis and Staphylococcal infections. **Swine:** Salmonellosis, Colibacilosis, Leptopirosis and dysentery caused by Treponema Hyodysenteriae.	**Contraindications:** It is contraindicated for intestinal disinfection when an obstruction is present, in animals with a known history for allergy to aminoglycosides and in new born or very young animals under. It should be used with great care in animals with renal or hepatic impairment, or with neuromuscular disorders and in those with impaired hearing. **Side effects:** Ototoxicity, neuromuscular blockade, nephrotoxicity, and acute renal failure may also occur due to prolong usage. Acute tubular necrosis and intestinal nephritis have also occurred. Decreased glomerular filtration is usually seen.	Singapore	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	c) **P-CTC 15% Water Soluble Powder** Chlortetracycline HCl 150 gm/Kg	Indicated for local and systemic infections due to gram positive and gram negative bacteria, protozoa such as Anaplasma and Theileria spp., Rickettsiae and some Mycoplasmata and ureaplasmata. Special indication for calves is primary and secondary respiratory infections caused by Pasturella haemolytica and Pasturella multocida. Special indications for poultry are Colibacillosis and CRD.	**Contra-indications:** Avoid usage of chlortetracycline during pregnancy due to risk of hepatotoxicity in the mother and on the developing fetus. Avoid usage of chlortetracycline during lactating period and in very youg animals **Side-effects:** GIT disturbance like nausea, vomiting, diarrhea are common. Othe reffects like dry mouth, glossitis, and discoloration of the tongue, stomititis and dysphagia. Pesophageal ulceration has laso been reported.	Singapore	Abyjgvb Kiv †h‡Z cv‡i	Abyjgvb Kiv nj	
		d) **Caninethic Plus Flavor Tablet For Dogs** Febantel 150 mg + Pyrantel Pamoate 150mg + Praziquantel 50mg	Roundworm and tapeworm remedy for use in dogs. For the treatment of mixed infestations with roundworms and tapeworms caused by: Roundworms: Ascarids, Hookworms, Whipworms Tapeworms: Echinococcus ranulosus, Echinococcus multilocularis, Multiceps multiceps etc.	**Contraindications:** Until sufficient studies have been performed in bitches in early pregnancy. Do not use during the first two thirds of gestation. Do not exceed the recommended dose. Do not administer concurrently with other anthelminthics. Do not exceed the stated dose or dosage period. **Side-effects:** Side effects of caninethic Plus may be common but are usually mild and transient. Headache, dizziness and restlessness, transient abdominal pain and diarrhea have been reported most frequently. Hypertensitivity reactions like rashes, prutitus, fever, and anaphylaxis can occur. They may be due to death of the infecting parasites. Raised liver enzyme values have been reported rately. Most animals with neurocysticerosis who are given praziquaental suffer CNS effects, including headache, hyperthermia, seizures and intercranial hypertension, which are thought to result from an inflammatory response to dead and dying parasites in the CNS.	Singapore	Abyjgvb Kiv †h‡Z cv‡i	Abyjgvb Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	e) **Cepha-C 50% Water Soluble Powder** **Antibiotic-Caphalosporin** Cephalexin Monohydrate 500 gm/Kg	It is broad antibacterial action against both gram positive and gram negative bacteria. This unique combination is effective against a range of both gram positive and gram negative organisms comprising staphylococci including beta lactamase producing strains, E.coli, Salmonella, Pasteurella, Clostridium, Actinomyces and Erysipelothrix. Cepha-C is especially indicated in poultry chronic reapiratory disease as well as enteritis and Salmonella infection.	**Contraindications:** Do not administer cephalexin to animals with a history of hypersensitivity. Do not administer Cephalexin to animals with a history of allergy. Do not administer Cephalexin to animals with a history of renal implairment. Avoid usage of Cepha-C 50% in new born animals, especially in pregnant and lactating animals. **Side effects:** May include gastro intestinal disturbances and hypersensitivity reactions, varying from slight urticaria to fetal anaphylactic shock though this rarely happens. Nausea, Diarrhea, may also happen to some animals. In some cases nephrotoxicity and CNS induced convulsion may occur.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	
		f) **Tiamulin Super 300 Water Soluble Powder** Tiamulin Hydrogen Fumarate 300gm/Kg	It is used in the prevention and control of infections caused by Mycoplasma app., Staphylococcus aureus. Treponema spp. And E.coli. Tiamulin is especially effective in threating chronic respiratory disease (CRD) swine. As a result, there would be better feed conversion efficiency and carcase quality. Tiamulin is more superior to Typosin and Erythromycin in treating Mycoplasmosis.	**Contraindications:** Do not administer to animals with renal impairment, sensitivity towards tiamulin. Do not exceed the stated dosse or prolong usage of Tiamulin Super 300. Avoid administration Tiamulin Super 300 to pregnantand lactating animals due to reduction of egg production in layers. **Side effects:** Adverse effects that can occur after administration of tiamulin are super-infections with non-sensitive mico-organisms such as fungi and moulds. Occasionally, diarrhoeas, abdominal discomfort and allergic reactions may occur.	Singapore	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	g) **Colistin 100 Water Soluble Powder** Colistin Sulphate 10,000 MIU/Kg	It is indicated for gastrointestinal infections caused by colistin sensitive bacteria, especially E.coli and salmonella in calves, pigs and poultry. A specific indication for cattle is acute colimastitis. Specific indications for calves, pigs and poultry are various types of gastro-enteritis caused by E.coli, salmonella spp and pseudomonas.	**Contraindications:** Normal doses of colistin is safe and without any adverse effects. As Colistin sulfate may precipitate out at P^H higer than 7.5, care should be given to avoid mixing it with alkaline water or medications. Avoid administering neuromuscular blockers and colistin. Avoid also the concurrent usage of other potentially nephrotoxic drugs including the aminoglycosides and cephalotin. Avoid exceeding the recommended dosage. Avoid or take precaution when administering to animals with renal impairment. Avoid excedding the recommended dosage. **Side-effects:** Colistin sulfate is poorly absorbed from the GIT and adverse effects do not normally occur with usual oral doses. Cough and bronchospasm may occur during inhalation. Overgrowth of non-susceptible organisms, particularlyproteus spp., may occur after prolonged use. Plasma concentration monitoring during systemic treatment is recommended in new bnorn or very young animals, animals with renal impairment, and those with cystic fibrosis. Peak plasma-colistin concentration of 10 to 15mg/litre is recommended.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK i v †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK i v nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	h) **Ciprox 50% Water Soluble Powder (Vet)** Ciprofloxacin HCl 500 gm/Kg **Antibacterial**	Ciprox 50% is broad spectrum bacterial quinolone water soluble powder.It is very effective for the treatment and control of poultry respiratory disease and intestinal infections caused by E.coli, Salmonella, pseudomonas aeruginosa, Enterobacteriaceaes, haemophilus influenza, pasteurella, mycoplasma and staphylococcus. Engrofloxacin can be absorbed and distributed in body tissue to inhibit bacterial cell by blocking the enzymes of the DNA replication.	**Contraindications:** Excessive dose of ciprofloxacin can cause neurotoxicity. Do not administer to animals with serious renal impairments. Avoid concomitant administration with nitrofuracin compounds, trimethoprim and chloramphenicol. Do not exceed the stated dose or dosage period. **Side effects:** Gastrointestinal disturbances include nausea, vomiting, diarrhea, abdominal pain and dyspepsia are the most frequent side effects. Pseudomembranous colitis has been reported rarely.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	
		i) **Amoxcilin 50% Water Soluble Powder (Vet)** Amoxicillin Trihydrate 500gm/Kg	Infection caused by Amoxicillin sensitive microorganisms as appeared in gastro-intestinal infections, respiratory infections, uro-genital infections, local inflammations secondary bacterial infections during viral diseases by claves and poultry.	**Contra-indications**: Do not use for treatment of infections caused by penicillinase producing staphylococci. Do not administer to new born animals, little herbivores, animals that are over sensitive to penicillin and animals with serious renal impairments. Avoid usage of Amoxicillin 50% in pregnant and lactating animals. **Side-effects:** Side-effects of administering of amoxicillin 50% may include gastrointestinal disturbances and hypersensitivity reactions, varying from slight urticaria to fatal anaphylactic shock though this rarely happens. Cross allergy between all penicillins can quickly occur.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	j) **Coccicide 125 Soluble Powder (Vet)** Sulfaquinoxaline 60 gm + Sodium Salicylate 57 gm + Vitamin K3 1gm/ 200 gm	It is indicated for the treatment and control of all kinds of simple and complex coccidiosis of poultry including caecal and intestinal coccidiosis. It is also effective against fowl cholera and pullorum	**Contraindications:** Do not administer to animals with renal impairment as this may lead to increased risk of crystalluria. Do not administer to animals with sensitivity towards sulphonamides. **Side effects:** In poultry prolonged usage of coccicide 125 may lead to a reduction of egg productivity. Occasionally, hypersensitivity, allergic reaction, arthopathy, anaemia, may occur. Prolonged overdose may also lead to thrombocytopenia, hepatopathy, and hypothyroidism.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	
		k) **Ivermectin 1% W/V Solution; Veterinary Injection** Ivermection 10 gm/1000 ml	**In Cattle**: Gastrointestinal round worms; cattle grubs; screw-worm fly lice; mites; ticks; biting lice. **In Sheep**: Gastrointestinal roud worms; lung worm; mange mites. **In Camels** : Gastrointestinal roundwormsl mange mites	**Contraindications:** Excessive use of ivermectin can cause Neurotoxicity. Avoid concomitant administration with neuro muscular blockers. Do not administer to animals with renal impairment **Side effects:** The adverse effects reported with ivermectin in animals with filariasis are generally consistent with a mild mazzotti reaction arising from its effect on microfilariae. They include fever, prutitus, skin rashes, arthralgia, myalgia, asthenia, orthostatic hypotension, tachycardia, oedema, lymphadenopathy, gastrointestinal symptoms sore throuat, cough and headache.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	l) **CRD Super 3 Soluble Powder (Vet)** Doxycycline Hyclate 200 gm + Enrofloxacin 200 gm/1000 gm	It is effective against complex chronic respiratory diseases caused by mycoplasma, E.coli and salmonella. It is also effective against gram positive and gram negative bacterial infections. Coryza, Fowl typhoid, Blue comb, Streptococcal and Staphylococcal infections as well as necrotic enteritis. Poultry: C.R.D. (Mycoplasmosis), Colibacillosis, Gastro-entritis	**Contraindictions:** Avoid tetracycline in animals with SLE, cross sensitivity may also occur. Do not use doxycycline during pregnancy due to the risk of hepatotoxicity in mother and fetus. Avoid doxycycline during lactating period and in very young animals. **Side effects:** the adverse effects of doxycycline are common to all tetracycline. Gastrointestinal effects like nausea, vomiting and diarrhea are common. Other effects lide dry mouth, glossitis, discoloration of the tongue, stomatitis, dysphagia, oesophageal ulceration are reported.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	
		m) **Coccicide 110 Soluble Powder (Vet)** Sulfadimethoxine Sodium 45.4 gm + Sodium Salicylate 57 gm + Vitamin K3 1gm/200 gm	It is indicated for the treatment and control of all kinds of simple and complex coccidiosis of poultry including caecal and intestinal coccidiosis. It is also effective against fowl cholera and pullorum	**Contraindications:** Do not administer to animals with renal impairment as this may lead to increased risk of crystalluria. Do not administer to animals with sensitivity towards sulphonamides. As the cocicide 110 formula is alkaline in nature, avoid usage with acidic water or medications. **Side effects:** In poultry prolonged usage of coccicide 125 may lead to a reduction of eff productivity. Occasionally, hypersensitivity, allergic reaction, arthopathy, anaemia, may occur. Prolonged overdose may alo lead to thrombocytopenia, hepatophathy, and hypothyroidism.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	n) **VI-Pro Water Soluble Powder** Amantadine HCl 60 gm + Ribavirin 15gm/200 gm	Vi-pro is a unique formula combing Amantadine and Ribavarine in the combat of Avian Influenza and other viral respiratory diseases. Amantadine is an antiviral that inhibits the replication of Inflenza type A virus. It is also used prophylactically against ingection with influenza type A virus and to ameliorate symptoms when given during the early stages of infection. Amandadine is usually given orally as the hydrochloride and the does below are expressed in therms of this salt.	**Contra-indications:** Do not use amanatadine in animals with a history of epilepsy or other seizure disorders, or gastri ulceration and untreated angle closure glaucoma. **Side-effects:** High does of amantadine or with long term therapy may develop ankle oedema in patients. CNS effect such as anxiety, inability to concentrate, dizziness, insomnia, nightmares, headache and changes in mood may occur.	SIngapore	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
02.	Vetpharm Lab.(S) Pte. Ltd., Singapore (Advance Animal Science Co. Ltd.)	o) **Tri-VAC 48% Poultry Suspension (Vet)** Sulfadiazine BP 400 gm + Trimethoprim BP 80 gm/Litre	For the treatment and control of outbreaks of primary and secondary bacterial infections associated with respiratory diseases in broilers and turkeys. - Coryza(nasal discharge, snot) - CRD(snoring) - Fowl Cholera (greenish droppings) - Pullorm (Bacillary white diarrhea)	**Contraindications:** TRI-BAC 48% poultry suspension should not be given to animals with a history of hypersensitivity to it or to the sulfadiazine or trimethoprim. It should be stopped at the first appearance of skin rash, or if blood disorders develop. It should be avoided in animals with severe hepatic impairment and used with caution in animals with lesser degress of impairment. Do not administer to animals with renal impairment. **Side-effects:** In poultry overdose of TRI-BAC 58% may lead to a reduction of egg productivity. Occasionally, hypersensitivity, allergic reaction, arthopathy, anemia may occur. prolonged overdose may lead to thrombocytopenia, hepatopathy and hypothyroidism	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	p) **Lincostine-C Soluble Powder (Vet)** Lincomycin Hydrochloride 90 gm + Colistin Sulphate 400 MIU/200 gm **Antibacterial**	Lincostine Soluble powder is specially formulated and indicated for the prevention, control and treatment of chronic respiratory diseases caused by Mycoplasma, E.coli salmonella. It is also effective against gram positive and negative bacterial infections as well as necrotic enteritis, Colibacillosis, gastro enteritis in poultry and cattle.	**Contraindications:** Solution of lincomycin salts has an acid pH and incompatibility may reasonably be expected with alkaline preparations, or with drugs unstable at law pH. **Side-effect:** Lincomycin is reported to produce diarrhea in many animals after systemic use; in some animals' severe antibiotic associated or pseudomembranous colitis may develop, and has proved fatal. C. difficile is more frequent in females and old animals.	Singapore	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		q) **Albenthic Plus Suspension (Vet)** Albendazole 25 gm/Litre **Antiparasital**	Albenthic Plus Suspension is used for the control of susceptible mature and immature gastrointestinal roundworms, large lungworms, liver fluke, and nasal bots; reduces output of viable worm and fluke effs and provides sustained control of barber's pole worm in sheep.	**Contraindications:** Excessive use of albendazole can caused severe side effects. Albendazole is teratogenic in rats. Albendazole and closantel are contraindicated in pregnant and lactating animals. **Side Effects:** GIT disturbance, such as transient abdominal pain and Diarrhea, and have tend to occur in animals being trated for heavy intestineal infection. Headache, dizziness and restlessness have been reported.	Singapore	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wewq Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	r) **Livaminthic 16% Water Soluble Powder (Vet)** Levamisole Hydrochloride 160 gm/Kg **Antiparasital**	Levaminthi soluble powder is used for the control and treatment of nematode infections in poultry and swine. Treatment with Levaminthic will remove both the mature and immaure stages of a wide range of important nematode species. In poultry: For treatment of common roundworm, caecal worms and hairworms. In swine: For treatment of ascarids, intestinal threadworms, lungworms, red stomach worms, nodular worms, whipworms and larval stages of parasites in swine.	**Contraindications:** Avoid levamisole in animals with pre-existing blood disorders. Excessive use of levamisole may produce cholinergic activity. **Side effects:** Headache, dizziness, nausea, abdominal pain, and restlessness have been reported. Prolonged use of Levaminthic causes hypersensitivity reactions like fever, a flu like syndrome, muscle pain, skin rashes etc. CNS effects like insomnia, headache, dizziness, leucopenia, thrombocytopenia, gastrointestinal disturbances like an abdominal teste in the mouth.	Singapore	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
		s) **Diclazuril 0.2% Powder Premix (Vet)** Diclazuril 2.00 gm + Vitamin K3 2.00 gm/Kg **(Antibiotic + Vitamin)**	It is used in the prevention, control and treatment of outbreak of coccidiosis caused by Eimeria acervulina, E. brunette, E. maxima, E. necatrix and E. mitis in chickens and E. adenoeides, E. meleagridis and E meleagrimitis in turkeys. Diclazuril acts against all intracellular development stages of coccidian. It does not however, interfere with the development of natural immunity	**Contraindications**: Do not administer to animals with renal impairment. Do not administer to animals with sensitivity towards diclazuril. Excessive use of diclazuril can cause hypersensitivity. **Side Effects:** Hypersensitivity, stomatitis and GIT Disturbances may occur in some cases. This is generally well tolerated. If the recommended dose is excedded beyond 3-5 times, there will be a decrease in water intake.	Singapore	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	t) **Tylophos 100 Premix Powder (Vet)** Tylosin Phosphate 100 gm/Kg	It is used for bacterial infection caused by gram positive and gram negative bacteria as well of treatment of mycoplasmosis, CRD and PPLO	**Contraindications:** A contraindication to the use of tylosin is occasionally occurring hypersensitivity for tylosin. Cross resistance with macrolides occurs and warrants special attention. Avoid using the aminoglycosides like gentamycin and neomycin. Mild side effects like diarrhea and ulticaria may occur. **Side effects:** GI Disturbance such as abdominal discomfort and Cramp, nausea, vomiting and diarrhea are fairly common after both oral and parental use. Hypersensitivity reactions appear to be uncommon, and include pruritis, urticaria and skin rash as well s occational case of anaphylaxis.	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	
	Vetpharm Lab(S) Pte Ltd. Singapore Advance Animal Science Co. Ltd., Dhaka	u) **Fosvet 250 Powder** Fosfomycin 200 gm + Tylosin Tartrate 50gm/Kg	Gram positive ad gram negatie bacterial infections. E.coli and salmonella infections, Fowl cholera, CRD, Streptococcal and staphylococcal infections.	**Contraindications:** Fosfomycin and tylosing are safe and generally without many side effects in recommended dosage. C contraindication to the use of Fosvet 250 is occasionally occurring hypersensitivity for tylosing. **Side Effects:** It is well tolerated when given in the recommended dosage. Sometimes, diarrhea and urticaria can also occur at the recommended dosage. GI disturbance including nausea and Diarrhea, transient increases in serum concentrations of amino transferase, headache, visual disturbance and skin rashes have been reported after use of fosfomycin	Singapore	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyK iv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
03.	Merial Saude Animal Ltda, Brazil (Advance Animal Science Co. Ltd.)	a) **Ivomec Super Injection** Ivermectin 1gm + Clorsulon 10gm/100ml	For the treatment & control of gastro intestinal roundworms, lungworm, adult liver fluke, warbles, eye worms, mites, and lice of cattle.	**Contra-indications:** Not to use in fish & aquatic life. **Side-effects:** Studies have demonstrated wide safety margin can the recommended use level had no adverse effect on breeding performance.	USA Brazil	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	
04.	Biomune Company, USA (ACI Ltd.)	a) **Vectormune HVT NDV & Rispens Vaccine** **1000, 2000 & 4000 doses in Glass ampoule** Marek's disease-Newcastle disease virus at least 2474 PFU's through expiration + Marek's disease Rispens CVI988 strain at least 1206 PFU's through expiration + Cryoprotectant No.1 + HVT and Rispens CVI988 strains 50-90% + Cryoprotectant No.2 10-50%/dose	It is recommended for in ovo vaccination in 18 to 19 days old embryonated eggs and for subcutaneous vaccination in day old chicks as an aid in the prevention of Newcastle disease and very virulent marek's disease.	**Contraindications:** No contraindications are known. **Side Effects:** Unknown.	USA	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	
		b) **Circomune Vaccine** **1000 doses in15ml glass or Plastic Vials & 2000 doses in 25ml glass or Plastic Vials** CAV del-Ros strain min $10^{4.9}$ $TCID_{50}$ + Glycerol 20%+ 20% FD+C blue dye No.1-1%/dose 0.01ml	This vaccine is recommended for use in healthy breeder chickens to provide maternal antibodies to progeny as an aid in the prevention of chicken infectious anemia due to chicken infectious anemia virus. It is administered only by wing web at 9 to 12 weeks of age	**Contraindications:** No contraindications are known. **Side Effects:** Unknown.	USA	Abyôgv`b Kiv †h‡Z cv‡i	Abyôgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
05.	Green Cross Veterinary Products Co. Ltd., Korea (ACI Ltd.)	a) **IB1 Living Vaccine** **500 & 1000 doses/Bottle** Infectious bronchitis virus (H-120 strain) more than $10^{5.0}$ EID_{50}/dose + Newcastle disease virus(B1 strain) more than $10^{6.5}$ EID_{50}/dose	Active immunization against Infectious Bronchitis and Newcastle disease.	**Contraindications:** Do not use in animals animal that has early history of shock or hypersensitivity associated with this vaccine, animals with fever or malnutrition, animal that infected with contagious diseases or parasites, animal that immune-suppressed by fungal or bacterial toxin. **Side effect:** Depending on health status of vaccinated flock, vaccine reaction such as anorexia, coughing and sneezing, could be observed.	Korea	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
	Green Cross Veterinary Products Co. Ltd., Korea (ACI Ltd.)	b) **Linpeccin Powder** **500gm, 1kg, 5kg, 10kg and 20kg** Lincomycin hydrochloride 22g(activity) + Spectinomycin sulfate 22g(activity)/1kg	Prevention and treatment of Mycoplasmosis.	**Contraindications:** Do not use in animals with known hypersensitivity to the active ingredients. **Side effect:** Loosening of faeces and /or mild swelling of the anus may occur, this is usually transient. On rare occasions, mild irritability and reddening of skin may occur. These conditions are usually self-correcting within five to eight days without discontinuing therapy.	Korea	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
06.	WooGene B&G Co., Ltd. Korea (ACI Ltd.)	a) **Superamino** **Injectable solution** **250ml, 500ml, 1000ml, 5L & 10L** L-Valine 8mg + L-Leucine 11mg + L-Isoleucin 5mg + Arginine HCl 5mg + Histidine HCl 3.5mg + L-Methionine 3mg + L-Phenylalanine 7mg + L-Threonine 4.6mg + L-Trypophan 2mg + Lysine HCl 10mg + Cysteine HCl 5mg + Vitamin B1 10mg + Riboflavine-5-Phosphate sodium 4mg + Calcium Pantothenate 5mg + Niacinamide 150mg + Vitamin B6 10mg + Vitamin B12 5µg + Sodium acetate 250mg + Calcium Chloride 2H2O 150mg + Potassium Chloride 200mg + Magnesium Sulfate 7H2O 200mg + Dextrose H2O 5g + Methyl Paraben 180mg + Propyl Paraben 20mg + Distilled water q.s./100ml	For the supply of high concentration of glucose, vitamin B complexes, amino acids and electrolytes for metabolizing in weakened animals	**Contraindications:** No contraindications are known. **Side Effects:** Unknown.	Korea	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	WooGene B&G Co., Ltd. Korea (ACI Ltd.)	b) **Superamino-C** **Injectable solution** **20ml, 50ml, 100ml, 250ml & 500ml** L-Valine 136mg + L-Leucine 187mg + L-Isoleucin 85mg + Arginine HCl 85mg + Histidine HCl 59.5mg + L-Methionine 51 mg + L-Phenylalanine 119mg + L-Threonine 78.2mg + L-Trypophan 34mg + Lysine HCl 170mg + Cysteine HCl 85mg +Vitamin B1 10mg + Riboflavine-5-Phosphate sodium 4mg + Calcium Pantothenate 5mg+ Niacinamide 150mg + Vitamin B6 10mg+Vitamin B12 5µg+Sodium acetate 250mg + Calcium Chloride 2H2O 150mg + Potassium Chloride 200mg+Magnesium Sulfate 7H2O 200mg + Dextrose H2O 5g + Methyl Paraben 180mg+Propyl Paraben 20mg + Distilled water q.s./100ml	For the supply of high concentration of glucose, vitamin B complexes, amino acids and electrolytes for metabolizing in weakened animals	**Contraindications:** No contraindications are known. **Side Effect:** Unknown.	Korea	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |
07.	Ceva Phylaxia Veterinary Biologicals Co. Ltd. (ACI Ltd.)	a) **CEVAC IBird** **Live, Freeze-Dried Vaccine** **500, 1000, 2500, 5000 & 8000 doses/glass vial** Avian Infectious Bronchitis virus, variant strain 1/96……at least 2.8 log10 EID50	It is recommended for the active immunization of chickens in order to reduce the respiratory clinical signs caused by variant strains of infectious bronchitis virus.	**Contraindications:** None. **Side Effects:** Vaccination with Cevac IBird may induce mild respiratory signs, which may persist for 4 to 5 days after vaccination, depending on the health and housing conditions of the chickens	Hungary	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
07.	Lallemand SAS, France (Square Pharmaceuticals)	a) **Bactocell Drink** **(Lactic acid Bacteria for Monogastrics)** ***Pediococcus acidilactici* CNCM MA 18/5M Strain 2.5X10⁹ CFU/gm** (Lactic acid Bacteria for Monogastrics) *Pediococcus acidilactici* CNCM MA 18/5M Strain 2.5X10⁹ CFU/gm	A probiotic feed additive that helps to enhance the nutrition and health of monogastrics.	**Contraindication:** None **Side effects:** No side effects at recommended dose.	France	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
08.	CEVA-PHYLAXIA VETERINARY Biological Co.Ltd (Navana Pharma)	a) **AVI IBD Plus Vaccine** Infectious Bursal Disease virus strain Winterfield 2512 G-16 at least $10^{2.0}$ EID_{50}	For the active immunization of chickens against Infectious Bursal Disease (Gumboro) virus.	**Contraindications:** AVI IBD Plus Vaccine should not be used for the immunization of flocks without maternally derived antibodies. Side-effect: None	Hungary	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
08.	EWABO Chemikalien GmbH, & Co. KG, Germany (Univet Ltd)	a) **Oxykol Water Soluble Powder (Vet)** Peracetic Acid 90gm/Kg **Disinfectant**	Oxykol is suitable for the following applications: - Disinfection in poultry production for broller, turkey, duck farms and breeding and layer units, hatcheries. - disinfection in pig, sheep, cattle, rabbit mink ang goat farming - disinfection in milking parlours and dairy firm - aerial disinfection in all kind of livestock - dringking water sanitation - Vehicle disinfection.	**Contraindications:** Not applicable **Side effects:** Not applicable.	Germany	Abyjgv`b Kiv †h‡Z cv‡i |	Abyjgv`b Kiv nj |
09.	Federal Governmental Budgetary Institution "Federal Centre for Animal Health" (FGBI "ARRIAH"), Russia. (**ONE PHARMA LTD.)**	a) **ARRIAH - VAC" (FMD) VACCINE** The vaccine consists of purified suspension of FMD virus, grown in BHK-21 cell culture, inactivated by 1, 2 Aminoethylethyleneimine, emulsified in oil adjuvant Montanid ISA-206 (not more than 50%)	The virus vaccine is intended for the prevention of FMD caused by the following strains A, O, C, Asia-1, SAT-1, SAT-2, SAT-3 for bovine cattle, small cattle, Sheep, Goat, buffalos, camels, deer, yalks and pigs.	**Contraindications:** It is the presence of acute infectious disease to vaccinate animals. **Side Effects:** During 1-3 days after vaccination, some animals may have an insignificant rise of body temperature and loss of appetite that don't request any special treatment. The animals that show an allergic reaction after immunization are given antihistaminic preparations.	Russia	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK¨vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Federal Governmental Budgetary Institution "Federal Centre for Animal Health" (FGBI "ARRIAH"), Russia. (**ONE PHARMA LTD.)**	b) **ARRIAH FMD (MONO-POLY) VACCINE** The virus vaccine is produced from inactivated FMD virus of one or several production strains A, O, Asia-1, SAT-1, SAT-2, SAT-3 types grown in culture cells BHK-21, Aluminium hydroxide and Saponin (Adjuvant).	The virus vaccine is intended for the prevention of FMD caused by the following strains A, O, C, Asia-1, SAT-1, SAT-2, SAT-3 for bovine cattle, small cattle, buffalos, camels, deer, yalks and Pigs.	**Contraindications:** It is the presence of acute infectious disease to vaccinate animals. It is prohibited to use vaccine in parallel with other live immunobiological drugs and medicines (Antibiotics, Sulfonamides etc.) **Side Effects:** During 1-3 days after vaccination, some animals may have an insignificant rise of body temperature and loss of appetite that don't request any special treatment.	Russia	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		c) **ARRIAH (IBD "BG") VACCINE** The virus vaccine is produced from extra-embryonic fluid, Carcass homogenate and chorioallantoic membranes of SPF embryonated eggs from chickens infected by infectious bursal disease attenuated virus ("BG" strain) adding as stabilizers lactalbumin hydrolysate (5%), saccharose (5%). Gelactose (0.5%). Infectious bursal disease virus "BG" strain replicated in 9-11 day old chicken SPF embryonated eggs At least 4.5 lg EID_{50} /cm^3	The virus vaccine is intended for the prevention of the infectious bursal disease in Chicks, in not favorable and threatening poultry farms of the different direction of breeding.	**Contraindication:** Vaccination contraindication is the presence of acute avian infectious disease on farm. **Side Effects:** If the virus vaccine is administered in compliance with the application instruction as a rule no side effects or morality are observed.	Russia	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
		d) **ARRIAH (IB "H-120") VACCINE** The vaccine is produced from extra-embryonic fluid of SPF embryonated eggs from chickens infected by infectious chicken bronchitis attenuated virus (strain "H-120", serotype Massachusetts) with the addition of stabilizers presented by 20% lactalbumin hydrolysate, 50% saccharose solution and 10% Gelactose solution. H-120 strain of IB Virus – 6.0 lg EID 50/CM3	The vaccine is intended for prevention of the Chicken infection bronchitis in chicks, replacement flock and laying hens in breeding and commercial poultry farms of different directions of growth.	**Contraindication:** Vaccination contraindication is the presence of acute avian infectious disease on farm. **Side Effects:** 3-4 days post vaccination 5-10% of vaccinated birds may demonstrate slide depression and mild rhinitis and conjunctivitis resolving spontaneously.	Russia	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
	Federal Governmental Budgetary Institution "Federal Centre for Animal Health" (FGBI "ARRIAH"), Russia. (**ONE PHARMA LTD.)**	e) **ARRIAH (IB+ND) VACCINE** The virus vaccine is produced from extra-embryonic fluid of SPF embryonated eggs from chickens infected by Chicken infectious bronchitis virus (IB) (strain H-120 Massachusetts serotype) and Newcastle disease virus (strain "La-Sota") adding as stabilizers presented by lactalbumin hydrolysate (25%), Gelactose (10%), saccharose (5%). IBV H-120 strain – 6.0 lg EID 50/CM3 ND virus (LaSota strain)–9.5 lg EID 50/CM3	The vaccine is intended for the prevention of the Chicken infection bronchitis and Newcastle disease virus in chicks, in not favorable and threatening poultry farms of the different direction of breeding. In pedigree, trade and other categories of poultry farms.	**Contraindication:** Vaccination contraindication is the presence of acute avian infectious disease on farm. **Adverse Effects:** In case there is dust in the air of poultry-houses and excessive ammonium concentration and if the poultry demonstrate signs of rhinitis, chronic and acute infectious disease (Infectious bursal disease, Marek's disease, leucosis, Mycoplasmosis) and invasions (Coccidiosis), 5-10% of the vaccinated poultry may demonstrate slight depression and rhinitis and conjunctivitis on day 3-4 post vaccination. All the symptoms disappear in 2-3 days or the vaccination effectiveness decreases.	Russia	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-Kvgvwi 61 Zg mfvi wm×vš	mfvi wm×vš
		f) **ARRIAH (ND "LA-SOTA") VACCINE** The vaccine is produced from extra-embryonic fluid of SPF embryos from chickens infected by Newcastle disease virus ("La-Sota" strain) with the addition of skimmed milk (40%) and lactalbumin hydrolysate (10%) as stabilizers. ND virus (LaSota) – 9.0 lg EID 50/CM3	The vaccine is intended for prevention of Newcastle disease on breeding and commercial poultry farms of different raising areas.	**Contraindication:** Vaccination contraindication is the presence of acute avian infectious disease on farm. **Adverse Effects:** If vaccine is used in accordance with these guidelines chicks may demonstrate malady, dispnoea, anorexia in 4 – 5 days and spontaneously resolving in 10 – 12 days. Adult birds usually don't demonstrate side effects or complications.	Russia	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
	Federal Governmental Budgetary Institution "Federal Centre for Animal Health" (FGBI "ARRIAH"), Russia. (**ONE PHARMA LTD.)**	g) **ARRIAH PENTAVIS (ND+IB+EDS+IBD+REO) VACCINE** The vaccine is produced from extra-embryonic liquid of chicken and duck embryos, homogenate of trunks and cell culture of fibroblasts of chicken SPF-embryos infected with Newcastle disease virus (strain "La-Sota"), chicken infectious bronchitis virus (strain "H-52", and/or "Tchapaevskiy"), infectious bursal disease virus (strains "K-58 or "BG"), Egg drop syndrome-76 virus (strain "BISS" or "B8/78"), avian reovirus (strain "1133") inactivated with dimer aminoethylenimin adding oil adjuvant Montanide ISA-70VG in the ratio 30/70. The vaccine can contain 1-5 from the mentioned virus antigens. [ND virus (LaSota) – 9.0 lg EID 50/CM3 Inactivated IBV (H-52 or Chapayevsky) – 7.5 lg EID 50/CM3 Inactivated EDSV-76 Virus (B8/78 or BISS)– 4.8 lg EID 50/CM3 Inactivated IBDV (BG or K-58)- 6.7 lg EID 50/CM3 Inactivated ReoV (1133)-7.3 lg TCID50/CM3]	The vaccine is intended for prevention of the Newcastle disease, infectious bursal disease, chicken infectious bronchitis, egg drop syndrome-76 and avian reovirus tenosynovitis in pedigree and commercial poultry farms of several breeding directions.	**Contraindications:** It is prohibited to use vaccine in parallel with other live immunibiological drugs and medicines (Antibiotics, Sulfonilamides etc.). **Side Effects:** The vaccine doesn't induce any clinically manifested reaction. In some cases a little tumor may develop in the injection site which will resolve in 2-3 weeks.	Russia	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Federal Governmental Budgetary Institution "Federal Centre for Animal Health" (FGBI "ARRIAH"), Russia. (**ONE PHARMA LTD.)**	h) **ARRIAH (REO) VACCINE** The virus vaccine is produced from cell culture of fibroblasts of SPF-embryonated eggs from chickens infected by avian reovirus tenosynovitis attenuated virus (REO strain "1133") adding as stabilizers lactalbumin hydrolysate (15%), saccharose (4%), Gelactose (3.5%). [Attenuated Avian Reovirus (Strain: 1133) – 7.0 lg TCID 50/CM3]	The vaccine is intended for prevention of the avian reovirus tenosynovitis in pedigree and commercial poultry farms of several breeding directions.	**Contraindications:** Vaccination contraindication is the presence of acute avian infectious disease on farm. No specific post vaccination reaction is observed. **Side Effects:** No specific post vaccination reaction is observed. It is necessary to avoid violations of vaccination procedure as they may lead to decrease in Avian Reovirus Tenosynovitis immumoprophilaxis efficiency.	Russia	Abyjgvb Kiv †hŠZ cvi‡i	Abyjgvb Kiv nj	
		i) **ARRIAH (ND+IB+EDS) VACCINE** The virus vaccine is produced from extra-embryonic liquid of chicken and duck embryos, infected with Newcastle disease virus (strain "La-Sota"), chicken infectious bronchitis virus (strain "H-52", Massachusetts and/or "Tchapaevskiy"), Egg drop syndrome-76 virus (strain "BISS" or "B8/78") inactivated with dimer aminoethylenimin adding oil adjuvant Montanide ISA-70VG in the ratio 30/70. [ND virus (LaSota) – 9.0 lg EID 50/CM3 Inactivated IBV (H-52 or Chapayevsky) – 7.5 lg EID 50/CM3 Inactivated EDS-76 Virus (B8/78 or BISS)– 4.8 lg EID 50/CM3]	The virus vaccine is intended for prevention of the avian Newcastle disease, chicken infectious bronchitis, egg drop syndrome-76 in pedigree and commercial poultry farms of several breeding directions.	**Contraindications:** It is prohibited to use vaccine in parallel with other live immunibiological drugs and medicines (Antibiotics, Sulfonilamides etc.) **Side Effects:** The vaccine doesn't induce any clinically manifested reaction. In some cases a little tumor may develop in the injection site which will resolve in 2-3 weeks.	Russia	Abyjgvb Kiv †hŠZ cvi‡i	Abyjgvb Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
10.	BIOVET a.s. Komenskeho 212, 683 23 Ivanovice na Hane, Czech Republic. (Eon Animal Health Products Ltd., 43, Mohakhali, Dhaka-1212)	a) **ORNIMIX CLONE B1+ H120** ParamyxoVirus Pseudopestis avium, strain Bio 52: NDV B1 min. $10^{6.0}$ EID_{50} –max. $10^{7.5}$ EID_{50} + Virus Bronchitidis infectiosae avium, strain Bio 53: IBV H 120 min. $10^{3.0}$ EID_{50} – max. $10^{4.8}$ EID_{50}	For active immunization of fowl against Newcastle avian disease and infectious bronchitis of Massachusetts type. For prevention of infection and mortality caused by Newcastle disease virus and by infectious bronchitis virus. Onset of immunity: The immunity against Newcastle disease and infectious bronchitis starts not later than 14 and 7 days after primovaccination, respectively, and maternal antibodies have no negative influence on the efficacy of vaccination. Time of immunity duration: The immunity persists for 6 weeks after spray and oculonasal primovaccination and 4 weeks after peroral primovaccination. After revaccination, the immunity persists for 6 weeks as a minimum. The level of immunity against Newcastle disease can be evaluated after revaccination on the basis of serological examination.	Contraindication: Only healthy animals should be vaccinated. Do not use in animals that are showing signs of disease. Side Effects: Post vaccinations may occur in particular after unsuitable vaccine application by spraying because fine micro droplets cause inhalation of the vccination virus into the lower air passeage respiratory diseases as its consquences.	Czech Republic.	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
11.	Komipharm International Co. Ltd., Korea (Rafique Medicine, College Road, Inshurdi, Pabna)	a) **Pro-Vac NDK Vaccine** Each 0.5 ml/dose Contain Attenuated Newcastle Disease virus 40%	For the active immunization against Newcastle Disease.	**Contraindications:** do not administer this product to the following ones: those with fever or serious nutritional disorder. Those with infectious disease, parasite infection, or stress. Those with weakened immunity due to mold or bacterial toxin.Those with shock or hypersensitiveness to this vaccine. **Side-effects:** Those administered with this product may show the side effects such as anorexia, vomiting, skin rash, convulsion and etc. In this case, it is recommended to perform enough massage and administer an epinephrine, according to the consult with veterinarians.	Korea	Abyjgv`b Kiv †h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **Pro-Vac AB Vaccine (Anthrax Blackleg Combine Live Vaccine)** Each dose (2ml/Dose) Contains : Anthrax (Stern strain) Solution Suspended in 50% Glycerin 47.5% Anthrax (Stern Strain) Spore Count ≥ 0.8 X 10^7CFU + Atienuated Black Leg Culture Solution 47.5% + Blackleg Spore Count ≥ 2.0 X 10^6CFU	Prevention of anthrax disease and Black Leg at the same time.	**Contraindications:** Do not administer this product to any anial with shock and hypersensitivity to this product. **Side effects:** Those administered with this product may show hypersensitive reaction i.e. anorexia, vomiting, skin rash, despondency, convulsions and others. As this case requires to massage or administer epinephrine, according to the veterinarian's instruction.	Korea	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj	
	Komipharm International Co. Ltd., Korea (Rafique Medicine, College Road, Inshurdi, Pabna)	c) **Linco 4.4 Powder** Lincomycin Hydrchloride USP 44 gm/Kg **(Antibiotic)**	Lincomycin is an antibiotic produced from streptomyces Lincolnensis and effects on gram positive bacillus and gram negative bacillus that has similar antibacterial spectrum as microcline antibiotics and especially on anerobic bacterium.	**Contraindications:** Do not use on animal had shock and hypersensitive reactios, hypathopathy and renal failure. Do not use in combination with penicillin group, Cephalosporin and Quinolone Group. **Side effects:** Lincomycin was toxic in mice and rats when administered per enterally and was practically non toxic after oral administration. Lincomycin was toxic to rabbits by all routes of administration.	Korea	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv †h‡Z cv‡i	c‡qvRb †bB wea|q Av‡e`b bvgÄyi Kiv nj	

		d) **Tydohexine Powder** Doxycycline Hyclate 200 gm + Tylosing Tartrate 100 gm + Bromhexine HCl (as Bromhexine) 20 gm/Kg	For the prevention and treatment of infectious disease, especially digestive and respiratory diseas, causative of pathogens susceptible to Tylosing and Doxycycline. **Calf:** Treatment of Pleuropneumonia, Staphhylococcosis, Streptococcosis, Mycolplasma **Chicken:** Treatment of CRD, CCRD, ILT, IT and causative of Mycoplasma, Haemophilus, Staphylococcosis, Streptococccsis.	**Contraindications:** Do not administer this product to the following ones: those with history of shock and hypersensitive reaction. Those with hepatopathy and renal failure. Do not use in combination with penicillin group, Cephalosporin and Quinoline Group. **Side effects:** Those administered with this product may show hypersensitive reaction i.e. anorexia, vomiting, skin rash despondency, convulsions and others. As this case requires to massge or administer epinephrine.	Korea	*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Ki‡Z cv‡i |*	*c‡qvRb †bB wea‡q Av‡e`b bvgÄyi Ki‡j nj |*
12.	Eli Lilly and Company Limited, Fleming Road, Speke, Liverpool L24 9LN. UK Under manufacturer company Lusomedicamenta-Sociedade Tecnica Farmaceutica, S.A. Estrade Consiglieri Pedroso, n.69/B, Queluz De Baixo, 2730-055 Baracarena, Portugal. Arifs (Bangladesh) Ltd Dhaka.	a) **Actifucin Spray** Enilconazole 150 mg/100ml emulsion	Environmental disinfection and prevention of infestations by dermatophyte fungi (ringworm in dogs, cats, rabbits, horses and cattle).	Contraindications: None Side-effects: None **Special Warnins:** Symptoms of poisoning: Dermatitis, severe eye irritation, vomiting, diarrhea, salivation, lachrymation, tremors.	Spain & Portugal.	*Abyjgv`b Ki‡Z †h‡Z cv‡i |*	*Abyjgv`b Ki‡j nj |*

2.6 Proposed Product for Import (Medical Devices Others)

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
01.	Shandong Weigao Group Medical Polymer Co., Ltd., China (Hospicare (Bd) Ltd.)	a) **Disposable Blood Transfusion Set** Disposible Blood Transfusion Set	It is used in clinical for blood transfusion.	**Contraindication:** None **Side Effects:** None.	China	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
02.	Sahnill Medical Instruments Co. Ltd., China (Hospicare (Bd) Ltd.	a) **Foley Catheter** Foley Catheter	Sterile tube inserted into the bladder to drain urine	**Contraindication:** None **Side Effects:** None.	China	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
03.	Anhul Tiankang Medical Products Co., Ltd., China (Charka Enterprise)	a) **Blood Transfusion Set with Needle** Blood Transfusion Set with Needle	It is use for blood transfusion.	**Contraindication:** None **Side Effects:** It may cause hypothermia especially in weak patients.	China	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
04.	Beijing Richen Force Science & Technology Co., Ltd. China (JAK International)	a) **Urea (13C) Breath Test Kit** Eatch kit contains: 5gm granules containing 75mg Urea (^{13}C) packed in high density polyethylene plastic bottle, Two breath collection bags, one registration card, two self adhesive sample labels and instruction.	Diagnosis of stomach detects *Halicobator Pylori* infection.	**Contraindications:** It is forbidden to use Heliforece for any subject allergic to one or more than one of its components. **Side-effects:** There is no side effect or adverse reaction has been reported up to know.	China	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbviK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-Kvgvi 61 Zg mfvi wm×vš	mfvi wm×vš
5	Bioject Medical Technologies Incorporated, USA (Authorized distributor: iHealthNet Bangladesh Limited)	a) **Biojector 2000 (B2000) device with needle-free syringes, parts cylinder and vial adapter** Biojector 2000 (B2000) device with needle-free syringes and parts cylinder	To be used to inject medication using needle-free syringe on IM, SC, ID almost without any pain.	**Contraindication & Side effects:** None found. To be used by trained personnel only.	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **Zetajet device with needle-free syringes** Zetajet device with needle-free syringes	To be used to inject medication using needle-free syringe on IM, SC almost without any pain.	**Contraindication & Side effects:** None found. To be used by trained personnel only.	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
06.	Shailesh Surgical, India (ARK International)	a) **Urine Collection/Drainage Bag-Adult 2000ml** Urine Collection Bag	To be used for as device for urine drainage system during urine collection	Contraindications: None Side effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **Volume Control IV Administration Set [Measured Volume Set]** IV Administration Set	To be used for as device for Transfusion of Fluid	Contraindication: None Side effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
		c) **Umbilical Cord Clamp** Umbilical Cord Clamp	Clamping the umbilical cord of newly born baby immediately after the birth.	Contraindication: None Side effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		d) **Blood Transfusion Set** Blood Transfusion Set	To be used as device for blood transfusion.	Contraindication: None Side effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		e) **Chest Drainage Catheter** Chest Drainage Catheter	Thoracic drainage Catheters are most suitable for pst operative drainage after cardiac thoracic and thoracic surgery.	Contraindication: None Side effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		f) **Ryl’es Tube** Ryl’es Tube	To be used as a device for naso-gastro introduction for nutritional pupose or aspiration of intestinal secretions.	Contraindication: None Side effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
6.	Changzhou Medical Bioengineering Co. Ltd., China (Mohota Trade International)	a) **Disposable Skin Stapler** Disposable Skin Stapler	Application for skin suture in operation room and emergency.	**Contraindications:** Disposable skin stapler is not suitable for the incision of the operation, which is required for docimasia after operation. It is prohibited to use the disposable skin stapler when the distance netween skin incision and interior tissue is less than 5mm. It is prohibited to use when the package is broken. **Side effects:** None	China	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
07.	Camurus AB, Sweden (Local agent: Radiant Export Import Enterprise, Uttara, Dhaka).	**a) EPISIL Oral Liquid 10ml Episil® is a medical device constituting an oromucosal liquid in a multidose container and is without active pharmaceutical ingredient. The orormucosal liquid transforms *in situ* to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid. Episile has a mechanical action indicated for the management of pain and relief of pain, by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies, including Oral Mucositis! Stomatitis (may be caused by chemotherapy or radiotherapy). The oromucosal liquid is made of six ingredients including glycerol dioleate, soy phosphatidyl choline, ethanol, propylene glycol, polysorbate 80, and peppermint oil, which are all GRAS for the intended use.** Glycerol dioleate 514.50mg+ Soya phosphatidylcholine 277.00mg+ Ethanol 94.00mg + Propylene glycol 47.00 mg+ Polysorbate 80 7.10mg+ Peppermint oil 0.50mg/ml	This is an oral liquid which forms a protective mechanical barrier that adheres to oral mucosal surfaces providing sustained relief of oral pain associated with oral lesions, including mucositis.	**Contraindication**: Should not use Episil if any patients have allergic (hypersensitive) to any of the ingredients. Episil contains purified soybeam oil (lecithin), if any patients have allergic to spy do not use this product. **Side effects:** None known	Sweden	Abyjgv`b Kiv ‡hZ cv‡i	Abyjgv`b Kiv nj|

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
08	Depro Medical Device, Italy Local agent: Radiant Export Import Enterprise. Uttara, Dhaka.	**a) Surgical Mesh, Plain** Monofilament Polypropylene Non-absorbable Surgical Mesh (Plain)	Indicated for the treatment of surgical repair of defects in the abdominal wall and inguinal region.	**Contraindication:** There are no known contraindications if the correct surgical technique is applied when positioning the mesh. **Side effects:** Possible adverse reactions include intestinal obstruction, adhesion, and expulsion, the formation of fistula, relapses, seroma, haematoma and inflammation.	Italy	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) Surgical Mesh, Composite Monofilament Polypropylene Non-absorbable Surgical Mesh (Composite)	Indicated for the treatment of surgical repair of defects in the abdominal wall and inguinal region for reinforcement & prevent adhesion formation.	**Contraindication:** There are no known contraindications if the correct surgical technique is applied when positioning the mesh. **Side effects:** Possible adverse reactions include intestinal obstruction, adhesion, and expulsion, the formation of fistula, relapses, seroma, haematoma and inflammation.	Italy	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
	Depro Medical Device, Italy Local agent: Radiant Export Import Enterprise. Uttara, Dhaka.	**c) Prosthetic System (Ingyne for female)** Uro-Gynecological Prosthetic System with introducer (Monofilament Polypropylene Non-absorbable Macroporous Mesh)	Indicated for the treatment of female stress urinary incontinence, prolapse and for the reinforcement of the pelvic floor.	**Contraindication:** There are no known contraindications if the correct surgical technique is applied when positioning the mesh. **Side effects:** Possible adverse reactions include intestinal obstruction, adhesion, and expulsion, the formation of fistula, relapses, seroma, haematoma and inflammation.	Italy	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
		d) Prosthetic System (Andromesh for male) Uro-Gynecological Prosthetic System with introducer (Monofilament Polypropylene Non-absorbable Macroporous Mesh)	Indicated for the treatment of male stress urinary incontinence.	**Contraindications:** There are no known contraindications if the correct surgical technique is applied when positioning the mesh. **Side effects:** Possible adverse reactions include intestinal obstruction, adhesion, and expulsion, the formation of fistula, relapses, seroma, haematoma and inflammation.	Italy	Abyjgv`b Kiv ‡hŧZ cv‡i	Abyjgv`b Kiv nj	
09	Synimed, France Local agent: Radiant Export Import Enterprise. Uttara, Dhaka.	**a) Synicem 1; Surgical Bone Cement** Acrylic Bone Cement 40g Powder (radio-opaque) with 20ml liquid Kit **(For manual application)**	Used for bone cementations and fixations	**Contraindications:** None **Side effects:** It does not produce any toxic effects regarding the reproductive and embryo/fetus function. It is neither potentially carcinogenic nor mutagenic.	France	Abyjgv`b Kiv ‡hŧZ cv‡i	Abyjgv`b Kiv nj	
		b) Synicem 1G; Surgical Bone Cement Acrylic Bone Cement with Gentamycin 40g Powder (radio-opaque) with 20ml liquid Kit **(For manual application)**	Used for bone cementations and fixations	**Contraindications:** Should not recommend for patients with hypersensitivity to Gentamycin or suffering from renal failure. **Side effects:** It does not produce any toxic effects regarding the reproductive and embryo/fetus function. It is neither potentially carcinogenic nor mutagenic.	Fance	Abyjgv`b Kiv ‡hŧZ cv‡i	Abyjgv`b Kiv nj	
		c) Synicem 3; Surgical Bone Cement Acrylic Bone Cement 60gm Powder (radio-opaque) with 30ml liquid Kit **(For syringe application)**	Used for bone cementations and fixations	**Contraindications:** None **Side effects:** It does not produce any toxic effects regarding the reproductive and embryo/fetus function. It is neither potentially carcinogenic nor mutagenic.	France	Abyjgv`b Kiv ‡hŧZ cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Synimed, France Local agent: Radiant Export Import Enterprise. Uttara, Dhaka.	**d) Synicem 3G; Surgical Bone Cement** Acrylic Bone Cement with Gentamycin 60gm Powder (radio-opaque) with 30ml liquid Kit **(For syringe application)**	Used for bone cementations and fixations	Contraindication: Should not recommend for patients with hypersensitivity to Gentamycin or suffering from renal failure. Side effect: It does not produce any toxic effects regarding the reproductive and embryo/fetus function. It is neither potentially carcinogenic nor mutagenic.	France	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
10	**C-K Dental Ind. Co., Ltd., Korea** **(ISP International, Dhaka)**	**a) C-K Jeet Brand Disposable Dental Needles** Disposable Dental Syringe Needles	Delivery of anesthetic materials.	Contraindications: None Side Effects: None	Korea	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
11	BLUE MEDICAL DEVICES BV Steenovenweg 19 5708 HN Helmond The Netherlands (DEVICE SOLUTIONS, Dhaka, Bangladesh)	**a) PTCA Dilatation Catheter Balloon** PTCA Dilatation Catheter Balloon	Indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial reperfusion.	**Contraindications:** the use of the balloon is contraindicated for: - Unprotected left main coronary artery - Coronary artery spasm in the absence of a significant stenosisi. **Side Effects:** The following complications, among others, can occur by performing of a Percutaneous Transluminal Coronary Angioplasty • Death. • Acute myocardial infarction. • Total occlusion of the coronary artery or bypass graft. • Coronary vessel dissection, perforation, rupture or injury. • Restenosis of the dilated vessel. • Haemorhage or haematoma. • Unstable angina. • Arrhythmias, including ventricular fibrillation. • Drug reactions, allergic reaction to contrast medium. • Hypo/hypertension. • Infection. • Coronary artery spasm. • Arteriovenous fistula. Embolism.	EC Certificate and FSC (Netherland) applied	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvMvwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwmbK`vj mve-KvgvUi 61 Zg mfvi wm×vš	mfvi wm×vš
12	Novo Nordisk A/S Needle Manufacturing & Sourcing Stenager Alle, 9800 Hjorring Denmark (Novo Nordisk Pharma (Pvt.) Ltd, Bangladesh)	a) **NovoTwist ®** **32G(0.23/0.25x5mm)** Needle hypodermic	Needle is indicated for use with Novo Nordisk disposable pen injector devices and Novo Nordisk durable pen injectors with a bayonet coupling for the subcutaneous injection of drugs, including insulin, somatropin and Liraglutide products	Contraindication: None Side Effects: None	Denmark	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
13	Nipro Medical Industries Ltd., Japan (Novo Nordisk Pharma (Pvt.) Ltd, Bangladesh)	a) **NovoFine ®** **31G (0.25x6mm)** Needle hypodermic	Needle is indicated for use with Novo Nordisk drug delivery systems for injection.	Contraindication: None Side Effects: None	Denmark	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
		b) **NovoFine ®** **32G Tip etw (0.23/0.25x6mm)** Needle hypodermic	Needle is indicated for use with Novo Nordisk drug delivery systems for injection.	Contraindication: None Side Effects: None	Denmark	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK¨vj mve-Kvgv‡Ui 61 Zg mfvi wm×vš	mfvi wm×vš
14	Boston Scientific Corporation, USA (Vastech Ltd.)	**a) Maverick2 Monorail 12/2.0 PTCA Dilation Catheter** Dilation Catheter	It is indicated for ballon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. It is also indicated for the post delivery expansion of ballon expandable stents.	**Contraindications:** - Unprotected left main coronary artery. - Coronary artery spasm in the absence of a significant stenosis. **Side Effects:** Possible side effects include but are not limited to the following: death, acute myocardial infarction, total occulusion of the coronary artery or bypass graft, coronary vessel dissection, perforation, rupture or injury, restenosis of the dilated vessel, hemorrhage or hematoma, angina or unstable angina, arrhythmias, including, ventricular fibrillation, drug reactions, allergic reaction to contrast media, hypo/hypertension, infection, coronary artery spasm, arteriovenous fistula, embolism, stroke, cardiovascular accident, transient ischemic attack, myocardial ischemic, pseudoanyreusm(at site of catheter insertion), cardiac tamponade, renal failure, coronary aneurysm, vessel trauma requiring surgical repair or intervention, cardiogenic shock, coronary artery bypass graft surgery.	USFDA	Abyhvqx `b Kiv ‡hZ cv‡i	Abyhvqx `b Kiv nj|

bs	c¯ZKvi‡Ki bvg	JI‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contraindication & Side-effect	FSC/CPP	‡UKwbK`vj mve-KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
	Boston Scientific Corporation, USA (Vastech Ltd.)	**b) ChoIce Guide Wires** **[H74912116011; 0.014", 300cm, Floppy straight/3cm]** ChoIce Guide Wires	It is intended to facilitate the placement of ballon dilation catheters or other therapeutic devices during PTCA or other intravascular interventional procedures. It is not intended for use in cerebral vasculature.	**Contraindications:** Not known **Side Effects:** Potential adverse events which may result from the use of the device include but are not limited to: allergic reaction to contrast media, embolism, Hemorrhage or hematoma, infection, local infection, systemic infection, pain at the access site, pseudoaneurysm, vascular thrombus, vessel spasm, vessel trauma (dissection, perforation, rupture or injury) In addition, when used for PTCA: abrupt closure, angina or unstable angina, arrhythmias, cardiac tamponade/pericardial effusion, contrast induced renal insufficiency or renal failure, death, Myocardial infarction or ischemia, stroke/cerebral vascular accident..	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
15	B Braun Melsungen AG, Germany [Asia Pacific Medicals Ltd.]	**a) Coroflex ISAR** Sirolimus eluting polimer free Coronary Stent system	Disposable use for coronary blockage.	Contraindication: None Side Effects: None	EC design examination Certificate & Germany	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
16	Sichuan Nigale Biomedical Co. Ltd., China (Swadesh)	**a) Disposable Blood Cell Apheresis Set** Disposable Blood Cell Apheresis Set	With ACD-A solution used in Blood Cell separator machine	Contraindication: None Side Effects: None	China	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	
17	Sutures India Pvt. Ltd., India (A.K. International)	**a) Foley Catheter** Foley Catheter	Sterile tube inserted into the bladder to drain urine	Contraindication: None Side Effects: None	India	Abyjgv`b Kiv ‡h‡Z cv‡i	Abyjgv`b Kiv nj	

2.7| ‡UKwbK¨vj mve-Kwgwdi 60 Zg mfvi wm×vš †gvZv‡eK cÖgj¤vq‡bi wbwg‡Ë Dc¯vcb Kiv nj |

bs	c¯ZKvi‡Ki bvg	Jl‡ai bvg I †RvlbwiK bvg	wb‡`kbv	Contra-indication & Side-effect	Status (New Molecule/ Existing)	Av‡e`bKvix c`Ë USFDA or MHRA Ref.	‡UKwbK¨vj mve-Kwgwdi 61 Zg mfvi wm×vš	mfvi wm×vš
1.	Beximco Pharma	a) Dextromethorphan Hydrobromide 15 mg Oral Thin Film Dextromethorphan Hydrobromide BP 15 mg **Antitussive**	Dextromethorphan is used to relieve dry cough caused by a cold, flu or other conditions.	**Contraindications:** Hypersensitivity to Dextromethorphan or any of the other constituents. **Side Effdects**: Adverse effects with this appear to be rare and may include dizziness and GI disturbances.	10mg/5ml Syrup		c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj |
		b) Diphenhydramine HCl 25mg Oral Thin Film Diphenhydramine HCl BP 25mg **Antihistamine**	It is indicated for the treatment of followings: Seasonal, perennial, vasomotor rhinitis, Urticaria, angioneurotic oedema, anaphylaxis Pruiritic conditions, Premedication for emesis and motion sickness, Miscellaneous like Ménière's disease and parkinsonism,An aid to the relief of temporary sleep disturbance.	**Contraindication:** Patients with known hypersensitivity to Diphenhydramine or any components of the product. Care should be taken in administration during pregnancy. **Side Effects:** Side effect includes sedation, dizziness, tinnitus, fatigue, ataxia, blurred vision, diplopia, euphoria, and epigastric discomfort.	50 mg Tablet	USFDA	Abyjgv`b Kiv ‡h‡Z cv‡i |	Abyjgv`b Kiv nj
2	Incepta Pharmaceuticals Ltd., Jirabo, Ashulia, Dhaka	a) Sodium Fluoride 50mg/100gm Gel Sodium Fluoride USP 50mg/100gm	As a supplemental source of Fluoride, it has been established that ingestion of fluoridated drinking water (1 ppm F) during the period of tooth development results in significant decrease in the incidence of dental caries.1 Sodium Fluoride Drops were developed to provide systemic Fluoride for use as a supplement in pediatric patients from 6 months to age 3 and older, living in areas where the drinking water Fluoride level does not exceed 0.6 ppm F.	**Contraindications:** Do not use in areas where drinking water exceeds 0.6 ppm F. Do not administer to pediatric patients less than 6 months old. **Side effects:** Allergic rash and other idiosyncrasies have been rarely reported.	New	USFDA	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv †h‡Z cv‡i |	c‡qvRb †bB weavq Av‡e`b bvgÄyi Kiv nj |

3|

3.1 Mifepriston 200mg Tablet I Misopristol 200mcg Tablet Gi combipack wn‡m‡e safety I efficacy Gi m¤ú‡K gZvgZ c`vb cm‡½t

Mifepriston 200mg Tablet c`wU wWmwm-241Zg mfvq Abyôgvw`Z Ges Misopristol 200mcg Tablet c`wU wWmwm-210Zg mfvq Abyôgvw`Z|

‡gmvm wRmKv dvgwmDwUK¨vjm wjt Gi D³ c` `ßvwU wfb w÷‡c GKwU c¨v‡K‡U K¤c¨vK (Kit) wn‡m‡e ÒTermination of Pregnancy up to 63 days" indication c`vb K‡i evRviRvZ Kivi Rb¨ Av‡e`b K‡ib| D³ Av‡e`‡bi cwi‡cw¶‡Z `ßvRb we‡klÁ (1) Aa¨vcK mv‡jnv †eMg †Pš—vix, †Pqvig¨vb, Aem GÛ MvBbx wefvM, e½eÜz‡kL gyRe †gvW‡Kj wekwe`¨vjq Ges (2) c‡dmi †di‡`Šmx Bmjvg, wefvMxq c`vb, Aem GÛ MvBbx wefvM, XvKv †gvW‡Kj K‡jR I nvmcvZvj Gi gZvgZ I myzwik MnY Kiv nq| Zviv Df‡qB c` `ßvwU wfb w÷‡c GKwU c¨v‡K‡U K¤c¨vK (Kit) wn‡m‡e ÒTermination of Pregnancy up to 63 days" indication c`vb K‡i Prescription Item wn‡m‡e evRviRvZ Kivi Abyôgv`b c`vb Kiv †h‡Z cv‡i e‡j gZvgZ c`vb K‡ib|

পদ দুইটির কম্বিনেশন সংক্রান্ত †idv‡iÝ BNF-65th Edition Ges WHO Gi Safe Abortion: technical and policy guidance for health systems (2nd Edition) Gi AwU‡K‡j D‡jL Av‡Q| D³ †idv‡iÝ Ges we‡klÁ gZvg‡Zi wfwË‡Z D³ c` `ßvwU K¤c¨vK wn‡m‡e evRviRvZ Kivi Abyôgv`b c`vb Kiv nq| c` `ßvwUi K¤c¨vKwU eZgv‡b 02 (`ß) wU cwZôvb evRviRvZ Ki‡Q| FDA Abjv‡Bb fvmb-G c` `ßvwUi K¤c¨vK wn‡m‡e e¨envi‡i Serious side effects i‡q‡Q e‡j D‡jwLZ |

GgZve¯vq, D³ c` `ßvwU K¤c¨vK wn‡m‡e e¨envi‡i Rb¯v‡¯¨i wbivcËv I KvhKwiZv cÖgyj¨vq‡Yi wbwg‡Ë mfvq Dc¯vcb Kiv nq|

‡UKwbK¨vjm mve-KwgwUi Av‡jvPbv t Jla ckvmb Awa`ß‡ii cwiPvjK (Pt`vt) Rbve †gvt †Mvjvg wKewiqv mfv‡K AewnZ K‡ib †h, Mifepriston 200mg Tablet I Misopristol 200mcg Tablet c` `ßvwU c„K c„Kfv‡e Jla ckvmb Awa`ß‡i KZ„K Abyôgvw`Z| c` `ßvwUi K¤c¨vK wbivc` n‡e wKbv G wel‡q wbwðZ nIqv c‡qvRb; G j‡¶¨B KwgwUi gZvg‡Zi Rb¨ Dc¯vcb Kiv n‡q‡Q|

G cm‡½, c‡dmi BmgvBj †nv‡mb e‡jb, Medical Abortion Gi c×wZ wn‡m‡e Mifepriston 200mg Tablet I Misopristol 200mcg Tablet c` `ßvwU †hŠ_ e¨envi WHO I FDA KZ„K Abyôgvw`Z| GwU evsjv‡`k miKv‡ii Family Planning Programme I Aš—f³ Kiv n‡q‡Q| mKj Jl‡ai Kg‡ekx cvk প্রতিক্রিয়া থাকে। K¤c¨vKwUi e¨envi‡ii DcKwiZv we‡ePbv K‡i Gi Abyôgv`b envj ivLv †h‡Z cv‡i|

Jla ckvmb Awa`ß‡ii cwiPvjK (Pt`vt) Rbve †gvt †Mvjvg wKewiqv D‡jL K‡ib, JlawU ïaygvÎ we‡klÁ wPwKrm‡Ki civgk Abyôvqx Zvi ZZvea‡b e¨envi Ki‡Z n‡e Ges D³ welqwU †j‡ej KvU‡b D‡jL _vK‡Z n‡e|

‡UKwbK¨vjm mve-KwgwUi myzwik t Mifepriston 200mg Tablet I Misopristol 200mcg Tablet c` `ßvwU wfb wfb ÷x‡c K¤c¨vK wn‡m‡e e¨envi‡ii Abyôgv`b envj ivLv †h‡Z cv‡i| D³ K¤c¨vK ïaygvÎ we‡klÁ wPwKrm‡Ki cZ¨¶ ZËvea‡b e¨envi Ki‡Z n‡e; Gi¦c wb‡`kbv †j‡ej, KvU‡b D‡jL _vK‡Z n‡e|

‡UKwbK¨vj mve-KwgwUi myzwik mfvq we¯wiZ Av‡jvPbv K‡i m`m¨MY †UKwbK¨vj mve-KwgwUi myzwik Abyôgv`‡bi welq GKgZ cKvk K‡ib|

mfvi wm×vš—t Mifepriston 200mg Tablet I Misopristol 200mcg Tablet c` `ßvwU wfb wfb ÷x‡c K¤c¨vK wn‡m‡e e¨envi‡ii Abyôgv`b Kiv nj Ges G K¤c¨vK ïaygvÎ we‡klÁ wPwKrm‡Ki cZ¨¶ ZËvea‡b e¨envi Ki‡Z n‡e; Gi¦c wb‡`kbv †j‡ej, KvU‡b D‡jL _vK‡Z n‡e|

3.2 Pioglitazone, Rosiglitazone, Gatifloxacin (except eye drops), Tegaserod I Sibutramine ‡R‡bwi‡Ki †iwR‡÷kb m¤ú‡K wm×vš— MnY cm‡½t

we‡ki wewfb ‡`‡k Pioglitazone, Rosiglitazone, Flupenthixol-Melitracen, Gatifloxacin (Except eye drops) Tegaserod & Sibutramine ‡gvU 06(Qq)wU ‡R‡bwi‡Ki Jla e¨envi‡i মারাত্মক বিরূপ প্রতিক্রিয়া পরিলক্ষিত হওয়ায় ঔষধগুলো গত ১২-03-2014 Zwi‡L Abyôv‡Z Adverse Drug Reaction Advisory Committee (ADRAC)-Gi mfvq D³ Jla¸‡jvi welq gZvgZ

Mn‡Yi j‡¶¨ Dc¯vcb Kiv nq| D³ mfvq we¯wiZ Av‡jvPbv K‡i Rb¯v‡¯¨i wbivcËvi K_v we‡ePbv K‡i Jla¸‡jv evsjv‡`‡k ewZj/wbwl× Ges Gme †R‡bwi‡Ki †Kvb KvRvgvj hv‡Z Avi bZzbfv‡e †Kvb cwZôvb Avg`wb Ki‡Z bv cv‡i Zvi c‡qvRbxq e¨e¯nv Mn‡Yi Rb¨ jvB‡mwÝs KZ„¶ (WvMm) ‡K mycwik Kiv nq| D³ mycwi‡ki Av‡jv‡K jvB‡mwÝs A_wiwU (WvMm) KZ„K Pioglitazone, Rosiglitazone, Gatifloxacin (Except eye drops) Tegaserod & Sibutramine ‡gvU 05(cvuP)wU ‡R‡bwi‡Ki Jla Drcv`b I evRviRvZKiY ¯wMZ Kiv nq Ges evsjv‡`k Jla wkí mwgwZi Av‡e`‡bi cwi‡cw¶‡Z Flupenthixol-Melitracen-Gi Kw¤‡bkb c`wUi wel‡q cvß Z_¨-DcvË I WK‡gv›Um AwaKZi chv‡jvPbv/we‡klYcwK Pewš wm×vš MnY Kiv Rb¨ ADRAC-Gi cieZx mfvq Dc¯Z Kiv n‡e e‡j mswkó cwZôvbmgn‡K AewnZ Kiv nq| বিরূপ প্রতিক্রিয়ার জন্য উ³ c`mg‡ni wefb ‡`‡k ewZj/wbwl× Kivi weeiY wb‡g †` Iqv njt

SL no.	Generic Name	Indication	Reason	Status
1.	Pioglitazone	Antidiabetic	Increased risk of bladder cancer	1. Banned on 2011 in France and Germany. 2. It is available in USA and other part of Europe with warning. It is approved in BNF, MHRA with a black box safety warning.
2.	Rosiglitazone 2mg,4mg & 8mg Tablet	Antidiabetic	Cardiovascular disorder.	1. Banned in Newzeland on 2011 and in India on 2010. 2. USFDA reviewed the clinical trial of Rosiglitazone in 2007 and according to trial it is approved in November 2013.
3.	Gatifloxacin (Except Eye Drops)	Anti infective.	17 times higher risk of developing hyperglycemia.	1. Banned in India. 2. Gatifloxacin Solutions approved in USFDA but not in tablet form. It is not included in BNF & MHRA.
4.	Tegaserod 2mg & 6mg tablet.	Irritable bowel syndrom, Constipation	Increased risk of cardiovascular adverse events, including heart attack and stroke.	1. Banned in USA, India 2. Tegaserod Tablet is not approved in BNF, MHRA and USFDA.
5.	Sibutramin	Treatment of obesity	Reduces b.p. It causes cardiovascular risk	Banned in USA by USFDA

GgZve¯vq, Rb¯v‡¯¨i wbivcËvi Rb¨ Pioglitazone, Rosiglitazone, Gatifloxacin (Except eye drops) Tegaserod & Sibutramine ‡R‡bwi‡Ki Jla¸wji †iwR‡÷kb m¤ú‡K wm×vš Mn‡Yi Rb¨ mfvq Dc¯vcb Kiv nq|

‡UKwbK¨vj mve-KwgwUi Av‡jvPbv t Pioglitazone, Rosiglitazone, Gatifloxacin (Except eye drops) Tegaserod & Sibutramine ‡R‡bwi‡Ki †iwR‡÷kb m¤ú‡K wm×vš– Mn‡Yi Rb¨ mfvq Dc¯vcb Kiv n‡j, ‡gRi †Rbv‡ij iweDj †nv‡mb mfvi mfvcwZ g‡nv`‡qi wbKU Rvb‡Z Pvb †h, D³ Jla ¸‡jvi RxebNwUZ †Kvb বিরূপ প্রতিক্রিয়ার রিপোর্ট বাংলাদেশে Av‡Q wKbv| mfvcwZ g‡nv`q mfv‡K AewnZ K‡ib †h, GZwØl‡q wefb †gW‡Kj K‡j‡Ri Aa¨vcK e‡›`i mgš‡q MVZ Adverse Drug Reaction Advisory Committee (ADRAC) Gi MZ 12-03-2014 Zwi‡L AbyôZ GK wgwUsG Dc¯vcb Kiv n‡j D³ mfvq we¯wiZ Av‡jvPbv K‡i Rb¯v‡¯¨i wbivcËvi K_v we‡ePbv K‡i Ilya¸‡jv evsjv‡`‡k ewZj/wbwl× Ges Gme †R‡bwi‡Ki †Kvb KvRvgvj hv‡Z Avi bZzbfv‡e †Kvb cwZôvb Avg`wb Ki‡Z bv cv‡i Zvi c‡qvRbxq e¨e¯nv Mn‡Yi Rb¨ Jla ckvmb Awa`ßi/jvB‡mwÝs KZ„¶ (WvMm) eivei mycwik Kiv nq|

evsjv‡`k Jla wkí mwgwZi gnvmwPe Rbve Ave`y gy³w`i বলেন, বাংলাদেশে এই ড্রাগগুলোর কোন বিরূপ প্রতিক্রিয়ার wi‡cvU cvIqv hvqwb| D³ KwgwU ïaywefb Rvbv‡j cKvwkZ wi‡cv‡Ui Dci wfwË K‡i Jla¸‡jv gj¨vqb K‡i‡Q|

XvKv wek¦e`¨vj‡qi Aa¨vcK †mwjg ‡iRv e‡jb, GB Jla¸‡jvi Clinical Toxic Effect c„_exi wefb †`‡k cgvbZ| evsjv‡`k GB mKj WvM Gi wKwbK¨vj Uvqv‡ji †Kvb myeav we`¨gvb †bB|

‡gRi †Rbv‡ij iweDj ‡nv‡mb e‡jb †h, c¯vebv Abyhvqx †hmKj †`‡k Gmg¯ ড্রাগ এর বিরূপ প্রতিক্রিয়া পরিলক্ষিত n‡q‡Q, †m mKj †`‡k G¸‡jv wel‡q e¨e¯v MnY Kiv n‡q‡Q| evsjv‡`‡k বিরূপ প্রতিক্রিয়া †Kvb wi‡cvU cvIqv hvqwb weavq Gme Ww‡Mi †iwR‡÷kb ewZj Kiv †h§w³K n‡ebv| Pioglitazone I Rosiglitazone ‡R‡bwi‡Ki Ilya¸‡jv hLb BNF ‡_‡K Acmwiz Kiv n‡e Ges MHRA ev USFDA KZ„K.ewZj Kiv n‡e, ZLb G¸‡jvi †iwR‡÷kb ewZ‡ji welqwU ¸i‡Zi mv‡_ we‡ePbv Kiv †h‡Z cv‡i| Z‡e Gatifloxacin (Except eye drops) Tegaserod I Sibutramine ‡R‡bwi‡Ki ওষুধগুলোর অস্বাভাবিক পার্শ্বপ্রতিক্রিয়ার কথা বিবেচনা করে †iwR‡÷kb ewZj Kiv †h‡Z cv‡i e‡j wZwb gZ cKvk K‡ib|

c‡dmi BmgvBj †nv‡mb e‡jb, me Jl‡aiB Adverse Drug Effects i‡q‡Q| Jla wbqšY KwgwUi †UKwbK¨vj mve-KwgwU mvavibZ †h wfwË‡Z (USFDA ev UKMHRA KZ„K Abyhvqx`Z A_ev BNF-G Aš—f³) bZyb Jla gj¨vqb K‡i _v‡K, †mB Av‡jv‡KB †Kvb Jla ewZj Kivi myZwik Kiv mgxPb n‡e|

evsjv‡`k Jla wkí mwgwZi gnvmwPe Rbve Ave`yj gy³w`i e‡jb, †hme Wvqv‡ewUK †ivMxi Pioglitazone I Rosiglitazone ‡R‡bwi‡Ki Jla e¨envi‡i DcKwiZv Av‡Q Zv‡`i K_v we‡ePbv Ki‡Z n‡e| cwi_ex‡Z gvÎ `yB †`‡k e¨vÛ Kiv n‡q‡Q Aewkó A‡bK †`‡kB GBme Jla cPwjZ Av‡Q|

c‡dmi BmgvBj Av‡iv e‡jb, Pioglitazone I Rosiglitazone ‡R‡bwiKe¨envi Kvix A‡bK †ivMx i‡q‡Q| D³ Jla `yBwU †iwR‡÷kb ewZj Kivi c‡e Wvqv‡e‡Uvjv‡R we‡klÁ‡`i gZvgZ MnY Kiv †h‡Z cv‡i| GZØI‡q, mfvq e½eÜz‡kL gyRe †gvW‡Kj wekwe`¨vjq, XvKv †gvW‡Kj K‡jR I nvmcvZvj, evi‡Wg nvmcvZv‡ji Wvqwe‡Uvjv‡R we‡klÁ‡`i mgš‡q wZwb GKwU KwgwU MVb Kivi c¯ve K‡ib| Zvuic¯v‡ei mv‡_ Dcw¯Z m`m¨MY GKgZ cKvk K‡ib Ges KwgwUi gZvg‡Zi Dci wfwË K‡i Pioglitazone I Rosiglitazone ‡R‡bwi‡Ki Jl‡ai †iwR‡÷kb envj ev ewZj wel‡q wm×vš †bqv †h‡Z cv‡i e‡j mfvq Dcw¯Z m`m¨MY gZ cKvk K‡ib|

‡UKwbK¨vj mve-KwgwUi myZwik t Pioglitazone I Rosiglitazone ‡R‡bwi‡Ki Jl‡ai †iwR‡÷kb envj ev ewZj wel‡q wm×vš Mn‡Yi j‡¶¨ সভায় সর্বসম্মতিক্রমে wbgewYZ m`m¨‡`i mgš‡q GKwU KwgwU MVY Kivi c¯ve Kiv nqt

ক্রমিক নং	bvg I c`ex	
1	‡gRi †Rbv‡ij †gvt RvnvsMxi †nv‡mb gwjK, gnvcwiPvjK, Jla ckvmb Awa`ßi, XvKv|	mfvcwZ
2	‡gRi †Rbv‡ij †gvt iweDj ‡nv‡mb, Kbmvj‡U›U wdwRwkqvb ‡Rbv‡ij, evsjv‡`k AvgW †dv‡mm †gvW‡Kj mwf‡mm|	m`m¨
3	Aa¨vcK BmgvBj Lvb, Aa¨¶, XvKv †gvW‡Kj K‡jR I nvmcvZvj	m`m¨
4	Aa¨vcK dwi`DÏxb Avn‡g`, †Pqvig¨vb, G‡ÛvKvB‡bvjwR wefvM, e½eÜz‡kL gyRe †gvW‡Kj wekwe`¨vjq|	m`m¨
5	Aa¨vcK Rwjj Avbmvix, †Pqvig¨vb, G‡ÛvKvB‡bvjwR wefvM, XvKv †gvW‡Kj K‡jR I nvmcvZvj	m`m¨
6	Aa¨vcK dvi¤K cvVvb, G‡ÛvKvB‡bvjwR wefvM, evi‡Wg nvmcvZvj	m`m¨

এবং সর্বসম্মতিক্রমে Gatifloxacin (Except eye drops), Tegaserod & Sibutramine ‡R‡bwi‡Ki †iwR‡÷kb ewZj Kivi myZwik Kiv nq|

‡UKwbK¨vj mve-KwgwUi myZwik mfvq we¯wiZ Av‡jvPbv K‡i m`m¨MY †UKwbK¨vj mve-KwgwUi myZwik Abyhvqv`‡bi welq GKgZ cKvk K‡ib|

<u>mfvi wm×vš t</u> ‡UKwbK¨vj mve-KwgwUi myZwik Abyhvqv`b Kiv nj|

3.3| wewfb cwZôv‡bi Abyf‡j wbe©vZ wbgewYZ Jla¸‡jv ড্রাগ কন্ট্রোল কমিটি (ডিসিসি) কর্তৃক অনুমোদন সংক্রান্ত †idv‡iÝ LvR cvIqv hvq bvB| Jla¸‡jv Abyhvqv`‡bi welq (Post Approval) myZwik c`v‡bi Rb¨ Dc¯vcb Kiv n‡j ‡UKwbK¨vj mve KwgwU c`¸‡jv Abyhvqv`b Kiv †h‡Z cv‡i e‡j gZvgZ c`vb K‡ib|

K| Human Product:

Sl.	Generic Name with Strength	Dosage form	‡UKwbK¨vj mve KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
1.	Dextromethorphan 10 mg +	Syrup	Abyhvqv`b Kiv ‡h‡Z	Abyhvqv`b Kiv nj|

	Pseudoephedrine HCl 30 mg + Triprolidine HCl 1.25 mg/5ml		cv‡i|	
2.	Spironolactone USP 100mg Tablet	Tablet	Abyjgv`b Kiv ‡h‡Z cv‡i|	Abyjgv`b Kiv nj|

L| Veterinary Product:

Sl.	Generic Name with Strength	Dosage form	‡UKwbK¨vj mve KwgwUi 61 Zg mfvi wm×vš	mfvi wm×vš
1.	Procain Penicillin G USP 200000 IU + Dihydrostreptomycin Sulfate USP 250 mg + Dexamethasone USP 1 mg/ml (Vet)	Injection	Abyjgv`b Kiv ‡h‡Z cv‡i|	Abyjgv`b Kiv nj|
2.	Vitamin A Propionate BP 25,00,000 IU + Vitamin D3 BP 1000000 IU + Vitamin E Acetate USP 5 gm/100 ml (Vet)	Injection	Abyjgv`b Kiv ‡h‡Z cv‡i|	Abyjgv`b Kiv nj|
3.	Maduramycin Ammonium BP 1 gm/100 gm Powder (Vet)	Powder	Abyjgv`b Kiv ‡h‡Z cv‡i|	Abyjgv`b Kiv nj|
4.	Toltrazuril BP 2.5 gm/100 ml Solution (Vet)	Solution	Abyjgv`b Kiv ‡h‡Z cv‡i|	Abyjgv`b Kiv nj|
5.	Diclazuril BP 0.5 gm/100 gm Powder (Vet)	Powder	Abyjgv`b Kiv ‡h‡Z cv‡i|	Abyjgv`b Kiv nj|

3.4| wWwmwm Gi 242Zg mfvq G g‡g wm×vš MnxZ nq †h, Jla ckvmb Awa`ßi KZK.†iwR‡÷kb c`vbKZ. nvevj Jlamgn- Jla wbqšY KwgwU (wWwmwm)†Z gj¨vqY/mycwi‡ki Rb¨ Dc¯vcb Ki‡Z n‡e| D³ wm×v‡ši Av‡jv‡K nvevj Jla G¨vWfvBRvix KwgwU KZK.wefb mfvq mycwikKZ.wb¤ewYZ 70 (mËi)wU c` Abyjgv`‡bi mfvq Dc¯vcb Ki nqt

Sl. No	General Name	Generic Name with Strength & Dosage Form	Indication
1	Spirulina	Spirulina Cap 500mg	1. Immune Enhancement, 2. Protein Suppliment, 3. Anemia
2	Ginko Biloba	Ginko Biloba Cap. 60mg (Ginco Biloba Extract)	1. Cerebral insufficiency, 2. Memony deficit, 3. Poor Concentration
3	Ginseng	Ginseng Cap. 500mg (Panax Ginseng Extract)	1. Adaptogen & General tonic, 2. Aphrodistiac, 3. Increase athletic performance of endrance, 4. Enhancement of physical and mental capacity
4	Saw palmetto	Saw palmetto Cap. 160mg (Serenoa Repens Extract)	1. Benign prostatic Hyperplasia Stage 1 & 11
5	ST John's Wort	ST John's Wort Cap 300mg (Hypericum Perforatum Extrect)	1. Depressicn, 2. Obessive Compulsive disorder, 3. Fatigue
6	Evening Primrose Oil	Evening Primrose Oil Cap. 500mg (Oenothero Bicnnis (Extract)	1. Premenstrual Syndrome 2. Breast Pain
7	Chamomile Oral Spray	Chamomile Oral Spray (Chamonil Extract 41.58mg) + Pepperment oil 2.07mg+ Sage Oil 0.67mg +Anise Oil 0.78mg +pine needle oil 0.11mg+Bergamot 0.056mg +Eucalyptol 0.56mg+Methyl salicylate 0.11mg	1. Acute gingivitis, 2. Pain after tooth Extraction, 3. Inflammatony affections of the boccal and pharyngeal Cavity

Sl. No	General Name	Generic Name with Strength & Dosage Form	Indication
8	Silymarin	Silymarin Cap 70mg	1. Hepatitis & Jaundice, 2. Alcoholic & toxic Liver damage, 3. Hepatic Cirrhosis
9	Ginkgo Biloba	Ginkgo Biloba Tablet 40mg (Ginkgo Biloba Extract)	1. Cerebral insufficiency, 2. Memony deficit, 3. Poor Concentration
10	Spirulina	Spirulina Capsule 250mg	1. Immune Enhancement, 2. Protein Suppliment, 3. Anemia
11	Spirulina	Spirulina Cap. 450mg	1. Immune Enhancement, 2. Protein Suppliment, 3. Anemia
12	Spirulina	Spirulina Powder 250mg	1. Immune Enhancement, 2. Protein Suppliment, 3. Anemia
13	Silymarin	Milk Thistle Cap. 500mg	1. Hepatitis & Jaundicl, 2. Alcoholic and toxic Liver damage, 3. Hepatic Cirrhosis
14	Saw Palmetto	Saw Palmetto Cap 500mg (Senenoa repens)	1. Prostate Complaints, 2. Iraitable bladder
15	Pumpkin	Pumpkin Cap 500mg (Cucurbita Pcpo)	1. Prostate Complaints, 2. Irritable bladder
16	St. John's Wort	St. John's Wort Cap 500mg (Hepericem Pertoratum)	1. Depression, 2. Obessive Compolsive disorder, 3. Fatigue
17	Garlic	Garlic Cap 300mg (Alliom Sativam)	1. Hypertension, 2. Arterioselerosis
18	Green Tea	Green Tea Dispersible Tablet 100mg (Camellia Sinensis)	1. Reduce risk of Cardiovascular disease, 2. Decreare Serum lipid Concentration
19	Ispaghula	Ispaghula Husk Powder 3.5gm (Plantago Ovata)	1. Constipation, 2. Haemorrhoids
20	Black Cohosh	Black Cohosh Cap. 40mg (Cimicifuga Racemosa)	1. Premenstrual Syndrome, 2. Climacteric Complaints
21	Echinacea	Ecninacea Pallida Capsule 450mg	1. Fever, 2. Cold
22	Marigold	Marigold (Ointment) 4% (Calendulla officinalis)	1. Inflammation of the mouth & Pharynx, 2. Wounds & Burns
23	Clove Oil	Clove (Liquid) 14% v/w (Syzygium aromaticum)	1. Dental Analgesic, 2. Inflammation of the mouths & Pharynx
24	Valerian	Valerian Cap 450mg	1. Insomnia, 2. Nervousness
25	Arnica	Arnica flower Ointment 15% (Amica montana Extract)	1. Rheumatics, 2. Inflammation of the Skin
26	Stevia	Stevia Tablet 500mg (Stevia rebauliana)	1. Used as natural Sweetener
27	Echinacea	Echinacea Cap. 400mg	1. Bronchitis, 2. Colds, 3. Cough, 4. Fever, 5. Sore Throat, 6. Boosts Immune System
28	Pepperment	Pepperment Oil Cap 0.2ml (187mg)	1. Appetite Ioss, 2. Bronchitis, 3. Colds, 4. Cough, 5. Fever, 6. Liver and gallbladder Problems, 7. Sore Throat
29	Omega	Omega 3 fish oil (EPA & DHA) 500mg Capsule	1. Hypertriglyeridemia, 2. For loweraig blood pressue, 3. For preventing restanosis, 4. For allveiting the Symptoms of rheumatoid asthritis and ulcerative colitis, 5. Prevent relapse in Crohn's disease
30	Coenzyme Q 10	Coenzyme Q 10 50mg Cap	1. Supplimental CoQ10 have cardioprotective, Cytoprotective and neuroprotective activities, 2. High cholesterol level, 3. Mascular dystrophy and Immune dysfunction

Sl. No	General Name	Generic Name with Strength & Dosage Form	Indication
31	Coenzyme Q 10	Coenzyme Q 10 100mg Cap	1. Supplimental CoQ10 have cardioprotective, Cytoprotective and neuroprotective activities, 2. High cholesterol level, 3. Mascular dystrophy and Immune dysfunction
32	Probiotic Preparation	Probiotic Preparation Cap (Lactobacillus acidophilus) (eqv. to 2 billion), 13.30mg Bifidubacterim Bifidum (eqv. to 1 billion), Lactobacillus bulgaricus (eqv. to 1 billion) Fructo 0legosaecharides 100mg	1. Probiotics have antimicrobial Immunomodulatory, antidiarrheal antiallergenic and anti oxidant activities, 2. Rotavirus diarrhea, antibiotic associated diarrhea, clostridiom difficile diarrhea and Traveler's diarrhea
33	Dong Quai	Dong Quai (Angelica Sinesis) Extract 530mg Cap	1. Treat memstrual Problems eg PMS., 2. Relieve menopausal Symptorns eg. hot flashes
34	Garlic Oil	Garlic Oil 10mg Cap (Garlic Oil Concentrates) (Allium Sativum Extract)	1. High blocl pressure (mild), 2. High cholesterol, 3. Hyper Lipidemia, 4. Atherosclerosis
35	Andrographis	Andrographis Cap 200mg (Andrcgraphis 200mg Stanclarized Extract)	1. Andrographes is used for the treatment of common cold, influenza etc
36	Chaste trce	Chaste trce Standardized Extrat 20mg Cap	1. Dysmenorrhea, 2. Hyperprolactinemia and corpus luteum insufficyency 3. premenstrual Syndrome (PMS.)
37	Green Tea	Green Tea (Camellia Sinensis) Extract 61mg effervescent Tab (EGCG eqv. to 50mg)	1. Reduces risks of Atherosclerosis, 2. Modulation of Plasma anti-oxidant capacity,3 Decrease Serum lipid Oncentration
38	Green tea	Green tea (Camellia Sinensis) Extract 30.5mg instant Powder for drinks (EGCG eqv. to 25mg)	1. Reduces risks of Atherosclerosis, 2. Cardiovascular disease, 3. Myocardial infaraction, 4. Modulaticn of plasma antioxident capacity, 5. Decrease Serum lipid Concentration
39	Probiotics	Probiotics Lactobacillus acidophilus Capsle 66.65mg (eqv. to 10 Billion)	Probiotics have antimicrobial, immunomodulatory and antidiarrheal effects.
40	Probiotics	Probiotics Sacchromyces boulardii Capsule 250mg (eqv. to 5 Billion)	Saccharomyces boulardii acts as a temporary flora to protect the intestinal tract and keep intestines functioning well. It works with the body to reestablish the micro-flora, thereby maintaining a digestive balance. Saccharomyces boulardii has been used in Europe for many decades to treat diarrhoea.
41	Probiotics	Probiotics Sacchromyces boulardii Capsule 500mg (eqv. to 10 Billion)	Saccharomyces boulardii acts as a temporary flora to protect the intestinal tract and keep intestines functioning well. It works with the body to reestablish the micro-flora, thereby maintaining a digestive balance. Saccharomyces boulardii has been used in Europe for many decades to treat diarrhoea.

Sl. No	General Name	Generic Name with Strength & Dosage Form	Indication
42	Muscle Rub	Muscle Rub Extract of Mentha Spp. Cinnamomum Camphora, oil of winter green and oleoresin Capsicem ointment (Extract of mentha Spp as I-mentho 2.54gm Extract of Cinnamemum Camphora as d-Champhora 1.43gm, Oil of Winter Green as methyl Sacioylate 0.42gm Extract of Capsicem as oleoresin Capsicem 0.005gm.	1. Effective relief from aches and Pains including muscular Stiffners, brusing, Sprains, fibrositis
43	Saw Palmetto	Saw Palmetto Standalized Extract, Liquid filled Hard Gelatin Cap 160.00mg	1. Benign prostatic Hyperplasia (BPH) Stages 1 & 11
44	Ginseng	Panax Ginseng Standardized Extract 500mg per 5ml Syrup	1. Adaptogen & general tonic, 2. Increase athletic per formance & endurance, 3. Vitality, 4. Fatique & Devility, 5. Endancement of physical & mental capacity
45	Silymarin	Silymarin (Milk Thistle Foruil Extract) Syrup 70mg per 5ml	1. Hepatitis and Ijaundice, 2. Alcoholic liver damage, 3. Toxic liver damage, 4. Hepatic cirrhosis etc.
46	Ashwagondha	Ashwagondha (Willtheria Somnifera) Root & Kostori Late (Abelmoschus moschatus) Seeds Each cap Contains 500mg Extract	1. Tonic (Helping to boost level of adaptation energy Physical, mental debilities
47	Sarpogandha	Sarpogandha (Rquwalifia Serpertina) 200mg Extract of Roots in Each 5ml Syrup	1. Hypertension, 2. Insomnia
48	Bhui Amla	Bhui Amla Phyllathus amarus Euphorbiaceae	Jaundice, Antiviral (Hepatitis-B)
49	Sonapata + Isobgul	Cassia angustifolia Caesalpiniaceae + Plantago Ovata Plantaginaceae	Stimulant laxative, Hemorrhoids, Anal fissures
50	Peppermint + Asafoetida	Mentha piperita Lamiaceae + Ferula asafoetida Apiaceae	Spasmolytic effect on the smooth muscle of the digestivetract, Chronic gastritis, dyspepsia and irritable colon.
51	Horse Chest nut	Horse Chest nut Aesculus hippocastanum L 50mg Tablet	Venous insufficiency, Varicosis, Severe cranio-cerebral trauma, Prevention and treatment of postoperative edema, traumatic head injury, Intracranial pressure, and Edema.
52	Horse Chest nut	Horse Chest nut Aesculus hippocastanum L 100mg Tablet	Venous insufficiency, Varicosis, Severe cranio-cerebral trauma, Prevention and treatment of postoperative edema, traumatic head injury, Intracranial pressure, and Edema.
53	Bilberry fruit Extract	Bilberry fruit Extract Vaccinium myrtilfus 80 Capsule	Hypertensive and diabetic retinopathy, night blindness, cataracts.
54	Bilberry fruit Extract	Bilberry fruit Extract Vaccinium myrtilfus 160mg Capsule	Hypertensive and diabetic retinopathy, night blindness, cataracts.
55	Red clover extract	Red clover extract Trifolium pretense 40mg Capsule	Menopausal symptoms : Hot flashes, Night sweats, Decrease loss of bone density.
56	Red clover extract	Red clover extract Trifolium pretense 40mg Tablet	Menopausal symptoms : Hot flashes, Night sweats, Decrease loss of bone density.
57	Valerian Valariana	Valerian Valariana officinalis L 100mg Tablet	Anxiety, insomnia, sleep disorders, restlessness based on nervous disorders.
58	Valerian Valariana	Valerian Valariana officinalis L 300mg Tablet	Anxiety, insomnia, sleep disorders, restlessness based on nervous disorders.

Sl. No	General Name	Generic Name with Strength & Dosage Form	Indication
59	Yohimbe	Yohimbe Pausinystalia Yohimbe 5.4mg Tablet	Yohimbe is used generally as a vitalizer and tonic. Recent studies suggested that Yohimbe can be used as a remedy for male impotence; especially that associated with diabetes.
60	Arnica Ointment	Arnica Ointment 15% (Standardized extract of Arnica Montana flower)	Treatment of bruises, sprains and inflammation caused by insect bites, symptomatic freatment of rheumatic complaints. For extemal use in injury and consequences of accident, e.g. hematoma, dislocations, contusions, edema due to the fracture etc.
61	Aswaganda	Withania somnifera (Standardized extracts) 500mg Capsule	Physical debility and Anabolic activity, Natural Stress reliever and Super antioxidant.
62	Ganoderma mycelium	Ganoderma lucidam 500 mg capsule	Strengthens the immune system Reduce cholesterol (LDL) and triglycerides Lower blood pressure Dispels phlegm, relieves cough
63	Herbal neck & shoulder rub	Extract of Mentha spp. as l –Menthol 80mg Extract of Cinamomum camphora as d-Camphor 45mg, Eucalyptus Oil 180 mg Mint Oil 10 mg per gram cream	Soothing relief to neck and shoulder aches and pains
64	Chirota	Chirota 400mg Hard Capsule	Chirota Stimulates the immune system. It protects the liver from damage. It helps to counter fever
65	Kalomegh	Kalomegh 400mg Hard Capsule	Kalomegh Stimulates the immune system. It protects the liver from damage. It helps to Counter fever
66	Bitter Melon	Bitter Melon 400mg Hard Capsule	Regulated blood sugar level, Improve pancreatic & liver function, Boost immunity & Natural Source of Vitamin C
67	Dandelion	Dandelion 425mg Hard Capsule	Dandelion id diuretic & helps in high blood pressure, infection of the urinary tract, Liver and gall bladder complaints and loss of appetite
68	Proantho-cyanidins	Pine bark extracts (Pinus maritimus) 50mg Capsule	Used in Asthma, Chronic venous insufficiency, Attention 05Deficient Hyperactivity Disorder (ADHD), Diabetes, Dysmenorrhea, High blood pressure, Male infertility, Skin care, It is act as a potent antioxidant
69	Echinacea	Purple coneflowers extract (Echinacea purpurea) 100mg Capsule	Used to fight off colds, flun and respiratory tract infection
70	St. John's wort	Saint John's wort extract (Hypericum perforatum) 150mg Capsule	Helps to treat symptoms of sleep disorders & depression (mild to moderate). Used as sedative for relief of restlessness of nervousness

4| wewea AvjvPbv t

wewfb mg‡q nvevj Jla Drcv`bKvix cwZôv‡bi Av‡e`‡bi cwi‡cwÿ‡Z wb¤ewYZ 7(mvZ)wU c‡`i wbeÜb Kiv nq| c`¸‡jvi nvevj Jla G¨WfvBRvix KwgwU KZK.সুপারিশ সংক্রান্ত কোন তথ্য খুঁজে পাওয়া যায়নি। পদগুলোর বিষয়ে wm×vš Mn‡Yi Rb¨ mfvq Dc¯vcb Kiv nqt

Sl. No	General Name	Generic Name with Strength & Dosage Form	Indication
1	Basaka	Adhatoda Vasica Extract 13.6gm+ Glycyrrhiza glabra Extract 135.6mg+Zingiber Oficinale extract 135.6mg+Cinnamomum Zelylanicum Extract 135.6mg+Eletteria cardamomum extract 135.6mg+Piper Iongum Extract 2.8gm+Terminalia chebula Fruit bark 1.46gm+Saussurea Iappa Root 135.6mg+Piper-nigrum Extract 135.6mg+Syzygium aromaticum Flower 135.6mg+ Cinnamomum tamala Extract 135.6mg +Myrica Nagi Fruit 135.6mg+Pistacia Integerrima Fruit 135.6mg/100ml Syrup	Relives Cough, Liquefies Phlegm, Helps in sore throat, Helps in chest congestion
2	Ginkgo Biloba	Ginkgo Biloba Capsule 120mg (Ginkgo Biloba Extract)	1. Cerebral insufficiency, 2. Memony deficit, 3. Poor Concentration
3	Andrographis	Andrographis Cap 400mg (Andrcgraphis 400mg Stanclarized Extract)	1. Andrographes is used for the treatment of common cold, influenza etc
4	Silymarin	Silymarin Cap 140mg	1. Hepatitis & Jaundice, 2. Alcoholic & toxic Liver damage, 3. Hepatic Cirrhosis
5	Green Tea	Green Tea Dispersible Tablet 60mg (Camellia Sinensis)	1. Reduce risk of Cardiovascular disease, 2. Decreare Serum lipid Concentration
6	Yohimbe	Yohimbe Pausinystalia Yohimbe 450mg Tablet	Yohimbe is used generally as a vitalizer and tonic. Recent studies suggested that Yohimbe can be used as a remedy for male impotence; especially that associated with diabetes.
7	Echinacea	Echinacea Cap. 500mg	1. Bronchitis, 2. Colds, 3. Cough, 4. Fever, 5. Sore Throat, 6. Boosts Immune System

mfvi Av‡jvPbv t mfvq Jla¸‡jvi wel‡q we¯wiZ Av‡jvPbv nq| c`¸‡jv `xN©`b hver †`‡k e¨eüZ n‡q Avm‡Q Ges †Kvb wei¡c cwZক্রিয়ার কোন তথ্য পাওয়া যায়নি।

mfvi wm×vš t c`¸‡jv wbivc`, KvhKi I c‡qvRbxq weavq Abyhvqx`b Kiv nj|

Ab¨ †Kvb Av‡jv”` weIq bv _vKvq mfvcwZ g‡nv`q Dc¯Z mKj‡K ab¨ev` Ávcb K‡i mfvi mgvß †NvlYv K‡ib|

‡gRi †Rbv‡ij †gvt RvnvsMxi †nv‡mb gwjK
gnvcwiPvjK
Jla ckvmb Awa`ßi
I
m`m¨-mwPe
Jla wbqšY KwgwU|

Gg Gg wbqvR DwÏb
mwPe
¯v¯¨ I cwievi Kj¨vY gšYvjq
I
mfvcwZ
Jla wbqšY KwgwU|